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1 Summary 
 
In cellular nucleic acids there are more than 100 modified nucleosides, which fine-tune and 
regulate the activity of most RNAs and of genes in DNA. Due to these important assignments 
these modifications have stimulated research for decades and thousands of publications 
describe their occurrences, biosyntheses, and functions. Most knowledge has been obtained 
by the study of individual modifications, although it is known that they generally occur 
concertedly and bias each other. 
Collective, quantitative investigation of biomolecules has led to tremendous advances in 
biochemistry during the current era of omics-research. For modified nucleosides such an 
approach is hampered by the lack of methodologies, which provide quantitative data of many 
modifications in parallel with the necessary sensitivity and accuracy. Therefore, a stable 
isotope dilution HPLC-MS method was established, which allows quantification of in 
principle all modified nucleosides from DNA and tRNA with high sensitivity and accuracy 
(Figure 1). 
 
 
Figure 1: Schematic outline of the quantification method for modified tRNA nucleosides established 
during this thesis work. Modified DNA nucleosides were quantified accordingly. 
 
It is composed of the following single steps: 
1. Isolation of DNA or tRNA from biological material. 
2. Purification of DNA or tRNA. 
3. Enzymatic digestion of the nucleic acids to nucleosides. 
4. Spiking of the nucleoside mixture with isotopically labeled standards. 
5. Analysis of the mixture by HPLC-MS. 
As a basis, the nucleosides of interest had to be synthesized in natural and isotopically labeled 
form. Thus, in the course of this thesis work nine modified nucleosides and their heavy atom 
labeled derivatives were synthesized (Figure 2). 
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Figure 2: Compilation of the 18 nucleosides prepared for mass spectrometric quantification in the 
course of this thesis work.  
 
Utilizing the prepared modified nucleosides genomic DNA and tRNA were investigated. The 
nucleosides 5-MedC and 5-HOMedC from DNA was studied, because recently the novel sixth 
DNA nucleoside 5-HOMedC has been reported, which is of outstanding scientific interest. tRNA 
was selected as a representative for RNAs, as it contains the highest amount and density of 
modified nucleoside. These influence the translation of mRNA at the ribosome, one of the 
most important biological processes in a cell.  
In an initial study of six modified nucleosides from E. coli, two cell lines (HeLa and 
HCT-116), and pork liver tRNA the feasibility of our method in conjunction with its high 
sensitivity and accuracy was proven (Figure 3 a). The initial measurements showed that the 
investigated cancer cell lines contain significantly different modification levels and that these 
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also vary from the levels in healthy tissue. In addition, the modified nucleoside ms2i6A, which 
is present in mitochondrial tRNA but not in the cytosolic tRNA, was not detected in cancer 
cell lines indicating an impaired mitochondrial activity in these cells in accordance with the 
Warburg hypothesis. 
 
 
Figure 3: Representative results of the four quantification studies of modified nucleosides performed in 
the course of this thesis work. 
a) tRNA modification levels in E. coli, pork liver, and cell lines (HeLa and HCT-116). b) Amounts of 
m2A measured in E. coli exposed to different environmental pH values. c) Ratio of 5-HOMedC to dG in 
the different tissues in percent. d) Color-coded tRNA modification levels in pork tissue. Error bars 
represent the determined standard deviations of at least two replicates and at least six HPLC-MS 
measurements. 
 
Changes of the modification levels in E. coli upon external stimulation were investigated in a 
second study, which employed m2A and m6A, to evaluate whether modified nucleosides 
might be involved in the stress response of cells (Figure 3 b). For a number of stimulations no 
alteration could be detected but variations of the environmental pH and treatment with 
antibiotics induced alterations in the modification levels, e.g. a 75 % loss of m2A at pH 9.5. 
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Quantification of the novel sixth nucleosides, 5-HOMedC, in DNA samples isolated from seven 
different brain regions with our method showed that 5-HOMedC is present in all of these 
confirming 5-HOMedC as a general post-replicatively formed DNA modification mainly in 
neuronal tissue (Figure 3 c). 
The largest screening was performed with pork tissue, which included ten tissues and twelve 
modified tRNA nucleosides (Figure 3 d). The levels of the mitochondrial modification ms2i6A 
were found to correlate with the mitochondrial activity in the investigated tissues. All other 
modified nucleosides exhibited a concordant, gradual variation of their amounts across tissues 
with only minor exceptions. They correlate with the protein synthesis rate of the tissues 
indicating a regulation of the protein synthesis capacity by tRNA modifications. Based on this 
correlation and the acceleration of the rate limiting step of translation by modified 
nucleosides, which is described in literature, the following general model was introduced: 
In prokaryotes modified tRNA nucleosides establish a fitness and proliferation advantage by 
optimizing the translation efficiency. In mammals the tissue-specific modification levels are 
responsible for maintaining the ideal translation rate and protein synthesis capacity of each 
tissue. 
 
Taken together, in the course of this thesis work it was possible to establish a quantification 
method for modified nucleosides, to utilize it for several studies, and to develop a novel, 
general concept for the functions of tRNA modifications from the obtained data. 
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2 Zusammenfassung 
 
Natürliche Nukleinsäuren enthalten mehr als 100 modifizierte Nukleoside, die die Aktivität 
von RNAs und von Genen in der DNA regulieren. Wegen dieser wichtigen Aufgaben werden 
Modifikationen seit Jahrzehnten untersucht und tausende Publikationen beschreiben ihr 
Vorkommen, ihre Biosynthesen und ihre Funktionen. Die meisten Informationen über sie 
wurden durch die Untersuchung einzelner Modifikationen erhalten, obwohl sie in der Regel 
gemeinsam auftreten und sich auch gegenseitig beeinflussen. 
In der aktuellen Ära der Omics-Forschung hat die kollektive, quantitative Untersuchung von 
Biomolekülen zu beachtlichen Fortschritten geführt. Bei modifizierten Nukleosiden wird 
dieser Ansatz durch das Fehlen passender Methoden, die parallel quantitative Daten zu vielen 
Modifikationen mit der nötigen Empfindlichkeit und Genauigkeit liefern, erschwert. Deshalb 
wurde eine HPLC-MS Isotopenverdünnungsmethode entwickelt, die die parallele 
Quantifizierung von prinzipiell allen modifizierten Nukleosiden aus DNA und tRNA mit 
hoher Empfindlichkeit und Genauigkeit ermöglicht (Abbildung 1). 
 
 
Abbildung 1: Skizze der Quantifizierungsmethode für modifizierte tRNA Nukleoside, die im Rahmen 
dieser Arbeit etabliert wurde. DNA Modifikationen wurden entsprechend quantifiziert. 
 
Sie besteht aus den folgenden Einzelschritten: 
1. Isolierung der DNA und tRNA aus biologischem Material. 
2. Aufreinigung der DNA und tRNA. 
3. Enzymatischer Verdau der Nukleinsäuren zu Nukleosiden. 
4. Zugabe der Isotopenstandards zu dem Gemisch. 
5. HPLC-MS Analyse des Gemisches. 
Zudem mussten die zu untersuchenden Nukleoside in natürlicher und isotopenmarkierter 
Form synthetisiert werden. Deshalb wurden im Verlauf dieser Arbeit 18 modifizierte 
Nukleoside zusammen mit ihren schweratommarkierten Derivaten dargestellt (Abbildung 2). 
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Abbildung 2: Übersicht der 18 Nukleoside, die im Rahmen dieser Arbeit für die massenspektrometri-
sche Quantifizierung synthetisiert wurden. 
 
Mit Hilfe der synthetisierten, modifizierten Nukleoside wurde genomische DNA und tRNA 
untersucht. In DNA wurden 5-MedC und 5-HOMedC quantifiziert, da vor kurzem von der 
Entdeckung des sechsten DNA Nukleosids 5-HOMedC berichtet wurde, das von großem 
wissenschaftlichem Interesse ist. tRNA wurde als Repräsentant für RNAs gewählt, weil sie 
die größte Menge und Dichte an modifizierten Nukleosiden aufweist. Diese beeinflussen die 
Translation der mRNA am Ribosom, die einer der wichtigsten Prozesse in einer Zelle ist. 
In einer ersten Studie wurde die Anwendbarkeit unserer Methode zusammen mit ihrer hohen 
Empfindlichkeit und Genauigkeit anhand von sechs modifizierten Nukleosiden aus tRNA von 
E. coli, zwei Zelllinien (HeLa und HCT-116) und Schweineleber bewiesen (Abbildung 3 a). 
Diese ersten Messungen zeigten zudem, dass die beiden untersuchten Zelllinien deutlich 
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unterschiedliche Modifikationsgrade besitzen und dass sich diese von den 
Modifikationsgraden in gesundem Gewebe unterscheiden. Das modifizierte Nukleosid 
ms2i6A, das in mitochondrialer aber nicht in zytosolischer tRNA vorkommt, wurde in den 
Zelllinien nicht gefunden, was in Übereinstimmung mit der Warburg Hypothese auf eine 
verminderte mitochondriale Aktivität in Krebszellen hinweist. 
 
 
Abbildung 3: Repräsentative Ergebnisse der vier Quantifizierungsstudien von modifizierten 
Nukleosiden, die im Rahmen dieser Doktorarbeit durchgeführt wurden. 
a) Modifikationslevels in E. coli, Schweineleber und Zelllinien (HeLa und HCT-116) tRNA. b) m2A 
Mengen in E. coli Zellen, die verschieden Umgebungs-pH-Werten ausgesetzt wurden. c) Farbcodierte 
tRNA Modifikationsgrade in Schweinegewebe. Fehlerbalken sind die Standardabweichungen von 
mindestens zwei Wiederholungen und mindestens sechs HPLC-MS Messungen. 
 
In einer zweiten Studie wurden die Veränderungen des m2A und m6A Modifikationsgrads in 
E. coli durch externe Stimulation untersucht, um zu bestimmen, ob modifizierte Nukleoside 
an der Stressantwort von Zellen beteiligt sein könnten (Abbildung 3 b). Für eine Reihe an 
Stimuli wurden keine Veränderungen festgestellt. Dagegen führten die Veränderung des 
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Umgebungs-pH-Werts und die Behandlung mit Antibiotika zu einer Änderung des 
Modifikationsgrads, zum Beispiel einer 75 %igen Abnahme von m2A bei pH 9.5. 
Die Quantifizierung des neuen sechsten Nukleosids 5-HOMedC in DNA aus sieben 
verschiedenen Gehirnregionen mit unserer Methode zeigte, dass 5-HOMedC in allen 
untersuchten Proben vorkam und damit dass 5-HOMedC eine generelle post-replikativ gebildete 
DNA Modifikation vorrangig in neuronalem Gewebe ist (Abbildung 3 c). 
Die größte Messreihe wurde mit zehn verschiedenen Schweinegeweben und zwölf 
modifizierten Nukleosiden durchgeführt (Abbildung 3 d). Die Menge der mitochondrialen 
Modifikation ms2i6A korreliert mit der mitochondrialen Aktivität der untersuchten Gewebe. 
Alle anderen Nukleoside weisen mit nur geringen Abweichungen eine übereinstimmende, 
graduelle Veränderung ihrer Mengen mit den Geweben auf. Diese korrelieren mit den 
Proteinsyntheseraten der Gewebe, was auf eine Regulation der Proteinsynthese durch tRNA 
Modifikationen hinweist. Basierend auf dieser Korrelation und der in der Literatur 
beschriebenen Beschleunigung des ratenbestimmenden Schritts der Translation durch 
modifizierte Nukleoside wurde das folgende, generelle Model aufgestellt: 
In Prokaryoten bewirken modifizierte tRNA Nukleoside durch die Optimierung der 
Translationseffizienz einen Fitness- und Proliferationsvorteil. In Säugetieren sorgen die 
gewebespezifischen Modifikationsgrade für eine ideale Translationsrate und 
Proteinsynthesekapazität der einzelnen Gewebe. 
 
Insgesamt wurde im Rahmen dieser Doktorarbeit eine Quantifizierungsmethode für 
modifizierte Nukleoside etabliert, diese für mehrere Studien eingesetzt und aus den erhaltenen 
Daten ein neues, allgemeines Konzept zur Funktion von tRNA Modifikationen erarbeitet. 
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3 Introduction 
3.1 Natural modified nucleosides in DNA and RNA 
Nucleic acids are the central “devices” in biological “information technology”. Present 
textbooks usually content themselves with four nucleosides for deoxyribonucleic acids (DNA) 
and ribonucleic acids (RNA) each: deoxyadenosine (dA), deoxycytidine (dC), 
deoxyguanosine (dG), and deoxythymidine (dT) for DNA and adenosine (A), cytidine (C), 
guanosine (G), and uridine (U) for RNA. This general statement, although sufficient for an 
understanding of the biological functions and processes involving nucleic acids, is all but 
exhaustive. Both DNA and RNA contain so called modified nucleosides. These are derived 
from the canonical ones but feature further substituents. Their additional groups, which are 
attached either to the heterocycle or to the C2'OH, range from simple methyl groups to 
advanced ring systems. Modified nucleosides are involved in the most fundamental processes 
in cells: inheritance, transcription, and translation. 
 
 
Figure 4: Structures of exemplary DNA and RNA modifications. 
DNA modifications: 5-MedC and 5-HOMedC, upper row; RNA modifications: m2G, m3Um, ms2io6A, and 
queuosine (Q); bottom row. Alterations relative to the canonical nucleoside are indicated in red. 
 
To date two modified nucleosides are known in DNA: 5-methyl deoxycytidine (5-MedC) and 
5-hydroxymethyl deoxycytidine (5-HOMedC). The modification 5-MedC is one of the key players 
in epigenetics and thus involved in the control of transcriptional activity.[1] Special 
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methyltransferases replace the H-atom at position C5 by a methyl group to form 5-MedC.[2] 
Methylation occurs in CpG sequences and is mostly responsible for the silencing of genes.  
The modification 5-HOMedC was established as a new post-replicatively formed DNA 
nucleoside in neuronal cells and stem cells in two recent back-to-back reports.[3] Nevertheless, 
the biosynthesis and the functions of 5-HOMedC are still unknown. 
Modifications in RNA are by far more numerous. More than 100 different modified RNA 
nucleosides have been identified to date.[4] The highest modification level is found in tRNA. 
More than 80 tRNA modifications are presently known making this RNA class the first 
choice for the investigation of modified nucleosides. They form about 12 % of the tRNA 
nucleosides with a median of eight modifications per tRNA.[5] Correspondingly, numerous 
functional groups are used by nature to establish such a high number of different yet related 
molecules. To implement the various modifications in tRNA a broad range of chemistry has 
to be performed and numerous enzymes are involved. The structural diversity of tRNA 
modifications is also reflected by a myriad of functions they mediate. For instance they are 
involved in cellular processes such as mRNA decoding, cell development, translation control, 
development of diseases, occurrence of virulence, adaption to the environment, proliferation, 
and metabolism. An exhaustive discussion of all biological pathways and functions related to 
modified nucleosides thus by far exceeds the scope of this thesis. For the modifications 
synthesized during this thesis work an overview about their biosyntheses and functions is 
given as a short introduction preceding the discussion of their syntheses (chapter 7). In 
addition, they are discussed in numerous review articles.[5-6] 
In general, all modified tRNA nucleosides effect the translation of genetic information from 
the messenger-RNA (mRNA) to proteins either by directly interacting with the mRNA and 
the ribosome or indirectly by influencing the three-dimensional structure of the tRNA. An 
impaired modification pattern of the tRNAs can thus severely impact the viability of the 
affected organism. In unicellular organisms this can lead to a reduced fitness or death.[7] In 
higher organisms it was shown that an altered tRNA modification pattern can cause severe 
diseases[8] and might be associated with progression and malignancy of cancer in humans.[9] 
As a foundation for the following discussion of this important topic all modified nucleosides 
in animals according to this work and Sprinzl and coworkers[4a, 4b] are summarized in Figure 5. 
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Figure 5: Summary of the modified nucleosides in animals according to this work and Sprinzl and 
coworkers.[4a, 4b] Alterations relative to the canonical nucleosides are indicated in red. 
 
3.2 Modified tRNA nucleosides in cancer 
3.2.1 tRNA methylation levels in tumor tissues 
Neoplastic tissues exhibit an altered methylation pattern in comparison to their nearest healthy 
tissues.[10] Both hyper- and hypomodification have been observed, while the activity of tRNA 
methylating enzymes is generally increased in neoplastic tissues. The direction and the extent 
of the tRNA methylation level changes vary between tissues. Similar alterations have also 
been detected for other modified nucleosides like wybutosine. 
When methylated bases were first observed in tRNA, they were suspected to control 
translation and thus to participate in differentiation including the development of cancer.[11] 
This assumption was supported by the finding that administration of carcinogenic 
dimethylnitrosamine to healthy animals induced development of tumors and, simultaneously, 
formation of methylated nucleosides not only in DNA but also in RNA.[12]  
Inspired by these observations various groups investigated the activity of methyltransferases 
in healthy and in tumor tissues. The general approach included the isolation of tRNA from 
one species (generally bacteria or yeast) and collection of the methyltransferases from the 
tissue of interest. As different species contain different methylation patterns, 
methyltransferases from one species can further methylate tRNA from another species. In a 
large number of investigations preparations of methyltransferases from neoplastic tissues 
introduced two to ten times more methyl groups in tRNA samples than identical preparations 
from the closest healthy tissue.[10-11, 13] Similar results were obtained for studies with cell 
cultures. Comparison of mouse embryo and Syrian hamster kidney cell line BHK21 with their 
respective transformed cell lines revealed an increased methylation capacity of the 
transformed cells.[14] In addition, analysis of cells transformed by DNA viruses, which cause 
cancer, led to the same results.[15]  
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The first direct investigations of cancer-related tRNA alterations were based on the 
chromatographical separation of tRNA species, because changes in the tRNA methylation 
pattern are reflected in an altered chromatographical behavior.[10, 13] By now, numerous 
studies have shown, that usually one to five tRNA species exhibit an altered methylation 
pattern, when tRNA samples from healthy and neoplastic tissues are compared.[16] 
Nevertheless, no general rule could be deduced from these investigations but it is noteworthy 
that differences are commonly found for tRNAPhe, tRNATyr and tRNASer.[10, 17] 
The most compelling proof for an increased methylation in tumor tissues comes from the 
direct determination of the methylation levels in tRNAs.[18] The most thorough investigation 
was performed by Viale and coworkers,[18c] who analyzed twelve different methylated 
nucleosides in eight distinct classes of brain cancer tissues and found significantly increased 
amounts of modifications in neoplastic tissues in comparison to normal brain (Table 1). 
Interestingly, a detailed look at the data in Table 1 (bold numbers) shows that higher grade 
tumors feature higher changes of the modified nucleoside levels. This was also found in 
several other investigations (chapter 3.2.2). Nevertheless, there are also examples from 
literature, where no changes of the modification contents in neoplastic tissues was 
observed.[9a, 13] 
 
Nucleo-
sides 
Normal 
brain  
Medullo-
blastoma 
Spongio-
blastoma
Astrocytoma Oligodendroglioma Glio-
blastoma 
Neurinoma 
Grade Grade 
I II – III I II – III 
m5C 0.12 0.26 0.72 0.24 0.64 0.33 0.30 0.72 0.36 
m6A 0.18 0.45 0.54 0.52 0.86 0.38 0.62 1.14 0.28 
m62A 0.12 0.36 0.32 0.32 0.56 0.32 0.45 0.68 0.28 
m1G 0.02 0.46 0.88 0.48 0.84 0.57 0.52 1.58 0.42 
m2G 0.32 0.74 0.72 0.90 0.62 0.72 0.64 1.86 0.33 
m22G 0.54 0.52 1.04 0.76 0.98 0.66 0.73 1.13 0.48 
T 0.32 0.08 0.36 0.64 0.42 0.51 0.36 0.62 0.21 
m1I 0.02 0.32 0.04 0.36 0.14 0.15 0.16 0.27 0.02 
Cm 0.12 0.26 0.20 0.14 0.48 0.18 0.37 0.58 0.30 
Am 0.04 0.06 0.08 0.08 0.35 0.12 0.16 0.42 0.17 
Gm 0.25 0.30 0.38 0.26 0.84 0.44 0.60 0.90 0.64 
Um 0.03 0.05 0.12 0.04 0.40 0.16 0.32 0.46 0.35 
Sum 2.08 3.86 5.4 4.74 7.13 4.54 5.23 10.36 3.84 
Table 1: Methylated nucleosides in tRNAs from human brain and brain tumors.[18c] 
 
To allow the investigation of in principle all ribose-unmethylated modified nucleosides 
Randerath and coworkers developed a tritium derivative method.[9a] Using this approach no 
changes in the modification levels in healthy and in tumor brain tissues could initially be 
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detected.[19] Only after extension of the studies to liver and hepatomas differences were 
observed.[20] In contrast to the results discussed above an undermethylation and 
undermodification of tRNAs from neoplastic tissues was detected. Especially mitochondrial 
tRNAs were found to contain reduced amounts of modified nucleosides with higher 
reductions in a rapidly growing, highly malignant hepatoma than in a slowly growing one.[9a, 
20b] Comparison of Morris hepatoma 5123D and normal liver cytoplasmic tRNA showed a 
60 % reduction of m2G in position 10 but not in position 6 of tRNALeu.[21] In the same 
neoplastic tissue a complete loss of Gm in tRNASerIGA was detected.[22] Moreover, Nishimura 
and coworkers[23] uncovered an alteration of the methylation pattern in ascites hepatoma 
tRNAs in comparison to rat liver tRNAs. tRNAVal in hepatoma features Gm and C, whereas 
this tRNA from healthy tissue contains G and Cm in positions 18 and 32, respectively. 
Similarly, a lack of the hypermodified nucleoside wybutosine has been detected in tumor 
tissues during several investigations.[24] Hyper- and hypomodifications for various modified 
nucleosides (e.g. m7G, m5C, and Q) in neoplastic tissues (e.g. Walker 256 carcinosarcoma, 
Morris Hepatoma 51231, and Ehrlich ascites cells) were observed in further studies.[17, 25] In 
non-small cell lung carcinomas increased expression levels of hDUS2, which is necessary for 
the biosynthesis of dihydrouridine in tRNA, were found and even could be associated with the 
course of disease.[26] 
3.2.2 Hypomodification of tumor tissue tRNAs in respect to queuosine 
The most intensively investigated tRNA modification in neoplastic tissues and in cancer cell 
lines is queuosine (Q, Figure 4). It is a hypermodified nucleoside, which occurs in the first 
position of the anticodon in tRNAHis, tRNAAsn, tRNAAsp, and tRNATyr of both eukaryotes and 
prokaryotes.[27] Mammals are not able to produce Q themselves but take up the corresponding 
base queuine from their nutrition or gut flora.[28] The base is then substituted for guanosine in 
tRNA at the wobble position by tRNA-guanine transglycosylases (TGTs).[29] Nucleoside Q is 
involved in numerous key processes, e.g. translation,[6c, 6n, 30] development,[28c, 31] cell 
proliferation,[32] metabolism,[32a] tyrosine biosynthesis,[33] and bacterial virulence.[34] 
It has been found early on that tRNAs in neoplastic tissues and in cancer cell lines are often 
hypomodified in respect to Q or even completely lack this complex modification. For 
instance, it is less abundant in rat ascites hepatomas,[35] mouse lymphomas,[36] mouse 
xenografts,[37] human leukemias and lymphomas,[38] lung cancer tissues,[39] and ovarian 
malignant tumors.[40] Presence of guanosine for queuine was also found in tRNAs isolated 
from various cancer cell lines.[37, 41] A compilation of published Q-deficient neoplastic tissues 
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and cancer cell lines is shown in Table 2 and Table 3, respectively. Neoplastic tissues and 
cancer cell lines, which are fully modified with respect to Q but included in these 
publications, are also summarized. 
 
tRNAs Q-deficient neoplastic tissues Fully Q-modified neoplastic tissues Ref. 
Bulk 
AH7974 rat ascites hepatoma 
Morris hepatoma 7794A 
Ehrlich mouse ascites tumor 
SN36 mouse ascites tumor 
Sarcoma 180 mouse ascites tumor 
MM46 mouse ascites tumor 
- [35b] 
Tyr, Asp, 
Asn, His Ehrlich mouse ascites tumor - 
[35a] 
His Ehrlich mouse ascites tumor - [35c] 
Bulk rat ascites hepatoma AH7974 - [35d] 
Bulk Dalton’s lymphoma ascites tumour - [36] 
His, Asp Mouse colon adenocarcinoma Mouse xenografts rhabdomyosarcoma - 
[37] 
Asp 
Breast adenocarcinoma 
Breast adenocarcinoma 
Colon adenocarcinoma 
Kidney metastatic renal cell carcinoma 
Lung carcinoma, metastasis to liver 
Skin metastatic melanoma 
Breast tumors 
Colon tumors 
Small bowel adenocarcinoma 
Kidney renal cell carcinoma 
Liver metastatic adenocarcinoma 
Lung adenocarcinoma 
Neck and head metastatic tumors 
Ovary metastatic tumors 
Pancreas metastatic tumors 
Prostate tumors 
Skin tumors 
Stomach tumors 
Chest wall recurrent adenocarcinoma 
[37] 
Bulk Human leukemias and lymphomas - [38] 
Bulk Lung tumors Lung tumors [39] 
Bulk 
Dysgerminoma 
Granulosa cell tumor 
Teratoma malignisatum 
Serious adenocarcinoma 
Carcinoma anaplasticum 
Carcinoma endometriale 
- [40] 
Bulk Walker 256 carcinosarcoma - [25a] 
Bulk Astrocytomas Meningiomas - 
[42] 
Table 2: Compilation of published Q-deficient tumor tissues. 
 
 
 
Chapter 3 Introduction 
8 
tRNA Q-deficient cancer cell lines Fully Q-modified cancer cell lines Ref. 
Asp 
GC 3/M 
GC 3/cl 
N-1000 
T84 cultured in <5% FBS 
HL-60 
Ei 28 
T84 cultured in >9% FBS 
MDA-MB-436 
MDA-MB-468 
Y-79 
[37] 
His, Asp TF-P10c FLc - 
[41a] 
Bulk HxGC3 MCF-7 - 
[41b] 
Bulk 1548 Morris cell line - [41c] 
Bulk C3H10T1/2 RasC4 - 
[41d] 
Asp, Tyr, 
Asn, His BALB/3T3 - 
[43] 
Bulk 
HPB-ALL 
Jurkat 
Molt-4F 
PEER 
HUT78 
- [44] 
Bulk Friend murine erythroleukemia cells 745A and M18 - 
[45] 
Asp, Tyr, 
Asn, His K562 - 
[46] 
Bulk Friend murine erythroleukemia cells 745A, clone DS19 - 
[47] 
Asp, Tyr, 
Asn, His 
Friend murine erythroleukemia cells 
745A, clone GM86 - 
[48] 
Table 3: Compilation of published Q-deficient cancer cell lines. 
 
In order to determine the Q-levels in tRNAs most studies listed here took advantage of the 
substrate specificity of E. coli TGT. The enzyme introduces queuine irreversibly into tRNA, 
but instead of queuine it also accepts guanine as a substrate for incorporation. Therefore, TGT 
can be used to introduce tritium labeled guanine in tRNAs, which are Q-deficient ((Q-
)tRNA), but not in Q-containing tRNAs ((Q+)tRNA). Treatment of tRNA, which was 
extracted from the tissue of interest, with TGTs and radioactively labeled guanine and 
subsequent measurement of the radioactivity therefore allows determination of the amount of 
Q-deficiency in the tRNAs of the sample.[35b, 49] 
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3.2.2.1 Origins of queuosine hypomodification in neoplastic tissues 
Several origins of the queuosine hypomodification have been proposed but a general 
description is still missing, mainly because the causes vary with the tissues examined. Based 
on the investigations presented hereafter the following origins for the hypomodification of 
tRNAs with respect to Q in neoplastic tissues have been proposed:[50] 
- Decreased bioavailability of queuine and increased demand for queuine. 
- Decreased activity of TGT. 
- Presence of TGT inhibitors. 
- Reduced queuine salvage. 
The most likely cause is the reduced bioavailability of queuine in fast growing tissues.[9b, 50] 
tRNAs in rapidly dividing reticulocytes are hypomodified with respect to Q.[51] Similarly, 
regenerating liver tissue contains reduced levels of queuosine.[35b] In some cell lines addition 
of exogenous queuine causes repletion of (Q+)tRNA.[41d] Thus, the insufficient supply of 
rapidly growing tissues, like tumors, with queuine together with an increased turnover of 
tRNA in neoplastic tissues[52] most likely is responsible for the Q-hypomodification. 
On the other hand, addition of large amounts of queuine to mice carrying Ehrlich tumors did 
not lead to normal Q-contents in their tRNA.[35c] This finding could be attributed to a reduced 
queuine salvage and decreased TGT activity, which was also detected in other mouse 
models.[37, 53] In contrast to these results several other investigations did not identify a similar 
absence of TGT activity in tumor tissues[35a, 35d] or even measured an increased expression of 
TGT in cancer cell lines.[44] 
The increase of (Q-)tRNA might also be due to the production of substances, which interfere 
with queuosine formation in tumor tissues. Pteridines have been shown to inhibit TGTs and 
thus interfere with incorporation of queuine in vivo.[31b] Pteridine metabolism is modified in 
neoplastic tissues[54] and might therefore produce a TGT inhibitor in cancer cells. Parniak and 
coworkers[45] could show that treatment of murine erythroleukemia (MEL) cells with inducers 
of differentiation (e.g. DMSO) leads to an increase in tetrahydrobiopterin, a TGT inhibitor, 
and subsequently to higher levels of (Q-)tRNA. Alternatively, the uptake of queuine might be 
impaired in neoplastic tissues. For example, interferon has been shown to induce inhibition of 
queuine uptake in human fibroblast cells.[55] 
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3.2.2.2 Queuosine hypomodification and grade of malignancy 
As illustrated in Table 2 and Table 3 lack of Q is common in neoplastic tissues and cancer cell 
lines but it is not a universal feature. Whether Q-hypomodification in cancerous tissues, if 
present, is somehow related to the development or propagation of cancer still remains an 
unanswered question. Such a relation is indicated by the involvement of queuosine in the 
phosphorylation of proteins and in the increase of the activity of proto oncogenes.[36b, 56] 
Furthermore, correlations between a decreased Q-content and grade of malignancy, tumor 
differentiation, and histopathological classification (Figure 6) imply an participation of 
Q-deficiency in the neoplastic process.[40] 
 
 
Figure 6: Correlations between (Q-)tRNA levels in tumor tissues and cancer classification. 
a) Amounts of (Q-)tRNA in normal tissue and tumors grouped according to their prognostic stages A, 
B, and C (Binet classification); b) (Q-)tRNA levels in human lung cancer tissues and in the 
corresponding healthy tissues according to their different histopathological classifications; 
c) and d) Abundance of (Q-)tRNA in normal tissue and human ovarian tumors grouped according to 
their c) histopathological type and d) differentiation grade. (Q-)tRNA levels were measured by tritium 
guanine incorporation rates. WD: well differentiated, MD: moderately differentiated, PD: poorly 
differentiated. Error bars indicate standard deviations. 
 
Kersten and coworkers[38] detected similar amounts of (Q-)tRNA in lymphomas in favorable 
stages and in healthy tissues, while high grade lymphomas show higher levels of Q-deficient 
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tRNA. The amounts of (Q-)tRNA in lymphomas increased with the prognostic state of the 
disease (Binet classification, Figure 6 a). 
Similarly, in tissues of lung cancer patients the amount of (Q-)tRNA was generally increased 
in tumors compared to samples from the respective healthy tissue.[39] In addition, a significant 
correlation between the state of the tumor differentiation and the (Q-)tRNA levels in these 
tumors was found (Figure 6 b). 
Investigation of Q-deficiency in 16 malignant ovarian tumors, six myoma (benign tumors), 
and four normal myometrium (healthy tissue) revealed that the levels of (Q-)tRNA in healthy 
and in benign tumors did not differ significantly, whereas they were generally increased in 
malignant tumors.[40] Furthermore, the amounts of (Q-)tRNA correlated with the 
histopathological type of the tumor (Figure 6 c) as well as with its grade of differentiation 
(Figure 6 d). 
In all three studies the detected correlations (Figure 6) were statistically significant. In 
addition, the level of Q-deficiency was also related to the course of disease and the survival 
rate.[38-40] Patients with high (Q-)tRNA levels died within the next one to four years and 
patients with medium Q-deficiency tumors suffered from recurrence of the disease. In contrast 
patients with the lowest (Q-)tRNA did not show any signs of recurrence until publication of 
the studies. 
A similar correlation of (Q-)tRNA levels with grades of differentiation was measured in 
human K562 erythroleukemia cells.[46] Differentiation of the K562 cells was induced by 
different reagents (araC, sodium butyrate, hemin, and azaC). In parallel with the increase of 
differentiation the levels of (Q-)tRNAs declined. These results are in accord with the 
detection of an increase of (Q+)tRNA with differentiation in murine erythroleukemia cells.[47] 
As outlined above, there are also contradictory results showing a decrease of (Q+)tRNA with 
differentiation initiated by DMSO treatment of leukemia cells.[45, 48] 
As Q-deficiency is expected to occur early during carcinogenesis, detection of 
Q-hypomodification in neoplastic tissues is a very promising candidate for straight-forward 
malignancy grading and prediction of the course of disease.[9b, 39-40] 
3.2.3 Urinary nucleosides as tumor markers 
Collection of information on the stage and progression of cancer as early as possible is highly 
important for an effective treatment. To allow this, tumor markers are necessary, which 
enable screenings and diagnosis at an very early stage ideally using noninvasive technologies. 
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As outlined above changes in the tRNA modification content occur early in carcinogenesis 
and are related to malignancy grading. These features make modified nucleosides outstanding 
tumor marker candidates. Urine samples are favored as they are easily available. 
As early as 1960 modified nucleoside levels in the urine of cancer patients have been 
investigated and were shown to differ from levels of healthy volunteers.[57] Since that time 
numerous studies have shown an increased amount of modified nucleosides in urine samples 
from cancer patients in comparison to reference samples. Many of these investigations 
achieved an excellent diagnostic accuracy and showed the applicability of modified 
nucleosides as tumor markers.[58] These studies have also been summarized in several 
reviews.[59] Table 4 compiles investigations, which use modification levels as tumor markers 
and simultaneously correlate them with course and stage of disease. Although a few modified 
nucleosides, which do not originate from tRNA, were also studied in literature, here only 
modified tRNA nucleosides are discussed, because they are the central theme of this thesis. 
 
Cancer type Levels Correlations Ref.
Stable Increased Stage of tumor Disease 
activity 
Course of 
disease 
Colon cancer m1A , ac4C, m1I, m2G, m22G
, ac4C, m1I, 
m2G, m22G
- - [60] 
Myelogenous 
leukemia - m
1I, , m22G m1I, , m22G m1I, , m22G m1I, , m22G [61] 
ALL m1A m
1I, m22G, , 
m1G - m
1I, m22G m1I, m22G [62] 
Lymphomas -     [63] 
Lymphomas, 
leukemias - m
1A,  m1A,  - m1A,  [64] 
Breast cancer - m
2
2G, m2G, 
m1A, m1I, m1G - 
m22G, m2G, 
m1A, m1I, m1G - 
[65] 
Breast cancer - t6A - t6A - [66] 
Breast cancer m7G m
5C, ac4C, m1A, 
m1I,  ac
4C,  m
1I, m5C, 
ac4C,  m
1A, m1I [67] 
Small cell lung 
cancer -   -  
[68] 
Small cell lung 
cancer - 
m1A, m1I, m2G, 
m22G, I 
- - m
1A, m1I, 
m2G, m22G, I 
[69] 
Liver cancer m5U m
1A, m1I, m1G, 
, ac4C, m2G 
m1A, m1I, m1G, 
, ac4C, m2G - - 
[70] 
Table 4: Modifications measured in urine samples of cancer patients and correlations with cancer. 
Levels: Stable or increased levels in comparison to urine samples from healthy humans. Correlations: 
Stage of tumor includes e.g. the tumor size and its differentiation state; disease activity for example 
refers to development of metastases and tumor growth rate; course of disease means the estimated 
or actual development of the disease. ALL: acute lymphoblastic leukemia. 
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Trewyn and coworkers[62a] showed in a study with 23 adults with acute lymphoblastic 
leukemia (ALL) or acute myeloid leukemia (AML) that all patients excreted increased 
amounts of m1I, m22G, , and m1G in comparison to the normal population. Based on these 
levels patients with ALL can also be distinguished from patients with AML, because the 
obtained values for m1I and m22G are significantly different. Furthermore, patients with ALL 
at initial diagnosis or in relapse excreted significantly more m1I (2 times) and m22G 
(1.5 times) than patients in remission. Therefore, measurement of the excretion levels of m1I 
and m22G allows to draw conclusions about disease activity. Interestingly, in a longitudinal 
study with one male ALL patient the initial values, which were obtained right after diagnosis, 
were significantly increased. In the course of treatment the modified nucleoside excretion 
declined with remission. When the patient relapsed after 17 months, he showed significantly 
elevated excretion levels similar to the ones measured initially. 
Investigation of several modified nucleosides in parallel allows even more advanced 
conclusions about cancer progression in humans. Different combinations of the obtained data 
for m5C, ac4C, m1A, m1I, and  levels of breast cancer patients correlated with different 
characteristics of the disease.[67] The excreted amounts of m1A and m1I were significantly 
increased in patients with a unfavorable prognosis and those who died within five years after 
sample collection. Patients with metastasis in bone marrow exhibited elevated levels of m1I, 
m5C, ac4C, and  excretion. Tumor size on the other hand correlated with the measured 
amounts of ac4C and . 
For leukemia,[61] breast cancer,[66] and nasopharyngeal cancer[71] modified nucleoside levels 
(e.g. m1I, t6A, , m1A, m1G, and m2G) were found to be superior to common tumor markers. 
When both types of markers were used in parallel an increase of the modified nucleoside 
levels was detected considerably earlier than a change in the common tumor marker. 
Measurement of modified nucleoside excretion levels allowed the prediction of a relapse for 
breast cancer patients three to six months and for leukemia patients 42 days prior to its 
detection with standard tumor markers. 
Kammerer and coworkers[72] analyzed the levels of 31 modified nucleosides in 212 urine 
samples (113 from breast cancer patients and 99 from healthy volunteers). Computational 
evaluation of the obtained data allowed breast cancer diagnosis with 88 % sensitivity and 
90 % specificity. This is a considerable improvement compared to currently applied tumor 
markers, like the CA15-3 tumor marker, whose specificity is roughly the same but whose 
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sensitivity is significantly lower (50 %). Similar results were obtained, when the urine of 
bladder cancer patients (100 % sensitivity, 90 % specificity) was analyzed.[73] 
 
3.3 Modified nucleosides in immunodeficiency diseases 
3.3.1 Modified nucleoside levels in urine as biomarkers for AIDS 
Modified nucleoside levels in urine have also been studied for a number of other diseases. For 
hepatitis, cirrhosis, acute pancreatitis, rheumatoid arthritis, and others modified nucleoside 
excretion levels did not differ significantly from those in reference samples, whereas patients 
with acute hepatitis, gout, and psoriasis show abnormal levels.[74] Similarly, bacterial 
infections lead to an increased excretion of modified nucleosides.[61-62] Generally, the 
differences are less common and reproducible across patients than those found for cancer. 
Only for the important immunodeficiency diseases acquired immune deficiency syndrome 
(AIDS) and severe combined immunodeficiency (SCID) significant and reliable alterations 
have been detected.[59d] Children with adenosine deaminase-SCID were found to excrete 
elevated levels of the methylated adenosine derivatives m1A, m6A, Am, and m6Am.[75] 
Similarly, patients with purine nucleoside phosphorylase-SCID exhibit elevated levels of I 
and G excretion, which follow the course of disease.[76] 
Excretion of the nucleosides m1I, m2G, and ac4C was elevated in adult male homosexuals 
with human immunodeficiency virus type 1 (HIV-1) antibodies compared to healthy males. 
Individuals with these antibodies have a 5-19 % likelihood to develop AIDS within the next 
five years. Measurement of modified nucleoside levels in urine might therefore help to 
identify individuals with a high risk of developing AIDS.[77] Individually elevated excretion 
levels were also measured for patients with lymphadenopathy syndrome, AIDS related 
complex and AIDS allowing approximation of the stage of disease.[77a] These studies again 
show that the parallel investigation of modified nucleosides gives reliable and meaningful 
data, which can be used as markers for high-impact diseases. 
3.3.2 Fully modified tRNALys,3 is the primer for HIV-1 reverse transcriptase 
Apart from being a potential biomarker for AIDS modified nucleosides also play a key role in 
the initial stages of HIV replication. HIV-1 recruits tRNALys,3 from its host during packaging, 
because it is the primer for reverse transcription of HIV-1 RNA in DNA. tRNALys,3 anneals to 
the primer binding sequence (PBS) of the viral RNA and, starting from the tRNALys,3 primer, 
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the reverse transcriptase copies the viral RNA into a single stranded DNA. Subsequently, the 
viral RNA is removed and a second primer binds to the DNA, from which the complementary 
DNA strand is produced. This way the viral RNA is faithfully translated into double stranded 
DNA, which can be introduced in the host DNA.[78] 
Binding of tRNALys,3 to the viral RNA occurs at different sequences (Figure 7 a). The actual 
primer is the 3'-end of the tRNA (red, nucleosides 59-76), which binds to the PBS region. The 
second sequence binding to the RNA of the virus is the 5'-end of the TC stem-loop (blue, 
nucleosides 48-55). It interacts with the primer activation sequence (PAS) in the viral nucleic 
acid. The HIV RNA also contains a loop region called HIV loop I, which pairs with the main 
part of the anticodon stem-loop (green, nucleosides 32-42). This duplex has been studies by 
NMR and is depicted in Figure 7 b.[79] 
 
 
Figure 7: tRNALys,3 and a duplex of the tRNALys,3 HIV-1 loop I complement and HIV-1 loop I. 
a) Color-coded crystal structure of human tRNALys,3 with the distinct regions binding to the viral 
RNA.[80] red: complement to the viral primer binding sequence (PBS), blue: primer activation sequence 
(PAS) complement, green: HIV-1 loop I complement. b) Color-coded NMR structure of the synthetic 
tRNALys,3 HIV-1 loop I complement (green) and HIV-1 loop I (gray) duplex.[79] The sequences of these 
strands are depicted at the right-hand side. Modification s2U was incorporated instead of the naturally 
occurring mcm5s2U. The natural modification ms2t6A is replaced by unmodified adenosine. Modified 
nucleosides s2U and  are indicated in brown. 
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The modified nucleosides in the anticodon stem-loop region mcm5s2U, ms2t6A, and  are 
important for the binding between tRNALys,3 and the viral RNA. Unmodified tRNALys,3 has 
almost no priming efficiency.[81] Modifications mcm5s2U and  enhance the base stacking, 
which results in an increased stability of the RNA duplex between tRNALys,3 and viral RNA. 
The sulfur moiety of mcm5s2U additionally decreases the flexibility of the free tRNA loop, 
further enhancing duplex formation.[79, 82] Davis and coworkers measured only a weakly 
stabilizing effect of the mcm5 residue, whereas the methylthio substituent of ms2t6A 
significantly contributes to the stabilization of the binding between tRNALys,3 and the RNA of 
the virus. The threonyl residue is suspected to destabilize the tRNA loop and thus to promote 
formation of an open tRNA conformation, which allows binding to the viral RNA.[83]  
The modified nucleoside m1A in the TC loop ensures efficacy and fidelity of the 
transcription.[78] The functions of the other modifications in tRNALys,3 have not been 
investigated yet. 
 
3.4 Lack of modified tRNA nucleosides induces mitochondrial diseases 
The human mitochondrial (mt) genome contains 13 proteins, two ribosomal RNAs, and 22 
tRNAs.[84] Mitochondrial genetics differs considerably from mendelian genetics. 
Mitochondria are polyploidy and they organize their mtDNAs in stable protein-DNA 
complexes called nucleoids, which may be exchanged between different mitochondria. 
Furthermore, they are only inherited via the maternal linage. Mitochondria in a cell constantly 
move, fuse, and divide. Turnover of mtDNA does not coincide with the cell cycle, though a 
connection has been suggested.[85] 
The mutation rate in mtDNA is at least 10-fold higher than in nuclear DNA due to increased 
oxidative damage. This is caused by the proximity of the mtDNA to the inner mitochondrial 
membrane, where reactive oxygen species are produced during respiration, and by the lack of 
histones. Out of the 250 mutations known in mtDNA about 150 are correlated with diseases. 
The mutations are summarized in the MitoMAP database.[86] One in 10,000 people have a 
clinically manifested mtDNA disease and one in 6,000 people are at risk to develop one.[85] 
From the pathogenic mutations two-thirds are present in tRNA genes, although only a small 
part (10 %) of the mtDNA encodes tRNAs.[87] This clearly shows the importance of integrity 
of the mitochondrial tRNAs for the fitness of mitochondria. 
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Typical diseases caused by mtDNA point mutations are myoclonus epilepsy associated with 
ragged-red fibers (MERRF) and mitochondrial encephalomyopathies, encephalopathy, lactic 
acidosis, and stroke-like episodes (MELAS). An A to G transition occurs at position 8344 of 
tRNALys in most MERRF patients.[88] 80 % of the MELAS patients have a point mutation in 
position 3243 of the gene for tRNALeu exchanging an A for a G. In addition, 10 % of these 
patients exhibit a T to C mutation in position 3271 of tRNALys.[89] 
Watanabe and coworkers[90] could show, that mitochondrial tRNALys and tRNALeu contain the 
two unusual modified nucleosides m5U and m5s2U, respectively,[8] while MELAS and 
MERRF mutant cells do not feature these modifications(Figure 8).[91] Probably, the mutated 
tRNAs are no longer recognized by the modifying enzymes.[90b] 
 
 
Figure 8: Modified nucleosides m5U and m5s2U present in mitochondrial tRNALys and tRNALeu, 
respectively. 
Alterations from the canonical nucleoside uridine are indicated in red. 
 
Fully m5U-modified tRNALys decodes the codons AAA and AAG. tRNALys isolated from 
MERFF-mutant cells, which lacks m5U, showed almost no 3H-lysine incorporation in in 
vitro translation assays for both codons and a complete loss of protein synthesis activity.[92] In 
vivo MERRF-mutant cybrid cells show a severely reduced mitochondrial protein synthesis.[93] 
Therefore, one can conclude, that the MERFF phenotype is caused by a deficiency of m5U in 
mitochondrial tRNALys. 
Similarly, lack of m5s2U in tRNALeu of MELAS patients results in a severely reduced 
translation of the codon UUG. The second leucine codon UUA is still fully translated.[94] 
Nevertheless, lack of m5s2U causes a severe phenotype, which is linked to a reduced 
expression of a respiratory chain complex I protein (ND6) in MELAS patients.[95] As this 
protein contains a large number of UUG codons, its expression is strongly impaired, when 
tRNALeu lacks m5s2U.[90b] In addition, Florentz and coworkers[96] measured a decreased level 
of m2G in tRNALeu isolated from the cell line 43B, which contains the MELAS specific 
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mtDNA mutation. It has been suggested that this deficiency is related to the expression of the 
MELAS phenotype by altering the binding of the tRNA to its partners during translation. 
An impact of the pathogenic T7512C and G7497A point mutations in tRNASer on the 
decoration of this tRNA with modifications has been suggested as a reason for the reduction 
of its level in osteosarcoma cybrid cells to only 10 % of its amount in reference cells.[97] In 
two other studies the lack of activity of two tRNA modifying enzymes, TRMU and PUS1, 
due to mutations of their corresponding genes has been shown to lead to aminoglycoside-
induced and nonsyndromic deafness[98] and mitochondrial myopathy and sideroblastic anemia 
(MLASA),[99] respectively. 
 
3.5 Summary 
The amounts of modified nucleosides in tRNAs, which were isolated from neoplastic tissues 
and cancer cell lines often differ to reference tRNAs collected from healthy tissues. 
Furthermore, correlations between the amount of modified tRNA nucleosides in tumors and 
their grade of malignancy and the course of disease were established. 
The abundances of modified nucleosides in urine can be applied as tumor markers with 
exceptional sensitivity and specificity outranging tumor markers, which are currently applied. 
Moreover, modified nucleoside excretion levels of AIDS patients correlated with the stage of 
their disease. 
The mitochondrial diseases MERFF and MELAS have been shown to originate from a lack of 
the modified nucleosides m5s2U and m5U in mitochondrial tRNA. 
Taken together, these investigations clearly demonstrate that the detailed knowledge about 
modified nucleoside levels in tissues will provide penetrating insights into the origin of 
diseases like cancer, AIDS, and mitochondrial dysfunctions. Furthermore, they will help to 
establish modified nucleosides as improved biomarkers for cancer and AIDS. This can only 
be achieved, if a large number of modified nucleosides can be studied in parallel with 
outstanding accuracy. 
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4 Aims of the project 
 
In living organisms RNAs have many functions. They are able to perform catalysis,[100] serve 
as guide structure for proteins,[101] are involved in protein synthesis (rRNA and tRNA) and 
cancer development,[102] and regulate gene expression,[103] proliferation,[102, 103c] and 
apoptosis.[104] The vast complexity of functions either performed or guided by the RNA led us 
to speculate that their chemical diversity may be of more fundamental importance than 
recognized today.  
As outlined in the introduction, most likely, a thorough understanding of the biosyntheses and 
functions of modified nucleosides would tremendously advance medicinal analytics and our 
understanding of important diseases like cancer and AIDS, because the decoration of tRNAs 
with modified nucleosides differs significantly between neoplastic and healthy tissues.  
Omics-research has led to great advances in biochemistry in recent years. Its central concept 
is the study of cellular components not isolated but in the context of whole biological systems 
and as a collective rather than individually.[105] For modified tRNA nucleosides the contexts 
are the investigated cells or tissues and the collective is the isolated bulk tRNA. 
 
 
Figure 9: Sketch of the quantification method for modified tRNA nucleosides aspired to establish 
during this thesis work. 
 
Therefore, the aim of this thesis was the establishment and evaluation of a method that allows 
the parallel quantification of in principle all modified nucleosides from tRNA with high 
accuracy and sensitivity. For this purpose the workflow depicted in Figure 9 was envisioned. 
After isolation and purification of bulk tRNA from the cells of interest its enzymatic digestion 
will yield a mixture of modified and unmodified nucleosides. To this solution isotopically 
labeled derivatives of the nucleosides of interest will be added. This spiked mixture will then 
be analyzed by HPLC-MS. 
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To establish this procedure several intermediate goals have to be reached: 
- Establishment of a protocol for the isolation of bulk tRNA from cells. 
- Creation of a method for its purification. 
- Synthesis of the natural and heavy atom labeled modified nucleosides of interest. 
- Creation of an HPLC approach for the separation of modified nucleosides. 
- Establishment of a mass spectrometric method for their analysis. 
This quantification method will be established and evaluated, by the measurement of 
modified nucleoside levels in E. coli, cancer cell lines, and healthy liver tissue. 
With a reliable and sensitive method in hands modified nucleosides in E. coli exposed to 
different external stimulations will be quantified to determine their contribution to cellular 
stress response.  
The most thorough investigation was envisioned for healthy pork tissues. These data will 
probably lead to novel insights in the functions of modified nucleosides in mammals. 
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5 Quantification of modified tRNA nucleosides 
5.1 Establishment of a stable isotope dilution method for quantification of 
tRNA modifications 
Quantitative studies of modified RNA nucleosides have already been achieved in the 60s and 
70s using HPLC/UV approaches.[59a, 106] Other methods utilized for the quantification of 
modified nucleosides are tritium post-labeling,[107] 14C-aminoacylation,[108] 
3H-aminoacylation,[109] and 2D-chromatography.[25d] Since these methods either have too high 
labor costs, do not provide the necessary sensitivity and accuracy, or do not allow non-
invasive quantification, an HPLC-MS approach was selected. Its feasibility for the 
quantification of two uridine derivatives has been shown before.[110]  
Omics research has evolved from a qualitative method, which facilitates comparison of data 
collected during a series of experiments, to a quantitative technique yielding absolute, 
generally comparable values. Analogous to proteomics, where the use of isotopically labeled 
media (e.g. SILAC) allows quantification,[111] recently, isotope-labeled HPLC-MS was used 
in metabolomics for a parallel determination of more than 100 absolute intracellular 
metabolite concentrations.[112] Thus, in this thesis work a stable isotope dilution HPLC-MS 
approach was selected as an ideal combination of high accuracy, outstanding sensitivity, and 
minimal work load once the method is established.  
 
The general approach is depicted in Figure 10 and consists of five main steps: 
1. tRNA isolation 
2. tRNA purification  
3. Enzymatic tRNA digestion 
4. Spiking with stable isotope labeled nucleosides 
5. Analysis by HPLC-ESI-MS 
A detailed description of this procedure is given in chapter 10.4.2. 
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Figure 10: Schematic outline of the quantification method for modified tRNA nucleosides. 
1. tRNA isolation: phenol extraction and precipitation of long chain nucleic acids; 2. tRNA purification: 
PD10 chromatography, anion exchange chromatography; 3. Enzymatic tRNA digestion: conversion of 
bulk tRNA mixture to nucleosides; 4. Spiking: addition of isotope labeled nucleosides; black symbols 
represent natural nucleosides; red symbols indicate added isotope labeled nucleosides; 5. HPLC-ESI-
MS analysis: chromatographic separation and mass spectrometric analysis of the nucleoside mixture. 
 
5.1.1 tRNA isolation 
A thorough literature search showed that all methods for the isolation of tRNA from bacteria 
are similar. They use a phenol extraction and a precipitation step. A detailed discussion of 
tRNA extraction has been published,[106b] which was chosen as a starting point for 
establishing a tRNA extraction protocol. In order to disrupt the cell walls and to separate the 
nucleic acids from most other cell components, e.g. proteins, the first step is a phenol 
extraction. Nucleic acids are retained in the aqueous layer, while other cell material is mostly 
found in the phenol layer. This is followed by extraction steps with phenol, water, and 
chloroform to ensure minimal residual phenol and cell compounds in the aqueous layer and 
minimal remaining nucleic acids in the phenol layer.  
Mature tRNAs have a length between 73 and 94 nucleotides and are therefore considerably 
shorter than other cellular nucleic acids, e.g. rRNA, mRNA, and DNA. This difference allows 
separation of tRNA from all other nucleic acids via a precipitation step. 2 M LiCl was found 
to be an ideal salt concentration to precipitate long nucleic acids but not shorter ones like 
tRNA.[106b] After centrifugation crude tRNA in the supernatant is isolated from most other 
nucleic acids in the pellet. 
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The method described here has been used for the isolation of tRNA not only from bacterial 
cells but also from yeast, plant, cancer, and pork tissue cells. For these only slight 
modifications of the procedure were necessary. Therefore, a scalable, straight forward method 
for the extraction of bulk tRNA from almost all kinds of cells has been established. 
5.1.2 tRNA purification 
The obtained, crude tRNA was subjected to purification by anion exchange chromatography. 
The crude mixture is applied to a column with a stationary phase containing positively 
charged residues. The negatively charged nucleic acids bind to the stationary phase and are 
therefore retained. Uncharged and positively charged material is washed from the column 
with a buffer containing a low salt concentration. Once the undesired material is removed the 
nucleic acids are eluted from the column with a buffer system containing an increased salt 
concentration. The salt concentration needed to break the binding of the nucleic acids to the 
stationary phase depends on the extent of their negative charge and is therefore directly 
related to their length. Thus, by gradually increasing the salt concentration in the eluant 
nucleic acids of different lengths can be separated. Remaining mRNA and most rRNAs are 
therefore efficiently removed. In addition, the obtained chromatogram allows to draw 
conclusions about the purity of the tRNA. A representative anion exchange chromatogram is 
shown in Figure 11.  
 
 
Figure 11: Representative anion exchange chromatogram. 
The UV-chromatograms at 280 nm and 254 nm are shown as blue and red lines, respectively. On the 
y-axis the UV-absorption is plotted in mAU. The green line represents the salt concentration of the 
elution buffer B in % used during the chromatography with the highest value being 1 M NaCl. 
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A certain class of rRNAs, the so-called 5 S rRNA, has 120 nucleotides and can therefore not 
be removed by size-dependent methods. Nevertheless, 5 S rRNA does not contain any 
modified nucleosides and is present only in very low amounts. Hence, it does not influence 
the results. 
Purification of tRNA as described above was successfully used for tRNA isolated from 
bacterial, yeast, plant, and cancer cells. When crude tRNA from tissue samples was directly 
applied to the anion exchange column it did not bind to the column, because the salt 
concentration of the sample itself was too high. For the necessary desalting of the sample a 
size exclusion chromatography step was introduced prior to anion exchange chromatography. 
A standard desalting column for biomolecules with a cross-linked dextran gel (Sephadex), 
namely a PD10 column, was used.  
The purity of the obtained bulk tRNA was analyzed by gel electrophoresis either using 1 % 
TBE agarose gels or NaOAc gels with 7.5 % acrylamide. A representative, randomly picked 
TBE agarose gel is shown in Figure 12. Lanes b – j contain purified tRNA, while lane k 
shows crude RNA. Comparison of lanes b – j with lane k clearly shows that tRNA, which was 
purified with the method established in the course of this thesis, is highly enriched and 
purified. The slight bands visible in the middle of the gel in lanes b, c, e, and f are remaining 
rRNAs with an estimated content of less than one percent of the sample. 
 
 
Figure 12: Gel electrophoresis (1 % TBE agarose) of tRNA samples from pork tissue. 
High sample loadings (~5000 ng) were used to visualize low amounts of contamination. a) marker; 
b) cerebellum tRNA sample 1; c) cerebellum tRNA sample 2; d) cerebrum tRNA sample 1; 
e) cerebellum tRNA sample 3; f) spleen tRNA sample 1; g) spleen tRNA sample 2; h) thyroid gland 
tRNA sample 1; j) thyroid gland tRNA sample 2; k) crude RNA extract sample obtained from 
V. Welzmiller.  
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5.1.3 Enzymatic tRNA digestion 
With pure tRNA in hands the enzymatic digestion of these polynucleotides to single 
nucleosides was optimized. As starting points the standard method established in the group 
for digestion of DNA oligonucleotides[113] and methods from literature for the digestion of 
RNA were chosen.[106f, 114] A thorough screening of digestion conditions led to the following 
procedure outlined in chapter 10.4.2.8. In brief a tRNA sample of 12 g was treated for 3 h 
with nuclease S1 and for additional 3 h with antarctic phosphatase and snake venom 
phosphodiesterase I. Absence of nucleotides and dinucleotides proved complete digestion of 
the tRNA samples by mass-spectrometry.[114] 
5.1.4 Spiking with stable isotope labeled standards 
Standard analysis by mass spectrometry allows to draw conclusions about the presence of the 
analytes but it does not provide quantitative information on these. The number of detected 
analytes depends on a large set of parameters not exactly definable and most importantly not 
reproducible between experiments. To turn mass spectrometry quantitative an internal 
standard is needed for every analyte, which has the same behavior in the mass spectrometer as 
the analyte. Therefore, the physical properties of the standard and the analyte have to match as 
closely as possible. In addition, standard and analyte have to reach the mass spectrometer at 
the same time to be analyzed under the same conditions. But they still have to be 
distinguishable. For HPLC-MS quantification this means that they have to have the same 
retention time to reach the spectrometer simultaneously and a different mass to be specifiable. 
These prerequisites are best met by isotopically labeled derivatives of the analyte. Therefore, 
heavy atom labeled derivatives of the modified tRNA nucleosides in question had to be 
synthesized (chapter 7.1). Addition of these labeled standards to the nucleoside mixture 
obtained from tRNA digestion enabled quantification of the natural tRNA modifications by 
HPLC-MS.  
After enzymatic digestion of the tRNA sample a mixture of different modified and canonical 
nucleosides was obtained. To allow quantification of the natural tRNA modifications 
(analytes) in this mixture by HPLC-MS the corresponding heavy atom labeled derivatives 
(standards) were added. To exclude systematic errors care was taken to add different amounts 
of the isotopically labeled standard to the nucleoside mixture when repeated measurements of 
the same bulk tRNA was performed.  
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Figure 13: Compilation of the nucleosides and their isotopically labeled derivatives prepared for mass 
spectrometric quantification in the course of this thesis work. 
 
During the course of this thesis nine modified nucleosides and their isotopically labeled 
derivatives were prepared (Figure 13). Their syntheses are discussed in chapter 7. All but the 
cytidine derivatives and ms2A have been used for HPLC-MS analysis until now. Other 
nucleosides used for quantification experiments were prepared by D. Globisch, P. Thumbs, 
I. Thoma, and A. Hienzsch. All labeled nucleosides utilized for the study of modified 
nucleosides are presented in Figure 14 with their respective positions in tRNA. Modifications 
adjacent to the anticodon loop are m6A, t6A, m6t6A, OHyW, i6A, m1G, ms2i6A, yW, and m2A. 
Q is found in the anticodon loop, while m1A, Am, m1G, m2G, and m22G are present in other 
positions. 
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Figure 14: Modified nucleosides investigated during this thesis and their positions in tRNA. 
The respective positions are indicated in a schematic tRNA. The isotope labels are marked in color.   
D = Deuterium, * = 13C or * = 15N. 
 
5.1.5 Analysis by HPLC-ESI-MS 
5.1.5.1 Calibration curves 
For the calculation of the exact analyte levels from the mass spectrometric data calibration 
curve equations are necessary. Their determination was executed as follows: Solutions of the 
labeled and the unlabeled nucleoside with defined concentration were prepared. In this way 
defined amounts of substance can easily be handled. Mass spectrometric data were collected 
for five different concentration ratios of the labeled and corresponding unlabeled nucleoside 
(Figure 15). For each concentration ratio an average value of three independent measurements 
was determined using three mixtures of the labeled nucleoside solution with one out of three 
solutions with different concentrations of the corresponding unlabeled nucleosides. By 
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plotting the weight ratios against the experimentally determined ion count area ratios the 
calibration curve and its corresponding calibration equation (Figure 15) were obtained. 
 
 
Figure 15: Representative example of a calibration curve and its equation. 
 
These are necessary, because the reagents used to incorporate heavy atoms in the standard are 
never 100 % labeled themselves. Commercially available LiAlD4 used here for example 
contains 98 % deuterium. Therefore, every standard solution also comprises a small amount 
of unlabeled material. In addition, measurement of three different concentrations of the 
unlabeled nucleoside against one concentration of the labeled nucleoside averages weighing 
errors. The use of calibration curves also compensates for systematic differences in the 
processing of labeled and unlabeled nucleosides, e.g. in the mass spectrometer. This is 
emphasized by Figure 15, where the slope is substantially higher than one. Calculation of the 
modification level without normalization using the calibration curve equation would thus 
result in a significant error. The calibration curves and equations for all other modifications 
studied in this work are compiled in chapter 10.6.2. 
5.1.5.2 HPLC method 
Advantageously, HPLC-MS quantification utilizes two levels of separation. First, the analytes 
are separated due to their different retention times during HPL chromatography (Figure 16) 
and, second, they are differentiated by their individual masses by mass spectrometry (Figure 
17 a). On the other hand, molecules with the same mass and the same retention time are not 
quantifiable individually. For HPLC-MS quantification of modified tRNA nucleosides all 
modifications with the same mass have to reach the mass spectrometer at different times. 
Otherwise the mass signals overlap and an individual quantification of the overlapping 
nucleosides becomes impossible. Unfortunately, modified nucleosides with the same mass 
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tend to have similar retention times, because they are structurally related. For example 
methyladenosines m2A and m6A show this effect (Figure 17 b). 
In addition, modified nucleosides have to be chromatographically separated from canonical 
nucleosides. The detector used here, a Thermo Finnigan LTQ Orbitrap XL, analyzes the ions 
reaching it in a two step process. First, a certain number of ions is collected. Then these 
accumulated ions are measured. The canonical nucleosides are present in the sample in high 
excess compared to the modified ones. Therefore, when a canonical nucleoside reaches the 
analyzer, it will be flooded by the ions of this nucleoside, which in turn leads to suppression 
of the ions of interest. The strength of suppression is proportional to the amount of the 
abundant nucleoside reaching the detector. Labeled and unlabeled nucleoside do not reach the 
mass spectrometer simultaneously due to a small difference of their retention times (e.g. 
0.2 min for m2A and d3-m2A, Figure 17). Therefore, their amounts, which reach the detector 
at the same time as the canonical nucleoside, are not identical. This leads to different ion 
suppressions of the nucleosides of interest and frustrates their reliable quantification. 
 
 
Figure 16: Representative HPL chromatograms and gradients. 
HPL chromatogram and gradient of tRNA nucleoside mixtures from a) E. coli; b) pork liver 
( = 260 nm). The HPLC gradient is depicted in red as percentage of buffer D. 
 
In order to circumvent these problems, a potent HPL chromatography method had to be 
established. There are numerous HPLC conditions known in literature for the separation and 
analysis of modified nucleosides,[59a, 106, 110] which either do not reach a sufficient level of 
separation or are not compatible with the equipment on site. For these reasons the HPLC 
method used in the Carell group for analysis of DNA digests was chosen as a starting 
point.[113] Additionally, the flow used for HPL chromatography (0.15 mL/min) lay within the 
range of the injection volume of the mass spectrometer and could therefore be adopted 
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without alterations and the buffer system was suitable for mass spectrometry (buffer C: 2 mM 
ammonium formiate, pH 5.5; buffer D: 2 mM ammonium formiate/MeCN 20/80, pH 5.5). 
With the general HPLC conditions in place a screening of various gradients for maximum 
separation of modified nucleosides was conducted resulting in similar gradients for the 
various tRNA nucleoside mixtures from the cells investigated (Figure 16). In addition, 
coinjection studies were conducted to determine the retention times of the nucleosides in 
question. Detailed HPLC conditions are described in chapter 10.6.1. To our knowledge, our 
HPLC method for the first time allows separation of m2A and m6A making these nucleosides 
quantifiable (Figure 17 b). 
Typical UV traces of the obtained E. coli and pork liver modification pattern are depicted in 
Figure 16 a and Figure 16 b, respectively. Next to the dominant signals for the canonical RNA 
nucleosides, the various modified nucleosides either appear as small signals or are hidden in 
the base line. Unambiguous assignment and quantification of the modifications is therefore 
only possible by MS analysis. 
 
 
Figure 17: Mass spectrometric measurements of m2A, m6A, d3-m2A, and d3-m6A. 
a) Relevant high resolution mass spectrometric data for unlabeled and labeled m2A. b) Positive ion 
currents of the protonated nucleosides m2A and m6A and the corresponding synthetic isotope labeled 
derivatives. 
 
5.1.5.3 Mass spectrometric analysis 
After high resolution separation of the modified nucleosides by the optimized HPLC 
conditions they were quantified by mass spectrometry as described below using the example 
of m2A and d3-m2A. The nucleoside mixture obtained from the digest is subjected to HPLC-
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MS. The nucleosides m2A and d3-m2A were separated from all other nucleosides. Due to their 
mass difference they appear in the mass spectra as two separate signals (Figure 17 a). After 
completion of the whole measurement the obtained data were analyzed with “Xcalibur”. The 
measurement of high resolution mass spectrometry employed here allows isolation of those 
ions produced by methylated adenosines. By setting a defined mass range (for 
methyladenosine: 282.1187 – 282.1207; for d3-methyladenosine: 285.1372 - 285.1392) the 
ion current of all methyladenosines and their labeled standards were extracted (Figure 16 b). 
Integration of the areas under the mass peaks yielded the ratio of m2A and d3-m2A ions. 
Substitution of this ratio into the corresponding calibration curve (chapters 5.1.5.1 and 10.6.2) 
gave the molar ratio of m2A and d3-m2A present in the measured sample. This ratio was 
charged against the known amount of d3-m2A added to the sample prior to the measurement. 
This way an exact determination of the amount of m2A in the sample was achieved. 
It is important to not inject the first 3 minutes of an HPLC run into the mass spectrometer. All 
salts from the sample do not adhere to the reverse phase material of the column and therefore 
elute with the void volume. Injection of these in the mass spectrometer would clog its 
entrance inevitably leading to adulterated results. 
As a control for the reliability and reproducibility of our approach intra- and inter-assay tests 
were performed for nucleosides m1A, i6A, ms2i6A, and m1G. During the intra-assay tests the 
determined values of labeled to unlabeled nucleosides of a sample after enzymatic digestion 
showed excellent reproducibility for each nucleoside (N=5; 2.5 % for m1A, 0.4 % for i6A, 
0.7 % for ms2i6A and 2.6 % for m1G). Inter-assay tests gave good area ratio reproducibility on 
six subsequent days (N=6; of 6.3 % for m1A, 1.0 % for i6A, 1.8 % for ms2i6A and 4.3 % for 
m1G). These tests attest the outstanding accuracy of the HPLC-MS quantification. The 
determined integrals for each labeled or unlabeled nucleoside not using the standards resulted 
in an average standard deviation of 34.5 % and showed insufficient reproducibility. 
Therefore, usage of the labeled nucleosides as standard is essential. No memory effect was 
observed during blank LC/MS experiments performed after several measurements of a sample 
excluding contamination by carry-over. Tuning of the spectrometer was performed with 
uridine. Further detailed description of the optimization of the digest, HPLC, and MS method 
will be discussed by D. Globisch in an upcoming Ph.D. thesis. 
In summary, in this thesis work a stable isotope based method was established (Figure 10), 
that allows efficient, direct, and parallel quantification of theoretically all tRNA modifications 
from any cell or tissue with extremely high sensitivity. 
Chapter 5 Quantification of modified tRNA nucleosides 
32 
5.2 Initial measurements of modified tRNA nucleosides in E. coli, HCT-116, 
HeLa, and pork liver 
After establishment of the general method for quantification of modified tRNA nucleosides 
the applicability, accuracy, and sensitivity of our approach had to be demonstrated. Thus, 
tRNA modifications and cells of substantial biochemical interest were selected. As 
representative tRNA modifications m6A, m2A, Am, t6A, i6A, and ms2i6A were chosen. These 
nucleosides are known to be mostly present directly 3'-adjacent to the anticodon[4, 115] (Figure 
14) and therefore likely to be directly involved in the decoding process.[116] While m6A, t6A, 
and i6A are present in eukaryotes and prokaryotes, m2A is found only in bacteria and Am only 
in eukaryotes.[4, 59a, 115, 117] These nucleosides are therefore ideal to verify the applicability of 
our method. Simultaneously, they are likely to provide initial insights concerning the 
functions of tRNA modifications adjacent to the anticodon. Moreover, the nucleoside ms2i6A 
is of particular interest, because it is present only in prokaryotes and in mitochondrial 
tRNAs.[4, 115] Its study may lead to insights into the mitochondrial tRNA modification levels. 
In addition, it is a good indicator for the sensitivity of our method, because mitochondrial 
tRNAs are only a minor constituent of the cellular tRNA, which is mainly composed of 
cytosolic tRNAs. 
E. coli and pork were chosen as common representatives of prokaryotes and eukaryotes, 
respectively. Pork tissues are known to be very similar to human ones. In addition, cancer cell 
lines were selected for the initial screening, because literature indicates that tumor cells 
possess a significantly altered tRNA modification pattern compared to normal cells.[9b, 72a, 90b] 
Such a study will lead to a better characterization of tumor cells and may enable deeper 
insight in the metabolism of tumor cells.[72a] 
 
Organism Am t6A m2A m6A i6A ms2i6A 
n/pmol 
E. coli - 63.0  ±2.4 121  ±3.4 29.3  ±0.5 5.2  ±0.1 55.6  ±3.2 
pork liver 9.00  ±1.5 97.1  ±6.5 - 28.6  ±2.1 18.1  ±1.7 1.50  ±0.1 
HCT-116 7.00  ±0.4 130  ±6.0 - 22.7  ±0.4 25.3  ±2.5 - 
HeLa 11.3  ±4.4 136  ±2.7 - 46.0  ±4.0 15.6  ±0.8 - 
Table 5: Summary of the modified tRNA nucleoside levels from E. coli, pork liver, HCT-116, and HeLa 
cells. 
Average values with standard deviations determined from two different preparations. For each 
experiment three independent digests and measurements were performed. 
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E. coli cells were harvested during exponential growth representing standard laboratory 
experimental conditions (chapter 10.4.1.1). Liver was chosen, because it is the most 
investigated tissue, easily manageable, available, and homogeneous (chapter 10.4.2.1). In 
addition, two epithelial cancer cell lines from different tissues HCT-116 (colonic epithelial 
cell line) and HeLa (cervical epithelial cell line) were investigated. 
The tRNA modification levels in E. coli, pork liver, HCT-116, and HeLa cells are 
summarized in Table 5. Each value and its corresponding standard deviation are calculated 
from two independent experiments, which in this context required to conduct the whole 
process outlined above: tRNA extraction, tRNA purification, digestion, spiking, and 
measurement. For each experiment three independent digests, spikings, and measurements 
were performed. 
In agreement with literature the modification m2A was detected only in E. coli and not in 
eukaryotic cells. In contrast, the modification Am was found only in eukaryotic cells.[4, 59a, 115, 
117] This confirmation of known data proves the general applicability of our quantification 
approach. Moreover, the low average error margin of only 5 % shows the outstanding 
accuracy of our method. Its high sensitivity is demonstrated by the reliable detection of as 
little as 1.5 pmol ms2i6A in 12 g bulk tRNA from pork liver with a standard deviation of 
only 7 %. 
The data summarized in Table 5 are presented graphically in Figure 18. The level of t6A in 
healthy pork liver is significantly lower than in both tumor cell lines, which indicates that the 
biosynthesis of this modification may be upregulated in HeLa and HCT-116 cells. Further 
significant differences between the tumor cell lines were found for m6A and i6A. HeLa cells 
contain 100 % more m6A than HCT-116 cells, which exhibit the same amount of m6A as pork 
liver tissue. The level of i6A is 30 % lower in HeLa cells compared to HCT-116 cells, 
whereas HeLa cells contain the same amount of i6A as healthy liver tissue. These results 
support the idea that the analysis of modified tRNA nucleosides is able to differentiate 
between tumorogenic and non-tumorogenic cells and that even discrimination of different 
cancer cell lines may become possible once the analysis is extended to a broader variety of 
nucleoside modifications. 
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Figure 18: Comparison of the modified tRNA nucleoside level comparison of E. coli, pork liver, HeLa 
and HCT-116 cell lines. 
a) m2A, t6A, Am, m6A, i6A, and ms2i6A levels of E. coli, pork liver, HeLa and HCT-116 tRNA. b) ms2i6A 
levels in pork liver, HeLa, and HCT-116 tRNA. Error bars represent the standard deviations calculated 
from multiple experiments. 
 
The modification ms2i6A is present only in prokaryotes and mitochondria.[4, 115] Its 
quantification therefore provides an insight into how the mitochondrial tRNA modification 
level changes in tumor cells. It has been known for some time that tumors have a reduced 
oxidative phosphorylation activity and that many tumor cells derive most of their needed 
energy from glycolysis,[118] which induces a reduced pH-value in tumor tissue.[118a] In order to 
investigate this phenomenon the ms2i6A level of tRNA from healthy tissue and cancer cells 
was quantified. The result of this analysis is depicted in Figure 18. As expected, the 
modification ms2i6A is present in E. coli as well as in small but significant amounts in pork 
liver. Surprisingly, the analyzed tumor cells do not contain the modification ms2i6A at all 
(Figure 18 b). The mitochondrial tRNA nucleoside is totally absent in both tumor cell lines 
indicating that mitochondrial tRNAs in tumor cells and normal cells indeed differ 
substantially. The result provides a first indication that the impairment of mitochondria in 
tumor cells (Warburg hypothesis)[119] is detectable using our isotope based analysis method. 
In summary, it could be shown that this quantification method possesses the applicability, 
accuracy, and sensitivity to allow direct and parallel quantification of in principle all tRNA 
modifications. Moreover, initial experiments revealed surprisingly large variations of the 
tRNA modification levels among tumor cell cultures as well as between tumor cell cultures 
Chapter 5 Quantification of modified tRNA nucleosides 
35 
and non-tumorogenic tissue. Furthermore, it could be shown, that tRNA from the studied 
cancer cell lines lacks ms2i6A. 
Assuming that different species, various mammalian tissues, and different tumor tissues 
possess substantially different modified tRNA nucleoside patterns,[16c, 106c] the here presented 
isotope method is a new tool for a detailed cell and tissue analysis and for a thorough analysis 
of the functions and biosyntheses of modified tRNA nucleosides. 
 
5.3 tRNA modification levels in mammalian tissues 
5.3.1 Measurement of the tRNA modification levels in tissues 
Encouraged by the success of our initial study and the high scientific and medicinal interest of 
modified nucleosides (see chapter 3) a detailed analysis of the tRNA modification contents in 
different types of mammalian tissues was performed. The modified tRNA nucleoside content 
of pork heart, cerebellum, tongue, cerebrum, kidney, liver, lung, spine marrow, spleen, and 
thyroid gland was studied. As representative tRNA modifications ms2i6A, t6A, m6t6A, i6A, 
OHyW, Q, m1G+Gm, m22G, m2G, m1A, and Am were chosen. Varying from abundant to rare 
modifications and covering modifications present at various positions in tRNAs, these 
nucleosides constitute a representative cross-section of all tRNA modifications. 
Modifications m1G and Gm were analyzed together with d3-m1G used for spiking, because 
they could not be separated by HPLC. Nucleoside m1A was observed to decompose to m6A 
due to the increased waiting times associated with this large screening. This resulted in 
irreproducible results for m6A, which were discarded. During the initial study (chapter 5.2) 
this did not pose a problem as the samples were measured quickly after processing. 
Quantification of m1A was still possible, because the standard d3-m1A was added right after 
the digest and degraded to the same extent as unlabeled m1A. 
Preparations and measurements were conducted as discussed above. All data points presented 
are based on at least four sample preparations and twelve measurements. The sample and data 
collection is illustrated in Figure 19. First, for each tissue type at least two organs from 
different individuals were cleaned and surface areas were removed. From each organ at least 
two tissue samples were taken. Isolation and purification of the tRNA was performed as 
described in chapter 10.4.2. From the bulk tRNA at least three samples were taken and 
digested independently. Each digest mixture was equipped with different amounts of each 
isotopically labeled standard nucleosides and analyzed via HPLC-ESI-MS. 
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Figure 19: Schematic depiction of the pork tissue sample and data collection. 
 
From the obtained quantification data average modification contents and the corresponding 
standard deviations for each sample were calculated (Figure 19). From these values average 
modification contents and the corresponding standard deviations for each organ were 
determined. These data finally yielded the average modification contents and the 
corresponding standard deviations for one tissue. This stepwise calculation process allows 
conclusions about the differences of the modification levels between tissue samples and 
between individuals. In all investigated cases the modification levels were stable between 
samples and individuals. The obtained data are summarized in Table 6 a and Table 7 and are 
given as the amount of each modification per 1000 tRNA molecules (‰) with descriptive, 
quantile-based color codes. 
5.3.2 ms2i6A levels correlate with mitochondrial activity 
As outlined in the previous chapter the nucleoside ms2i6A is found in bacterial tRNA and in 
mitochondrial tRNA of eukaryotes.[4, 115] Therefore, its amounts in tissues are expected to be 
associated with their mitochondrial activity. As a measure for this activity previously 
described ATP content,[120] mitochondrial protein abundance,[121] and activity[122] in the 
investigated tissues were collected. Comparison of these data with our measured modification 
levels showed an excellently correlation (Table 6; r = 1.00, sig. < 0.01 between ms2i6A values 
and mitochondrial MDH mRNA levels). Spleen, lung, and liver tissue feature low 
mitochondrial activity, thus correspondingly low ms2i6A levels were determined. As 
expected, for tissues with high mitochondrial activities, such as muscle (heart and tongue) and 
brain tissues (cerebellum and cerebrum), a high ms2i6A content was found. The obtained 
ms2i6A levels shown in Table 6 exhibit an even finer graduation as the accordant literature 
data for ATP content, mitochondrial protein abundance, and activity. The presented study 
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therefore allows a very close look at the mitochondrial activity of the investigated tissues 
from an unprecedented point of view. 
 
 
Table 6: Levels of ms2i6A in pork tissues, data about respective mitochondrial activity, and their 
correlation. 
a) tRNA nucleoside values are given per 1000 tRNA molecules (‰). Repeated measurements of 
samples resulted in an average error of about 5 %. Relative ATP contents, mitochondrial MDH mRNA 
concentrations, and citrate synthase activity are obtained from literature. b) Correlations of ms2i6A 
level with mitochondrial measurements. * P < 0.05, ** P < 0.01. Correlations are calculated as 
Pearson’s r coefficients with 2-tailed significance values. 
 
5.3.3 Tissues exhibit individual modification levels 
The quantitative data for all other modifications in different tissues are shown in Table 7 
revealing that each tissue type uses a discrete level of tRNA modification for the translation 
of genetic information into peptide sequences. While liver and cerebellum tRNA contain a 
large number of modified nucleosides, tRNA isolated for example from lung and kidney 
tissue features fewer modifications. Significantly lower amounts were measured in the muscle 
tissue heart and tongue. The lowest value was measured for thyroid gland. At this point of the 
investigation no evident explanation can be provided for the steep drop of modification levels 
in thyroid gland in comparison to other tissues. One might speculate about a link to the high 
specialisation of this tissue, where synthesis of large amounts of certain proteins might 
necessitate a specialized translation apparatus. Except for ms2i6A the only nucleoside not 
following the general trend is Am. Am is surprisingly abundant in cerebrum and thyroid 
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gland, which are the tissues that feature the lowest global modification levels. The reason for 
this difference is at this point unclear but modified nucleoside are known to stabilize the 
tertiary structure of the tRNAs and due to its location in the amino acid acceptor stem Am 
might potentially have a general tRNA stabilizing function.[117] In this scenario its level is 
increased in order to maintain the tertiary structure of the tRNAs, which otherwise might be 
considerably destabilized or even lost due to the lack of other modifications. 
 
 
Table 7: Color-coded tRNA modification levels in pork tissue. 
All tRNA nucleoside values are given per 1000 tRNA molecules (‰). Repeated measurements of 
samples resulted in an average error of about 5 %. Color code is based on quantile calculations; red: 
highest value, yellow: 50% quantile, green: lowest value, colorless: thyroid gland, for intermediate 
values appropriate shades of color were calculated. Traces: less than 1 modification per 1000 tRNAs. 
 
In addition, the divergence between cerebrum and cerebellum is noteworthy, which indicates 
that the number of modifications does not simply reflect the tissue affiliation but has to be 
correlated with the particular function of the tissue. Moreover, relatively large amounts of the 
Q-nucleoside were detected in cerebellum and cerebrum. Currently, no explanation for these 
results is available due to the limited literature available on the functions of Q in the brain. 
Nevertheless, these observations support the idea that Q might be of higher importance in 
brain than in other tissues. The base queuine is essential for the formation of Q in eukaryotes. 
As queuosine is present in brain tissues, queuine can obviously cross the blood brain barrier. 
Nevertheless, it has been observed that bone marrow cells do not contain Q. They do not 
transport queuine across their plasma membrane. Based on these observations Farkas and co-
workers[123] suggested, that Q is more important in brain than in other tissues. They ascribe 
the increased importance to a reduced tolerance of the central nervous system to aberrant 
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polypeptides. Furthermore, the production of one superoxide dismutase, which is necessary in 
high amounts in brain, is induced by Q.[124]  
5.3.4 tRNA modifications are conserved across mammalia 
The significance of the detected correlation to a large extent depends on its general validity 
for mammals. To determine the conservation of modified nucleosides across mammals the 
available information from literature, tRNA sequences, and databases was evaluated. 
Concerning modification levels in literature it was found, that the data obtained here for pork 
liver are in excellent agreement with a study of modified tRNA nucleosides in mouse liver by 
Hoffman and McCoy.[125] The percentages of the modifications m6A+m1A, m22G, m2G, and 
m1G, which were measured both during this thesis and by Hoffman and McCoy, are 
summarized in Table 8. Although only a limited number of modifications has been measured 
in both surveys the concordance of modification levels implies their conversation across 
mammals. Even more so, if one considers that the studies are more than 30 years apart and 
different methods were used. 
 
 
Animal model Modified nucleosides / % 
m6A + m1A m22G m2G m1G 
Carell group Pork liver 28 16 32 24 
Hoffman & McCoy Mouse liver 27 15 29 29 
Table 8: Relative amounts of m6A+m1A, m22G, m2G, and m1G found in pig and mouse in percent. 
 
In addition, a number of tRNA sequences (tRNAAsn, tRNAiMet, tRNAPhe, and tRNAVal) are 
conserved in higher eukaryotes also implying a preservation of tRNA modifications in 
mammals.[126] An investigation of the modification content in liver from rat, beef, sheep, and 
rabbit clearly showed that the content does not vary significantly between these 
mammals.[106c] Similar observations were made by others.[107b] 
Therefore, the tRNA sequence information from the Sprinzl database,[4a] which is today’s 
biggest collection of tRNA sequences including modified nucleosides, was searched in regard 
to the modified tRNA nucleosides under investigation during this thesis. Amongst others the 
database information includes tRNA sequences from homo sapiens, bos taurus, mus 
musculus, and rattus norvegicus. A calculation showed that modifications in tRNAs, which 
code for the same amino acid, are generally conserved across mammalia (for details see 
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chapter 10.5). In only 6 % of all cases the number of a certain modified nucleoside varied, 
when the same tRNAs from various mammals were compared. 
Based on this evidence for a conservation of tRNA modifications across mammals we expect 
the data concerning modification levels in pork tissues (Table 6 and Table 7) to be valid for a 
broad range of mammalian species including humans. 
5.3.5 Potential origins of tissue-specific modification levels 
5.3.5.1 Codon bias 
Some codons are translated faster and more accurately than others. These efficient codons 
became more abundant to encode highly translated proteins in the course of evolution. The 
resulting, non-statistical distribution of codons in favour of more efficient ones is called 
codon bias.[127] It is only advantageous, if there is also an analogously high percentage of aa-
tRNAs, which recognize the prefered codons. Consequently, the codon bias led to an 
adjustment of the tRNA composition.[127] It has indeed been found, that highly specialized 
tissues, like reticulocytes, which produce large quantities of a few proteins, have a specialized 
aminoacyl-tRNA (aa-tRNA) composition.[128] Therefore, a distinct codon bias in different 
tissues could explain the observed tissue-specific modification levels. 
This could be a possible explanation for the unusually low modification content of thyroid 
gland. But at present no experimental support or literature precedence can be presented 
backing this suggestion.  
Nevertheless, for all other tissues investigated here the protein demand is very diverse and a 
large fraction of the proteins, which are synthesized in these tissues, is identical. This in itself 
does not exclude the presence of codon bias and recently a tissue specific codon bias has been 
statistically proven in mammalia.[129] But its effect is so small that it cannot explain the 
differences in tRNA modification levels observed in this thesis work.[130] 
5.3.5.2 General tRNA composition in tissues 
Independent of the codon bias, the tRNA composition might still be tissue specific for some 
other reason. A microarray analysis performed by Dittmar et al.[131] indicates tissue-specific 
differences in the tRNA mixture. On the other hand chromatographic investigations of 
aa-tRNAs have shown that the numbers of isoaccepting tRNAs are stable between different 
organs.[6l, 132] In addition, in recent years tRNA gene copy numbers have been used fruitfully 
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as a measure for the cellular tRNA abundance.[133] As this number is the same in all tissues 
the applicability of this assumption implies that the tRNA composition is stable across tissues. 
The data collected during this study complement evidences from literature against a tissue-
specific tRNA composition as follows. Assuming a tissue-specific variation in tRNA 
composition, when different tissues are compared, the percentage of some tRNAs would go 
up while the percentage of others would necessarily go down. This would inevitably mean 
that the content of some modifications had to go up, while the content of others had to 
decline. In contrast the same trend of modification levels with tissues was observed here for 
all nucleosides but ms2i6A and Am (Table 7). The modifications OHyW and i6A are rather 
scarce, present in a very limited number of tRNA species, and do not share a single common 
tRNA species, whereas the modifications m2G and m1A are present in almost all tRNAs. 
Nevertheless, they all show the same behavior in all investigated tissues. 
These observations and data from literature indicate that the relative amounts of tRNAs do not 
change significantly across tissues. They rather hint at an additionally regulatory role of the 
modification levels in tRNAs. 
5.3.5.3 Protein synthesis capacity 
Roe & Tsen uncovered that an increased ribothymidine content in mammalian tRNAs leads to 
an increased maximum velocity for the overall synthesis of poly(Phe), while the apparent 
Michaelis constant (Km) remained essentially unchanged. Based on this finding they 
postulated that “the modified nucleoside ribothymidine might be involved in the regulation of 
protein synthesis at the level of translation in mammalian liver.”[134] 
Taking the lead from this hypothesis our tissue-specific tRNA modification levels might be 
interpreted as a mechanism to regulate the protein synthesis capacity in mammalian tissues. It 
is not desirable for all tissues in one organism to produce the same amount of proteins. Some 
tissues will have to produce large quantities of proteins (e.g. liver), while others need only 
small amounts (e.g. heart). Nevertheless, all cells in a certain organism generally have the 
same translational apparatus. The numbers of single proteins are usually regulated on the 
transcriptional level by different copy numbers of their mRNA and on the translational level 
by sequence-specific RNA-binding proteins and microRNAs.[135] Global regulation of the 
translation efficiency is possible by modulation of initiation factor activites. Additionally, the 
different levels of tRNA modification in tissues might serve as a tool for the adjustment of 
tissue-specific protein synthesis rates. 
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Table 9: Modification levels and protein synthesis capacity of tissues and their correlation. 
Nucleosides m6t6A, m22G, and m1A are depicted as representative examples for rare and abundant 
modified nucleosides. For the normalized average all modification levels except Am and ms2i6A were 
normalized to the liver measurement and averaged. Color codes are based on quantile calculations; 
red: highest value, yellow: 50% quantile, green: lowest value, for intermediate values appropriate 
shades of color were calculated. b) Correlations of normalized nucleoside levels (excluding ms2i6A and 
Am) with protein synthesis rates. ** P < 0.01. Correlations are calculated as Pearson’s r coefficients 
with 2-tailed significance values. 
 
In this case the tissue-specific modification content should reflect the protein production of 
the individual tissues and thus correlate with the protein synthesis rates in tissues. In order to 
test this hypothesis, literature information about protein production yields was collected 
(Table 9 a).[136] Comparison of these data with the measured modification levels shows a 
surprisingly good correlation (Table 9 b) between average protein synthesis rate and average 
normalized modification levels. In all cases the observed modification levels compare well 
with the measured protein biosynthesis capacity, with liver having large quantities of 
modifications and a high protein synthesis capacity. Heart in contrast features fewer 
modifications and shows lower protein biosynthesis. 
In addition, in vitro translation of globulin in rabbit reticulocyte lysates has been found to 
depend on the nature of the supplied rabbit tRNA.[137] In vitro translation with tRNA isolated 
from brain is significantly slower than with kidney, liver, or reticulocyte tRNA (Figure 20 a). 
Furthermore, liver tRNA facilitates a faster translation than tRNA isolated from kidney. The 
slopes of the graphs obtained for low tRNA concentrations, which are a measure for the 
activity of tRNAs during translation, correlate with the normalized average modification 
levels (Table 9) determined in pork tissue (Figure 20 b; r = 1.000, significance: 0.012, N = 3). 
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Figure 20: tRNA dependent in vitro translation rates and their correlation with modification levels. 
a) 14C-valine incorporation during hemoglobin syntheses in reticulocyte lysates with its natural tRNA 
(blue), brain (black), kidney (red), and liver (green) tRNA. The tRNA concentrations were adjusted for 
the reduced amino acceptor activities of brain, kidney, and liver tRNAs in comparison to reticulocyte 
tRNA in the lysate. b) Plot of the slopes obtained from linear fits of the data for low tRNA 
concentrations (< 2 A260*10-2) against normalized average modification levels. 
 
Taken together, these significant correlations suggest that the amount of tRNA modifications 
determines the protein manufacturing fitness in mammalian tissues. In this scenario, the tRNA 
modification level regulates the overall protein production capacity, which is indeed tissue 
specific in complex organisms. 
5.3.6 High levels of modified tRNA nucleosides in cancer cell lines 
In order to gain further support for this hypothesis the modification levels in cancer cell lines 
were determined. These were chosen, because they have an increased proliferation and 
protein synthesis rate and according to our theory should thus contain a modification content 
at least as high as the most abundantly modified tissues, liver and cerebellum. 
In all investigated cancer cell lines a complete set of the modified nucleosides was detected 
(Table 10). They were found to generally possess modification levels close to or even above 
those detected for liver tissue, which is the highest modified tissue. The increase is specially 
high for t6A, whose levels in cell lines exceed those in liver. SK-HEP-1, a cancer cell line 
derived from a liver tumor, shows an almost identical modification pattern as liver tissue.  
The measured high modification levels in cancer cells compare well with reports from 
literature, which describe an increased modification of tumor tRNA and high excretion levels 
of modified nucleosides by cancer patients, although there are also reports of 
hypomodification in neoplastic tissues (chapter 3.2). The Q-hypomodification of MCF-7 
stated in literature[41b] could not be confirmed. 
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Table 10: Color-coded quantitative data for the investigated tRNA modifications in cancer cell lines. 
Color code is based on the absolute coloring in Table 7 for better visualization. n.q. = not quantifiable 
as m1A LC-MS signals for cell lines overlap with guanosine LC-MS signals. Measurements were 
performed by M. Wagner and D. Globisch. 
 
Generally reduced amounts were measured only for OHyW and Am. The latter has already 
been identified as a special case before and no explanation for its scarcity in cancer cell lines 
can be provided at present. For OHyW reduced levels were found probably due to its 
particularly complex biosynthesis that might be impaired in cell lines, e.g. by the lack of an 
enzyme or a cofactor. A similar reduction of OHyW has been found in tumors.[24] 
At present, it cannot be ruled out, that the high modification content measured for cancer cell 
lines is rooted in their growth in cell cultures, rather than in their nature as cancer cells. 
Whatever the reason, the investigated cells have a high proliferation rate, which in turn 
necessitates a high protein production capacity. Therefore, their high modification levels 
coincide with high protein synthesis rates. This is a further evidence for our hypothesis that 
modified tRNA nucleosides regulate the overall protein production capacity and are thus 
coupled to efficient protein synthesis and cellular growth. 
5.3.7 Modified tRNAs as regulators of protein synthesis? 
In order to collect further information on the impact of tRNA modification on the translational 
process literature concerning this topic in prokaryotes was studied. Generally, the growth and 
protein synthesis rate of prokaryotes is reduced, when they are lacking one or more tRNA 
modifications. For instance, the loss of pseudouridine in S. typhimurium tRNA has been 
shown to lead to a reduction of protein synthesis in vivo by 20 to 25 %. The reduction 
occurred predominantly at the level of translation.[138] This finding is supported by a number 
of independent studies, which consistently show that hypomodification results in a diminished 
decoding efficiency,[139] a reduced aminoacylation rate,[140] and an impaired growth.[141] These 
investigation exemplify the impact of modified tRNA nucleosides on the translational process 
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and its impairment due to hypomodification supplying further hints at a regulation of protein 
synthesis capacity by tRNA modifications. 
For an assessment of the feasibility of our hypothesis, its fit with the current pictures about 
the rate limiting step of translation and about the general functioning of modified tRNA 
nucleosides is evaluated. The rate-limiting step in the elongation of each codon is the 
stochastical search of the ribosome for a cognate tRNA in the A-site. The subsequent 
translation and translocation steps are much faster.[142] Therefore, the translation rate of 
mRNA into proteins depends on the availability of cognate aa-tRNAs and on the selection of 
these from the excess of near- and non-cognate ones.[143] This selection process is dominated 
by the competition between near-cognate and cognate aa-tRNAs for the binding to the 
ribosome. Therefore, the key factor that determines the protein synthesis capacity is the 
competitive, non-specific binding of the tRNAs to the ribosome.[144] 
A broad range of functions are attributed to tRNA modifications, e.g. restriction of codon 
recognition, expansion of the base-pairing capacity of the anticodon (wobble), enabling of 
translocation, and maintenance of the mRNA reading frame. Recently, a unifying concept for 
all of these functions was introduced by Paul F. Agris that attributes them to a single effect of 
modified tRNA nucleosides in the anticodon domain.[6a] According to this theory modified 
tRNA nucleosides restrict the three-dimensional structure of the anticodon optimizing its fit to 
the ribosomal A-site. The reduction of the dynamics and of the fluctuation of the anticodon 
minimizes the need of the ribosome to constrain or remodel each tRNA for binding 
diminishing the entropic penalty for the interaction between ribosome and tRNA. Thus the 
translational process is optimized by tRNA modifications providing an evolutionary 
advantage and the physicochemical basis for their conservation. 
It is generally accepted that most modified nucleosides influence the tRNA tertiary structure. 
While the modifications in the anticodon stem-loop contribute to its structural fine-tuning, 
modifications in other regions of the tRNA are often responsible for its general structural 
integrity and have thus even been termed “structural modifications”.[145] Therefore, it seems 
reasonable to extend Agris’ concept to all tRNA modifications regardless of their position in 
the tRNA. 
The introduction of modified nucleosides increases the fit of the tRNAs to the ribosome. 
Simultaneously, the entropic penalty for their binding is reduced. Therefore, the presence of 
modified nucleosides decreases the time and energy cost of the interaction between tRNAs 
and the ribosome. As the competitive, non-specific binding of tRNAs to the ribosome is the 
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rate limiting step during translation, this in turn results in a faster screening of the available 
tRNAs for the cognate one decreasing the ribosomal step time. Conclusively and in line with 
our hypothesis, this results in an increased protein synthesis capacity.  
For unicellular organisms an optimized translation of mRNA into proteins probably facilitates 
a high proliferation rate and provides the means to save energy and time.[6a] Modifications 
may have evolved as a growth advantage improving the translation efficiency in bacteria and 
unicellular organisms. Taking into account the species-specific codon bias, which is very 
pronounced in unicellular organisms, tRNA modification levels should be divergent across 
these, if this assumption is true. A look at the available tRNA sequences, e.g. from the Sprinzl 
database,[4a] confirms this divergence. It was also shown by a screening of the modification 
levels of various bacteria with our method. Furthermore, cluster analysis of these data 
furnished a phylogenetic tree identical with those obtained for phylogenetic analysis of 
rRNAs. This screening was mainly performed by D. Globisch (unpublished data). 
Higher organisms must have different reasons for maintaining modified nucleosides, because 
an optimized protein production of each cell would burn huge amounts of energy regardless 
of the actual needs of the organism. In biological systems, which contain highly specialized 
cells, each compartment has individual task and therefore individual needs for proteins. This 
applies not only for types but also for amounts of proteins. Rather than making as much 
proteins as possible, it seems more appropriate for each part of an organism to adjust its 
protein synthesis capacity to its actual needs. This way efficient use is made of the available 
resources and thus the fitness of the whole organism is maximized. If the modification levels 
are a general tool to adjust protein synthesis rates, they should be stable across mammals, in 
contrast to their divergence across prokaryotes. And indeed, the modification content is highly 
conserved across mammals (chapter 5.3.4). As uncovered in the course of this thesis in 
mammalian tissues the tRNA modification level correlates with the corresponding protein 
synthesis capacity implying the use of specific modification levels for the regulation of 
protein production.  
Based on the discussed concepts, literature data, and the insights gained during this thesis we 
would like to suggest the following general model: 
In prokaryotes modified tRNA nucleosides establish a fitness and proliferation advantage by 
optimizing the translation efficiency. In mammals the tissue-specific modification levels are 
responsible for maintaining the ideal translation rate and protein synthesis capacity of each 
tissue. 
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5.4 Stress response of tRNA modification levels in E. coli 
As discussed in the previous chapter tRNA modifications regulate the general protein 
synthesis capacity in cells by modulating their translational efficiency. Alternatively to this 
broad regulatory mechanism, they might also have a more specific regulatory function 
mediated by their presence or absence. 
Numerous publications unanimously state that the chromatographic behavior of tRNAs is 
changed upon application of stress to the cells, from which they originate.[146] Amongst others 
the stress condition examined include growth of bacterial cells under thermal stress,[146e, 147] 
amino acid deprivation,[146a, 146b, 147a] antibiotic treatment,[146a, 146b, 148] exposure to various 
chemicals,[149] and starvation for essential ions.[146b-d, 150] These observations lead to the 
question, whether the changes of the tRNAs are induced by hypo- or hypermodification as a 
response mechanism to external stimulation. 
Almost all known literature on changes of tRNAs with external stimuli relates to bacteria. 
Their main advantages in this respect are a high viability under hostile environmental 
conditions and a straight-forward managability. Of all prokaryotes E. coli was chosen, 
because it is the standard prokaryote for biochemical studies. 
A stress-related alteration of modified tRNA nucleoside content is most likely to occur in 
connection with the translation of mRNA to proteins. Therefore, modifications m2A and m6A 
are of interest here, as they are present 3'-adjacent to the anticodon in position 37 and thus 
directly involved in the translational process. Other modifications present in the anticodon 
loop were not available, because the study was performed at an early stage of this thesis. 
Nucleosides m2A and m6A occur at the same position in different tRNAs, are both 
methylated, and have a similar biosynthesis. This way comparability was maximized. 
Importantly, they are synthesized by two different enzymes allowing the occurrence of 
independent responses to external stimuli. Nucleoside m6A carries its methyl group at the 
exocyclic nitrogen, while m2A is methylated at position 2 of the heterocycle and thus the only 
modified purine tRNA nucleoside assembled by a carbon-carbon bond formation.[151] 
Nucleoside m6A is present in one tRNA species, while m2A is present in six different tRNA 
species.[4a] The details of all experiments presented hereafter are outlined in chapter 10.4.1. 
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Growth conditions n(m2A) [pmol] n(m6A) [pmol] 
Aerob (full medium) 121  ±3.4 29.3  ±0.5 
Anaerob (full medium) 125  ±4.3 28.2  ±1.4 
Aerob (minimal medium) 125  ±7.2 29.4  ±0.1 
Anaerob (minimal medium) 125  ±5.4 30.9  ±1.9 
Addition of desferal 110  ±5.2 31.2  ±0.5 
Addition of 2-fluor-adenosine 106  ±4.1 29.9  ±1.3 
Table 11: Content of m2A and m6A in E. coli tRNA under growth conditions. 
Full medium: LB, minimal medium: MOPS. Amounts of m2A and m6A with standard deviations from 
12 ng of total extracted tRNA. Reference values are depicted in bold letters. 
 
As reference values, we detected 121.4 pmol m2A and 29.3 pmol m6A in 12 ng total tRNA 
from aerobically grown E. coli K12 at 37 °C using LB medium (Table 12). All presented 
values are average values of two independent experiments under the same conditions and six 
independent digests and HPLC-ESI-MS measurements. 
A screening of the m2A and m6A content under various growth conditions was performed. 
E. coli cells were cultured aerobically in shaken cultures utilizing LB and in a fermenter using 
LB as well as Neidhardt’s minimal MOPS medium[152] (Table 11). In contrast to what was 
expected from literature,[146a, 146b, 147a] growth of E. coli in a minimal medium lacking amino 
acids and all other non-essential nutrients did not lead to an alteration of its tRNAs with 
respect to the modifications m2A and m6A. 
Identical experiments under anaerobic conditions yielded similar modification contents. Thus 
large differences of the E. coli metabolism between aerobic and anaerobic growth were not 
reflected by the levels of m2A and m6A in tRNA (Table 11). 
It has been shown in literature, that deprivation of essential ions from the medium, especially 
of iron, leads to altered tRNAs.[146b-d, 150] Therefore, E. coli was grown in LB medium 
supplemented with desferal,[150c] which complexes iron and thus leads to a reduced 
concentration of these essential ions in the medium. This external stimulation did not lead to 
altered m2A and m6A levels in comparison to reference conditions. Similarly, addition of 
2-fluoro-adenosine to the medium did not produce altered modification levels in E. coli. 
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Growth conditions n(m2A) [pmol] n(m6A) [pmol] 
Reference 121.4  ±3.4 29.3  ±0.5 
OD = 0.5, pH = 5.5 125.1  ±3.2 30.1  ±0.3 
OD = 1.0, pH = 5.5 98.8  ±7.2 28.1  ±1.2 
OD = 2.0, pH = 5.5 120.5  ±9.3 30.6  ±1.0 
Table 12: Content of m2A and m6A in E. coli tRNA at different cell densities. 
E. coli was grown under aerobic conditions in full medium to different cell densities (OD). Then the 
medium was adjusted to pH = 5.5. Amounts of m2A and m6A with standard deviations from 12 ng of 
total extracted tRNA. 
 
When the proton concentration in the medium was increased, differences in the nucleosides 
levels were detected. During growth in a medium with pH 5.5 the amounts of m2A and m6A 
were both reduced by roughly 10 % (Table 12). In addition, dependence of this phenomenon 
on the optical density (OD), which reflects the cell density in the medium, was detected. The 
given ODs indicate the cell density at the initiation of the external stimulation. The stress was 
applied for different periods depending on the nature of the stimulation. When adjusting the 
pH of the medium to 5.5 at OD = 1.0 decreased nucleoside levels for both nucleosides m2A 
and m6A were found. For initiation of the pH stress at OD = 0.5 and OD = 2.0 no differences 
in regard to the reference values were detected (Table 12). At this point of the investigation an 
explanation for this observation is not possible. As a consequence stress initiation was strictly 
applied at OD = 1.0 for all following experiments. 
 
Figure 21: pH-dependent changes of m2A and m6A levels in E. coli. 
Amounts of a) m2A and b) m6A with standard deviations from 12 ng of total extracted tRNA. Changes 
of the pH value of the medium were performed after E. coli K12 was grown under aerobic conditions in 
full medium to OD = 1.0.  
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A broad range of pH conditions was screened. The pH value of the medium during normal 
growth was determined to be 6.5. All experiments of this screening were performed as 
follows: E. coli was grown in full medium and under aerobic conditions to OD=1. At this 
point the pH of the medium was adjusted to the desired value with 4 M H3PO4 for pH values 
lower than 7.5 and 2 M NaOH for pH values higher than 7.5. The pH of the medium was 
changed to three different values of acidic stress (pH = 4.2, 4.6, and 5.5) and three different 
values of alkaline stress (pH = 7.5, 8.6, and 9.5).  
For nucleoside m2A the decrease in nucleoside level was significant for all variations from the 
normal pH value ranging from 20 % to 40 % with one exception (Figure 21 a). For pH = 9.5 a 
reduction of 75 % was detected. All changes of nucleoside levels were reproducible with high 
accuracy ruling out arbitrary alterations due to impaired cell growth or death. In the case of 
m6A no or only moderate changes were detected for the pH range of 5.5 to 8.6 in contrast to 
more pronounced variations of m2A under these conditions (Figure 21 b). For acidic 
conditions lower than 5.5 a reproducible decrease of 25 % was detected and for basic 
conditions the reduction was 30 %. 
These results show a small dependence of the modified tRNA nucleoside level on outer 
stimuli and a distinct, individual reduction of the m2A and m6A amounts. Possible reasons for 
the drop of the modified nucleoside contents could be a reduced amount of the specific tRNA 
species in the cell or biosynthetic activity changes of the modifying enzymes. 
The detection of this variation spurred further screenings of the impact of other external 
stimuli on the modified nucleoside levels in E. coli tRNA. In addition to the above mentioned 
stimulations salt (0.4 M NaCl),[153] oxidative (150 μl 30 % H2O2 in 1 L medium),[154] and heat 
stress (50 °C)[155] were applied to E. coli at OD=1 during exponential growth. In contrast to a 
constant m2A nucleoside level under salt stress reduced nucleoside levels of approximately 
10 % were detected for heat and oxidative stress (Figure 22 a). For the nucleoside m6A 
moderate changes were found (Figure 22 b). Its amount stayed constant under heat stress and 
decreased during oxidative stress. In contrast, it increased, when elevated salt concentrations 
were applied. These incoherent results for both investigated nucleosides indicate an individual 
response of single tRNA modifications to stress conditions. 
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Figure 22: Stress-dependent changes of m2A and m6A levels in E. coli. 
Amounts of a) m2A and b) m6A with standard deviations from 12 ng of total extracted tRNA. 
Stimulation by salt (0.4 M NaCl), oxidative (150 μl 30 % H2O2 in 1 L medium), heat stress (50 °C), and 
pH stress (2 M NaOH) after E. coli K12 was grown under aerobic conditions in full medium to 
OD = 1.0.  
 
The impact of antibiotics on the tRNA nucleoside levels was also investigated. The content of 
m2A and m6A in E. coli bulk tRNA after application of five different ribosome-binding 
antibiotics was determined. These directly influence the bacterial translational process and are 
thus likely to induce changes in the translational apparatus. Furthermore, an impact of 
Chloramphenicol on bacterial tRNAs has been shown in literature before.[146a, 146b, 148] 
Antibiotics targeting the bacterial cell walls were excluded from the study, because they 
probably do not influence translation. Non-lethal concentrations of Streptomycin, 
Chloramphenicol, Spectinomycin, and Gentamycin were applied to exponentially growing 
E. coli. 
The exposure of E. coli to antibiotics resulted in a decrease of the level of m2A and variable 
changes in the m6A nucleoside content in its tRNA. While for Chloramphenicol, 
Spectinomycin and Gentamycin the amount of m2A was decreased by 5 % to 12 %, the 
impact of Streptomycin was more pronounced reducing the m2A level by 25 % (Figure 23 a). 
The amount of the modification m6A was only reduced after Streptomycin application, while 
its level was raised when Chloramphenicol, and Spectinomycin were applied. The changes for 
nucleoside m6A ranged from 6 % to 12 % (Figure 23 b). For treatment with Gentamycin the 
amount of m6A remained constant compared to reference data. Streptomycin, an 
aminoglycoside like Spectinomycin and Gentamycin, had a markedly different impact 
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compared to the other investigated antibiotics. It induced an at least two fold higher reduction 
of the m2A amount then all other antibiotics and a unique decrease of the m6A level. These 
results additionally show an individual alteration of the modified nucleoside level to external 
stimulation. Even specific changes to different antibiotics could be detected. 
 
 
Figure 23: Antibiotic-dependent changes of m2A and m6A levels in E. coli. 
Amounts of a) m2A and b) m6A with standard deviations from 12 ng of total extracted tRNA. E. coli 
K12 grown under aerobic conditions in full medium was treated with Streptomycin, Chloramphenicol, 
Spectinomycin, and Gentamycin.  
 
In summary, an individual, stress-dependent response of the modified tRNA nucleosides m2A 
and m6A to different external stimulations was found. Next to a surprising OD-dependence, 
for many stresses applied considerable reductions of the m2A and m6A levels in total tRNA 
were observed. The main impacts on these translationally important nucleosides were 
detected during alkaline and antibiotic treatment yielding variations up to 75 % for m2A and 
up to 25 % for m6A. These reproducible changes imply directed nucleoside level variations as 
a reaction to external stimulation. 
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6 Isotope based quantification of the new sixth DNA-nucleoside 
hydroxymethyl-dC in brain 
 
The genetic code is established by the sequence of the four canonical DNA nucleosides dA, 
dC, dG, and dT.[156] Of these four nucleosides dC can be chemically modified inside cells of 
higher organisms to control transcriptional activity (Figure 24).[1] Special methyltransferases 
replace the H-atom at position C5 by a methyl group to form 5-MedC.[2] Methylation occurs in 
CpG sequences and is mostly responsible for the silencing of genes. In two recent back-to-
back reports 5-hydroxymethyl-deoxycytidine (5-HOMedC) was established as a new post-
replicatively formed DNA nucleoside. 
 
 
Figure 24: Structure of the post-replicatively formed DNA modifications 5-MedC and 5-HOMedC and of the 
four canonical nucleosides dA, dG, dT, and dC. Alterations to the canonical nucleosides are indicated 
in red. 
 
Kriaucionis and Heintz[3a] detected 5-HOMedC as a new sixth base in cerebrellar purkinje 
neurons. Rao, Aravind, Liu and co-workers[3b] reported the presence of 5-HOMedC traces 
(~0.032 % of all nucleosides) in mouse embryonic stem cells and observed this nucleoside in 
CpG sequences in human embryonic kidney cells when they overexpressed the hydroxylating 
2-oxoglutarate and Fe(II) dependent TET enzymes in these cells. It was additionally shown 
that these TET enzymes are able to oxidize the 5-methyl group of 5-MedC to give the 
hydroxymethyl group in vitro. The new base was detected using thin layer chromatography 
and radioactive labeled [32P]5-HOMedC. Its function is currently unclear but it is speculated that 
it may establish another level of transcriptional control. 
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DNA nucleoside 5-HOMedC is an ideal candidate for the expansion of the here established 
quantification method. To this end 5-HOMedC, 5-MedC, and their heavy atom labeled derivatives 
had to be synthesized. In addition, the HPLC-ESI-MS and the digestion procedure had to be 
adjusted and an approach for the isolation of pure DNA from tissues had to be established. 
For method establishment cerebrum and cerebellum pork tissue samples were used, because 
these are available in large quantities and very likely to contain 5-HOMedC. 
 
 
Figure 25: Isotope labeled nucleosides 5-MedC, 5-HOMedC, d3-5-MedC, and 18O-5-HOMedC. 
 
Both nucleosides, 5-MedC and 5-HOMedC, were synthesized by M. Münzel in natural (5-MedC and 
5-HOMedC) and isotope labeled form (d3-5-MedC and 18O-5-HOMedC, Figure 25).[157] In addition, 
the HPLC-ESI-MS procedure established for the quantification of modified tRNA nucleosides 
was adjusted to allow analysis of these modified DNA nucleosides by D. Globisch. With 
these DNA modifications and the adjusted HPLC-ESI-MS approach in hand the calibration 
curve equations were determined as discussed in chapters 5.1.5.1 and 10.6.2.[158] In both cases 
linear plots were obtained with R2-values of 0.999. The protocol established for the digestion 
of tRNAs was found to be applicable for genomic DNA, too. Completeness of the digestion to 
single nucleosides was proven as described in chapter 5.1.3.  
For the isolation and purification of genomic DNA, initially, the use of the standard DNA 
isolation kit “QIAamp DNA Mini Kit” was envisioned. This turned out to allow isolation of 
highly purified DNA from tissue samples within one day. Unfortunately, the amounts of DNA 
gained from most samples were not sufficient for the quantification of the rare nucleoside 
5-HOMedC. Therefore, an new DNA purification method had to be established, which allows 
collection of larger quantities. Based on the experiences from the isolation of tRNA and of 
DNA with the QIAGEN kit the following approach was established. For disruption of the 
cells and removal of the RNAs from the sample, the initial steps of the novel protocol, the 
QIAamp DNA Mini Kit was utilized. These steps were scaled up by a factor of four in 
comparison to the specifications from the kit to satisfy our need for increased amounts of 
DNA. In addition, the RNA digestion step was executed in duplicate to ensure full digestion 
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of the RNAs in the sample. Subsequently, a phenol/chloroform extraction, similar to the one 
used for tRNA isolation, was utilized to remove proteins and other cell components from the 
sample. After several precipitation steps pure DNA was obtained as analyzed by agarose gel 
electrophoresis (Figure 26). Comparison between the bands from the samples and the DNA 
ladder clearly shows that only very long nucleic acids, namely genomic DNA, are present in 
the samples. The details of this method are outlined in chapter 10.4.2.5. 
 
 
Figure 26: Representative analysis of DNA isolated from mouse brain samples via agarose gel 
electrophoresis. 
a) retina DNA sample; b) hippocampus DNA sample from 1 d old mice; c) cerebellum DNA sample 1; 
d) cerebellum DNA sample 2; e) cortex DNA sample 1; f) cortex DNA sample 2; g) brainstem DNA 
sample 1; h) brainstem DNA sample 2; j) hippocampus DNA sample from 90 d old mice; k) 1 kd DNA 
ladder. 
 
In agreement with literature analysis of brain cancer cell lines (Table 13) showed reduced 
5-MedC content (from typical 4.5 % to 3.1 %) proving the validity of our method.[159] In 
addition, it revealed that the new nucleoside 5-HOMedC is absent in neuroblastal (Neuro-2a) and 
glial (U-87) cell lines. 
 
Cell line Origin 5-HOMedC/dG [%] 5-MedC/dG [%] 
U-87 MG Homo sapiens, astrocytoma - 3.05 
Neuro-2a Mus musculus, neuroblastoma - 3.09 
Table 13: Ratio of 5-HOMedC and 5-MedC to dG in a neuronal and a glial cell line in percent. 
 
The modified nucleoside 5-HOMedC was found predominantly in neuronal cells.[3a] Therefore, 
an initial quantification of 5-HOMedC and 5-MedC was performed using various mouse brain 
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tissues. To this end hypothalamus, cortex, hippocampus, olfactory bulb, brainstem, 
cerebellum and retina of 90 days old mice were supplied by S. Michalakis from the Biel 
group. In addition, pork liver and kidney was investigated to evaluate the distribution of 
5-HOMedC in non-neuronal tissues. DNA isolation and digestion were executed as outlined 
above and in chapters 10.4.2.5 and 10.4.2.8. Afterwards, known amounts of the isotope 
labeled compounds d3-5-MedC and 18O-5-HOMedC were added and the nucleoside mixture was 
analyzed by LC-MS measurements on a Thermo Finnigan LTQ Orbitrap XL. In all 
experiments 5-HOMedC and 5-MedC eluted with retention times of 12.3 min and 18.5 min, 
respectively. Quantification was performed by comparing the areas of the ion currents of 5-
MedC and 5-HOMedC using the calibration curve equations. From repeated experiments an 
average error for the quantification data of ± 5.6 % for 5-MedC and ± 7.2 % for 5-HOMedC was 
determined (Table 14). 
 
Mammal Tissue %(5-MedC/dG) %(5-HOMedC/dG) 
Pig Cerebellum 6.18  ±0.39 0.72  ±0.04 
Pig Cerebrum 5.78  ±0.57 0.67  ±0.03 
Pig Liver 6.04  ±0.45 - 
Pig Kidney 5.89  ±0.39 0.14  ±0.04 
Mouse Hypothalamus 3.33  ±0.40 0.69  ±0.03 
Mouse Cortex 4.50  ±0.23 0.65  ±0.04 
Mouse Brain Stem 4.50  ±0.12 0.55  ±0.04 
Mouse Olfactory Bulb 4.54  ±0.13 0.53  ±0.02 
Mouse Cerebellum 4.39  ±0.12 0.33  ±0.00 
Mouse Retina 4.48  ±0.15 0.31  ±0.01 
Mouse Hippocampus 4.31  ±0.31 0.59  ±0.04 
Mouse Hippocampus (1 day old) 3.48  ±0.04 0.34  ±0.02 
Table 14: Ratios of 5-MedC and 5-HOMedC to dG in the DNA of pork and mouse tissues. 
Standard deviations are given in absolute values. dG was chosen as a reference, because it forms 
base pairs with dC, 5-HOMedC, and 5-MedC in DNA. 
 
Between 0.3 % and 0.7 % of all dC nucleosides are hydroxymethylated at position C5. Pork 
cerebellum and cerebrum contain the same amounts of 5-MedC and 5-HOMedC. In the non-
nervous tissues, liver and kidney, similar amounts of 5-MedC as in brain tissues were measured 
but significantly less or no 5-HOMedC was detected in accordance with literature.[3a] This is a 
further hint, that 5-HOMedC is mainly a neuronal cell specific DNA modification. 
Comparison of the data obtained for both investigated mammals reveals that pork has 
generally higher amounts of 5-MedC and similar levels of 5-HOMedC as mouse. Samples from 
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pork cerebrum were collected from the outer regions of the brain and are therefore considered 
as comparable with mouse cortex as a first approximation. Interestingly, this comparison 
shows that both mammals exhibit the same levels of 5-HOMedC in the cortex, but significantly 
varying ones in cerebellum. In mouse cerebellum only half as much 5-HOMedC as in pork 
cerebellum was detected. A possible explanation for the observed dissimilarities are the 
different preparations of the brain samples. For pork cerebellum samples parts of the 
cerebellar cortex were collected, whereas for mouse whole cerebellums were analyzed. 
Cerebellar cortex might contain higher levels of 5-HOMedC than whole cerebellums. 
Alternatively, a connection with different functions of the cerebellum in mouse and pork is 
imaginable.  
 
Figure 27: Brain regions investigated and the ratios of 5-HOMedC and 5-MedC to dG in their DNA. 
a) Depiction of a sagittal section of the mouse brain. Brain areas highlighted in color were studied 
here. b) Ratio of 5-HOMedC and 5-MedC to dG in the different tissues in percent. Error bars represent the 
determined standard deviations. dG was chosen as a reference, because it forms base pairs with dC, 
5-HOMedC and 5-MedC in DNA. 
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The new nucleoside 5-HOMedC was clearly detected in all brain tissues (Table 14) establishing 
5-HOMedC as a new post-replicatively formed nucleoside in brain regions other than 
cerebellum. Figure 27 illustrates the different brain regions analyzed. The amount of 5-HOMedC 
varied significantly in the investigated mouse brain tissues. The previous report observed 
5-HOMedC predominately in purkinje neurons,[3a] which are found in the cerebellum. Here, the 
amount of the nucleoside is even larger in cortex and hippocampus, where purkinje cells are 
not present indicating the presence of 5-HOMedC also in brain cells, which are not purkinje 
neurons. 
Following these data the possibility arises to roughly divide the mouse brain into three 
different areas (Figure 27 b). Most 5-HOMedC is found in hippocampus and cortex (I), which 
are the brain areas that have higher cognitive functions. Brainstem, and the olfactory bulb 
form a second category, which possesses intermediate 5-HOMedC levels (II). Cerebellum and 
retina finally contain significantly less 5-HOMedC (III). Surprisingly, these initial data also show 
a relatively high level of 5-HOMedC in the hypothalamus, which is part of the endocrine system 
that controls hormone based processes.  
There is no correlation between the amount of 5-HOMedC and 5-MedC in the investigated tissues. 
This would be expected, if 5-HOMedC is exclusively generated from 5-MedC as a precursor. The 
5-MedC values are significantly lower in hippocampus and hypothalamus, where high 5-HOMedC 
values were detected. In accord with literature[160] in all other tissues the 5-MedC values were 
stable at roughly 4.5 %, while the 5-HOMedC levels are significantly varying. This hints at a 
function of 5-HOMedC that does not go hand in hand with a reduced 5-MedC value. 
Finally, the impact of the animal’s age on the values for 5-MedC and 5-HOMedC was 
investigated. Thus hippocampus tissue of only one day old mice (Figure 28) was analyzed. In 
contrast to a previous report by Heintz,[3a] who could not see an ageing effect, significant 
differences were detected here. In young mice the levels of 5-MedC and 5-HOMedC were both 
significantly reduced. The 5-MedC value increased with age from 3.5 ±0.1 % to 4.1 ±0.2 %. 
More significantly, the amount of 5-HOMedC was raised in 90 days old mice in comparison to 
1 day old mice by approximately 80 % from 0.34 ±0.02 % to 0.62 ±0.02 %. Again the amount 
of 5-MedC and 5-HOMedC were not inversely correlated. In order to exclude that 5-HOMedC 
accumulated due to oxidative stress in older animals the damaged base 8-oxodG, which is a 
typical oxidative stress marker, was analyzed. Here no difference could be detected, which 
shows that 5-HOMedC in the brain is not the result of accumulation of oxidative DNA 
damage,[161] but a post-replicatively modified nucleoside. 
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Figure 28: Ratio of 5-HOMedC and 5-MedC to dG in the hippocampus of 1 day and 90 days old mice in 
percent. 
 
In summary, our method for the quantification of modified tRNA nucleosides has been 
expanded to modified DNA nucleosides allowing quantification of 5-MedC and 5-HOMedC in 
tissues with excellent accuracy. The successful broadening of the method is based on the 
synthesis of 5-MedC, 5-HOMedC, d3-5-MedC, and 18O-5-HOMedC, the adjustment of the 
HPLC-ESI-MS procedure for the quantification of these nucleosides, and the development a 
protocol, which allows high-yielding isolation of pure DNA from tissue samples. 
Using this extended quantification method 5-HOMedC was confirmed as a post-replicatively 
formed nucleoside. It was found that 5-HOMedC is widely distributed in brain and that it is 
particularly prominent in those brain tissues, which are involved in higher cognitive functions. 
Finally, reduced levels of 5-HOMedC in new born mice were uncovered. The established 
procedure will allow a detailed analysis of the distribution of 5-HOMedC in response to different 
kinds of stimuli and may substantially contribute to the development of this brand new field 
in epigenetic research. 
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7 Syntheses 
7.1 Syntheses of natural nucleosides and their heavy atom labeled derivatives 
Apart from the mass spectrometry equipment the main tools for quantification via a stable 
isotope dilution approach are the molecules to be quantified and their heavy atom labeled 
derivatives. Both are needed to establish the calibration equations (chapter 10.6.2) essential 
for accurate quantification of the analyte. The natural nucleosides (analytes) and their heavy 
atom labeled derivatives (standards) of interest during this thesis work were not commercially 
available and thus had to be synthesized.  
The main purpose of all syntheses presented in the following was to supply sufficient amounts 
for HPLC-MS quantification. Thus, as soon as this purpose was accomplished no second 
synthesis or further optimization of the reaction conditions were performed. For the 
nucleosides presented hereafter all analytical data are in good to excellent agreement with 
literature. 
For each unlabeled nucleoside the discussions in this chapter will generally have the 
following layout: 
1. General information on the nucleoside like biological activities and appearances in 
RNA 
2. Functions 
3. Biosynthesis 
4. Known syntheses 
5. Synthesis performed as part of this thesis 
For the corresponding labeled nucleosides the realized syntheses will be discussed. 
7.1.1 Syntheses of isopentenyl and methylthioadenosines 
7.1.1.1 Synthesis of i6A 
Nucleoside i6A has been shown to inhibit cell proliferation, induce apoptosis in a human 
colon cancer cell line DLD1,[162] and to be a potential therapeutic agent for a variety of 
epithelial cancers.[163] Furthermore, it is also a potent cytokinin and as such has stimulated 
research early on.[164] 
The nucleoside i6A has been found to be essential for the maturation of selenocystein 
tRNA[165] but its general functions are still unclear.  
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The biosynthesis of i6A in tRNA has recently been characterized thoroughly. Different stages 
of the transformation of adenosine to i6A in the anticodon loop of E. coli tRNAPheGAA by 
MiaA were crystallized.[166]  
The first synthesis was published in 1966.[167] Apart from the preparation of the natural 
nucleoside a 14C-labeled derivative was synthesized early on.[168] More recently it has also 
been incorporated into RNA strands.[169] 
 
 
Scheme 1: Synthesis of i6A. 
Reagents and conditions: a) LiAlH4, EtO2, 0 °C to rt, 15 min; b) PBr3, Et2O, 0 °C, 30 min; c) KPhth, 
DMF, 80 °C, 30 min, 64 % (3 steps); d) hydrazine hydrate, 2 M HCl, MeOH, rt, 20 h, 99 %; e) 5, EtOH, 
60 °C, 18 h, 69 %. 
 
General features of the adenosine nucleoside syntheses presented hereafter are the use of 
acetyl protecting groups and the introduction of the allylamine moiety in position 4 by 
nucleophilic substitution of a chlorine substituent. This combination allows simultaneous 
attachment of the allylamine and removal of all protection groups in the last step minimizing 
the length of the syntheses. 
As discussed above mass spectrometric quantification is based on the simultaneous, but 
individual measurement of the ions from the analyte and the standard. This is only possible 
for a mass deviation between analyte and standard of at least two. For a difference of only one 
significant amounts of the analyte have the same mass as the standard, because roughly 10 % 
of all carbons in natural compounds are 13C. Therefore, all syntheses have to allow 
incorporation of at least two heavy atoms. 
The most convenient approach usually is introduction of deuterium via a reduction. Attempts 
to synthesize i6A by reduction of dimethylacrylonitrile with LiAlH4 as described in the 
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original synthesis[167] failed. Therefore, a more reactive carbonyl compound, namely 
3,3-dimethylacrylic acid ethyl ester 1, was chosen for the reduction with LiAlH4. The ester 
was reduced successfully to the corresponding alcohol 2. This hydroxyl compound was 
converted into the bromo alkene 3. Nitrogen was introduced by a Gabriel synthesis. 
Replacement of bromine with KPhth yielded compound 4. Subsequent hydrazine induced 
deprotection furnished amine 5 in 63 % yield over 4 steps. This reaction sequence was 
optimized in a way that all four steps could be performed in 24 h yielding several grams of 
amine 5. Nucleoside 6 was obtained from D. Globisch. Following the strategy outlined above 
treatment of chloro nucleoside 6 with allylamine 5 yielded i6A in a straightforward manner. 
The synthesis of i6A was accomplished in 7 steps and 33 % overall yield. 
7.1.1.2 Synthesis of d2-i6A 
 
 
Scheme 2: Synthesis of d2-i6A. 
Reagents and conditions: a) LiAlD4, EtO2, rt, 5 min, 98 %; b) PBr3, Et2O, 0 °C, 30 min, 59 %; c) KPhth, 
DMF, 80 °C, 30 min, 80 %; d) hydrazine hydrate, 2 M HCl, MeOH, rt, 18 h, 95 %; e) 1-dideutero-3-
methylbut-2-en-1-amine, EtOH, 60 - 80 °C, 21 h, 85 %. 
 
The corresponding standard, d2-i6A, was synthesized as described for the natural nucleoside 
but using LiAlD4 instead of LiAlH4. The reaction sequence is illustrated in Scheme 2. 
Standard d2-i6A was obtained in 7 steps and 30 % overall yield. 
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7.1.1.3 Synthesis of ms2i6A 
Nucleoside ms2i6A is a cytokinin and has been isolated from tRNA in 1966 for the first 
time.[170] It is present in bacterial, chloroplast, and mitochondrial tRNA.[4a, 4b, 158a]  
Numerous functions of ms2i6A in RNA have been found: 
- Prevention of codon misreading in E. coli.[171] 
- Influence on the development of B. subtilis.[172] 
- Influence on the structural stability of the anticodon loop.[173]  
- Prerequisite for the virulence of S. flexneri.[116b, 174] 
- Regulatory switch of the aromatic amino acid transport under iron deficiency.[146c, 175] 
In addition to the incorporation of the allyl moiety by MiaA as described for i6A introduction 
of the methyl thioether in position 2 is necessary. This is accomplished by MiaB, a radical-S-
adenosylmethionine (SAM) enzyme[176] with two essential [4Fe-4S] clusters.[177] 
Chemical studies of ms2i6A include its synthesis and incorporation in RNA.[169b] Isotopically 
labeled derivatives of ms2i6A have also been synthesized before.[168, 178] 
 
 
Scheme 3: Synthesis of ms2i6A. 
Reagents and conditions: a) 2-Methyl-3-buten-2-ol, NaH, trichloro acetonirile, THF, Et2O, 0 °C to rt, 
2 h; b) toluene, 115 °C, 2 h, 67 % (2 steps); c) 3 N KOH, DMF, rt, 4 h, 45 %; d) Ac2O, DMF, pyridine, 
75 °C, 1.5 h, 87 %; e) POCl3, DMA, Et4NCl, MeCN, 100 °C, 10 min, 51 %; f) Dimethyldisulfide, 
N-pentyl-nitrite, MeCN, 70 °C, 1.5 h, 65 %; g) 5 (neat), 50 °C, 1.5 h, 74 %. 
 
Nucleoside ms2i6A was prepared as outlined in Scheme 3. Isopentenylamine 5 was 
synthesized from allylalcohol 7 on a multi-gram scale as described in literature.[179] This route 
was established when mass spectrometric quantification was not part of the project yet. As 
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discussed above this approach to allylamine 5 does not permit straightforward incorporation 
of heavy atoms. Therefore, for the synthesis of i6A and d2-i6A an alternative route to amine 5 
was chosen. An interesting feature of this reaction sequence is the Overman 
Rearrangement[180] of allyltrichloracetimidate 8 to allylamide 9.  
 
 
Figure 29: Crystal structure of nucleoside 11. 
 
For the synthesis of the second building block (Scheme 3) guanosine (G) was protected with 
acetic acid anhydride under standard conditions to give acetylated nucleoside 10.[181] 
Conversion of the oxo to a chloro substituent yielded nucleoside 11.[182] The crystal structure 
of this nucleoside is shown in Figure 29. The methylthio residue was introduced as described 
by Kierzek et al.[169b] Nucleoside 11 was diazotized with N-pentyl-nitrite. The diazo-
intermediate was trapped with dimethyldisulfide to give nucleoside 12.[183] Treatment of 
chloro nucleoside 12 with isopentenylamine 5 yielded ms2i6A in 7 steps and 6 % overall yield 
on a gram scale. 
The crystal structure of nucleoside ms2i6A could be determined and is presented in Figure 30. 
Interestingly, in the crystal ms2i6A forms a hydrogen bond between C5'OH and N1. 
 
 
Figure 30: Crystal structure of ms2i6A. 
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7.1.1.4 Synthesis of d3-ms2i6A 
 
 
Scheme 4: Synthesis of d3-ms2i6A. 
Reagents and conditions: a) d6-Dimethyldisulfide, N-pentyl-nitrite, MeCN, 70 °C, 5 min, 78 %; 
b) 5 (neat), 40 °C, 16 h, 39 %. 
 
When the synthesis of labeled ms2i6A was planed, i6A had not been a target molecule of this 
thesis work. Thus the route to deuterated allylamine via a reduction of 3,3-dimethylacrylic 
acid ethyl ester had not been established yet. At this time use of deuterated dimethyldisulfide 
was identified as the most convenient approach to isotopically label ms2i6A. Chloro 
nucleoside 11 is available on a multi-gram scale with little effort. Therefore, the reaction 
conditions for the conversion of the amine 11 to the d3-methyl thioether 13 were optimized 
for minimal d6-dimethyldisulfide consumption. All other reactions were performed as 
described for ms2i6A. Scheme 4 shows the reactions performed during the synthesis of d3-
ms2i6A, which have not already been discussed in chapter 7.1.1.3. 
7.1.1.5 Synthesis of io6A 
In the course of this thesis work it could be shown that io6A is both present in eukaryotes and 
bacteria. Functions and biosynthesis of io6A in tRNA are still unidentified. One might 
speculate that it is a potential biosynthetic intermediate towards ms2io6A. But there is not 
enzyme know to catalyze the necessary methylthiolation, while the hydroxylation of ms2i6A 
has been studied.  
Synthesis of the allylammonium salt 14 was performed on the basics of a synthesis of 
2-deoxy-ms2io6A by Evidente et al. (Scheme 5).[184] Commercially available aldehyde 15 was 
converted into the Z-allyl ester 16 under conditions derived from the Horner-Wadsworth-
Emmons reaction. Subsequent reduction to allylalkohol 17 and deprotection yielded amine 14 
in good yields and gram quantity. Reaction of chloro compound 6 with allylammonium 
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chloride 14 in Et3N and MeOH gave io6A in 6 steps and 9 % overall yield. Major losses were 
experienced in the last step due to the rigorous purification via HPL chromatography. 
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Scheme 5: Synthesis of io6A. 
Reagents and conditions: a) 2-(Diethoxy-phosphoryl)-propionic acid ethyl ester, nBuLi, THF, -78 °C to 
rt, 3 h, 55 %; b) LiAlH4, Et2O, -78 °C to rt, 2 h, 75 %; c) 2 M HCl, rt, 4 h, 94 %, d) 14, Et3N, MeOH, 
60 °C, 48 h, 28 %. 
 
7.1.1.6 Synthesis of d2-io6A 
 
 
Scheme 6: Synthesis of d2-io6A. 
Reagents and conditions: a) LiAlD4, Et2O, -78 °C to rt, 3 h, 87 %; b) 2 M HCl, 60 °C, 30 min, 73 %; 
c) 19, Et3N, MeOH, 60 °C, 16 h, 13 %. 
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Ester 16 was synthesized as described above. Reduction of its ester moiety with LiAlD4 
allowed introduction of two deuterium atoms (Scheme 6) and yielded alcohol 18. Acidic 
deprotection gave ammonium salt 19, which was used to convert chloro nucleoside 6 into 
d2-io6A. 
7.1.1.7 Synthesis of ms2io6A 
Ribosyl-zeatin (ms2io6A) is the most important cytokinin of the isopentenyladenosine 
family.[185]  
The functions of ms2io6A in tRNA have been studied thoroughly in bacteria.[186] It is present 
in S. typhimorium tRNA, where it is a possible regulator for aerobiosis.[187] It also regulates 
the growth on citric acid cycle intermediates via presence or absence of its side-chain 
hydroxyl group.[188] 
Incorporation into tRNA takes place by conversion of ms2i6A to ms2io6A catalyzed by 
MiaE.[189] 
There is literature precedence for the synthesis of ms2io6A[184, 190] and its heavy atom labeled 
derivative.[191] 
 
 
Scheme 7: Synthesis of ms2io6A. 
Reagents and conditions: 14, Et3N, MeOH, 60 °C, 24 h, 26 %. 
 
Nucleoside 12 and ammonium salt 14 were prepared as described in chapter 7.1.1.3 and 
chapter 7.1.1.5, respectively. As depicted in Scheme 7 the reagents were stirred under slightly 
basic conditions to give ms2io6A with 26 % yield. 
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7.1.1.8 Synthesis of d2-ms2io6A 
 
 
Scheme 8: Synthesis of d2-ms2io6A. 
Reagents and conditions: 19, Et3N, MeOH, 60 °C, 16 h, 2 %. 
 
The synthesis of d2-ms2io6A is illustrated in Scheme 8. Reaction of nucleoside 12 
(chapter 7.1.1.3) with the deuterated ammonium salt 19 (chapter 7.1.1.6) under slightly basic 
conditions yielded d2-ms2io6A. 
7.1.1.9 Synthesis of ms2A 
 
 
Scheme 9: Synthesis of ms2A. 
Reagents and conditions: NH3, rt, 24 h, 81 %. 
 
Nucleoside ms2A has not been found in tRNA yet but it is a potential biosynthetic precursor 
of several natural methylthio nucleosides and might there be of interest at later stages of the 
larger project initiated with this thesis work. In addition, it is a convenient product obtained 
from treatment of chloro nucleoside 12 with ammonia. Thus, ammonia was condensed in a 
flask with nucleoside 12 and stirred for 24 h giving ms2A in 81 % yield. The overall yield of 
this 4 step sequence was 23 %. 
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7.1.1.10 Synthesis of d3-ms2A 
 
 
Scheme 10: Synthesis of d3-ms2A. 
Reagents and conditions: NH3, rt, 24 h, 17 %. 
 
To allow quantification of ms2A the corresponding heavy atom labeled nucleoside has been 
synthesized by treatment of trideutero nucleoside 13 with ammonia. 
7.1.2 Syntheses of methyladenosines 
7.1.2.1 Synthesis of m2A 
Another class of modified nucleosides are methylated adenosines. Out of the eight known 
methyladenosines m2A is the most striking one, because of its unusual methylation site. 
Introduction of a methylation in position 2 of the heterocycle necessitates activation of a C-H 
bond and formation of a novel C-C bond. Nevertheless, m2A is a rather common and 
abundant modification. It was first found in 1960[192] and is present in bacterial and 
chloroplast tRNA[4b, 151, 193] and in rRNA.[194] 
Its function in tRNA is not yet known. 
In rRNA it is introduced via YfgB.[195] The corresponding enzyme for tRNA modification is 
still unidentified. 
The first synthesis of m2A was published in 1952 with the title “Some synthetic analogs of the 
natural purine nucleosides”.[196] As it turned out later m2A actually is a natural purine 
nucleoside, too. Later other syntheses of this interesting adenosine derivative followed.[197] 
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Scheme 11: Synthesis of m2A. 
Reagents and conditions: a) I2, CH2I2, CuI, N-pentyl-nitrite, THF, 70 °C, 2 h, 61 %; b) ZnCl2, MeMgCl, 
Pd(PPh3)4, THF, 0 °C to rt, 4 h, 86 %; c) NH3, rt, 36 h, 71 %. 
 
The first two steps of the route to m2A are identical with those of the synthesis of ms2i6A 
(chapter 7.1.1.3). The common intermediate 11 is converted into iodo nucleosides 20 by use 
of a similar reaction as described for the introduction of the methylthio moiety. N-pentyl-
nitrite, CuI, and CH2I2 are used for the functional group interconversion via a diazotation of 
amine 11. Subsequent Negishi coupling yielded the 2-methylnucleoside 21. The zinc organic 
compound used for this cross coupling reaction was prepared by reaction of MeMgCl with 
ZnCl2. Treatment of nucleoside 21 with ammonia simultaneously led to deprotection and 
conversion of the chloro to the amino substituent. m2A was obtained in 17 % overall yield in a 
5 step linear sequence. 
7.1.2.2 Synthesis of d3-m2A 
 
 
Scheme 12: Synthesis of d3-m2A. 
Reagents and conditions: a) ZnCl2, d3-MeMgCl, Pd(PPh3)4, THF, 0 °C to rt, 5 h, 25 %; e) NH3, rt, 36 h, 
6 %. 
 
For the synthesis of trideuterated nucleoside 22 the heavy atoms were introduced by use of 
d3-MeMgCl. It was utilized for preparation of the methyl zinc species of the Negishi coupling. 
Except for this all reactions were carried out as described above yielding d3-m2A.  
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7.1.3 Syntheses of cytidine derivatives 
7.1.3.1 Synthesis of ac4C 
The modification ac4C is present in position 12 in eukaryotic tRNA. There, it probably 
stabilizes the tRNA structure already in an early stage of the tRNA maturation.[198] In 
bacterial tRNA ac4C occurs at the wobble position. It improves codon recognition and inhibits 
mistranslation of the isoleucine codon AUA.[199] 
The enzyme Tan1p is involved in the biosynthesis of ac4C in eukaryotes.[200] In prokaryotes 
the acetylation is catalyzed by an enzyme called TmcA, whose structure could be solved 
recently.[201] 
 
 
Scheme 13: Synthesis of ac4C. 
Reagents and conditions: Ac2O, EtOH, 80 °C, 6 h, 79 %. 
 
The straight forward synthesis of ac4C starting from cytidine (C) was performed similar to a 
synthesis published by Watanabe and Fox.[202] This approach yielded the acetylated 
nucleoside in one step, good yield and large quantity. 
7.1.3.2 Synthesis of d3-ac4C 
 
 
Scheme 14: Synthesis of 13C2-ac4C. 
Reagents and conditions: 13C4-Ac2O, EtOH, 60 °C, 6.5 h, 13 %. 
Chapter 7 Syntheses 
72 
Initially, heavy atom labeled ac4C was prepared by use of d6-Ac2O. Unfortunately, it turned 
out that the deuterium atoms in d3-ac4C exchange with proton from the HPLC buffer under 
the condition currently used for HPLC-MS analysis here. Therefore, significantly more 
expensive 13C4-Ac2O was utilized. In view of cost for 13C4-Ac2O a screening of reaction 
conditions with unlabeled Ac2O was conducted, which led to a procedure requiring 
considerably reduced amounts of acetic acid anhydride in comparison to the literature 
approach. Reaction conditions were established, which employ only one equivalent of acetic 
acid anhydride for the formation of ac4C. 
7.1.3.3 Synthesis of Cm 
Cm is found in the anticodon stem-loop and in the amino acid acceptor stem of eukaryotic,[117, 
203] archaeal,[204] and bacterial tRNA.[205] 
In both positions it stabilizes the structure of the tRNA.[203] As part of the anticodon loop it 
also enhances the efficiency of the codon recognition[206] and prevents misreading of 
condons.[207] 
Cm is incorporated into tRNA by enzymes with a S-Adenosyl-L-methionin (SAM) cofactor. 
Trm7p[203] and YfhQ[205] are enzymes synthesizing Cm in yeast and bacterial anticodon loops, 
respectively. In position 4 of eukaryotic tRNA Cm is introduced by Trm13.[117] In archaeal 
tRNA its biosynthesis is accomplished by Trm56.[204] 
Cm has been introduced in RNA strands showing its stabilizing effect on RNA duplexes.[208] 
Cm has been synthesized by Quaedflieg et al.[209] in 1991 by a straight forward one pot 
methylation. 
 
 
Scheme 15: Synthesis of Cm. 
Reagents and conditions: NaH, MeI, DMF, 0 °C to rt, 4.5 h, 16 %. 
 
This approach was chosen here, too. In terms of purification of the product it is quite 
disadvantageous as a mixture of numerous methylated cytidine derivatives was obtained. Cm 
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could be isolated from the mixture by subsequent column chromatography and 
recrystallisation in 16 % yield (Scheme 15). Attempts to purify the numerous side-products 
were partially successfully. The obtained nucleosides 23, 24, 25, 26, and 27are summarized in 
Figure 31. 
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Figure 31: Nucleosides 23, 24, 25, 26, and 27 isolated from the reaction of cytidine with MeI. 
 
7.1.3.4 Synthesis of d3-Cm 
 
 
Scheme 16: Synthesis of d3-Cm. 
Reagents and conditions: NaH, d3-MeI, DMF, 0 °C to rt, 4.5 h, 19 %. 
 
Nucleoside d3-Cm was obtained in 19 % yield from the reaction of cytidine with NaH and d3-
MeI under identical conditions as used for the synthesis of its undeuterated analogue. 
7.1.4 Synthesis of queuosine 
The hypermodified nucleoside queuosine is present in the wobble position of four tRNAs 
(Tyr, His, Asn, and Asp) in bacteria and eukaryotes.[210] 
Numerous functions of queuosine have been discovered. It is suspected to influence 
development,[211] decoding,[212] biosynthesis of nitrite reductase,[213] and cancer cells.[9b, 35b, 42, 
47-48] 
Chapter 7 Syntheses 
74 
Most of its complex biosynthesis has been disclosed. It features an uncommon class of 
enzymes the so-called tRNA guanine transglycosylases (TGTs).[29a-c] 
A thorough discussion of the biosynthesis and the functions of queuosine is inappropriate 
here. Furthermore, there is a multitude of excellent reviews discussing the individual aspects 
of queuosine biosynthesis[6c, 6d, 6f, 29a, 29c, 29d, 214] and functions.[6c-j] 
One route to Q was known,[215] when the queuosine project was started in the Carell group. As 
this synthesis is lengthy and costly and it was expected that large quantities of queuosine 
would be needed for biochemical studies, a novel approach towards queuosine has been 
established. 
 
 
Scheme 17: Studies towards the synthesis of queuosine. 
Reagents and conditions: a) Bromoacetaldehyde diethyl acetal, HCl, NaOAc, water, 90 °C and 80 °C, 
4 h, 74 %; b) POCl3, reflux, 2 h, 78 %; c) Pivaloyl chloride, pyridine, rt, 2 h, 64 %; d) NIS, THF, rt, 1 h, 
81 %; e) 1-Acetyl-2,3,5-tribenzoyl-ribose, bistrimethylsilyl acetamide, trimethylsilyl triflate, MeCN, 
50 °C, 24 h, 59 %, f) DABCO, CsOAc, NaOAc, DMF, rt, 45 h, 57 %; g) Pd2(dba)3, triphenylphosphine, 
CO, Bu3SnH, toluene, 50 °C, 2 h, 93 %. 
 
During this thesis the route towards queuosine was followed until formylnucleoside 28 was 
obtained. The final steps of the queuosine synthesis were performed by I. Thoma as part of a 
master thesis supervised during this thesis. The steps performed personally are depicted in 
Scheme 17 and will be discussed hereafter. Reactions performed by I. Thomas are discussed 
in detail in her master thesis. 
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Bromoacetaldehyde diethyl acetal was condensed with pyrimidinone 29. Functional group 
interconversion yielded chloro compound 30. Protection of the amine as pivaloylamide 
moiety and introduction of iodine with NIS yielded nucleobase 31. For the glycosylation the 
Silyl-Hilbert-Johnson Reaction under Vorbrüggen Conditions was used to couple 
commercially available 1-acetyl-2,3,5-tribenzoyl-ribose with deazapurine base 31 resulting in 
nucleoside 32.[216] After conversion of the chloro to the oxo substituent[217] nucleoside 33 was 
obtained. Palladium catalyzed formylation with CO and Bu3SnH gave nucleoside 28 in 
excellent yield. The final steps to Q include a reductive amination to introduce the 
cyclopenten moiety and a two step deprotection. 
Heavy atom labeled 13C-d2-Q was synthesized in collaboration with I. Thoma. As mentioned 
above nucleoside 28 was synthesized during this thesis and provided for the final steps of the 
synthesis of heavy atom labeled 13C-d2-Q. These were conducted as part of I. Thoma’s master 
thesis work supervised during this thesis work. The incorporation of the heavy atoms was 
achieved by use of Bu3SnD and 13CO. 
 
7.2 Syntheses of other nucleosides 
In addition to the syntheses of the nucleosides and their heavy atom labeled derivatives 
presented in the last chapter several other unlabeled nucleosides were prepared. The 
methylated nucleosides discussed in this chapter are naturally occurring modified nucleosides 
or potential biosynthetic precursor. As such they are of general interest for mass spectrometric 
elucidation. But they have not been investigated further up to now, either because additional 
HPLC studies would be necessary to allow quantification or because they have not been 
found in the samples analyzed so far. PreQ0 and archaeosine have been synthesized as part of 
a natural product synthesis project. 
7.2.1 Synthesis of PreQ0 and archaeosine 
PreQ0 is a biosynthetic precursor of archaeosine. Archaeosine is present in position 15 in the 
majority of archaeal tRNAs.[29a] 
It was proposed that archaeosine has a highly stabilizing effect on the structural integrity of 
archaeal tRNAs.[218] Under physiological pH it carries a positive charge at its amidinium 
moiety. This positive charge is positioned in a cleft with a high negative electrostatic 
potential.[29a] In addition, loss of the structural element containing Q* (archaeosine) leads to 
denaturation of the tRNA.[219] 
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Biosynthetic precursor PreQ0 has been synthesized before[220] while Q* was prepared for the 
first time in the course of this thesis work.[221] 
PreQ0 and archaeosine analysis in archaea has not been performed yet as no archaeal samples 
are available at the moment. In addition, quantification of the levels of archaeosine is not 
likely to lead to further insights. Due to our interest in deazaguanosines the routes to PreQ0 
and archaeosine (Scheme 18 and Scheme 19, respectively) were established as a natural 
product synthesis project.  
 
 
Scheme 18: Synthesis of PreQ0. 
Reagents and conditions: a) HCOOMe, NaOMe, THF, 0 °C to 10 °C, 4 h; b) NaOAc, 
2,6-diaminopyrimidine-4-one, water, THF, 50 °C to reflux, 3 h, 38 % (2 steps); c) Pivaloyl chloride, 
pyridine, 85 °C, 2.0 h, 75 %; d) POCl3, Triethylbenzylammonium chloride (TEBA), DMA, acetonitrile, 
90 °C, 1 h, 75 %; e) Acetone, conc. HCl, 0 °C, 2 h, 87 %; f) TBDMSCl, imidazole, DMF, rt, 16 h, 83 %; 
g) HMPA, tetrachloromethane, THF, -78 °C to rt, 4 h; h) NaH, acetonitrile, 0 °C to rt, 20 h, 20 %; j) 
Et3N, DABCO, NaOAc, DMF, rt, 48 h, 81 %; k) Trifluoroacetic acid, water, 0 °C, 4 h, 77 %; l) 28 % 
Ammonia in water, 60 °C, 17 h, 99 %. 
 
Synthesis of the heterocyclic building block 34 started from chloroacetonitrile 35. 
Reaction of nitrile 35 with formic acid methylester and 2,6-diaminopyrimidine-4-one in a 
one pot procedure as established by Migawa et al.[222] gave nitrile nucleobase 36. Pivaloyl 
protection of amine 36 yielded compound 37. Subsequently, the heterocycle 37 was 
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activated for the subsequent glycosylation reaction by replacement of the hydroxyl group 
at the aromatic system for chlorine.[223] By that route nucleobase 34 was obtained in 21 % 
overall yield in only four steps. 
The second building block 38 was synthesized starting from ribose 39. Protection of the 
2',3'-OH groups with acetone gave compound 40.[224] Treatment of the crude product with 
TBDMSCl provided the 5'-O-protected sugar 41 in 72 % yield. Conversion of ribose 
derivative 41 into the glycosyl donor 38 was achieved with HMPA and CCl4.[225] Due to 
the lability of compound 38, it was used for the glycosylation reaction without further 
purification. 
Glycosylation of nucleobase 34 was achieved by deprotonation of 1.4 equivalents of 
deazapurine base 34 with NaH and subsequent addition of chloro sugar 38 to the reaction 
mixture.[226] This reaction provided the nucleoside 42 in 20 % yield. Slow addition of 
sugar 38 at 0 °C and rigorously dried solvents and reagents are very important for the success 
of the reaction. 
The configuration of the obtained product 42 was verified by HMBC and NOESY 
spectroscopy. Clear interactions could be observed between C1'H and C6, C5 and C7a in the 
HMBC spectrum. Furthermore, interactions between C6H and C1' were clearly detected. 
The corresponding NOESY spectrum proved the β-configuration of the obtained 
nucleoside 42. A strong interaction between C6H and C2'H was observed. Additional 
interactions (C6H – C3'H and C6H – C5'H) usually observed for β-configured nucleosides and 
the absence of typical interactions (C6H – C4'H) in α-nucleosides further supported the 
stereochemical assignment. 
Conversion of the chloro to the needed oxo substituent in position 4 of the nucleoside 42 was 
achieved with DABCO, Et3N and NaOAc yielding nucleoside 43 (Scheme 18).[227] The 
protecting groups at the sugar moiety of the nucleoside 43 were removed using a 
water / trifluoroacetic acid mixture to give triole 44. The best method for the deprotection of 
the amine in position 2 of the nucleoside 44 proved to be 28 % ammonia in water. By this 
method the conversion of amide 44 to PreQ0 was quantitative. The transformation of 
nucleoside 42 to PreQ0 was therefore possible with 62 % yield in only three steps. The 
analytical data obtained from PreQ0 compared very well with those published by Kondo et 
al.[228] and Cheng et al.[229] 
Treatment of a solution of PreQ0 in methanol with HCl (g) for 3 h, followed by the 
removal of the solvent and stirring of the resulting white solid in 7 N ammonia in 
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methanol following classical Pinner conditions[230] indeed gave archaeosine Q* as a white 
solid as depicted in Scheme 19. 
 
 
Scheme 19: Synthesis of archaeosine. 
Reagents and conditions: HCl (g), MeOH, 7 M NH3 in MeOH, rt, 19 h, 30 %. 
 
Archaeosine was purified by reversed phase HPLC with a 0.1 M triethylammonium acetate 
buffer. The resulting white solid turned out to be archaeosine obtained as its acetate salt plus a 
small amount of additional triethylammonium acetate. Attempts to completely remove the 
excess triethylammonium acetate under high vacuum caused degradation of archaeosine 
partly back to PreQ0. However, the analytical data obtained for the product were in excellent 
agreement with those presented by Gregson et al.[218]  
In summary, a short and efficient synthesis of PreQ0 (2 % overall yield, 11 steps) and of 
archaeosine (0.6 % overall yield, 12 steps) was established. 
7.2.2 Synthesis of PreQ0 and archaeosine via the queuosine route 
 
 
Scheme 20: Synthesis of PreQ0 via the queuosine route. 
Reagents and conditions: a) MeMgCl, iPrMgCl•LiCl, TosCN, toluene, -78 °C to rt, 18 h, 60 %; 
b) 28 % NH3 in H2O, 60 °C, 16 h, 78 %. 
 
After the synthesis of PreQ0 and Q* was performed as described above, the route to queuosine 
was established. An intermediate of the queuosine synthesis, nucleoside 33, was identified as 
Chapter 7 Syntheses 
79 
an ideal precursor for PreQ0 and Q*. Starting from nucleoside 33 PreQ0 and archaeosine are 
available in a two step procedure. 
For the synthesis of PreQ0 a palladium catalyzed cross-coupling was envisioned to introduce 
the nitrile moiety. Unfortunately, cross-coupling of iodo nucleoside 33 with Cu(CN)2 did not 
reliably give acetylated PreQ0. Instead of a cross-coupling approach the iodine can also be 
converted into a metal-organic functionality. Treatment of iodo compound 33 with 
iPrMgCl•LiCl successfully created the corresponding grignard reagent, which could be 
trapped with water as an electrophile. By screening numerous reaction conditions the 
procedure for the iodine-magnesium-exchange was optimized. First, MeMgCl is used to 
deprotonate the amide groups of nucleoside 33. The iodine-magnesium-exchange is most 
efficient, when diluted turbo-grignard[231] is added very slowly at -78 °C. As shown by TLC 
and HPLC studies the exchange is almost quantitative under the conditions described in 
chapter 10.11.2.1. Trapping of the magnesium species with an electrophile turns out to be the 
lossy process in this reaction. The obtained Grignard reagent does not seem to be potent 
enough to react at -78 °C, but increasing the temperature of the reaction mixture leads to 
decomposition of the nucleoside. Therefore, the best results were obtained, when the 
electrophile was added at -78 °C and the mixture was subsequently allowed to slowly warm to 
room temperature. When TosCN was used as an electrophile nitrile nucleoside 45 was 
obtained in 60 % yield. To our best knowledge this is the first Grignard reaction with a 
nucleoside tolerating labile functional groups like esters and amides. 
Deprotection of nucleoside 45 with NH3 in water readily gave PreQ0 in 78 % yield. 
Establishment of this novel reaction and the new route to PreQ0 allows its synthesis in only 
8 steps and 5 % overall yield. This novel route reduces the number of steps and increases the 
overall yield of the PreQ0 synthesis significantly compared to the procedure published before. 
 
 
Scheme 21: Synthesis of archaeosine via the queuosine route. 
Reagents and conditions: HCl (g), MeOH, 7 M NH3 in MeOH, rt, 19 h, 40 %. 
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With nitrile nucleoside 45 in hands, the final step of the synthesis to archaeosine (Q*) is the 
conversion of this nucleoside to Q* under Pinner conditions. This approach not only converts 
the nitrile into the amidinium moiety but also removes all protecting groups in one step. 
Archaeosine was therefore obtained in 8 steps and 2 % overall yield. This novel approach to 
archaeosine improves the published routes towards this nucleosides in terms of number of 
steps and yield considerably.  
Identification of nucleoside 33 as a versatile building block in deazaguanosine synthesis and 
establishment of a reliable, functional group tolerating Grignard reaction for the introduction 
of the nitrile functionality has turned the efficient route to Q into a divergent strategy for the 
preparation of almost all deazaguanosine nucleosides. 
7.2.3 Synthesis of ms2m6A and ms2m62A 
In addition to the adenosine nucleosides presented above one natural and one unnatural 
adenosine nucleoside were synthesized without their corresponding heavy atom labeled 
derivatives. ms2m6A is a naturally occurring modification in bacterial tRNA,[232] but nothing 
is known about its biological significance. Therefore, it has not been in our main focus and 
synthesized only in unlabeled form so far. The other adenosine nucleoside prepared without 
the corresponding heavy atom labeled derivative is ms2m62A. It has not been found in RNA so 
far. 
 
 
Scheme 22: Synthesis of ms2m6A and ms2m62A. 
Reagents and conditions: a) MeNH2, rt, 16 h, 73 %; b) Me2NH, 60 °C, 16 h, 67 %. 
 
Synthesis of ms2m6A and ms2m62A were performed by treatment of nucleoside 12 with 
MeNH2 and Me2NH, respectively. Nucleoside ms2m6A was received in 73 % yield. Hence, a 
3 step route to ms2m6A with 32 % overall yield was established. Similarly, ms2m62A was 
isolated in 67 % yield resulting in a 3 step synthesis with 30 % overall yield. 
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7.2.4 Synthesis of m3C 
Methylated cytidine m3C is present in eukaryotic tRNA in position 32 and is expected to 
influence the structure of the anticodon loop.[6b] Its biosynthesis is still unknown. Due to its 
presence in eukaryotes and in the anticodon loop its quantification would be of considerable 
interest.  
 
 
Scheme 23: Synthesis of m3C. 
Reagents and conditions: Dimethylsulfate, DMF, 37 °C, 2 d, 7 %. 
 
It was synthesized following a procedure of Brookes and Lawley.[233] Dimethylsulfate was 
used as methylating agent at 37 °C for 2 days. The resulting mixture was recrystallized twice 
from MeOH to yield m3C in high purity. 
With an authentic sample in hands coinjection studies were conducted to determine the 
chromatographic properties of m3C. Unfortunately, the HPLC conditions used during this 
thesis are not suitable for separating m3C from all other methylcytidines. Therefore, an 
individual quantification of m3C is not possible at present and the synthesis of its heavy atom 
labeled derivative is not expedient at present. 
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8 Studies towards the incorporation of ms2i6A, m2A, and Q in 
RNA 
 
The investigation of biosynthesis pathways, enzyme mechanisms, and functions of 
biomolecules is to the main part based on studies with the corresponding substrates. These 
usually are truncated intermediates or the biomolecules themselves. For the investigation of 
modified nucleosides in tRNA unmodified, partially modified, or fully modified tRNAs or 
tRNA sequences, e.g. an anticodon stem-loop, can be envisioned. Completely unmodified 
tRNAs are available as transcripts of the T7 RNA polymerase[234] but the tertiary structure of 
these unmodified tRNAs in many cases differs substantially from the three-dimensional 
structure of their fully or partially modified analogs. Therefore, they are often unsuitable for 
biochemical investigations. Fully modified tRNAs or tRNAs lacking only one or two 
modification are usually necessary to allow reliable and meaningful biochemical analysis. 
These are still hardly or not at all accessible. This shortage severely hampers investigation of 
modified nucleosides.[235] Therefore, it is imperative to establish a reliable, high yielding 
method for the preparation of fully or partially modified tRNAs or tRNA sections. 
Phosphoramidite solid phase synthesis is currently the most efficient and reliable method to 
achieve this goal. 
Therefore, in the course of this thesis work the incorporation of the modified nucleosides 
ms2i6A, m2A, and Q in tRNA or tRNA sequences by phosphoramidite chemistry was studied. 
With these RNA strands in hand a door will be opened for numerous biochemical studies, 
which in turn will hopefully advance our knowledge of the biosyntheses and functions of 
modified tRNA nucleosides significantly. 
Preparation of RNA strands with modified nucleosides via phosphoramidite chemistry 
requires the availability of the modified nucleosides as phosphoramides with appropriate 
protecting groups. These are TBDMS at C2'OH and DMT at C5'OH. Several other protecting 
groups are available for C2'OH.[236] They have not been used here, because there is no consent 
in literature, which protecting group is superior and TBDMSCl is still the least expensive 
reagent in this context. 
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Scheme 24: Alternative routes to DMT-TBDMS-protected phosphoramidite 50. 
Reagents: a) DMTCl; b) TBDMSCl; c) (NiPr2)2P(OCH2CH2CN) d) tBu2Si(OTf)2, TBDMSCl; 
e) HF-pyridine; f) DMTCl. 
 
Scheme 24 shows the two usual routes used for the protection chemistry preceding solid 
phase oligonucleotide synthesis. On the left-hand side strategy the DMT-group is attached 
first.[237] DMTCl preferentially reacts with the primary alcohol at C5' of nucleoside A due to 
its high steric demand. Then TBDMSCl is used to protect the C2'OH moiety of nucleoside B. 
The regioselectivity of this reaction is generally low and usually almost equimolar amounts of 
C2'OH protected C and undesirable C3'OH protected nucleoside D are isolated. These have to 
be separated before conversion of nucleoside C to phosphoramidite D with the Bannwarth 
Reagent.  
The second strategy is outlined in Scheme 24 on the right-hand side.[238] It features an 
additional protecting group. This silyl-clamp (tBu2Si(OTf)2) is attached to nucleoside A and 
selectively masks its C3'OH and C5'OH. At this point the TBDMS group is regioselectively 
introduced at C2'OH to yield fully protected nucleoside F. After removal of the silyl-clamp 
with HF-pyridine C5'OH is selectively protected with DMTCl, which reacts with the less 
hindered primary alcohol, giving nucleoside C. Additionally, the secondary alcohol at C3' is 
shielded by the sterically demanding TBDMS group at C2'OH. In summary, the first strategy 
is shorter by one step but most likely leads to higher losses during the synthesis due to its 
lower regioselectivity.  
In consideration of the high amounts of protected nucleosides needed the second approach 
was chosen (Scheme 24 right-hand side). The reaction sequences described hereafter were 
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optimized in a way that only the final product of the sequence had to be purified by column 
chromatography. This is only possible with a highly regioselective reaction sequence and 
reduces labor time and material requisition considerably. This is especially important as it was 
anticipated that these nucleosides would be need in gram quantity and that the reactions 
would be performed repeatedly. 
 
8.1 Studies towards the incorporation of ms2i6A in RNA 
The tRNA nucleoside ms2i6A is highly modified carrying an isopentenyl and a methylthio 
substituent. Nevertheless, it was chosen as model compound to establish the protecting group 
chemistry necessary prior to attachment of the phosphoramidite moiety and solid phase 
synthesis. It was envisioned that neither the secondary amine nor the methylthio residue 
would be affected by the solid phase synthesis chemistry. Secondary amines are known to be 
compatible with phosphoramidite chemistry and Kierzek et al.[169b] have incorporated 
2-methylthio-adenosines in RNA before. The accuracy of this assumption was verified by 
prolonged treatment of ms2i6A with all reagents used during RNA synthesis. 
 
 
Scheme 25: Synthesis of nucleoside 46. 
Reagents and conditions: a) tBu2Si(OTf)2, imidazole, TBDMSCl, DMF, 0 °C to 60 °C, 3 h; 
b) HF-pyridine, pyridine, DCM, MeOTMS, 0 °C, 2 h; c) DMTCl, pyridine, MeOH, 0 °C, 16 h, 52 % 
(3 steps). 
 
For the synthesis of nucleoside 46 the conditions originally published by Serebryany and 
Beigelman[238] were used. They proofed to give good results for the protection of ms2i6A 
(Scheme 25). Introduction of the silyl-clamp and the TBDMS group gave fully protected 47 
in a one-pot reaction. Subsequently, the C3'OH-C5'OH-protecting group was removed with 
HF-pyridine and the DMT group was introduced. The crude product was purified by column 
chromatography to give nucleoside 46 in 52 % yield over 3 steps. 
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8.2 Studies towards the incorporation of m2A in RNA 
 
 
Scheme 26: Synthesis of nucleoside 48 and DMF-protected nucleoside 49. 
Reagents and conditions: a) tBu2Si(OTf)2, imidazole, TBDMSCl, DMF, 0 °C to 60 °C, 3 h. 
 
For protection of m2A with tBu2Si(OTf)2 and TBDMSCl the conditions published in 
literature[238] and used for ms2i6A gave nucleoside 48 only in unsatisfactory yields. Under 
these conditions imidazole is used as base during the silyl protection. For m2A it was found 
that imidazole catalyzes the formation of a dimethylformimide at the primary amine with 
DMF, which is used as solvent in the reaction to give side-product 49 (Scheme 26). This side-
reaction could potentially be turned into a convenient method for the protection of the amine 
at the base. But no clean conversion to imide 49 was observed under various conditions. On 
the other hand reaction conditions omitting imidazole completely inhibited formation of the 
imide and were therefore preferred. A screening of reaction conditions revealed that reduction 
of the reaction temperature to -5 °C led to good yields (Scheme 27). 
 
 
Scheme 27: Synthesis of nucleoside 51. 
Reagents and conditions: a) tBu2Si(OTf)2, TBDMSCl, DMF, -5 °C to rt, 21 h; b) Isobutyryl chloride, 
pyridine, DMF, 0 °C, 25 min; c) HF-pyridine, pyridine, DCM, MeOTMS, -13 °C to rt, 2 h; d) DMTCl, 
pyridine, MeOH, rt, 3.5 h, 37 % (4 steps). 
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In contrast to ms2i6A, for which all functional groups at the base are compatible with RNA 
solid phase synthesis, m2A features a primary amine, which has to be masked for 
phosphoramidite chemistry. Several protecting groups are conceivable. The first one tested 
here, iso-butyryl chloride, was found to give good results and was thus utilized to prepare 
amine-protected nucleoside 50 (Scheme 27). 
Nucleoside 50 turned out to be more reactive during HF deprotection than ms2i6A 
derivative 47. To achieve satisfactory yields the reaction temperature was reduced in 
comparison to the conditions established for ms2i6A and in comparison to literature.[238] 
Subsequent DMT protection proofed to be most efficient when conducted at room 
temperature for 3.5 h. This reaction sequence provided protected nucleoside 51 in 4 steps and 
37 % yield. 
 
8.3 Studies towards the incorporation of Q in RNA 
Studies towards the incorporation in RNA were conducted for three different nucleosides in 
this thesis. Of these queuosine is by far the most complex one. The final step of the current 
Q-synthesis is the acidic removal of an acetonide protecting group.[239] The highly acidic 
conditions necessary for this reaction would lead to decomposition of any RNA strand. The 
acetonide protecting group is not appropriate for incorporation of Q in RNA. Therefore, a 
post-synthetic approach was envisioned. It has been shown before, that aldehydes are 
compatible with phosphoramidite chemistry[240] and that reductive aminations can be 
performed in DNA and RNA strands.[241] Combination of these facts led to an auspicious 
strategy with two stages: First an aldehyde containing deazaguanosine nucleoside is 
incorporated in RNA. After successful RNA synthesis and deprotection of the RNA strand the 
unprotected cyclopenten moiety will be selectively attached to the aldehyde by reductive 
amination. Apart from being an ideal precursor for postsynthetic completion of the 
Q-synthesis the deazaguanosine aldehyde can also be used to attach any other amine to the 
RNA strand. The versatility of the aldehyde as linker to the RNA strand thus connects this 
project with biochemical research (e.g. by attachment of dyes or tags) and material science 
(e.g. by attachment of metals).[241b]  
During the oligonucleotide synthesis the amine at C2 of the heterocycle has to be protected. 
The pivaloyl protecting group was used during solid phase oligonucleotide synthesis before 
and is cleavable under standard deprotection conditions afterwards.[242] It can either be 
reintroduced after complete deprotection of nucleoside 33 or the benzoyl groups can be 
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removed selectively. From these two possible approaches the second one was favored as it is 
shorter by one step. 
 
 
Scheme 28: Synthesis of nucleoside 52. 
Reagents and conditions: a) 2 M NaOH, dioxane, rt, 50 min, 60 %; b) tBu2Si(OTf)2, imidazole, 
TBDMSCl, DMF, 0 °C – rt, 22 h; c) HF-pyridine, pyridine, DCM, MeOTMS, -5 °C to rt, 3 h; d) DMTCl, 
pyridine, MeOH, rt, 16 h, 69 % (3 steps); e) Pd2(dba)3, PPh3, CO, toluene, 55 °C, 1 h, 81 %. 
 
The strategy outlined above makes nucleoside 52 the final product before introduction of the 
phosphoramidite group. Formylnucleoside 52 was expected to be available via a five step 
sequence starting from fully protected 33 an intermediate of the Q-synthesis (Scheme 28). For 
this route to nucleoside 52 the first step, a chemoselective deprotection, and the last step, a 
palladium catalyzed formylation, are the key reactions. 
Full deprotection of nucleoside 33 was achieved in a straight forward manner under various 
conditions, but the chemoselective removal of all benzoyl groups, while leaving the pivaloyl 
amide untouched, proved to be challenging. A range of reaction conditions was tested. The 
only reagent giving amide 53 in more than 20 % yield was a mixture of 2 M NaOH and 
dioxane. Under these conditions nucleoside 53 was obtained in reasonable yield (60 %, 
Scheme 28).  
Introduction of the silyl-clamp and the TBDMS group to give nucleoside 54 was 
accomplished under standard conditions. For the subsequent HF-pyridine deprotection a 
reaction temperature below 0 °C was found to increase the yield considerably. DMT 
protection was executed at rt for 16 h producing iodo nucleoside 55 in 3 steps and 69 % yield. 
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The final step of this sequence was introduction of the formyl moiety. This reaction was 
performed as described in chapter 7.1.4. Fortunately, these conditions proofed to be 
compatible with the altered protecting group pattern giving nucleoside 52 in 81 % yield. 
 
In the course of this thesis work the nucleosides 46, 51, and 52, the final stable intermediates 
before RNA solid phase synthesis were prepared. Once the phosphoramidite group is 
introduced the nucleosides are air-labile and ideally should be used for RNA synthesis at 
once. The studies towards the incorporation of ms2i6A, m2A and Q in RNA strands have 
therefore been promoted to a stage, where everything is set up to start working on the actual 
RNA solid phase synthesis. At this point the project has been paused in favor of the 
quantification studies described in chapter 5, because these are currently more promising in 
terms of the scientific impact of the expected results. 
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9 Outlook 
 
In the course of the last three years almost all natural modified adenosine and many guanosine 
derivatives in RNA have been synthesized. These cover rare and abundant nucleosides as well 
as different positions in tRNA enabling a representative investigation of tRNA modifications. 
Nevertheless, it is desirable to further extend our library to facilitate the investigation of a 
larger collective of modifications. Towards this goal some methylated cytidines have already 
been synthesized during this thesis work. Further interesting cytidine modifications are m5C, 
m5Cm, f5C, and f5Cm. Prior to an extension of our library to uridine derivatives a higher 
sensitivity of their detection via mass spectrometry has to be achieved. Switching from the 
positive to the negative detection mode in concert with a higher pH of the HPLC-MS buffer is 
likely to enhance the ionization and thus the sensitivity of their measurement considerably. 
Some questions, which arose during this thesis work, like the high levels of Q in brain, remain 
unanswered and might lead to further interesting projects. A more detailed analysis of 
different brain regions and knock-outs of Q-incorporation in cell lines or mice might help to 
uncover the reasons for the high amounts of Q in the brain. 
The hypothesis, that regulation of the translational capacity in tissues is procured by modified 
nucleoside levels, rests upon the correlation between protein synthesis rates and modification 
levels in pork tissues. Especially the correlation between different in vitro translation rates 
and modification levels is currently based on limited data. To verify this correlation for all 
tissues, in vitro translation rates with tRNAs from all pork tissues should be measured. 
Similarly, the mitochondrial activity in all tissues, which were studied here, should be 
determined. Measurement of modification levels in other mammals than pig, e.g. mouse, with 
our method would probably also help to further strengthen our hypothesis and the concept of 
a conservation of modification levels across mammals, which is currently based on 
comparison of tRNA sequences. In addition, determination of protein synthesis rates and 
modified nucleoside levels in prokaryotes with and without knockouts and under different 
growth conditions might also show a correlation between these and translational activity. 
In more general terms it will be interesting to expand our quantification method to further 
natural nucleic acids, like mRNA, rRNA, mitochondrial tRNA, and viral RNA. In addition, 
and further samples, like plants, fungi, and especially tumors should be investigated. 
Application of our approach for the measurement of modified nucleosides as tumor markers 
would most likely also advance this field considerably.  
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10 Experimental 
10.1 General chemical materials and methods 
Chemicals and solvents were purchased from ABCR, Alfa Aesar, Acros, Fluka, Sigma-
Aldrich or TCI in the qualities puriss., p.a. or purum, unless stated otherwise. For all solutions 
injected into the mass spectrometer MilliQ water and mass spectrometry grade solvents and 
reagents were used. Dry solvents (< 50 ppm H2O) were obtained from Fluka and Acros. All 
reactions employing dry solvents were performed under inert atmosphere (N2). Technical 
grade solvents were distilled prior to use for column chromatography and liquid-liquid 
extractions on a rotary evaporator (RV-05-ST, Janke und Kunkel or Heidolph Laborota 4000). 
Reaction products were dried at high vacuum (10 mbar). Aqueous solutions were dried on a 
SpeedVac plus CS110A or SPD 111V from Savant or lyophilized (Christ ALPHA 2-4). 
Column chromatography was performed with silica gel 60 from Merck.  
Thin layer chromatography (TLC) was performed with aluminum plates (silica gel 60 F254, 
10 × 5 cm). Substances were visualized by illumination with UV-light (λ = 254 nm) or by 
staining with subsequent heating. The staining was performed using potassium permanganate 
solution (1.0 g KMnO4 in 100 mL H2O), anisaldehyde solution (2.2 g anisaldehyde, 2.0 mL 
conc. H2SO4, in 100 mL acetic acid), ninhydrin solution (20 g ninhydrin in 600 mL ethanol), 
or molybdatophosphoric acid solution (10 g Ce(SO4)2*H2O, 25 g molybdatophosphoric acid, 
and 60 mL H2SO4 in 940 mL H2O). 
HPLC was performed on a Merck-Hitachi system (L-7400 UV detector, L-7480 fluorescence 
detector, L-7100 pump), on a Waters system (alliance 2695 with PDA 2996 or 996 and 
fluorescence detector 2475; preparative HPLC: 1525EF with 2484 UV detector), and on a 
Dionex system (Ultimate 3000 HPLC). As columns VP 250/32 Nucleosil 100-7 C18, VP 
250/10 Nucleosil 100-7 C18, CC 250/4 Nucleosil 120-3 C18, VP 250/10 Nucleodur 100-5 
C18 ec, VP 250/4 Nucleodur 100-5 C18 ec, and CC 250/4 Nucleodur 120-3 C18 ec columns 
from Macherey-Nagel and Uptisphere120-3HDO columns from Interchim were used. 
Mass spectrometry data for EI-MS were collected with a MAT CH 7A from Varian. ESI-MS 
was performed on a Finnigan LTQ FTICR and on a Thermo Finnigan LTQ Orbitrap XL. 
MALDI-TOF was performed on a Bruker Autoflex II spectrometer with 6-aza-2-thiothymine 
(ATT) as matrix (10 mg ATT in 1 mL H2O). 
Melting points were measured with a Büchi Melting Point B-540. 
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Infrared spectroscopy was performed on a Perkin Elmer Spectrum BX FT-IR-System. The 
detection ranged from 400 to 4000 cm-1. The following abbreviations were used for the 
characterization of the bands: s (strong), m (medium), w (weak). 
NMR spectra were recorded on the following spectrometers: Varian Oxford 200, Bruker AC 
300, Varian XL 400 and Bruker AMX 600. The chemical shifts () are given in ppm, the 
coupling constants (J) in Hz. 
 
10.2 Buffers 
Name Composition 
Buffer A 0.10 M Tris-HCl, pH 7.5, 0.01 M MgCl2 
Buffer B 0.10 M Tris-HCl, pH 7.5, 0.01 M MgCl2, 1.0 M NaCl 
Buffer C 2 mM HCOONH4 in H2O, pH 5.5 
Buffer D 2 mM HCOONH4 in H2O/MeCN 20/80, pH 5.5 
Buffer E 0.1 M triethylamine/acetic acid in water 
Buffer F 0.1 M triethylamine/acetic acid in 20 % water and 80 % MeCN 
Buffer 1 0.01 M Mg(OAc)2, 0.05 M NaOAc, 0.15 M NaCl, pH 4.5 
Buffer 2 300 mM ammonium acetate, 100 mM CaCl2, 1 mM ZnSO4, pH 5.7 
Buffer 3 500 mM Tris-HCl, 1 mM EDTA, pH 8.0 
10 x NaOAc buffer NaOAc (1 M) 
2 x NaOAc-urea-
sample buffer 
0.5 M NaOAc, 6 % Ficoll™ Type 400, 0.005 % bromophenol blue, 
0.025 % xylene cyanol, 3.5 M urea 
Agarose gel buffer tris base (89 mM), boronic acid (89 mM), EDTA (2 mM) 
Agarose gel running 
buffer tris base (45 mM), boronic acid (45 mM), EDTA (1 mM) 
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10.3 Biochemical materials 
10.3.1 Equipment 
Equipment Supplier 
Äkta purifier chromatography system GE, Munich 
Agarose gel electrophoresis chamber Biorad, Munich 
Autoclave Vakulab S3000 Systec, Gießen 
Biofuge pico Heraeus, Hanau 
BioPhotometer 6131 Eppendorf, Hamburg 
Blender, Waring, 37-110 mL VWR, Darmstadt 
Centrifuge 5810R Eppendorf, Hamburg 
Fermenter Minifors Infors AG, Bottingen 
French pressure cell press Thermo, Dreieich 
Elisa Reader, FP Spectrometer Tecan, Crailsheim 
Gel scanner IDA Raytest, Straubenhardt 
Gel documentation device LAS3000 Raytest, Straubenhardt 
Inkubator 1S Noctua, Wiesloch 
Inkubator 44R New Brunswick, 
Mini Protean 3 Cell Biorad, Munich 
Multicaster Biorad, Munich 
Nanodrop UV-spectrometer Peqlab, Erlangen 
pH meter MP220 Mettler Toledo, Gießen 
Sorvall centrifuge, Evolution RC Kendro, Dreieich 
Thermomixer Comfort Eppendorf, Hamburg 
Tissue grind tube, SZ 24 VWR, Darmstadt 
TissueLyser Qiagen, Hilden 
Deep-freezer Sanyo, Bad Nenndorf 
Desktop centrifuge 5415R Eppendorf, Hamburg 
ultrasonic bath Bandelin, Berlin 
Vortexer VWR, Darmstadt 
Water bath Labora, Mannheim 
Waters Millipore System Millipore, Schwalbach 
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10.3.2 Strains 
Strain Genotype Supplier 
E. coli AG1 F
- recA1 endA1 gyrA96 thi-1 hsdR17(rk- 
mk+) supE44 relA1 
ME Collection 
E. coli 
BW25113 
rrnB DElacZ4787 HsdR514 
DE(araBAD)567 DE(rhaBAD)568 rph-1 ME Collection 
E. coli K12 wild type DSMZ, Braunschweig 
E. coli yfiF BW25113; ΔyfiF kan KEIO Collection 
E. coli ygdE BW25113; ΔygdE kan KEIO Collection 
Rosetta 2 F
– ompT hsdSB(rB– mB–) gal dcm 
pRARE23 (CamR) Novagen, Schwalbach 
S. cerevisiae wild type DSMZ, Braunschweig 
HCT-116  Cell Lines Service, Eppelheim 
HeLa  Cell Lines Service, Eppelheim 
MDA-MB-
231  Cell Lines Service, Eppelheim 
Neuro-2a  Cell Lines Service, Eppelheim 
SK-HEP-1  Cell Lines Service, Eppelheim 
MCF 7  Cell Lines Service, Eppelheim 
BT-549  Cell Lines Service, Eppelheim 
SK-MEL-2  Cell Lines Service, Eppelheim 
SK-MEL-5  Cell Lines Service, Eppelheim 
SK-MEL-28  Cell Lines Service, Eppelheim 
U-87 MG  Cell Lines Service, Eppelheim 
T-47D  Cell Lines Service, Eppelheim 
IGR-1  Cell Lines Service, Eppelheim 
 
10.3.3 Specialized system 
Name Application Supplier 
QIAamp DNA Mini Kit (250) Isolation of genomic DNA Qiagen, Hilden 
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10.3.4 Tissue samples 
Pork tissue samples were obtained from the local slaughterhouse (Schweineschlachtung 
München GmbH) right after sacrifice. All samples were processed within 4 hours after 
sacrifice. 
Mouse brain tissue samples were obtained from the Biel group. All samples were stored in 
liquid nitrogen until usage. 
10.3.5 Media 
LB medium: pH 7.5, 1.0 % (w/v) peptone, 0.5 % (w/v) yeast extract, and 0.5 % (w/v) 
sodium chloride 
Medium agar:  respective medium containing 1.5% (w/v) agar 
YPD medium: pH 7.5, 2.0 % (w/v) peptone, 1.0 % (w/v) yeast extract, and 2.0 % (w/v) 
glucose 
MOPS minimal medium was prepared according to literature with a final concentration of 
0.2 % glucose.[152] 
10.3.6 Enzymes 
Nuclease S1 (Aspergillus oryzae) was obtained from Sigma, snake venom 
phosphodiesterase I (Crotalus adamanteus venom) from USB corporation, antarctic 
phosphatase from New England Biolabs. 
 
10.4 Biochemical methods 
10.4.1 Microbiological methods 
10.4.1.1 E. coli cultures 
Bacteria were stored as glycerol stocks at -80 °C before usage. During the studies they were 
kept on LB agar at 4 °C and transferred to a new agar plate every second week. Inocula 
(50 mL) were grown over night at 37 °C shaking at 240 rpm in the medium, in which the later 
experiment was performed. 
For shaken cultures LB medium (1 L) was inoculated with an overnight culture (5 to 8 mL) 
and shaken at 240 rpm at 37 °C until OD 1 (600 nm) was reached, unless stated otherwise. To 
gain reference modification levels samples were taken at this point. For stress response 
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studies the stress factor was introduced at this point and the culture was shaken at 240 rpm at 
37 °C, unless stated otherwise, for the time indicated in Table 15. 
 
Stress type pH salt H2O2 antibiotics anaerob heat desferal 2-fluoro-adenosine 
Duration [min] 75 75 35 120 120 70 80 120 
Table 15: Summary of durations of stress exposures. 
 
For stress response studies the cultures were treated with the following chemicals: 
pH:  4 M H3PO4 for pH values lower than 7.5, 2 M NaOH for pH values 
higher than 7.5 
Salt:    addition of 5 M NaCl to a 0.4 M final concentration in the medium[153] 
Antibiotics:   chloramphenicol (0.5 and 50 g/L),[148a] streptomycin 
(0.5 and 5.0 g/L),[243] gentamycin (0.5 g/L) and spectinomycin 
(100 g/L) 
H2O2:    addition of 150 μl 30 % H2O2 in 10 mL water to the medium[154] 
Desferal:  addition of desferal to 0.5 mM final concentration in the medium[150c] 
2-Fluoro-adenosine: addition of 2-fluoro-adenosine to 0.1 M final concentration in the 
medium 
For heat stress response studies the cultures were shaken at 50 °C.[155] 
For fermentation experiments E. coli was grown in a Minifors fermenter (Infors AG, 
Bottingen). LB broth (3.0 L) was inoculated with an overnight culture (50 mL) and stirred at 
490 to 610 rpm and 37 °C. The oxygen concentration was kept at 20 % by introduction of air. 
The pH of the culture was kept at 7.5 by appropriate addition of 4 M NaOH or 4 M H3PO4. 
For aerobic growth samples (0.8 L) were taken during exponential growth at OD 2.8. 
Subsequently, medium (1.0 L) was added and the air was substituted for nitrogen. Nitrogen 
bubbled through the medium until all oxygen was removed. E. coli was fermented for another 
120 min under anaerobic conditions before a sample (0.8 L) was taken. 
For investigation of the impact of minimal medium on the modification content E. coli was 
grown in MOPS minimal medium[152] under the same conditions as stated above. Samples 
were also taken as stated in the previous paragraph. 
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Sample collection was performed as follows. After completion of growth and/or stress 
exposure the culture was quickly transferred to two precooled 500 mL centrifugal tubes 
equipped with ice. After centrifugation (8 min, 10816 g, 4 °C) the supernatants were 
discarded. The pellets were suspended in buffer 1 (10 mL, 0.01 M Mg(OAc)2, 0.05 M NaOAc, 
0.15 M NaCl, pH 4.5). The suspensions were combined in a 50 mL Falcon tube and 
centrifuged (30 min, 3220 g, 4 °C). The supernatant was discarded and the pellet was stored at 
-80 °C until further use. 
10.4.1.2 S. cerevisiae cultures 
S. cerevisiae was stored as a glycerol stock at -80 °C before usage. During the studies it was 
kept on YPD agar at 4 °C and transferred to a new agar plate every second week. Inocula 
(50 mL) were grown over night at 30 °C shaking at 240 rpm in YPD broth. 
Typically, YPD broth (1 L) was inoculated with an overnight culture (5 to 8 mL) and shaken 
at 240 rpm at 37 °C until OD 1 (600 nm) was reached. After completion of growth the culture 
was quickly transferred to two precooled 500 mL centrifugal tubes equipped with ice. After 
centrifugation (8 min, 10816 g, 4 °C) the supernatants were discarded. The pellets were 
suspended in buffer 1 (10 mL). The suspensions were combined in a 50 mL Falcon tube and 
centrifuged (30 min, 3220 g, 4 °C). The supernatant was discarded and the pellet was frozen 
at -80 °C until further use. 
10.4.1.3 Cell cultures 
Cell culture experiments were performed by Mirko Wagner. All cell lines were grown to 80 to 
90 % confluence at 37 °C and 5 % CO2 in RPMI 1640 medium containing L-glutamine 
(Invitrogen GmbH, Karlsruhe, Germany). RPMI 1640 was supplemented with 
10 % (v/v) fetal bovine serum and penicillin (10 mg/L) / streptomycin (0.025 mg/L). 
10.4.2 Molecular biological methods 
10.4.2.1 tRNA isolation from pork tissue I – phenol extraction and LiCl precipitation 
Tissue samples were cut out from inside the organ omitting surface areas, inhomogeneous 
areas, and vessels. For brain samples meninges and surface blood vessels were removed 
before processing, because for these samples surface areas could not be omitted.  
All extraction steps were performed on ice or at 4 °C. A Waring Blender was equipped with 
pork tissue (5 g), buffer 1 (15 mL) and ice. The mixture was blended until a homogenous 
suspension was obtained and transferred to a 50 mL Falcon tube. After addition of 80 % aq. 
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phenol (15 mL) the suspension was shaken vigorously for 30 min. The mixture was 
centrifuged (30 min, 3220 g). The aq. layer was collected and treated again with 80 % aq. 
phenol (20 mL). The suspension was shaken vigorously for 1 min, centrifuged (30 min, 
3220 g) and the layers were separated. The second phenol layer was extracted with buffer 1 
(5 mL). The aq. layer was collected, all aq. layers were combined and extracted with 80 % aq. 
phenol (5 mL). The aq. layer was collected and extracted with chloroform (5 mL) twice. The 
aq. layer was collected and 20 % KOAc, pH 4.5 (0.1 vol) and 12 M LiCl were added to a 
2.0 M final LiCl concentration. DNA and long RNAs were precipitated on ice for 4 h and 
pelleted by centrifugation afterwards (20 min, 38724 g). The supernatant was added to abs. 
EtOH (3.0 vol) in a 500 mL centrifugal tube and kept at -20 °C over night. After 
centrifugation (60 min, 24336 g) the supernatant was discarded and the pellet was dried. 
10.4.2.2 tRNA isolation II - desalting 
A PD10 column (GE health care) was preequilibrated with buffer A (25 mL, 0.10 M Tris-
HCl, pH 7.5, 0.01 M MgCl2). The tRNA pellet obtained from pork tissue was dissolved in 
buffer A (2.5 mL) and applied on the PD10 column. The suspension containing the crude 
tRNA was allowed to enter the column and the flow-through was discarded. The crude tRNA 
was eluted with buffer A (10 to 15 mL) until the eluant showed no UV absorbance any more. 
The obtained solution containing crude tRNA was kept at -80 °C until subjection to anion 
exchange chromatography. The utilized PD10 column was reequilibrated with buffer A 
(25 mL) and reused up to ten times. For storage PD10 columns were equilibrated with 20/80 
ethanol/water (25 mL). 
10.4.2.3 tRNA isolation from bacteria, yeast, and cancer cell lines 
The cell pellet was allowed to thaw on ice and suspended in buffer 1 (15 mL) and 80 % 
aq. phenol (15 mL) was added. Further tRNA isolation was performed as described in chapter 
10.4.2.1 for pork liver tissue. Desalting was not necessary for tRNAs isolated from bacteria, 
yeast, and cancer cell lines. The obtained tRNA pellet was kept at -80 °C until anion exchange 
chromatography was performed. 
Isolation of tRNA from cancer cell lines was performed by M. Wagner. 
10.4.2.4 tRNA purification - anion exchange chromatography 
The isolated tRNA was further purified by anion exchange chromatography. All associated 
steps were performed on ice or at 4 °C. The tRNA pellet from bacteria, yeast, and cell culture 
cells were dissolved in buffer A (10 mL). Crude tRNA from pork liver tissue entered this 
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purification phase already in solution. Remaining impurities were removed from the tRNA 
samples by weak anion exchange chromatography (DEAE Sepharose Fast Flow 5 mL, 
column volume (CV): 5 mL) utilizing an ÄKTA purifier. The gradient was 5 CV, 
0 % buffer B (25 mL, 0.10 M Tris-HCl, pH 7.5, 0.01 M MgCl2, 1.0 M NaCl); 10 CV, 0 % → 
40 % buffer B; 5 CV, 100 % buffer B; 3 CV, 0 % buffer B. The fractions eluting at about 
20 % to 40 % buffer B and showing approximately a 2:1 ration for the absorption at 254 nm 
and 280 nm were collected. To the combined fractions abs. EtOH (3.0 vol) was added and the 
mixture was kept at -20 °C over night. After centrifugation (60 min, 24366 g) the supernatant 
was discarded and the pellet was dissolved in MilliQ water (2 x 1.0 mL). In case the resulting 
tRNA concentration proved to be too low for the subsequent digestion (< 140 ng/μl) another 
EtOH precipitation step was conducted. 
10.4.2.5 DNA isolation from tissue samples and cancer cell lines 
Pork tissue samples were collected as described in chapter 10.4.2.1. Tissue samples from 
mouse brain were obtained from the Biel group. 
Early DNA isolation steps were performed on the basis of the QIAamp DNA Mini Kit. All 
steps discussed in this paragraph (except RNase) were performed as described in the kit. For 
tissues samples with more than 25 mg weight all quantities were scaled up accordingly. First, 
the samples were weighed. Tissue samples (80 mg) or whole tissues (for tissue weights 
< 80 mg), PBS and a stainless steel bead (5 mm) were added to a 2 mL reaction tube. The 
sample was homogenized in a TissueLyser (Qiagen, 30 Hz, 2 min). ATL and proteinase K 
were added and the solution was mixed by vortexing. The sample was incubated and shaken 
(600 rpm) at 56 °C for 2 h. Afterwards it was transferred into a 2 mL reaction tube removing 
the steel bead in the process. The tube was centrifuged briefly to collect the sample at the 
bottom of the tube and DNase-free RNase A (4 L per 25 mg tissue, 100 mg/mL) was added. 
After mixing the sample was incubated and shaken (600 rpm) at rt for 5 min. A second 
portion of DNase-free RNase A was added and the mixture was again incubated and shaken 
(600 rpm) at rt for 5 min. The tube was centrifuged briefly to remove drops from the lid and 
buffer AL was added. The sample was mixed by 15 s pulse-vortexing and incubated and 
shaken at 70 °C for 10 min. The tube was centrifuged briefly to remove drops from the lid. 
Following this step the sample was no longer processed on the basis of the QIAamp DNA 
Mini Kit. 
The sample was distributed equally to two 2 mL reaction tubes, if necessary. A 1/1 mixture of 
Roti®Phenol/chloroform (1.0 vol) was added and the tube was shaken vigorously at rt for 
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5 min. The tube was centrifuged (12100 g, 15 min) and the aq. layer was collected. This 
procedure was repeated once. To the obtained aq. layer chloroform (1.0 vol) was added and 
the tube was shaken at rt for 1 min. After centrifugation (12100 g, 5 min) the aq. layer was 
collected. During collection of the aq. layers special care was taken to include the interphase. 
The sample was distributed equally to two 2 mL reaction tubes, if necessary. Ethanol (3 vol) 
was added. The sample was left to stand at rt for approximately 2 h. After precipitation of the 
DNA the tube was centrifuged (12100 g, 30 min). The supernatant was discarded and the 
pellet was dried. Subsequently, it was dissolved in water (200 L). The solution was 
centrifuged (12100 g, 30 min) and the supernatant was collected. 
Isolation of DNA from cancer cell lines was performed by M. Wagner. 
10.4.2.6 Agarose gel electrophoresis 
Isolated tRNAs were analyzed on 1 % TBE agarose gels. These were run with a horizontal 
cell (Sub-Cell Bio-Rad) at 100 V. The tRNA was stained with ethidium bromide. The bands 
were visualized using a Raytest IDA gelscanner. 
Gel buffer:  tris base (89 mM), boronic acid (89 mM), EDTA (2 mM) 
Running buffer: tris base (45 mM), boronic acid (45 mM), EDTA (1 mM) 
EtBr: 1 mg/mL 
RNA-ladder: ssRNA ladder, New England BioLabs 
Isolated DNAs were analyzed on 0.8 % TAE agarose gels. These were run with a horizontal 
cell (Sub-Cell Bio-Rad) at 100 V. The DNA was stained with ethidium bromide. The bands 
were visualized using a Raytest IDA gelscanner. 
Gel buffer:  tris base (40 mM, pH 8.3), EDTA (2 mM), pH adjusted with sodium acetate 
Running buffer: tris base (20 mM, pH 8.3), EDTA (1 mM), pH adjusted with sodium acetate 
EtBr: 1 mg/mL 
RNA-ladder: 1 kb ladder, New England BioLabs 
10.4.2.7 Polyacrylamide gel electrophoresis 
Isolated tRNAs were analyzed by polyacrylamide gel electrophoresis. NaOAc gels with 7.5 % 
acrylamide (Rotiphorese sequencing gel concentrate, Roth) were used in a Mini-Protean 3-
Chamber from Biorad. Gel thickness was 0.75 mm. The gels were run at 25 or 50 mA 
constant current with a maximum voltage of 200 V. The polyacrylamide gels were stained 
agitation in SYBR Green II solution (1:10000 dilution) for 10 min. 
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Diluter: 8.3 M Urea 
10 x NaOAc buffer: NaOAc (1 M) 
2 x NaOAc-urea-sample buffer: 0.5 M NaOAc, 6 % Ficoll™ Type 400, 0.005 % bromophenol 
blue, 0.025 % xylene cyanol, 3.5 M urea 
RNA ladder: Low range ssRNA ladder, New England BioLabs 
10.4.2.8 Enzymatic digestion 
For the enzymatic digestion solutions of bulk tRNA from all samples in water (12 µg in 
100 µL final volume) were heated to 100 °C for 3 min to denature tRNA and then rapidly 
cooled on ice. After addition of buffer 2 (10 μL, 300 mM ammonium acetate, 100 mM CaCl2, 
1 mM ZnSO4, pH 5.7) and nuclease S1 (80 units, Aspergillus oryzae) the mixture was 
incubated for 3 h at 37 °C. Addition of buffer 3 (12 μL, 500 mM Tris-HCl, 1 mM EDTA, 
pH 8.0), antarctic phosphatase (10 units), snake venom phosphodiesterase I (0.2 units, 
Crotalus adamanteus venom) and incubation for further 3 h at 37 °C completed the digestion. 
All labeled nucleosides of interest were added. Then the sample was centrifuged (12100 g, 
15 min). The supernatant was removed and lyophilized to a total volume of 105 µL. Each 
digestion and HPLC-ESI-MS measurement was performed at least in triplicate with three 
independent concentrations of the appropriate labeled nucleosides. The concentrations of 
standard solutions were chosen to be in the expected range of the sample nucleoside 
concentration. 
 
10.5 Calculation of conservation of modified tRNA nucleosides in mammals 
All tRNA sequences from different mammals were collected and categorized according to the 
amino acid they carry. For each tRNA sequence the numbers of each modification of interest 
in this study were counted. The count was executed regardless of the positions of the 
modifications, because our method also does not differentiate positions in tRNA. An 
exemplary list of modification numbers for tRNAGlu is shown in Table 16. Then, the number 
of modifications in a certain tRNA were listed and compared with the number obtained for 
tRNA sequences of other mammals within this category. The differences were summed up. 
The number of theoretically possible differences was calculated. The number of actual 
differences was divided by the theoretical ones. This yielded the percentage of non-conserved 
modifications. 
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Table 16: Exemplary modification count for tRNAGlu sequences from the Sprinzl database. 
 
For tRNAGlu the modification counts are presented in Table 16. An exemplary calculation 
using only these data is discussed in the following. First, these modification number 
comparisons were made: H. sapiens – M. musculus (0 differences), H. sapiens – R. novegicus 
(2 differences), M. musculus – R. norvegicus (2 differences). Out of the nucleosides presented 
in this table five occur in position 37 (Figure 14). This means, only one of these can be 
present in a certain tRNA at a time and these five count only for one theoretically possible 
difference. Q is present in position 34 and six modifications occur at various positions in 
tRNA. Hence, there are eight theoretically possible differences for each comparison. Three 
comparison thus yield 24 theoretically possible differences. This results in 17 % non-
conserved modifications for tRNAGlu according to this calculation. 
 
10.6 HPLC-ESI-MS Materials and Methods 
10.6.1 HPLC-ESI-MS 
The samples (100 µL injection volume) were analyzed by LC-ESI-MS on a Thermo Finnigan 
LTQ Orbitrap XL and were chromatographed by a Dionex Ultimate 3000 HPLC system with 
a flow of 0.15 mL/min over an Uptisphere120-3HDO column from Interchim. The column 
temperature was maintained at 30 °C. Eluting buffers were buffer C (2 mM HCOONH4 in 
H2O, pH 5.5) and buffer D (2 mM HCOONH4 in H2O/MeCN 20/80, pH 5.5). The gradient 
was 0 → 41.25 min; 0 % → 8 % buffer D; 41.25 → 80 min; 8 % → 60 % buffer D; 80 → 
82 min; 60 % → 100 % buffer D; 82 → 100 min; 100 % buffer D; 100 → 105 min; 100 → 
0 % buffer D; 105 → 115 min; 0 % buffer D or 0 → 55 min; 0% → 8 % buffer D; 55 → 100 
min; 8% → 60% buffer D; 100 → 102 min; 60 % → 100% buffer D; 102 → 120 min; 100% 
buffer D; 120 → 125 min; 100 → 0% buffer D; 125 → 135 min; 0% buffer D. The elution 
was monitored at 260 nm (Dionex Ultimate 3000 Diode Array Detector). The 
chromatographic eluant was directly injected into the ion source without prior splitting. Ions 
were scanned by use of a positive polarity mode over a full-scan range of m/z 200-1000 with a 
resolution of 30.000. Parameters of the mass spectrometer were tuned with a freshly mixed 
solution of adenosine (5 µM) in buffer C. The parameters used in this section were sheath gas 
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flow rate, 16 arb; auxiliary gas flow rate, 10 arb; sweep gas flow rate, 4 arb; spray voltage, 
5.0 kV; capillary temperature, 200 °C; capillary voltage, 25 V, tube lens 60 V. 
10.6.2 Calibration curves and equations 
Calibration curves were measured by D. Globisch. Mass calibration curves were obtained at 
five different concentration ratios of the labeled and corresponding unlabeled synthesized 
nucleosides. For each concentration ratio an average value of three independent 
measurements was determined. Each labeled nucleoside solution was mixed with three 
solutions with different concentrations of the corresponding unlabeled nucleosides. The areas 
of labeled and unlabeled nucleosides from LC-MS measurements were determined using the 
Qualbrowser program by extraction of the accurate mass range with a mass filter (Table 17) 
from the total ion current (TIC).  
Nucleoside 
Nucleosides 
mass range m/z 
Labeled nucleosides 
mass range m/z 
Am, m6A, m1A, m2A 282.1142-282.1262 285.1335-285.1435 
t6A 413.1315-413.1475 418.1420-418.1580 
i6A 336.1606-336.1716 338.1740-338.1840 
ms2i6A 382.1484-382.1594 385.1679-385.1789 
m22G 312.1248-312.1368 315.1441-315.1561 
m2G, m1G 298.1076-298.1196 301.1276-301.1396 
Q 410.1640-410.1730 413.1778-413.1898 
m6t6A 427.1532-427.1622 430.1707-430.1807 
OHyW 525.1879-525.2029 528.2065-528.2195 
yW 509.1937-509.2037 512.2138-512.2238 
io6A 352.0915-352.2315 354.1041-354.2441 
ms2io6A 398.1423-398.1563 400.0918-400.2318 
Cm 258.0384-258.1784 261.0573-261.1973 
Table 17: High resolution mass ranges of natural and corresponding labeled nucleosides used for 
quantification. 
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From these data the area ratios unlabeled to corresponding labeled nucleoside were 
determined. The amount ratios unlabeled to corresponding labeled nucleoside were calculated 
from the employed amounts, which were known. The obtained area ratios were plotted 
against the amount ratios. The linear fits of these gave R2-values of minimum 0.9990 (Figure 
32). 
The linear fit equations were used for calculation of the exact nucleoside contents in bulk 
tRNA samples. Synthetic labeled nucleosides were added to the digest solutions and the areas 
of labeled and unlabeled nucleosides were determined as described above. The amount of 
each nucleoside was calculated from the obtained area ratios and the linear fit equations of the 
calibration curves.  
 
 
Figure 32: Calibration curves and equations for m2A, Q, ms2i6A, ms2io6A, i6A, and io6A. Calibrations 
curves for all other modified nucleosides studied in the course of this thesis will be reported by 
D. Globisch, M. Münzel, V. Welzmiller, and A. Hienzsch. 
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10.6.3 Intra- and inter-assay test 
The intra-assay test was performed by D. Globisch for nucleosides m1A, i6A, ms2i6A and 
m1G. Detailed data will be reported by D. Globisch. The determined values of labeled to 
unlabeled nucleosides using the calibration curves of a sample after enzymatic digestion 
showed good reproducibility for each nucleoside (N=5); 2.5 % for m1A, 0.4 % for i6A, 0.7 % 
for ms2i6A and 2.6 % for m1G. The single area values of each labeled or unlabeled nucleoside 
in the intra-assay test resulted in an average value of 4.1 %. The inter-assay test gave an area 
ratio reproducibility (N=6) of 6.3 % for m1A, 1.0 % for i6A, 1.8 % for ms2i6A and 4.3 % for 
m1G on six subsequent days. The determined area values on their own for each labeled or 
unlabeled nucleoside resulted in an relative standard deviation of 34.5 %. This insufficient 
reproducibility proves the necessity of the labeled nucleosides as reference. No memory effect 
was observed during blank LC/MS experiments performed after several measurements of a 
sample. The blank analyses were not contaminated by carry-over. 
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10.7 Syntheses of isopentenyl-adenosines 
10.7.1 Synthesis of i6A 
 
 
Scheme 29: Synthesis of i6A. 
Reagents and conditions: a) LiAlH4, EtO2, 0 °C to rt, 15 min; b) PBr3, Et2O, 0 °C, 30 min; c) KPhth, 
DMF, 80 °C, 30 min, 64 % (3 steps); d) hydrazine hydrate, 2 M HCl, MeOH, rt, 20 h, 99 %; e) 5, EtOH, 
60 °C, 18 h, 69 %. 
 
10.7.1.1 3-Methyl-but-2-en-1-ol (2).[244] 
 
HO  
 
LiAlH4 (7.20 g, 188 mmol, 1.10 eq) was added slowly to 3,3-dimethylacrylic acid ethyl 
ester 1 (24.0 mL, 171 mmol, 1.00 eq) in dry Et2O (100 mL) at 0 °C. After stirring at rt for 
15 min sat. NH4Cl solution (100 mL) was added carefully. The organic layer was collected. 
The aq. layer was extracted with Et2O (100 mL) twice. The organic layers were combined, 
dried over MgSO4 and the solvent was removed carefully in vacuo to a final volume of 
200 mL.  
 
Rf = 0.46 (Isohexane/ethyl acetate 1/1); 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.40 – 5.28 (m, 1H; CH), 4.13 – 4.00 (m, 2H; CH2), 
1.74 – 1.66 (m, 3H; CH3), and 1.65 – 1.58 ppm (m, 3H; CH3); 
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13C NMR (75 MHz, CDCl3, 27 °C): δ = 136.25 (Cq), 123.78 (CH), 59.33 (CH2), 25.87 (CH3), 
and 17.93 ppm (CH3); 
HR-MS (EI+) for [C5H10O]•+: calc.: 86.0726, found: 86.0713. 
 
10.7.1.2 1-Bromo-3-methyl-but-2-ene (3).[245] 
 
 
 
The equivalents given in this protocol refer to the amount of 3,3-dimethylacrylic acid ethyl 
ester 1 employed in this three step reaction sequence. The total solution obtained from the 
preceding reaction was cooled to 0 °C. PBr3 (23.0 g, 85.5 mmol, 0.50 eq) was added dropwise 
at 0 °C. After stirring at 0 °C for 30 min sat. NH4Cl solution (100 mL) was added. The 
organic layer was collected. The aq. layer was extracted with Et2O (30.0 mL) twice. The 
organic layers were combined, dried over MgSO4 and the solvent was removed carefully in 
vacuo (> 300 mbar) to yield crude bromide 3 (16.6 g). 
 
Rf = 0.79 (Isohexane/ethyl acetate 1/1); 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.55 – 5.42 (m, 1H; CH), 4.01 – 3.93 (m, 2H; CH2), 
1.76 – 1.72 (m, 3H; CH3), and 1.70 – 1.67 ppm (m, 3H; CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 140.31 (Cq), 120.93 (CH), 29.91 (CH2), 25.96 (CH3), 
and 17.70 ppm (CH3). 
 
10.7.1.3 3-Methyl-1-phthalimido-but-2-ene (4).[246] 
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The total crude product 3 (16.6 g, 112 mmol, 1.00 eq) obtained from the previous reaction 
was dissolved in DMF (100 mL), treated with KPhth (22.6 g, 122 mmol, 1.10 eq) and stirred 
at 80 °C for 30 min. The suspension was allowed to cool to rt and treated with sludge 
(100 mL). The resulting white solid was collected by filtration and dried under high vacuum 
for 18 h yielding alkene 4 (15.2 g, 64 %, 3 steps). 
 
Rf = 0.55 (Isohexane/ethyl acetate 1/1); 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 7.84 – 7.76 (m, 2H; HCAr), 7.71 – 7.62 (m, 2H; 
HCAr), 5.29 – 5.18 (m, 1H; HC), 4.27 – 4.18 (m, 2H; CH2), 1.83 – 1.76 (m, 3H; CH3), and 
1.68 – 1.66 ppm (m, 3H; CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 168.38 (CO), 137.45 (Cq,Ar), 134.00 (HCAr), 132.47 
(Cq), 123.33 (HCAr), 118.41 (CH), 36.02 (CH2), 25.85 (CH3), and 18.14 ppm (CH3); 
HR-MS (EI+) for [C13H13NO2]•+: calc.: 215.0941, found: 215.0941. 
 
10.7.1.4 3-Methyl-2-buten-1-amine (5).[179, 247] 
 
 
 
Bromide 4 (2.00 g, 9.30 mmol, 1.00 eq) and hydrazine hydrate (2.20 mL, 28.0 mmol, 3.30 eq) 
were suspended in MeOH (50.0 mL). After stirring for 2 h at rt aq. HCl (2 M, 9.30 mL) was 
added and the solution was stirred for 18 h. The precipitate was removed by filtration. The 
solution was adjusted to pH = 2 with HCl (conc. and 2 M) and extracted with Et2O (50.0 mL) 
three times. The resulting solution was adjusted to pH = 12 with NaOH (pellets and 2 M) and 
extracted with Et2O (50.0 mL) twice. These organic layers were combined and dried over 
MgSO4. The solvent was removed in vacuo (> 300 mbar) yielding amine 5 (0.78 g, 99 %) as 
colorless liquid. 
 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.28 – 5.19 (m, 1H; CH), 3.97 – 3.90 (m, 2H; CH2), 
1.78 – 1.73 (m, 3H; E-CH3), and 1.73 – 1.68 ppm (m, 3H; Z-CH3); 
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13C NMR (75 MHz, CDCl3, 27 °C): δ = 132.8 (Cq), 126.1 (CH), 39.7 (CH2), 25.6 (E-CH3), 
and 17.6 ppm (Z-CH3); 
IR: 3362 m (N-H valence), 3290 m (N-H valence), 2969 s (C-H valence), 2915 s (C-H 
valence), 2861 s (C-H valence), 1664 w (C=C valence), 1592 w (N-H deform.), 1448 m (C-H 
deform.), and 1376 cm-1 m (CH3 deform.); 
HR-MS (EI+) for [C5H11N]•+: calc.: 85.0886, found: 85.0872. 
 
10.7.1.5 6-Isopentenylamino-9-(β-D-ribofuranosyl)-9H-purine (i6A).[167, 248] 
 
 
 
Chloro-nucleoside 6 was synthesized according to literature and provided by D. Globisch. 
Nucleoside 6 (100 mg, 0.24 mmol) in EtOH (2 mL) was treated with amine 5 (0.2 mL) and 
stirred at 60 °C for 18 h. The suspension was allowed to cool to rt and the precipitate was 
collected by filtration. The solvent was removed in vacuo from the remaining solution. The 
yellow oil was treated with iPrOH and cooled to 0 °C. After standing at 0 °C for 1 h the 
precipitate was collected by filtration. The combined white solids were dried under high 
vacuum yielding i6A (56 mg, 69 %). 
Alternatively, the solvent was removed from the reaction mixture and the resulting mixture 
was recrystallized from MeOH or iPrOH. 
 
Rf = 0.60 (DCM/MeOH 8/1); 
M.p.: 130.5 – 131.2 °C; 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.27 (s, 1H; HC8), 8.25 (s, 1H; HC2), 5.98 (d, 
3J(HC1',HC2')=6.5 Hz, 1H; HC1'), 5.45 – 5.38 (m, 1H; CH2CHC(CH3)2), 4.78 (dd, 
3J(HC2',HC1')=6.5 Hz, 3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.36 (dd, 3J(HC3',HC2')=5.2 Hz, 
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3J(HC3',HC4')=2.5 Hz, 1H; HC3'), 4.20 (m, 3H; CH2CHC(CH3)2 and HC4'), 3.92 (dd, 
3J(HaC5',HbC5')=12.5 Hz, 3J(HaC5',HC4')=2.5 Hz, 1H; HaC5'), 3.78 (dd, 
3J(HbC5',HaC5')=12.5 Hz, 3J(HbC5',HC4')=2.7 Hz, 1H; HbC5'), and 1.84 – 1.76 ppm (s, 6H; 2x 
CH3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 156.19 (C6), 153.67 (C2), 149.26 (C4), 141.57 
(C8), 137.34 (CH2CHC(CH3)2), 121.62 (2C; CH2CHC(CH3)2 and C5), 91.46 (C1'), 88.37 
(C4'), 75.61 (C2'), 72.86 (C3'), 63.67 (C5'), 39.71 (CH2CHC(CH3)2), 25.97 (CH3), and 
25.40 ppm (CH3); 
IR: 3321.2 m (O-H valence, N-H valence), 3146.8 m (O-H valence, N-H valence), 2919.6 m 
(O-H valence, N-H valence), 1621.1 s (N-H deform.), 1589 m (N-H deform., aromatic 
vibration), and 1053.4 cm-1 m (C-O valence); 
HR-MS (EI+) for [C15H21N5O4]•+: calc.: 335.1588, found: 335.1588. 
 
10.7.2 Synthesis of d2-i6A. 
 
 
Scheme 30: Synthesis of d2-i6A. 
Reagents and conditions: a) LiAlD4, EtO2, rt, 5 min, 98 %; b) PBr3, Et2O, 0 °C, 30 min, 59 %; c) KPhth, 
DMF, 80 °C, 30 min, 80 %; d) hydrazine hydrate, 2 M HCl, MeOH, rt, 18 h, 95 %; e) 59, EtOH, 
60 - 80 °C, 21 h, 85 %. 
 
10.7.2.1 1-Dideutero-3-methyl-but-2-en-1-ol (56).[244a] 
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LiAlD4 (1.00 g, 25.0 mmol, 0.95 eq) was added slowly to 3,3-dimethylacrylic acid ethyl 
ester 1 (4.90 mL, 26.5 mmol, 1.00 eq) in dry Et2O (50.0 mL) at rt. After stirring at rt for 5 min 
the solution was carefully treated with sat. NH4Cl solution (50.0 mL). H2O (30.0 mL) was 
added and the organic layer was collected. The aq. layer was extracted with Et2O (50.0 mL). 
The organic layers were combined and the solvent was removed carefully in vacuo to yield 
alcohol 56 (2.30 g) as a colorless oil. 
 
Rf = 0.46 (Isohexane/ethyl acetate 1/1); 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.41 – 5.32 (m, 1H; CH), 1.74 – 1.68 (m, 3H; CH3), 
and 1.68 – 1.62 ppm (m, 3H; CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 136.70 (Cq), 123.64 (CH), 58.83 (q, 
1J(CD2,CD2)=22 Hz; CD2), 25.95 (CH3), and 18.01 ppm (CH3);  
2D-NMR (46 MHz, CDCl3, 27 °C): δ = 4.07 ppm (CD2); 
HR-MS (EI+) for [C5H8D2O]•+: calc.: 88.0852, found: 88.0844. 
 
10.7.2.2 1-Bromo-1-dideutero-3-methyl-but-2-ene (57).[244a, 245] 
 
 
 
The total crude product (2.30 g, 26.1 mmol, 1.00 eq) obtained from the preceding reaction 
was cooled to 0 °C. PBr3 (3.50 g, 13.0 mmol, 0.50 eq) was added dropwise at 0 °C. After 
stirring at 0 °C for 30 min sat. NH4Cl solution (50.0 mL) was added carefully. The organic 
layer was collected. The aq. layer was extracted with Et2O (20.0 mL) twice. The organic 
layers were combined, dried over MgSO4 and the solvent was removed carefully in vacuo 
(> 300 mbar) to yield bromide 57 (2.28 g) as a colorless liquid. 
 
Rf = 0.79 (Isohexane/ethyl acetate 1/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 5.51 – 5.47 (m, 1H; CH), 1.77 – 1.73 (m, 3H; CH3), 
and 1.71 – 1.68 ppm (m, 3H; CH3); 
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13C NMR (75 MHz, CDCl3, 27 °C): δ = 140.41 (Cq), 120.83 (CH), 29.57 (q, 
1J(CD2,CD2)=23 Hz; CD2), 25.99 (CH3), and 17.76 ppm (CH3);  
2D-NMR (46 MHz, CDCl3, 27 °C): δ = 3.99 ppm (s; CD2). 
 
10.7.2.3 1-Dideutero-3-methyl-1-phthalimido-but-2-ene (58). 
 
N
O
O
D D
 
 
The total crude product (2.28 g, 15.2 mmol, 1.00 eq) obtained from the preceding reaction 
was dissolved in DMF (20.0 mL), treated with KPhth (3.12 g, 16.9 mmol, 1.11 eq) and stirred 
at 80 °C for 30 min. The suspension was allowed to cool to rt and treated with sludge 
(20.0 mL). The resulting white solid was collected by filtration and dried under high vacuum 
for 18 h yielding alkene 58 (2.65 g, 49 %, 3 steps). 
 
Rf = 0.55 (Isohexane/ethyl acetate 1/1); 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 7.85 – 7.74 (m, 2H; HCAr), 7.72 – 7.62 (m, 2H; 
HCAr), 5.28 – 5.19 (m, 1H; CH), 1.82 – 1.77 (m, 3H; CH3), and 1.70 – 1.66 ppm (m, 3H; 
CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 168.35 (CO), 137.52 (Cq,Ar), 133.98 (CHAr), 132.49 
(Cq), 123.31 (CHAr), 118.29 (CH), 35.55 (q, 1J(CD2,CD2)=21 Hz; CD2), 25.85 (CH3), 
18.15 ppm (CH3). 
 
10.7.2.4 1-Dideutero-3-methyl-2-buten-1-amine (59). 
 
H2N
D D
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Phthalimide 58 (2.65 g, 12.2 mmol, 1.0 eq) and hydrazine hydrate (2.9 mL, 36.4 mmol, 
3.0 eq) were suspended in MeOH (50 mL). After stirring for 1.5 h at rt aq. HCl (2 M, 
12.0 mL) was added and the solution was stirred for 18 h. The precipitated solid was removed 
by filtration. The solution was adjusted to pH = 2 using HCl (2 M and 37 %) and the 
precipitate was removed by filtration. The resulting solution was adjusted to pH = 12 (pellets 
and 2 M) and extracted twice with Et2O (30 mL). The combined organic layers were dried 
over MgSO4. The solvent was removed in vacuo (> 300 mbar) yielding a 3 to 1 mixture of 
MeOH and amine 59 (2.13 g, 95 %) as determined by CDCl3-NMR) as colorless liquid. 
 
1H NMR (300 MHz, CD3OD, 27 °C): δ = 5.32 – 5.28 (m, 1H; CH), 1.77 – 1.75 (d, 3H; E-
CH3), and 1.71 – 1.68 ppm (d, 3H; Z-CH3); 
13C NMR (75 MHz, CD3OD, 27 °C): δ = 134.58 (Cq), 126.04 (CH), 39.7 (q, 1J(CD2, 
CD2)=21 Hz; CD2), 25.99 (E-CH3), and 17.85 ppm (Z-CH3); 
2D-NMR (61 MHz, CD3OD, 27 °C): δ = 3.32 ppm (CD2); 
HR-MS (EI+) for [C5H9D2N]•+: calc.: 87.1012, found: 87.1012. 
 
10.7.2.5 6-(1-Dideutero-3-methyl-2-buten-1-amino)-9-(β-D-ribofuranosyl)-9H-purine 
(d2-i6A). 
 
N
N
N
N
O
OHOH
HO
NH
D D
 
 
Nucleoside 6 (623 mg, 1.50 mmol, 1.00 eq) in EtOH (7.30 mL) was treated with amine 65 
(1040 mg, 12.0 mmol, 8.00 eq) and stirred at 60 °C for 18 h and at 80 °C for 5 h. The solvent 
was removed in vacuo and the resulting mixture was recrystallized from iPrOH three times. 
The white solid was dried under high vacuum to yield d2-i6A (435 mg, 85 %) with less than 
3 weight% iPrOH as determined by NMR. 
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Rf = 0.60 (DCM/MeOH 8/1); 
1H NMR (600 MHz, CD3OD, 27 °C): δ = 8.24 (s, 1H; HC8), 8.22 (s, 1H; HC2), 5.95 (d, 
3J(HC2',HC1')=6.5 Hz, 1H; HC1'), 5.41 – 5.34 (m, 1H; CD2CHC(CH3)2), 4.74 (dd, 
3J(HC2',HC1')=6.5 Hz, 3J(HC2',HC3')=5.1 Hz, 1H; HC2'), 4.32 (dd, 3J(HC3',HC2')=5.1 Hz, 
3J(HC3',HC4')=2.5 Hz, 1H; C3'H), 4.17 (ddd, 3J(HC4',HbC5')=2.6 Hz, 3J(HC4',HC3')=2.5 Hz, 
3J(HC4',HaC5')=2.4 Hz, 1H; HC4'), 3.89 (dd, 3J(HaC5',HbC5')=12.6 Hz, 3J(HaC5',HC4')=2.4 Hz, 
1H; HaC5'), 3.74 (dd, 3J(HbC5',HaC5')=12.6 Hz, 3J(HbC5',HC4')=2.6 Hz, 1H; HbC5'), and 
1.18 ppm (m, 6H; 2x CH3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 156.21 (C6), 153.66 (C2), 149.09 (C4), 
141.59(C8), 137.40 (CH2CHC(CH3)2), 121.48 (2C; CH2CHC(CH3)2 and C5), 91.46 (C1'), 
88.39 (C4'), 75.59 (C2'), 72.88 (C3'), 63.68 (C5'), 26.00 (CH3), and 25.40 ppm (CH3); 
HR-MS (ESI+) for [C15H20D2N5O4]+: calc.: 338.1790, found: 338.1781. 
 
10.7.3 Synthesis of ms2i6A 
 
 
Scheme 31: Synthesis of ms2i6A. 
Reagents and conditions: a) 2-Methyl-3-buten-2-ol, NaH, trichloro acetonirile, THF, Et2O, 0 °C to rt, 
2 h; b) toluene, 115 °C, 2 h, 67 % (2 steps); c) 3 N KOH, DMF, rt, 4 h, 45 %; d) Ac2O, DMF, pyridine, 
75 °C, 1.5 h, 87 %; e) POCl3, DMA, Et4NCl, MeCN, 100 °C, 10 min, 51 %; f) Dimethyldisulfide, 
N-pentyl-nitrite, MeCN, 70 °C, 1.5 h, 65 %; g) 5 (neat), 50 °C, 1.5 h, 74 %. 
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10.7.3.1 2,2,2-Trichloro-acetimidic acid 1,1-dimethyl-allyl ester (8).[179] 
 
O CCl3
NH  
 
NaH (60 % in paraffin oil, 1.20 g, 25 mmol, 0.22 eq) was suspended in dry hexane (20.0 mL). 
The solids were allowed to settle and the solvent was removed by use of a syringe. This 
procedure was repeated once. The remaining hexane was removed in vacuo. The resulting 
solid was suspended in dry THF (5.00 mL) and cooled to 0 °C. 2-Methyl-3-buten-2-ol 7 
(12.0 mL, 116 mmol, 1.00 eq) in dry THF (10.0 mL) and added dropwise to the NaH 
suspension. After stirring for 1 h at rt, the suspension was added slowly to trichloro 
acetonitrile (11.6 mL, 116 mmol, 1.00 eq) in ether (100 mL) at 0 °C. The resulting suspension 
was stirred for 1 h at 0 °C. The solvent was removed in vacuo (> 330 mbar, 40 °C). 
 
10.7.3.2 N-(3-Methyl-2-butenyl)-2,2,2-trichloroacetamide (9).[179] 
 
N
H
CCl3
O
 
 
Crude 8 was diluted with toluene (100 mL) and heated to 115 °C for 2 h. The solvent was 
removed in vacuo. The resulting mixture was distilled at 90 °C – 140 °C and 30 – 14 Pa to 
give allyl amide 9 (17.8 g, 67 %, 2 steps) as white solid.  
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.25 – 5.21 (m, 1H; CH), 3.95 – 3.91 (m, 2H; CH2), 
1.75 (s, 3H; E-CH3), and 1.71 ppm (s, 3H; Z-CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 161.86 (CO), 138.85 (Cq), 118.31 (CH), 92.84 (CCl3), 
39.67 (CH2), 25.89 (E-CH3), and 18.22 ppm (Z-CH3); 
HR-MS (ESI+) for [C7H11Cl3NO]+: calc.: 229.9901, found: 229.9893. 
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10.7.3.3 3-Methyl-2-buten-1-amine (5).[179] 
 
NH2 
 
Molten 9 (17.8 g, 78.0 mmol) was added dropwise to 3 N KOH (200 mL) and DMF 
(4.00 mL). The mixture was stirred at rt for 4 h. The resulting solution was extracted with 
diethyl ether (50.0 mL) three times. The combined organic phases were washed with brine 
(50.0 mL). Careful removal of the solvent yielded a light yellow liquid, which was purified by 
distillation (95 – 100 °C, atmospheric pressure) to give amine 5 (3.00 g, 45 %) as colorless 
liquid.  
 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.28 – 5.19 (m, 1H; CH), 3.97 – 3.90 (m, 2H; CH2), 
1.78 – 1.73 (m, 3H; E-CH3), and 1.73 – 1.68 ppm (m, 3H; Z-CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 132.8 (Cq), 126.1 (CH), 39.7 (CH2), 25.6 (E-CH3), 
and 17.6 ppm (Z-CH3); 
IR: 3362 m (N-H valence), 3290 m (N-H valence), 2969 s (C-H valence), 2915 s (C-H 
valence), 2861 s (C-H valence), 1664 w (C=C valence), 1592 w (N-H deform.), 1448 m (C-H 
deform.), and 1376 cm-1 m (C-H deform.); 
HR-MS (EI+) for [C5H11N]•+: calc.: 85.0886, found: 85.0872. 
 
10.7.3.4 6-Oxo-2-amino-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine (10).[181] 
 
 
 
Guanosine (5.00 g, 18.0 mmol, 1.00 eq) was suspended in pyridine (10.0 mL) and DMF 
(12.0 mL). Acetic acid anhydride (20.0 mL, 212 mmol, 12.0 eq) was added and the mixture 
was stirred at 75 °C until all solid material disappeared (approximately 1.5 h). Ethanol 
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(1.00 mL) was added and the solution was filtered. The solvent was removed in vacuo and the 
resulting gummy white solid was refluxed in isopropanol (20.0 mL). After cooling to 0 °C 
Nucleoside 10 (6.33 g, 87 %) precipitated as white solid and was collected.  
 
Rf = 0.20 (DCM/MeOH 16/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 10.69 (s, 1H; HN), 7.92 (s, 1H; HC8), 6.52 (s, 
2H; NH2), 5.98 (d, 3J(HC1',HC2')=6.4 Hz, 1H; HC1'), 5.79 (dd, 3J(HC2',HC1')=6.4 Hz, 
3J(HC2',HC3')=6.0 Hz, 1H; HC2'), 5.49 (dd, 3J(HC3',HC2')=6.0 Hz, 3J(HC3',HC4')=4.2 Hz, 1H; 
HC3'), 4.40 (dd, 2J(HaC5',HbC5')=11.8 Hz, 3J(HaC5',HC4')=4.0 Hz, 1H; HaC5'), 4.31 (ddd, 
3J(HC4',HbC5')=5.8 Hz, 3J(HC4',HC3')=4.2 Hz, 3J(HC4',HaC5')=4.0 Hz, 1H; HC4'), 4.26 (dd, 
2J(HaC5',HbC5')=11.7 Hz, 3J(HbC5',HC4')=5.8 Hz, 1H; HbC5'), 2.11 (s, 3H; H3CCO), 2.04 (s, 
3H; H3CCO), and 2.04 ppm (s, 3H; H3CCO); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 170.0 (CH3CO), 169.3 (CH3CO), 169.1 
(CH3CO), 156.5 (C4), 153.8 (C2), 151.0 (C6), 135.5 (C8), 116.7 (C5), 84.3 (C1'), 79.4 (C4'), 
71.9 (C2'), 70.2 (C3'), 63.0 (C5'), 20.4 (CH3CO), 20.3 (CH3CO), and 20.1 ppm (CH3CO); 
IR: 3408 m (N-H valence), 3164 m (N-H valence), 2864 w (C-H valence), 2735 w (C-H 
valence), 1755 m (C=O valence), 1740 m (C=O valence), 1692 s (C=O valence), 1669 s (C=O 
valence), 1600 m (N-H deform.), 1379 m (CH3 deform.), 1224 s (C-O-C valence), and 
1204 cm-1 s (C-O-C valence); 
HR-MS (ESI+) for [C16H20N5O8]+: calc.: 410.1306, found: 410.1305. 
 
10.7.3.5 6-Chloro-2-amino-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine (11).[181] 
 
N
N
N
Cl
NH2NO
OAcOAc
AcO
 
 
Acetylated G 10 (1.00 g, 2.44 mmol, 1.00 eq), Et4NCl (0.81 g, 4.88 mmol, 2.00 eq), DMA 
(0.30 mL, 2.44 mmol, 1.00 eq), and POCl3 (1.40 mL, 16.6 mmol, 6.00 eq) were dissolved in 
MeCN (5.00 mL) and the mixture was stirred at 100 °C for a period of 10 min. The solvent 
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was removed in vacuo and the resulting oil was treated with water (30.0 mL). The solution 
was extracted with CHCl3 (3 × 30.0 mL). The combined organic phases were washed with sat. 
NaHCO3 (50.0 mL) and dried over MgSO4. Purification via column chromatography gave 
nucleoside 11 (0.54 g, 51 %) as white foam.  
 
Rf = 0.20 (DCM/MeOH 16/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 8.35 (s, 1H; HC8), 7.04 (s, 2H; NH2), 6.10 (d, 
3J(HC1',HC2')=6.0 Hz, 1H; HC1'), 5.87 (dd, 3J(HC2',HC1')=6.0 Hz, 3J(HC2',HC3')=5.9 Hz, 1H; 
HC2'), 5.54 (dd, 3J(HC3',HC2')=5.9 Hz, 3J(HC3',HC4')=4.2 Hz, 1H; HC3'), 4.40 (dd, 
2J(HaC5',HbC5')=11.2 Hz, 3J(HaC5',HC4')=4.2 Hz, 1H; HaC5'), 4.43 (ddd, 
3J(HC4',HbC5')=5.3 Hz, 3J(HC4',HC3')=4.2 Hz, 3J(HC4',HaC5')=4.2 Hz, 1H; HC4'), 4.28 (dd, 
2J(HbC5',HaC5')=11.2 Hz, 3J(HbC5',HC4')=5.3 Hz, 1H; HbC5'), 2.12 (s, 3H; H3CCO), 2.04 (s, 
3H; H3CCO), and 2.03 ppm (s, 3H; H3CCO); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 170.0 (CH3CO), 169.3 (CH3CO), 169.1 
(CH3CO), 159.8 (C4), 153.6 (C6), 149.8 (C2), 141.1 (C8), 123.4 (C5), 84.8 (C1'), 79.6 (C4'), 
71.8 (C2'), 70.1 (C3'), 62.8 (C5'), 20.4 (CH3CO), 20.3 (CH3CO), and 20.1 ppm (CH3CO); 
IR: 3475 w (N-H valence), 3361 w (N-H valence), 3212 w (N-H valence), 2941 w (C-H 
valence), 1741 s (C=O valence), 1610 s (N-H deform.), 1561 s (N-H deform.), 1370 w (CH3 
deform.), and 1211 cm-1 s (C-O-C valence); 
HR-MS (ESI+) for [C16H19ClN5O7]+: calc.: 428.0968, found: 428.0963. 
 
10.7.3.6 6-Chloro-2-methylthio-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 
(12).[169b] 
 
N
N
N
Cl
SN
O
OAcOAc
AcO
 
 
Nucleoside 11 (100 mg, 0.23 mmol, 1.00 eq) and dimethyldisulfide (0.21 mL, 2.30 mmol, 
10.0 eq) were dissolved in dry MeCN (2.00 mL). N-pentyl-nitrite (0.16 mL, 1.15 mmol, 
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5.00 eq) was added and the mixture was stirred 1 h at rt and 1.5 h at 70 °C. The solvent was 
removed in vacuo and the resulting oil was purified via column chromatography yielding 
nucleoside 12 (70 mg, 65 %) as yellow foam.  
 
Rf = 0.58 (DCM/MeOH 16/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 8.68 (s, 1H; HC8), 6.29 (d, 
3J(HC1',HC2')=4.2 Hz, 1H; HC1'), 6.04 (dd, 3J(HC2',HC1')=4.2 Hz, 3J(HC2',HC3')=6.0 Hz, 1H; 
HC2'), 5.69 (dd, 3J(HC3',HC2')=6.0 Hz, 1H; HC3'), 4.44 – 4.37 (m, 2H; HaC5' and HC4'), 
4.26 - 4.18 (m, 1H; HbC5'), 2.62 (s, 3H; SCH3), 2.11 (s, 3H; H3CCO), 2.07 (s, 3H; H3CCO), 
and 1.95 ppm (s, 3H; H3CCO); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 169.93 (CH3CO), 169.36 (CH3CO), 169.23 
(CH3CO), 165.52 (C2), 151.97 and 149.54 (C6 and C4), 145.17 (C8), 128.58 (C5), 86.70 
(C1'), 79.07 (C4'), 72.02 (C2'), 69.51 (C3'), 62.45 (C5'), 20.34 (CH3CO), 20.29 (CH3CO), 20.21 
(CH3CO), and 14.19 ppm (SCH3); 
IR: 2933 w (C-H valence, O-H valence), 1742 s (C=O valence), 1595 m (N-H deform., 
aromatic vibration), 1548 m (N-H deform.), 1361 m (C-N valence), and 1205 cm-1 s (C-O-C 
valence); 
HR-MS (ESI+) for [C17H20ClN4O7S]+: calc.: 459.0736, found: 459.0742. 
 
10.7.3.7 6-(3-methyl-2-butenyl-1-amino)-2-methylthio-9-(β-D-ribofuranosyl)-9H-purine 
(ms2i6A).[170b] 
 
 
 
Nucleoside 12 (1.50 g, 3.38 mmol, 1.00 eq) was dissolved in amine 5 (3.00 mL) and stirred at 
50 °C for 1.5 h. The solvent was removed in vacuo. The resulting oil was coevaporated with 
DCM (10.0 mL) three times. The obtained solid was refluxed in MeCN (5.00 mL) for 5 min. 
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After cooling to rt a white solid was collected by filtration and refluxed in water (5.00 mL) for 
5 min. After cooling to rt the white solid was collected by filtration to give ms2i6A (0.95 g, 
74 %) as white solid. 
 
Rf = 0.49 (DCM/MeOH 8/1); 
M.p.: 192.6 – 193.3; 
1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 8.21 (s, 1H; HC8), 7.97 (s, 1H; HN), 5.83 (d, 
3J(HC1',HC2')=5.8 Hz, 1H; HC1'), 5.42 (d, 3J(C2'OH,HC2')=5.4 Hz, 1H; C2'OH), 5.32 – 5.25 
(m, 1H; CH2CHC(CH3)2), 5.18 (d, 3J(C3'OH,HC3')=4.2, 1H; C3'OH), 5.04 (t, 
3J(C5'OH,H2C5')=4.9 Hz, 1H; C5'OH), 4.63 – 4.57 (m, 1H; HC2'), 4.18 – 4.13 (m, 1H; HC3'), 
4.10 – 3.98 (m, 2H; CH2CHC(CH3)2), 3.96 – 3.89 (m, 1H; HC4'), 3.68 – 3.59 (m, 1H; HaC5'), 
3.57 – 3.50 (m, 1H; HbC5'), 2.48 (s, 3H; SCH3), 1.70 (s, 3H; CH3), and 1.66 ppm (s, 3H; CH3); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 164.15 (C2), 153.48 (C4), 149.39 (C6), 138.51 
(C8), 133.29 (CH2CHC(CH3)2), 121.92 (CH2CHC(CH3)2), 117.25 (C5), 87.32 (C1'), 85.48 
(C4'), 73.32 (C2'), 70.50 (C3'), 61.58 (C5'), 37.62 (CH2CHC(CH3)2), 25.42 (CH3), 17.86 (CH3), 
and 13.83 ppm (SCH3); 
IR: 3250 m (N-H valence), 2946 w (C-H valence), 1611 s (N-H deform.), 1579 m (N-H 
deform.), 1298 m (C-N valence), and 1079 cm-1 m (C-O valence); 
HR-MS (ESI+) for [C16H24N5O4S]+: calc.: 382.1544, found: 382.1535. 
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10.7.4 Synthesis of d3-ms2i6A 
 
 
Scheme 32: Synthesis of d3-ms2i6A. 
Reagents and conditions: a) d6-Dimethyldisulfide, N-pentyl-nitrite, MeCN, 70 °C, 5 min, 78 %; 
b) 5 (neat), 40 °C, 16 h, 39 %. 
 
10.7.4.1 6-Chloro-2-trideuteromethylthio-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-
purine (13). 
 
 
 
Nucleoside 11 (905 mg, 2.12 mmol, 2.00 eq) and d6-dimethyldisulfide (100 mg, 1.06 mmol, 
1.00 eq) were dissolved in dry MeCN (4.00 mL). N-pentyl-nitrite (0.56 mL, 4.24 mmol, 
4.00 eq) was added and the mixture was stirred for 5 min at 70 °C. Silica gel was added and 
the solvent was removed in vacuo. Purification via column chromatography yielded 
nucleoside 13 (382 mg, 78 %) as yellow foam. 
 
Rf = 0.58 (DCM/MeOH 16/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 8.08 (s, 1H; HC8), 6.09 (d, 3J(HC1',HC2')=4.5 Hz, 
1H; HC1'), 5.96 (dd, 3J(HC2',HC1')=4.5 Hz, 3J(HC2',HC3')=5.5 Hz, 1H; HC2'), 5.62 (dd, 
3J(HC3',HC2')=5.5 Hz, 1H; HC3'), 4.43 – 4.39 (m, 2H; HaC5' and HC4'), 4.31 – 4.26 (m, 1H; 
HbC5'), 2.14 (s, 3H; H3CCO), 2.12 (s, 3H; H3CCO), and 2.08 ppm (s, 3H; H3CCO); 
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13C NMR (151 MHz, CDCl3, 27 °C): δ = 170.50 (CH3CO), 169.70 (CH3CO), 169.51 
(CH3CO), 167.60 (C2), 152.12 and 151.48 (C6 and C4), 142.39 (C8), 129.25 (C5), 87.27 
(C1'), 80.24 (C4'), 73.14 (C2'), 70.34 (C3'), 62.91 (C5'), 20.91 (CH3CO), 20.70 (CH3CO), 20.59 
(CH3CO), and 14.52 ppm (sept, 1J(CD3,CD3)=21 Hz; CD3); 
HR-MS (ESI+) for [C17H17D3ClN4O7S]+: calc.: 462.0921, found: 462.0932. 
 
10.7.4.2 6-(3-methyl-2-butenyl-1-amino)-2-trideuteromethylthio-9-(β-D-ribofuranosyl)-
9H-purine (d3-ms2i6A). 
 
 
 
Nucleoside 13 (50 mg, 0.11 mmol) was dissolved in amine 5 (0.5 mL) and stirred at 40 °C for 
18 h. The solvent was removed in vacuo. The resulting oil was coevaporated with DCM 
(10 mL) three times. The obtained solid was purified by HPL chromatography to give d3-
ms2i6A (16 mg, 39 %) as white solid. 
 
Rf = 0.49 (DCM/MeOH 8/1); 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.32 (s, 1H; HC8), 6.16 (d, 3J(HC1',HC2')=5.8 Hz, 
1H; HC1'), 5.67 – 5.59 (m, 1H; CH2CHC(CH3)2), 5.02 (dd, 3J(HC2',HC1')=5.8 Hz, 
3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.60 (dd, 3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=3.7 Hz, 1H; 
HC3'), 4.49 – 4.41 (m, 2H; CH2CHC(CH3)2), 4.37 (ddd, 3J(HC4',HC3')=3.7 Hz, 
3J(HC4',HC5b')=3.4 Hz, 3J(HC4',HC5a')=2.8 Hz, 1H; HC4'), 4.11 (dd, 2J(HaC5',HbC5')=12.3 Hz, 
3J(HaC5',HC4')=2.8 Hz, 1H; HaC5'), 3.98 (dd, 1H; 2J(HbC5',HaC5')=12.3 Hz, 
3J(HbC5',HC4')=3.4 Hz, HbC5'), 2.02 (s, 3H; CH3) and 2.01 ppm (s, 3H; CH3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 140.29 (C8), 136.92 ((CH3)2CCH2), 122.03 (CH), 
118.74 (C5), 91.00 (C1'), 87.72 (C4'), 75.33 (C2'), 72.55 (C3'), 63.51 (C5'), 39.49 (CH2), 25.98 
(CH3), and 18.19 ppm (CH3); 
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HR-MS (ESI+) for [C16H21D3N5O4S]+: calc.: 385.1729, found: 385.1736; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 0 % H2O, 100 % MeCN in 45 min; retention 
time = 26.6 min; flow 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
 
10.7.5 Synthesis of io6A 
 
 
Scheme 33: Synthesis of io6A. 
Reagents and conditions: a) 2-(Diethoxy-phosphoryl)-propionic acid ethyl ester, nBuLi, THF, -78 °C to 
rt, 3 h, 55 %; b) LiAlH4, Et2O, -78 °C to rt, 2 h, 75 %; c) 2 M HCl, rt, 4 h, 94 %, d) 14, Et3N, MeOH, 
60 °C, 48 h, 28 %. 
 
10.7.5.1 Z- and E-4-tert-butoxycarbonylamino-2-methyl-but-2-enoic acid ethyl ester 
(16).[249] 
 
 
 
nBuLi (2.5 M, 2.64 mL, 6.60 mmol, 1.05 eq) was added dropwise to 2-(diethoxy-phosphoryl)-
propionic acid ethyl ester 15 (1.01 mL, 6.60 mmol, 1.05 eq) in dry THF (30.0 mL) at rt. The 
resulting solution was cooled to -78 °C and (2-Oxo-ethyl)-carbamic acid tbutyl ester (1.00 g, 
6.28 mmol, 1.00 eq) in dry THF (30.0 mL) was added dropwise at -78 °C. The mixture was 
stirred at -78 °C for 3 h. The reaction was allowed to warm to rt and H2O (40.0 mL) and sat. 
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NH4Cl solution (40.0 mL) was added carefully. The organic layer was collected. The aq. layer 
was extracted with DCM (50.0 mL) twice. The combined organic layers were extracted with 
brine (50.0 mL) and dried over MgSO4. The solvent was removed in vacuo and the resulting 
oil was purified by column chromatography (Isohexane/ethyl acetate 3/2) to yield ester 16 
(698 mg, 46 %) and its E-derivative (136 mg, 9 %). 
 
Z-alkene (16): 
Rf = 0.66 (Isohexane/ethyl acetate 1/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 6.64 – 6.60 (m, 1H; CH2CHC(CH3)CO2Et), 
4.70 - 4.59 (m, 1H, HN), 4.17 (q, 3J(CO2CH2CH3,CO2CH2CH3)=7.1 Hz, 2H; CO2CH2CH3), 
3.94 – 3.82 (m, 2H; CH2CHC(CH3)CO2Et), 1.88 – 1.80 (m, 3H; CH2CHC(CH3)CO2Et), 1.43 
(s, 9H; C(CH3)3), and 1.27 ppm (t, 3J(CO2CH2CH3,CO2CH2CH3)=7.1 Hz, 3H; CO2CH2CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 171.34 (CO2C(CH3)3), 167.77 (CO2Et), 155.92 
(CH2CHC(CH3)CO2Et), 138.03 (CH2CHC(CH3)CO2Et), 129.80 (CH2CHC(CH3)CO2Et), 
79.91 (C(CH3)3), 60.95 (CO2CH2CH3), 28.60 (C(CH3)3), 14.46 (COOCH2CH3), and 
12.78 ppm (CHCCH3COOEt); 
HR-MS (ESI+) for [C12H25N2O4]+: calc.: 261.1809, found: 261.1802. 
 
E-alkene: 
Rf = 0.61 (Isohexane/ethyl acetate 1/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 5.98 – 5.84 (m, 1H; CH2CHC(CH3)CO2Et), 
5.13 - 4.96 (m, 1H, HN), 4.16 (q, 3J(CO2CH2CH3,CO2CH2CH3)=7.1 Hz, 2H; CO2CH2CH3), 
4.04 – 3.92 (m, 2H; CH2CHC(CH3)CO2Et), 1.82 – 1.78 (m, 3H; CHCCH3CO2Et), 1.34 (s, 9H; 
C(CH3)3), and 1.25 ppm (t, 3J(CO2CH2CH3,CO2CH2CH3)=7.1 Hz, 3H; CO2CH2CH3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 167.66 (CO2C(CH3)3), 167.48 (CO2Et), 156.09 
(CH2CHC(CH3)CO2Et), 140.45 (CH2CHC(CH3)CO2Et), 129.06 (CH2CHC(CH3)CO2Et), 
79.39 (C(CH3)3), 60.78 (CO2CH2CH3), 28.49 (C(CH3)3), 20.19 (CH2CHC(CH3)CO2Et), and 
14.46 ppm (CO2CH2CH3); 
HR-MS (ESI+) for [C12H22NO4]+: calc.: 244.1543, found: 244.1536. 
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10.7.5.2 (Z)-(4-Hydroxy-3-methyl-but-2-enyl)-carbamic acid tbutyl ester (17).[184, 249b, 250] 
 
 
 
Alkene 16 (500 mg, 2.06 mmol, 1.00 eq) in dry Et2O (2.50 mL) was cooled to -78 °C. LiAlH4 
(1 M, 2.26 mL, 2.26 mmol, 1.10 eq) was added dropwise. The mixture was stirred at -78 °C 
for 2 h, allowed to warm to rt and afterwards carefully treated with sat. NH4Cl solution 
(10.0 mL) and water (10.0 mL). Et2O (20.0 mL) was added and the layers were separated. 
The aq. layer was extracted with Et2O (20.0 mL) twice. The combined organic layers were 
extracted with brine (30.0 mL) and dried over MgSO4. Removal of the solvent in vacuo 
(> 300 mbar) yielded crude alcohol 17 (331 mg, 75 %) as colorless oil.  
 
Rf = 0.21 (Isohexane/ethyl acetate 1/1); 
1H NMR (200 MHz, CDCl3, 27 °C): δ = 5.32 – 5.20 (m, 1H; CH), 4.14 – 4.07 (m, 2H, CH2O), 
3.77 – 3.67 (m, 2H; CH2N), 1.84 – 1.77 (m, 3H, CH3), and 1.41 ppm (s, 9H, C(CH3)3). 
 
10.7.5.3 (Z)-4-Ammonium-2-methyl-but-2-en-1-ol chloride (14).[249b] 
 
 
 
Crude 17 (310 mg, 1.55 mmol) in aq. HCl (2 M, 10.0 mL) was stirred at rt for 4 h. The 
solvent was removed in vacuo. The resulting oil was treated with MeOH (10.0 mL) and the 
solvent was removed in vacuo. This coevaporation was repeated once. The resulting red solid 
was dried under high vacuum for 16 h yielding crude 14 (206 mg, 94 %). 
 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.48 – 5.40 (m, 1H; CH), 4.18 – 4.15 (m, 2H; 
CH2O), 3.69 – 3.64 (m, 2H; CH2N), and 1.88 – 1.85 ppm (m, 3H; CH3); 
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13C NMR (75 MHz, CDCl3, 27 °C): δ = 145.38 (Cq), 119.02 (CH), 62.01 (CH2O), 37.81 
(CH2N), and 21.95 ppm (CH3); 
HR-MS (EI+) for [C5H9NO]•+: calc.: 99.0679, found: 99.0673. 
 
10.7.5.4 6-[(Z)-4-Amino-2-methyl-but-2-en-1-ol]-9-(β-D-ribofuranosyl)-9H-purine 
(io6A).[184] 
 
 
 
Nucleoside 6 (195 mg, 0.43 mmol, 1.00 eq) in MeOH (11.7 mL) was treated with amine 14 
(332 mg, 3.29 mmol, 7.70 eq) and Et3N (1.37 mL, 9.90 mmol, 23.0 eq). The mixture was 
stirred at 60 °C for 48 h and subsequently all volatile components were removed in vacuo. A 
portion (100 mg) of the crude product (723 mg) was purified via HPL chromatography to 
yield io6A (6 mg, 28 %) as white solid. 
 
Rf = 0.48 (DCM/MeOH 4/1); 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.25 (s, 1H; HC8), 8.22 (s, 1H; HC2), 5.95 (d, 
3J(HC1',HC2')=6.5 Hz, 1H; HC1'), 5.51 – 5.45 (m, 1H; CH2CHC(CH3)CH2OH), 4.74 (dd, 
3J(HC2',HC3')=5.0 Hz, 3J(HC2',HC1')=6.5 Hz, 1H; HC2'), 4.32 (dd, 3J(HC3',HC2')=5.0 Hz, 
3J(HC3',HC4')=2.4 Hz, 1H; HC3'), 4.30 – 4.23 (m, 2H; CH2CHC(CH3)CH2OH), 4.22 – 4.21 
(m, 2H; CH2CHC(CH3)CH2OH), 4.18 – 4.15 (m, 1H; HC4'), 3.88 (dd, 
2J(HaC5',HbC5')=12.7 Hz, 3J(HaC5',HC4')=2.4 Hz, 1H; HaC5'), 3.74 (dd, 
2J(HbC5',HaC5')=12.7 Hz, 3J(HbC5',HC4')=2.4 Hz, 1H; HbC5'), and 1.83 ppm (m, 3H; 
CH2CHC(CH3)CH2OH); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 156.13 (C6), 153.38 (C2), 143.77 
(CH2CHCCH3CH2OH), 141.55 (C8), 91.29 (C1'), 88.22 (C4'), 75.45 (C2'), 72.71 (C3'), 63.52 
(C5'), 61.60 (CH2CHCCH3CH2OH), 30.83 (CH2CHC(CH3)CH2OH), and 21.83 ppm 
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(CH2CHC(CH3)CH2OH); Quaternary carbons C4 and C5 cannot be assigned unambiguously 
due to the small amount of material available for NMR analysis. 
HR-MS (ESI+) for [C15H21N5O5Na]+: calc.: 374.1440, found: 374.1435; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 60 % H2O, 40 % MeCN in 45 min; retention 
time = 27.6 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
 
10.7.6 Synthesis of d2-io6A 
 
 
Scheme 34: Synthesis of d2-io6A. 
Reagents and conditions: a) LiAlD4, Et2O, -78 °C to rt, 3 h, 87 %; b) 2 M HCl, 60 °C, 30 min, 73 %, 
c) 19, Et3N, MeOH, 60 °C, 16 h, 13 %. 
 
10.7.6.1 (Z)-(4-Dideutero-4-hydroxy-3-methyl-but-2-enyl)-carbamic acid tbutyl ester 
(18). 
 
 
 
Ester 16 (2.50 g, 10.3 mmol, 1.00 eq) in dry Et2O (30.0 mL) was cooled to -78 °C. LiAlD4 
(0.95 mg, 22.6 mmol, 2.20 eq) was added. The mixture was stirred at -78 °C for 3 h, allowed 
to warm to rt and treated with sat. NH4Cl solution (30.0 mL) and H2O (30.0 mL). Et2O 
(40.0 mL) was added and the layers were separated. The aq. layer was extracted with Et2O 
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(30.0 mL) twice. The combined organic layers were extracted with brine (50.0 mL) and dried 
over MgSO4. Removal of the solvent in vacuo (> 300 mbar) yielded crude 18 (1.79 g, 87 %) 
as colorless oil. 
 
Rf = 0.21 (Isohexane/ethyl acetate 1/1); 
1H NMR (300 MHz, CDCl3, 27 °C): δ = 5.28 – 5.18 (m, 1H; CH), 3.72 – 3.64 (m, 2H; 
CH2N), 1.80 – 1.76 (m, 3H, CH3), and 1.39 ppm (s, 9H, C(CH3)3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 156.44 (NHCOOC(CH3)3), 139.06 (Cq), 123.88 
(CH), 79.88 (C(CH3)3), 38.00 (CH2), 28.58 (C(CH3)3), and 22.13 ppm (CH3). 
 
10.7.6.2 (Z)-4-Amino-1-dideutero-2-methyl-but-2-en-1-ol (19). 
 
 
 
Crude 18 (1.80 g, 8.87 mmol) in aq. HCl (2 M, 50.0 mL) and MeOH (25.0 mL) was stirred at 
60 °C for 30 min. The solvent was removed in vacuo. The resulting oil was treated with 
MeOH (10 mL) and the solvent was removed in vacuo. This procedure was repeated once. 
The resulting red solid was dried under high vacuum for 16 h yielding crude 19 (896 mg, 
73 %). 
 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 5.40 – 5.34 (m, 1H; CH), 3.61 – 3.56 (m, 2H; 
CH2N), and 1.81 – 1.77 ppm (m, 3H; CH3); 
2D-NMR (61 MHz, CD3OD, 27 °C): δ = 4.10 ppm (s; CD2); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 145.30 (Cq), 119.11 (CH), 62.52 (q, 
1J(CD2,CD2)=21 Hz; CD2), 37.82 (CH2N), and 21.92 ppm (CH3). 
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10.7.6.3 6-[(Z)-4-Amino-1-dideutero-2-methyl-but-2-en-1-ol]-9-(β-D-ribofuranosyl)-9H-
purine (d2-io6A). 
 
N
N
N
N
O
OHOH
HO
NH
HO D
D
 
 
Nucleoside 6 (100 mg, 0.24 mmol, 1.0 eq) in MeOH (6.0 mL) was treated with amine 19 
(170 mg, 1.22 mmol, 5.1 eq) and Et3N (0.70 mL, 6.9 mmol, 28.8 eq). The mixture was stirred 
at 60 °C for 16 h and subsequently all volatile components were removed in vacuo. The crude 
product was purified by HPL chromatography (100 % H2O, 0 % MeCN → 60 % H2O, 40 % 
MeCN in 45 min; retention time: 27.7 min, Nucleosil 120-3-C18) to yield d2-io6A (11 mg, 
13 %) as white solid. 
 
1H-NMR (400 MHz, D6-DMSO, 25°C): δ = 8.34 (s, 1H; HC8), 8.20 (s, 1H, HC2), 7.87 (s, 
1H; HN), 5.88 (d, 3J(HC1',HC2')=6.2 Hz, 1H; HC1'), 5.45 – 5.41 (m, 1H; C2'OH), 5.40 – 5.31 
(m, 2H; C5'OH and CH2CHCCH3CD2OH), 5.16 (d, 3J(C3'OH,HC3')=4.4 Hz, 1H; C3'OH), 4.67 
– 4.62 (s, 1H; CH2CHCCH3CD2OH), 4.62 – 4.57 (m, 1H; HC2'), 4.17 – 4.12 (m, 3H; HC3' and 
CH2CHCCH3CD2OH), 3.99 – 3.93 (m, 1H; HC4'), 3.71 - 3.63 (m, 1H; HaC5'), 3.59 – 3.51 (m, 
1H; HbC5'), 1.72 – 1.67 ppm (m, 3H; CH2CHCCH3CD2OH); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 154.25 (C6), 152.25 (C2), 148.29 (C4), 139.69 
(CH2CHCCH3CD2OH), 137.67 (C8), 123.12 (CH2CHCCH3CH2OH), 119.76 (C5), 87.88 
(C1'), 85.84 (C4'), 73.45 (C2'), 70.59 (C3'), 61.62 (C5'), 59.02 (quint, 1J(CD2,CD2)=21 Hz; CD2), 
36.69 (CH2CHCCH3CD2OH), and 21.13 ppm (CH2CHC(CH3)CD2OH); 
HR-MS (ESI+) for [C15H20D2N5O5]+: calc.: 354.1741, found: 354.1741; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 60 % H2O, 40 % MeCN in 45 min; retention 
time = 27.7 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
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10.7.7 Synthesis of ms2io6A 
 
 
Scheme 35: Synthesis of ms2io6A. 
Reagents and conditions: 14, Et3N, MeOH, 60 °C, 24 h, 26 %. 
 
10.7.7.1 6-[(Z)-4-Amino-2-methyl-but-2-en-1-ol]-2-methylthio-9-(β-D-ribofuranosyl)-9H-
purine (ms2io6A).[190] 
 
 
 
Nucleoside 12 (85 mg, 0.19 mmol, 1.00 eq) and amine 14 (150 mg, 1.49 mmol, 8.00 eq) were 
dissolved MeOH (5.00 mL) and triethylamine (0.50 mL). After stirring at 60 °C for 24 h the 
solvent was removed in vacuo. Recrystallisation from iPrOH gave the desired product as a 
white solid. Further purification was performed using HPL chromatography yielding ms2io6A 
(20 mg, 26 %) as white solid. 
 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.13 (s, 1H; HC8), 5.94 (d, 3J(HC1',HC2')=5.9 Hz, 
1H; HC1'), 5.56 – 5.49 (m, 1H; CH2CHC(CH3)CH2OH), 4.73 (dd, 3J(HC2',HC1')=5.9 Hz, 
3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.36 (dd, 3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=3.3 Hz, 1H; 
HC3'), 4.34 – 4.26 (m, 2H; CH2CHC(CH3)CH2OH), 4.25 – 4.22 (s, 2H; 
CH2CHC(CH3)CH2OH), 4.15 (ddd, 3J(HC4',HC3')=3.3 Hz, 3J(HC4',HbC5')=3.2 Hz, 
3J(HC4',HaC5')=2.8 Hz, 1H; HC4'), 3.90 (dd, 2J(HaC5',HbC5')=12.4 Hz, 3J(HaC5',HC4')=2.8 Hz, 
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1H; HaC5'), 3.76 (dd, 2J(HbC5',HaC5')=12.4 Hz, 3J(HbC5',HC4')=3.2 Hz, 1H; HbC5'), 2.59 (s, 3H; 
SCH3), and 1.89 - 1.84 ppm (m, 3H; CH2CHC(CH3)CH2OH); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 167.47 (C2), 155.20 (C6), 150.67 (C4), 140.37 
(C8), 139.87 (CH2CHC(CH3)CH2OH), 124.75 (CH2CHC(CH3)CH2OH), 118.79 (C5), 90.93 
(C1'), 87.66 (C4'), 75.35 (C2'), 72.55 and 72.55 (C3' and CH2CHC(CH3)CH2OH), 63.48 (C5'), 
61.72 (CH2CHC(CH3)CH2OH), 21.83 (CH2CHC(CH3)CH2OH), and 14.74 ppm (SCH3); 
HR-MS (ESI+) for [C16H24N5O5S]+: calc.: 398.1493, found: 398.1485; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 60 % H2O, 40 % MeCN in 5 min and 40 % H2O, 
60 % MeCN in 40 min; retention time = 39.4 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleodur 120-3-C18 ec. 
 
10.7.8 Synthesis of d2-ms2io6A 
 
 
Scheme 36: Synthesis of d2-ms2io6A. 
Reagents and conditions: 19, Et3N, MeOH, 60 °C, 16 h, 2 %. 
 
10.7.8.1 6-[(Z)-4-Amino-1-dideutero-2-methyl-but-2-en-1-ol]-2-methylthio-9-(β-D-
ribofuranosyl)-9H-purine (d2-ms2io6A). 
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Nucleoside 12 (100 mg, 0.24 mmol, 1.00 eq) and amine 19 (170 mg, 6.90 mmol, 28.8 eq) 
were dissolved in MeOH (6.00 mL) and triethylamine (0.70 mL). After stirring at 60 °C for 
16 h the solvent was removed in vacuo. Purification was performed using HPL 
chromatography to yield d2-ms2io6A (2 mg, 2 %) as white solid. 13C NMR analysis could not 
be performed, because d2-ms2io6A was obtained in insufficient amounts. 
 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.08 (s, 1H; HC8), 6.09 – 5.79 (m, 1H; HC1'), 
5.56 – 5.47 (m, 1H; CH2CHC(CH3)CH2OH), 4.74 – 4.75 (m, 1H; HC2'), 4.42 – 4.21 (m, 3H; 
HC3' and CH2CHC(CH3)CH2OH), 4.17 – 4.09 (m, 1H; HC4'), 3.91 – 3.82 (m, 1H; HaC5'), 
3.79 – 3.70 (m, 1H; HbC5'), 2.57 (s, 3H; SCH3), and 1.85 – 1.77 ppm (m, 3H; 
CH2CHC(CH3)CH2OH); 
HR-MS (ESI+) for [C16H22D2N5O5S]+: calc.: 400.1618, found: 400.1618; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 60 % H2O, 40 % MeCN in 5 min and 40 % H2O, 
60 % MeCN in 40 min; retention time = 39.4 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleodur 120-3-C18 ec. 
 
10.8 Syntheses of methyl-adenosines 
10.8.1 Synthesis of m2A 
 
 
Scheme 37: Synthesis of m2A. 
Reagents and conditions: a) I2, CH2I2, CuI, N-pentyl-nitrite, THF, 70 °C, 2 h, 61 %; b) ZnCl2, MeMgCl, 
Pd(PPh3)4, THF, 0 °C to rt, 4 h, 86 %; c) NH3, rt, 36 h, 71 %. 
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10.8.1.1 6-Chloro-2-iodo-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine (20).[251] 
 
 
 
Nucleoside 11 (430 mg, 1.00 mmol, 1.00 eq), I2 (254 mg, 1.00 mmol, 1.00 eq), CH2I2 
(0.81 mL, 10.0 mmol, 10.0 eq) and CuI (200 mg, 1.05 mmol, 1.05 eq) were dissolved in dry 
THF (5.00 mL). N-pentyl-nitrite (0.40 mL, 3.00 mmol, 3.00 eq) was added and the mixture 
was stirred at 70 °C for 2 h. The solvent was removed in vacuo and the resulting oil was 
purified via column chromatography (DCM/MeOH 200/1) yielding iodo nucleoside 20 
(330 mg, 61 %) as yellow foam.  
 
Rf = 0.56 (DCM/MeOH 16/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 8.81 (s, 1H; HC8), 6.29 (d, 
3J(HC1',HC2')=5.0 Hz, 1H; HC1'), 6.04 (dd, 3J(HC2',HC3')=5.4 Hz, 3J(HC2',HC1')=5.0 Hz, 1H; 
HC2'), 5.64 (dd, 3J(HC3',HC2')=5.4 Hz, 3J(HC3',HC4')=5.3 Hz, 1H; HC3'), 4.43 (ddd, 
3J(HC4',HC3')=5.3 Hz, 3J(HC4',HbC5')=5.2 Hz, 3J(HC4',HaC5')=3.7 Hz, 1H; HC4'), 4.40 (dd, 
2J(HaC5',HbC5')=12.0 Hz, 3J(HaC5',HC4')=3.7 Hz, 1H; HaC5'), 4.29 (dd, 
2J(HbC5',HaC5')=12.0 Hz, 3J(HbC5',HC4')=5.2 Hz, 1H; HbC5'), 2.12 (s, 3H; H3CCO), 2.06 (s, 
3H; H3CCO), and 2.01 ppm (s, 3H; H3CCO); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 169.94 (CH3CO), 169.28 (CH3CO), 169.16 
(CH3CO), 152.15 and 148.96 (C6 and C4), 145.93 (C8), 131.63 (C5), 118.33 (C2), 86.21 
(C1'), 79.83 (C4'), 72.45 (C2'), 68.0 (C3'), 62.59 (C5'), 20.54 (CH3CO), 20.33 (CH3CO), and 
20.20 ppm (CH3CO); 
IR: 2959 w (C-H valence), 1740 s (C=O valence), 1584 m (N-H deform.), 1551 m (N-H 
deform.), 1335 m (C-N valence), and 1205 cm-1 s (C-O-C valence); 
HR-MS (ESI+) for [C16H17ClIN4O7]+: calc.: 538.9825, found: 538.9830. 
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10.8.1.2 6-Chloro-2-methyl-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 
(21).[252] 
 
 
 
ZnCl2 (1.0 M in diethyl ether, 0.28 mL, 0.28 mmol, 1.50 eq) was cooled to 0 °C and slowly 
treated with MeMgCl (2.56 M in THF, 0.22 mL, 0.56 mmol, 3.00 eq). The suspension was 
stirred for 2 h at 0 °C. Nucleoside 20 (100 mg, 0.19 mmol, 1.00 eq) and Pd(PPh3)4 (22 mg, 
0.02 mmol, 0.10 eq) were dissolved in dry THF (1.00 mL) and cooled to 0 °C. The suspension 
was diluted with dry THF (1.00 mL) and added to the nucleoside solution. The resulting 
mixture was stirred at 0 °C for 10 min, then allowed to warm to rt and stirred at this 
temperature for 2 h. Saturated NaH2PO4 solution (10.0 mL) was added to the reaction 
mixture. The organic phase was collected and the aqueous phase was extracted with DCM 
(15.0 mL) three times. The combined organic phases were washed with brine (30.0 mL) and 
dried over MgSO4. Purification via column chromatography (DCM/MeOH 200/1) yielded 
nucleoside 21 (68 mg, 86 %) as white foam. 
 
Rf = 0.39 (DCM/MeOH 18/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 8.15 (s, 1H; HC8), 6.15 (d, 3J(HC1',HC2')=5.0 Hz, 
1H; HC1'), 5.93 (dd, 3J(HC2',HC3')=5.2 Hz, 3J(HC2',HC1')=5.0 Hz, 1H; HC2'), 5.69 (dd, 
3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=4.9 Hz, 1H; HC3'), 4.44 (ddd, 3J(HC4',HC3')=4.9 Hz, 
3J(HC4',HbC5')=4.6 Hz, 3J(HC4',HaC5')=3.4 Hz, 1H; HC4'), 4.42 (dd, 2J(HaC5',HbC5')=12.2 Hz, 
3J(HaC5',HC4')=3.4 Hz, 1H; HaC5'), 4.35 (dd, 2J(HbC5',HaC5')=12.2 Hz, 3J(HbC5',HC4')=4.6 Hz, 
1H; HbC5'), 2.78 (s, 3H; H3C), 2.13 (s, 3H; H3CCO), and 2.07 ppm (s, 6H; H3CCO); 
13C NMR (151 MHz, CDCl3, 27 °C): δ = 170.43 (CH3CO), 169.71 (CH3CO), 169.51 
(CH3CO), 163.30 (C2), 151.92 (C6), 151.22 (C4), 143.09 (C8), 130.31 (C5), 86.99 (C1'), 
80.57 (C4'), 73.28 (C2'), 70.69 (C3'), 63.17 (C5'), 25.91 (CH3), 20.91 (CH3CO), 20.73 
(CH3CO), and 20.59 ppm (CH3CO); 
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IR: 2957 w (C-H valence), 2925 w (C-H valence), 1744 s (C=O valence), 1399 m (CH3 
deform.), 1368 m (CH3 deform.), and 1207 cm-1 s (C-O-C valence); 
HR-MS (ESI+) for [C17H20ClN4O7]+: calc.: 427.1015, found:427.1009. 
 
10.8.1.3 6-Amino-2-methyl-9-(-D-ribofuranosyl)-9H-purine (m2A).[196-197] 
 
 
 
Ammonia (2.00 mL) was condensed into a pressurisable tube equipped with nucleoside 21 
(1.50 g, 3.52 mmol). The tube was sealed and allowed to warm to rt. After stirring for 36 h the 
ammonia was removed. The resulting orange oil was dissolved in methanol and subsequently 
dried in vacuo. Addition of methanol and removal of the solvent were repeated twice. 
Purification via column chromatography (DCM/MeOH 10/1) yielded m2A (704 mg, 71 %) as 
white solid. 
 
Rf = 0.13 (DCM/MeOH 8/1); 
M.p.: 128.0 – 128.6 °C; 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 8.24 (s, 1H; HC8), 7.28 (s, 2H; NH2), 5.83 (d, 
3J(HC1',HC2')=6.8, 1H; HC1'), 5.79 (dd, 3J(C5'OH,HbC5')=8.1 Hz, 3J(C5'OH,HaC5')=3.3 Hz, 1H; 
C5'OH), 5.41 (d, 3J(C2'OH,HC2')=6.1 Hz, 1H; C2'OH), 5.19 (d, 3J(C3'OH,HC3')=3.4 Hz, 1H; 
C3'OH), 4.63 (dd, 3J(HC2', HC1')=6.8 Hz, 3J(HC2',C2'OH)=6.1 Hz, 1H; HC2'), 4.14 – 4.09 (m, 
1H; HC3'), 4.00 – 3.95 (m, 1H; HC4'), 3.70 – 3.64 (m, 1H; HaC5'), 3.60 – 3.51 (m, 1H; HbC5'), 
and 2.38 ppm (s, 3H; CH3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 161.02 (C2), 155.83 (C4), 149.57 (C6), 
139.66 (C8), 117.68 (C5), 88.07 (C1'), 86.29 (C4'), 73.21 (C2'), 70.99 (C3'), 61.96 (C5'), and 
25.11 ppm (CH3); 
Chapter 10 Experimental 
135 
IR: 3326 s (N-H valence), 3182 bs (O-H valence, N-H valence), 2925 m (C-H valence), 1645 s 
(N-H deform.), 1599 s (N-H deform., aromatic vibration), 1584 s (N-H deform.), 1402 s (C-H 
deform.), 1333 m (C-N valence), and 1084 cm-1 m (C-O valence); 
HR-MS (ESI+) for [C11H16N5O4]+: calc.: 282.1196, found: 282.1195; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 0 % H2O, 100 % MeCN in 45 min; retention 
time = 13.7 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
 
10.8.2 Synthesis of d3-m2A 
 
 
Scheme 38: Synthesis of d3-m2A. 
Reagents and conditions: a) ZnCl2, d3-MeMgCl, Pd(PPh3)4, THF, 0 °C to rt, 5 h, 25 %; e) NH3, rt, 36 h, 
6 %. 
 
10.8.2.1 6-Chloro-2-trideuteromethyl-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-
purine (22). 
 
 
 
ZnCl2 (1.0 M in diethyl ether, 2.80 mL, 2.80 mmol, 1.50 eq) was cooled to 0 °C and slowly 
treated with d3-MeMgCl (1.0 M in THF, 5.58 mL, 5.58 mmol, 3.00 eq). The suspension was 
diluted with dry THF (10.0 mL) and stirred for 2 h at 0 °C. Nucleoside 20 (1.00 g, 1.86 mmol, 
1.00 eq) and Pd(PPh3)4 (22 mg, 0.02 mmol, 0.01 eq) were dissolved in dry THF (15.0 mL) 
and cooled to 0 °C. The suspension was added to the nucleoside solution. The resulting 
mixture was allowed to warm to rt and stirred at this temperature for 3 h. Saturated NaH2PO4 
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solution (50.0 mL) was added to the reaction mixture. The organic phase was collected and 
the aqueous phase was extracted with DCM (30.0 mL) three times. The combined organic 
phases were washed with brine (50.0 mL) and dried over MgSO4. Purification via column 
chromatography (DCM/MeOH 200/1 and 150/1) yielded nucleoside 22 (199 mg, 25 %) as 
white foam. 
 
Rf = 0.38 (DCM/MeOH 18/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 8.16 (s, 1H; HC8), 6.16 (d, 3J(HC1',HC2')=5.0 Hz, 
1H; HC1'), 5.93 (dd, 3J(HC2',HC3')=5.2 Hz, 3J(HC2',HC1')=5.0 Hz, 1H; HC2'), 5.69 (dd, 
3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=4.9 Hz, 1H; HC3'), 4.43 (ddd, 3J(HC4',HC3')=4.9 Hz, 
3J(HC4',HbC5')=4.6 Hz, 3J(HC4',HaC5')=3.4 Hz, 1H; HC4'), 4.42 (dd, 2J(HaC5',HbC5')=12.4 Hz, 
3J(HaC5',HC4')=3.4 Hz, 1H; HaC5'), 4.35 (dd, 2J(HbC5',HaC5')=12.4 Hz, 3J(HbC5',HC4')=4.6 Hz, 
1H; HbC5'), 2.13 (s, 3H; H3CCO), and 2.07 ppm (s, 6H; H3CCO); 
13C NMR (151 MHz, CDCl3, 27 °C): δ = 170.44 (CH3CO), 169.73 (CH3CO), 169.52 
(CH3CO), 163.25 (C2), 151.92 (C6), 151.22 (C4), 143.09 (C8), 130.32 (C5), 86.98 (C1'), 
80.56 (C4'), 73.28 (C2'), 70.68 (C3'), 63.17 (C5'), 25.02 (CD3), 20.92 (CH3CO), 20.74 
(CH3CO), and 20.60 ppm (CH3CO); 
HR-MS (ESI+) for [C17H17D3ClN4O7]+: calc.: 430.1203, found: 430.1213. 
 
10.8.2.2 6-Amino-2-trideuteromethyl-9-(-D-ribofuranosyl)-9H-purine (d3-m2A). 
 
 
 
Ammonia (2.00 mL) was condensed into a pressurisable tube equipped with nucleoside 22 
(200 mg, 0.47 mmol). The tube was sealed and allowed to warm to rt. After stirring for 72 h 
the ammonia was removed. The resulting orange oil was dissolved in methanol and 
subsequently dried in vacuo. Addition of methanol and removal of the solvent were repeated 
Chapter 10 Experimental 
137 
twice. Purification via column chromatography (DCM/MeOH 10/1) yielded d3-m2A (8 mg, 
6 %) as white foam. 
 
Rf = 0.13 (DCM/MeOH 8/1); 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.21 (s, 1H; HC8), 5.94 (d, 3J(HC1',HC2')=6.8, 1H; 
HC1'), 4.80 (dd, 3J(HC2',HC1')=6.8 Hz, 3J(HC2',HC3')=5.1 Hz, 1H; HC2'), 4.35 (dd, 
3J(HC3',HC2')=5.1 Hz, 3J(HC3',HC4')=2.0 Hz, 1H; HC3'), 4.21 (dd, 3J(HC4',HaC5')=2.3 Hz, 
3J(HC4',HbC5')=2.3 Hz, 3J(HC4',HC3')=2.0 Hz, 1H; HC4'), 3.93 (dd, 3J(HaC5',HbC5')=12.6 Hz, 
3J(HaC5',HC4')=2.3 Hz, 1H; HaC5'), and 3.77 ppm (dd, 3J(HbC5',HaC5')=12.6 Hz, 
3J(HbC5',HC4')=2.3 Hz, 1H; HbC5'); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 163.50 (C2), 157.38 (C4), 150.68 (C6), 
142.02 (C8), 119.43 (C5), 91.71 (C1'), 88.67 (C4'), 75.33 (C2'), 73.12 (C3'), and 63.88 ppm 
(C5'); 
2D-NMR (61 MHz, CD3OD, 27 °C): δ = 2.45 ppm (CD3); 
HR-MS (ESI+) for [C11H13D3N5O4]+: calc.: 285.1385, found: 285.1388; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 0 % H2O, 100 % MeCN in 45 min; retention 
time = 13.7 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
 
10.9 Syntheses of methylthio-adenosines 
10.9.1 Synthesis of ms2m62A 
 
 
Scheme 39: Synthesis of ms2m62A. 
Reagents and conditions: Me2NH, 60 °C, 16 h, 67 %. 
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10.9.1.1 6-Dimethylamino-2-methylthio-9-(β-D-ribofuranosyl)-9H-purine (ms2m62A).[253] 
 
 
 
Nucleoside 12 (0.50 g, 1.10 mmol, 1.00 eq) was dissolved in Me2NH (33 % in EtOH, 
2.50 mL, 14 mmol, 12.7 eq) and stirred at 60 °C for 16 h. The solvent was removed in vacuo. 
The resulting oil was dissolved in DCM (20.0 mL). The oil was applied to a silica plug. The 
silica plug was flushed with DCM (100 mL). The crude product was eluted with DCM/MeOH 
20/1. After removal of the solvent in vacuo the yellow solid was recrystallized from iPrOH to 
yield ms2m62A (251 mg, 67 %) as white solid. 
 
Rf = 0.40 (DCM/MeOH 8/1); 
M.p.: 173.3 – 174.3 °C; 
1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 8.05 (s, 1H; HC8), 5.89 (d, 
3J(HC1',HC2')=6.0 Hz, 1H; HC1'), 4.72 (dd, 3J(HC2',HC1')=6.0 Hz, 3J(HC2',HC3')=5.2 Hz, 1H; 
HC2'), 4.31 (dd, 3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=3.2 Hz, 1H; HC3'), 4.15 (ddd, 
3J(HC4',HC3')=3.2 Hz, 3J(HC4',HbC5')=3.0 Hz, 3J(HC4',HaC5')=2.6 Hz, 1H; HC4'), 3.90 (dd, 
2J(HaC5',HbC5')=12.4 Hz, 3J(HaC5',HC4')=2.6 Hz, 1H; HaC5'), 3.76 (dd, 
2J(HbC5',HaC5')=12.4 Hz, 3J(HbC5',HC4')=3.0 Hz, 1H; HbC5'), 3.46 (s, 6H; N(CH3)2), and 
2.53 ppm (s, 3H; SCH3); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 166.23 (C2), 155.38 (C4), 152.22 (C6), 139.21 
(C8), 139.21 (N(CH3)2), 119.40 (C5), 90.96 (C1'), 87.66 (C4'), 75.20 (C2'), 72.53 (C3'), 63.50 
(C5'), and 14.67 ppm (SCH3); 
IR: 3128 m (O-H valence, N-H valence), 2922 m (O-H valence, N-H valence), 1582 s (N-H 
deform., aromatic vibration), 1303 m (C-N valence), and 1029 cm-1 m (C-O valence); 
HR-MS (ESI+) for [C13H20N5O4S]+: calc.: 342.1231, found: 342.1231. 
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10.9.2 Synthesis of ms2m6A 
 
 
Scheme 40: Synthesis of ms2m6A. 
Reagents and conditions: MeNH2, rt, 16 h, 73 %. 
 
10.9.2.1 6-Methylamino-2-methylthio-9-(β-D-ribofuranosyl)-9H-purine (ms2m6A).[253b] 
 
 
 
Nucleoside 12 (0.50 g, 1.10 mmol) was dissolved in MeNH2 (33 % in EtOH, 2.50 mL, 
20.0 mmol, 18.2 eq) and stirred at rt for 16 h. The solvent was removed in vacuo. The 
resulting oil was purified via column chromatography (DCM/MeOH 20/1). After removal of 
the solvent in vacuo the white solid was recrystallized from iPrOH to yield ms2m6A (261 mg, 
73 %) as white solid. 
 
Rf = 0.34 (DCM/MeOH 8/1); 
M.p.: 110.2 – 111.9 °C; 
1H NMR (600 MHz, CD3OD, 25 °C): δ = 8.11 (s, 1H; HC8), 5.94 (d, 3J(HC1',HC2')=6.0 Hz, 
1H; HC1'), 4.78 (dd, 3J(HC2',HC1')=6.0 Hz, 3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.36 (dd, 
3J(HC3',HC2')=5.2 Hz, 3J(HC4',HC3')=3.2 Hz, 1H; HC3'), 4.16 (ddd, 3J(HC4',HC3')=3.2 Hz, 
3J(HC4',HbC5')=3.2 Hz, 3J(HC4',HaC5')=2.8 Hz, 1H; HC4'), 3.90 (dd, 2J(HaC5',HbC5')=12.4 Hz, 
3J(HaC5',HC4')=2.8 Hz, 1H; HaC5'), 3.77 (dd, 2J(HbC5',HaC5')=12.4 Hz, 3J(HbC5', HC4')=3.2 Hz, 
1H; HbC5'), 3.38 (s, 3H; NCH3), and 2.59 ppm (s, 3H; SCH3); 
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13C NMR (101 MHz, CD3OD, 27 °C): δ = 167.48 (C2), 156.08 (C4), 150.44 (C6), 140.26 
(C8), 139.21 (N(CH3)2), 118.88 (C5), 90.95 (C1'), 87.68 (C4'), 75.31 (C2'), 72.54 (C3'), 63.50 
(C5'), 50.00 (NHCH3), and 14.67 ppm (SCH3); 
IR: 3315 m (O-H valence, N-H valence), 2925 m (O-H valence, N-H valence), 1616 s (N-H 
deform.), 1581 m (N-H deform., aromatic vibration), and 1297 cm-1 m (C-N valence); 
HR-MS (EI+) for [C12H17N5O4S]•+: calc.: 327.0996, found: 327.0994. 
 
10.9.3 Synthesis of ms2A 
 
 
Scheme 41: Synthesis of ms2A. 
Reagents and conditions: NH3, rt, 24 h, 81 %. 
 
10.9.3.1 6-Amino-2-methylthio-9-(β-D-ribofuranosyl)-9H-purine (ms2A).[196, 254] 
 
 
 
Nucleoside 12 (3.50 g, 11.2 mmol) was introduced in a pressurisable tube and cooled to 
-78 °C. Ammonia (5.00 mL) was condensed into the tube. The tube was close and allowed to 
warm to rt. The solution was stirred at rt for 24 h. The tube was cooled to -78 °C and opened. 
After removal of the ammonia the resulting oil was dissolved in MeOH. The solvent was 
removed in vacuo. The coevaporation step was repeated once. The resulting oil was dissolved 
in DCM (20.0 mL). The oil was applied to a silica plug. The silica plug was flushed with 
DCM (100 mL). The crude product was eluted with DCM/MeOH 10/1. After removal of the 
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solvent in vacuo the yellow solid was recrystallized from MeOH to yield ms2A (1.95 g, 81 %) 
as white solid. 
 
Rf = 0.23 (DCM/MeOH 4/1); 
M.p.: 227.8 – 228.3 °C; 
1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 8.18 (s, 1H; HC8), 5.94 (d, 
3J(HC1',HC2')=5.8 Hz, 1H; HC1'), 4.75 (dd, 3J(HC2',HC1')=5.8 Hz, 3J(HC2',HC3')=5.1 Hz, 1H; 
HC2'), 4.34 (dd, 3J(HC3',HC2')=5.1 Hz, 3J(HC3',HC4')=3.5 Hz, 1H; HC3'), 4.12 (ddd, 
3J(HC4',HC3')=3.5 Hz, 3J(HC4',HbC5')=3.4 Hz, 3J(HC4',HaC5')=2.9 Hz, 1H; HC4'), 3.86 (dd, 
2J(HaC5',HbC5')=12.3 Hz, 3J(HaC5',HC4')=2.9 Hz, 1H; HaC5'), 3.74 (dd, 
2J(HbC5',HaC5')=12.3 Hz, 3J(HbC5', HC4')=3.4 Hz, 1H; HbC5'), and 2.54 ppm (s, 3H; SCH3); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 167.56 (C2), 156.96 (C4), 151.53 (C6), 140.81 
(C8), 118.33 (C5), 90.79 (C1'), 87.50 (C4'), 75.38 (C2'), 72.42 (C3'), 63.39 (C5'), and 14.62 ppm 
(SCH3); 
IR: 3454 w (N-H valence), 3302 m (N-H valence), 3193 m (O-H valence, N-H valence), 
3123 m (O-H valence, N-H valence), 2911 m (C-H valence, O-H valence), 2865 m (C-H 
valence, O-H valence), 2587 m (O-H valence), 2491 m (O-H valence), 2407 m (O-H valence), 
1599 s (N-H deform., aromatic vibration), 1575 s (N-H deform., aromatic vibration), and 
1459 cm-1 m (aromatic vibration); 
HR-MS (ESI+) for [C11H16N5O4S]+: calc.: 314.0918, found: 314.0919. 
 
10.9.4 Synthesis of d3-ms2A 
 
 
Scheme 42: Synthesis of d3-ms2A. 
Reagents and conditions: NH3, rt, 24 h, 17 %. 
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10.9.4.1 6-Amino-2-trideuteromethylthio-9-(β-D-ribofuranosyl)-9H-purine (d3-ms2A). 
 
 
 
Nucleoside 12 (50 mg, 0.11 mmol) in a pressurisable tube was cooled to -78 °C. Ammonia 
(2.00 mL) was condensed into the tube. The tube was close and allowed to warm to rt. The 
solution was stirred at rt for 24 h. The tube was cooled to -78 °C and opened. After removal 
of the ammonia the resulting oil was dissolved in MeOH. The solvent was removed in vacuo. 
The MeOH step was repeated once. The resulting oil was purified by HPL chromatography to 
yield d3-ms2A (6 mg, 17 %) as white solid.  
 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 8.20 (s, 1H; HC8), 5.96 (d, 
3J(HC1',HC2')=5.8 Hz, 1H; HC1'), 4.77 (dd, 3J(HC2',HC1')=5.8 Hz, 3J(HC2',HC3')=5.2 Hz, 1H; 
HC2'), 4.37 (dd, 3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=3.5 Hz, 1H; HC3'), 4.17 (ddd, 
3J(HC4',HC3')=3.4 Hz, 3J(HC4',HbC5')=3.4 Hz, 3J(HC4',HaC5')=3.0 Hz, 1H; HC4'), 3.89 (dd, 
2J(HaC5',HbC5')=12.3 Hz, 3J(HaC5',HC4')=3.0 Hz, 1H; HaC5'), and 3.77 ppm (dd, 
2J(HbC5',HaC5')=12.3 Hz, 3J(HbC5',HC4')=3.4 Hz, 1H; HbC5'); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 167.54 (C2), 156.95 (C4), 151.52 (C6), 140.81 
(C8), 118.32 (C5), 90.78 (C1'), 87.50 (C4'), 75.37 (C2'), 72.42 (C3'), and 63.38 ppm (C5'); 
HR-MS (ESI+) for [C11H13D3N5O4S]+: calc.: 317.1106, found: 317.1109. 
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10.10 Syntheses of cytidines 
10.10.1 Synthesis of ac4C 
 
 
Scheme 43: Synthesis of ac4C. 
Reagents and conditions: Ac2O, EtOH, 80 °C, 6 h, 79 %. 
 
10.10.1.1 N-[2-Oxo-1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-4-yl]-acetamide 
(ac4C).[202] 
 
 
 
Cytidine (C) (2.00 g, 8.40 mmol, 1.00 eq) and acetic acid anhydride (0.80 mL, 8.40 mmol, 
1.00 eq) were refluxed in EtOH (20.0 mL) at 80 °C for 2 h. After this time acetic acid 
anhydride (0.80 mL, 8.40 mmol, 1.00 eq) was added and the white suspension was refluxed 
for an additional 4 h. The suspension was filtered hot and the resulting solid was washed with 
EtOH (10.0 mL). Crude ac4C (1.9 g, 79 %) was obtained and 200 mg of which were further 
purified by HPL chromatography yielding highly purified ac4C (153 mg, extrapolated: 61 %) 
as white solid. 
 
Rf = 0.50 (DCM/MeOH 3/1); 
M.p.: 194.4 – 195.8 °C; 
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1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 10.88 (s, 1H; HN), 8.42 (d, 
3J(HC6,HC5)=7.5 Hz, 1H; HC6), 7.17 (d, 3J(HC5,HC6)=7.5 Hz, 1H; HC5), 5.77 (d, 
3J(HC1',HC2')=2.7 Hz, 1H; HC1'), 5.65 – 5.06 (m, 3H; C5'OH, C3'OH and C2'OH), 3.99 – 3.93 
(m, 2H; HC2' and HC3'), 3.91 – 3.87 (m, 1H; HC4'), 3.73 (dd, 2J(HaC5',HbC5')=12.3 Hz, 
3J(HaC5',HC4')=2.7 Hz, 1H; HaC5'), 3.59 (dd, 2J(HbC5',HaC5')=12.3 Hz, 3J(HbC5',HC4')=3.0 Hz, 
1H; HbC5'), and 2.09 ppm (s, 3H, COCH3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 171.06 (COCH3), 162.32 (C4), 154.70 (C2), 
145.41 (C6), 95.19 (C5), 90.16 (C1'), 84.22 (C4'), 74.56 (C2'), 68.66 (C3'), 59.93 (C5'), and 
24.40 ppm (CH3); 
IR: 3236 bm (O-H valence, N-H valence), 2936 w (C-H valence), 1651 s (C=O valence), 
1536 m (N-H deform., C-N valence), 1494 m (C=O deform.), 1379 m (CH3 deform.), 1306 w 
(C-N valence), 1101 m (C-O-C valence), and 788 cm-1 m (=C-H deform.); 
HR-MS (ESI+) for [C11H15N3O6Na]+: calc.: 308.0859, found: 308.0853; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 50 % H2O, 50 % MeCN in 45 min; retention 
time = 15.0 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
 
10.10.2 Synthesis of 13C2-ac4C 
 
 
Scheme 44: Synthesis of 13C2-ac4C. 
Reagents and conditions: 13C4-Ac2O, EtOH, 60 °C, 6.5 h, 13 %. 
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10.10.2.1 N-[2-Oxo-1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-4-yl]-(13C2)-
acetamide (13C2-ac4C). 
 
 
 
Cytidine (559 mg, 2.30 mmol, 1.00 eq) and 13C4-acetic acid anhydride (250 mg, 2.30 mmol, 
1.00 eq, 99 atom% 13C) were stirred in EtOH (5.70 mL) at 60 °C for 6.5 h. The suspension 
was filtered hot and dissolved in MeOH. Et2O was added until a white precipitate appeared. 
The suspension was kept at 4 °C for 16 h. The solid was collected by filtration and dried in 
vacuo. The white solid was further purified by HPL chromatography yielding 13C2-ac4C 
(86 mg, 13 %) as white solid. 
 
Rf = 0.53 (DCM/MeOH 3/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 10.88 (s, 1H; HN), 8.42 (d, 
3J(HC6,HC5)=7.5 Hz, 1H; HC6), 7.18 (d, 3J(HC5,HC6)=7.5 Hz, 1H; HC5), 5.77 (d, 
3J(HC1',HC2')=2.8 Hz, 1H; HC1'), 5.53 – 5.45 (m, 1H; C2'OH), 5.21 – 5.12 (m, 1H; HOC5'OH), 
5.10 – 5.02 (m, 1H; HOC3'OH), 4.00 – 3.86 (m, 3H; HC2', HC3', and HC4'), 3.78 – 3.69 (m, 
2J(HaC5',HbC5')=12.2 Hz, 1H; HaC5'), 3.62 – 3.55 (m, 2J(HbC5',HaC5')=12.2 Hz, 1H; HbC5'), and 
2.01 ppm (dd, 1J(13CH3,13CH3)=128.7 Hz, 2J(13CO,13CH3)=6.4 Hz, 3H, 13CO13CH3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 171.06 (d, 1J(13CO13CH3,13CO13CH3)=51.7 Hz, 
113C; 13CO13CH3), 162.33 (d, 2J(C4,13CO13CH3)=3.0 Hz, 1C; C4), 154.71 (C2), 145.41 (C6), 
95.20 (C5), 90.15 (C1'), 84.21 (C4'), 74.54 (C2'), 68.69 (C3'), 59.94 (C5'), and 24.36 ppm (d, 
1J(13CO13CH3,13CO13CH3)=51.7 Hz, 113C; 13CH3); 
HR-MS (ESI+) for [C913C2H15N3O6Na]+ : calc.: 310.0926, found: 310.0920; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 50 % H2O, 50 % MeCN in 45 min; retention 
time = 14.9 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
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10.10.3 Synthesis of Cm 
 
 
Scheme 45: Synthesis of Cm. 
Reagents and conditions: NaH, MeI, DMF, 0 °C to rt, 4.5 h, 16 %. 
 
10.10.3.1 4-Amino-1-(2'-O-methyl-β-D-ribofuranosyl)-pyrimidin-2-1H-one (Cm).[209] 
 
 
 
Cytidine (5.00 g, 20.6 mmol, 1.00 eq) was suspended in dry DMF (83 mL) at 0 °C. NaH 
(60 % in mineral oil, 1.00 g, 24.7 mmol, 1.20 eq) was added carefully. The mixture was 
stirred at 0 °C for 1 h. MeI (1.32 mL, 21.2 mmol, 1.03 eq) was added and the white 
suspension was stirred for 2.5 h at 0 °C. The suspension was allowed to warm to rt and stirred 
for 1 h. The solution was filtered and the solvent was removed in vacuo. The resulting oil was 
dissolved in MeOH (20.0 mL). The solvent was removed in vacuo. The MeOH treatment was 
repeated twice. Silica and MeOH (20.0 mL) were added and the solvent removed in vacuo. 
The resulting solid was treated with MeOH (20.0 mL) and dried in vacuo twice. The dried 
mixture was applied to column chromatography (DCM/MeOH 20/1 to 10/1). The fractions 
containing the desired product were dried in vacuo. The resulting solid was recrystallized from 
MeOH to yield Cm (846 mg, 16 %) as white solid.  
 
Rf = 0.46 (DCM/MeOH 2/1); 
M.p.: 255.3 – 257.2 °C; 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 7.90 (d, 3J(HC6,HC5)=7.5 Hz, 1H; HC6), 7.20 
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(s, 2H; NH2), 5.85 (d, 3J(HC1',HC2')=4.0 Hz, 1H; HC1'), 5.71 (d, 3J(HC5,HC6)=7.5 Hz, 1H; 
HC5), 5.10 (t, 3J(C5'OH,H2C5')=5.2 Hz, 1H; C5'OH), 5.06 (d, 3J(C3'OH,HC3')=6.3 Hz, 1H; 
C3'OH), 4.05 (ddd, 3J(HC3',C3'OH)=6.3 Hz, 3J(HC3',HC4')=5.9 Hz, 3J(HC3',HC2')=5.1 Hz, 1H; 
HC3'), 3.81 (ddd, 3J(HC4',HC3')=5.9 Hz, 3J(HC4',HbC5')=3.2 Hz, 3J(HC4',HaC5')=3.0 Hz 1H; 
HC4'), 3.70 – 3.62 (m, 2H; HC2' and HaC5'), 3.55 (ddd, 2J(HbC5',HaC5')=12.1 Hz, 
3J(HbC5',C5'OH)=5.2 Hz, 3J(HbC5',HC4')=3.2 Hz, 1H; HbC5'), and 3.38 ppm (s, 3H; C2'OCH3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ=165.63 (C4), 155.13 (C2), 141.15 (C6), 93.96 
(C5), 87.01 (C1'), 84.19 (C4'), 83.28 (C2'), 68.08 (C3'), 60.24 (C5'), and 57.57 ppm (CH3); 
IR: 3322 bs (O-H valence), 3187 bm (N-H valence), 3063 w (C-H valence), 2903 w (C-H 
valence), 1642 s (C=O valence), 1611 s (C=O valence), 1496 s (N-H deform.), 1201 m 
(C-O-C valence), 1075 m (C-O-C valence), and 786 cm-1 w (C-H deform.); 
HR-MS (ESI-) for [C10H15N3O5]- : calc.: 256.0939, found: 256.0936; 
HPLC: gradient: 100 % H2O, 0 % MeCN → 92 % H2O, 8 % MeCN in 45 min; retention 
time = 22.1 min; flow: 0.5 mL/min; column: CC 250/4 Nucleosil 120-3-C18. 
 
10.10.4 Side products of the Synthesis of Cm 
The side products of the reaction towards Cm (Chapter 10.10.3.1) were isolated via 
HPL chromatography (HPLC buffer E: 0.1 M triethylamine/acetic acid in water, HPLC 
buffer F: 0.1 M triethylamine/acetic acid in 20 % water and 80 % MeCN). 
 
10.10.4.1 4-Imino-3-methyl-1-(2'-O-methyl-β-D-ribofuranosyl)-3,4-
dihydropyrimidin-2(1H)-one (23). 
 
 
 
 
Rf = 0.60 (DCM/MeOH 3/1); 
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1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.25 (d, 3J(HC6,HC5)=8.0 Hz, 1H; HC6), 6.09 (d, 
3J(HC5,HC6)=8.0 Hz, 1H; HC5), 5.86 (d, 3J(HC1',HC2')=3.4 Hz, 1H; HC1'), 4.35 (dd, 
3J(HC2',HC3')=4.8 Hz, 3J(HC1',HC2')=3.4 Hz, 1H; HC2'), 4.13 (ddd, 3J(HC4',HC3')=6.2 Hz, 
3J(HC4',HaC5')=2.6 Hz, 3J(HC4',HbC5')=2.6 Hz, 1H; HC4'), 3.91 (dd, 2J(HaC5',HbC5')=12.4 Hz, 
3J(HaC5',HC4')=2.6 Hz, 1H; HaC5'), 3.83 (dd, 3J(HC3',HC4')=6.2 Hz, 3J(HC3',HC2')=4.8 Hz, 1H; 
HC3'), 3.73 (dd, 2J(HbC5',HaC5')=12.4 Hz, 3J(HbC5',HC4')=2.6 Hz, 1H; HbC5'), and 3.45 ppm 
(2 s, 6H; C3'OCH3, N3CH3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 161.02 (C4), 149.93 (C2), 141.03 (C6), 96.58 (C5), 
92.77 (C1'), 84.26 (C4'), 79.39 (C3'), 74.41 (C2'), 61.51 (C5'), 58.43 (C3'OCH3), and 30.68 ppm 
(N3-CH3); 
HR-MS (ESI+) for [C11H18N3O5]+ : calc.: 272.1246, found: 272.1241; 
HPLC: gradient: 100 % HPLC buffer E, 0 % HPLC buffer F → 92 % HPLC buffer E, 8 % 
HPLC buffer F in 45 min; retention time = 13.3 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleosil 120-3-C18. 
 
10.10.4.2 4-Imino-3-methyl-1-(3'-O-methyl-β-D-ribofuranosyl)-3,4-
dihydropyrimidin-2(1H)-one (24).[255] 
 
 
 
Rf = 0.60 (DCM/MeOH 3/1); 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.34 (d, 3J(HC6,HC5)=8.0 Hz, 1H; HC6), 6.09 (d, 
3J(HC5,HC6)=8.0 Hz, 1H; HC5), 5.91 (d, 3J(HC1',HC2')=2.2 Hz, 1H; HC1'), 4.22 (dd, 
3J(HC3',HC4')=7.5 Hz, 3J(HC3',HC2')=5.0 Hz, 1H; HC3'), 4.01 (ddd, 3J(HC4',HC3')=7.5 Hz, 
3J(HC4',HbC5')=2.5 Hz, 3J(HC4',HaC5')=2.4 Hz, 1H; HC4'), 3.94 (dd, 2J(HaC5',HbC5')=12.5 Hz, 
3J(HaC5',HC4')=2.4 Hz, 1H; HaC5'), 3.85 (dd, 3J(HC2',HC3')=5.0 Hz, 3J(HC2',HC1')=2.2 Hz, 1H; 
HC2'), 3.78 (dd, 2J(HbC5',HaC5')=12.5 Hz, 3J(HbC5',HC4')=2.5 Hz, 1H; HbC5'), 3.58 (s, 3H; 
C2'OCH3), and 3.46 ppm (s, 3H; N3CH3); 
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13C NMR (101 MHz, CD3OD, 27 °C): δ = 161.05 (C4), 149.64 (C2), 141.17 (C6), 96.31 (C5), 
90.33 (C1'), 85.88 (C4'), 85.07 (C2'), 69.00 (C3'), 60.72 (C5'), 58.93 (C2'OCH3), and 30.69 ppm 
(N3CH3); 
HR-MS (ESI+) for [C11H18N3O5]+: calc.: 272.1246, found: 272.1241; 
HPLC: gradient: 100 % HPLC buffer E, 0 % HPLC buffer F → 92 % HPLC buffer E, 8 % 
HPLC buffer F in 45 min; retention time = 18.6 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleosil 120-3-C18. 
 
10.10.4.3 4-Amino-1-(2',3'-di-O-methyl-β-D-ribofuranosyl)-pyrimidin-2(1H)-one 
(25).[256] 
 
 
 
Rf = 0.60 (DCM/MeOH 3/1); 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.13 (d, 3J(HC6,HC5)=7.5 Hz, 1H; HC6), 5.95 (d, 
3J(HC1',HC2')=2.7 Hz, 1H; HC1'), 5.91 (d, 3J(HC5,HC6)=7.5 Hz, 1H; HC5), 4.05 (ddd, 
3J(HC4',HC3')=6.9 Hz, 3J(HC4',HbC5')=2.7 Hz, 3J(HC4',HaC5')=2.6 Hz, 1H; HC4'), 3.98 (dd, 
3J(HC2',HC3')=4.8 Hz, 3J(HC2',HC1')=2.7 Hz, 1H; HC2'), 3.94 – 3.83 (m, 2H; HaC5' and HC3'), 
3.73 (dd, 2J(HbC5',HaC5')=12.5 Hz, 3J(HbC5',HC4')=2.7 Hz, 1H; HbC5'), 3.55 (s, 3H; C2'OCH3), 
and 3.41 ppm (s, 3H; C3'OCH3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 167.62 (C4), 158.09 (C2), 142.68 (C6), 95.89 (C5), 
89.93 (C1'), 83.70 (C4'), 83.36 (C2'), 78.17 (C3'), 61.37 (C5'), 58.69 (C2'OCH3), and 58.31 ppm 
(C3'OCH3); 
HR-MS (ESI-) for [C11H16N3O5]-: calc.: 270.1090, found: 270.1092; 
 
 
HPLC: gradient: 100 % HPLC buffer E, 0 % HPLC buffer F → 92 % HPLC buffer E, 8 % 
Chapter 10 Experimental 
150 
HPLC buffer F in 45 min; retention time = 26.0 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleosil 120-3-C18. 
 
10.10.4.4 4-Methylamino-1-(2'-O-methyl-β-D-ribofuranosyl)-pyrimidin-2(1H)-one 
(26), 4-Methylamino-1-(3'-O-methyl-β-D-ribofuranosyl)-pyrimidin-2(1H)-one* 
(27).[256] 
 
 
 
Rf = 0.60 (DCM/MeOH 3/1); 
1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 7.81 (d, 3J(HC6,HC5)=7.5 Hz, 1H; HC6), 7.79 
(d, 3J(HC6*,HC5*)=7.5 Hz, 1H*; HC6*), 7.70 – 7.63 (m, 1H, 1H*; HN, HN*), 5.86 (d, 
3J(HC1',HC2')=4.2 Hz, 1H; HC1'), 5.74 (d, 3J(HC1'*,HC2'*)=4.4 Hz, 1H*; HC1'*), 5.73 – 5.69 
(m, 1H and 1H*; HC5 and HC5*), 5.32 (s, 1H*; C2'OH*), 5.06 (s, 1H; C3'OH), 4.13 – 4.09 
(m, 1H*; HC2'*), 4.08 – 4.04 (m, 1H; HC3'), 3.92 – 3.89 (m, 1H*; HC4'*), 3.80 (ddd, 
3J(HC4',HC3')=5.9 Hz, 3J(HC4',HbC5')=3.1 Hz, 3J(HC4',HaC5')=2.8 Hz, 1H; HC4'), 3.68 – 3.61 
(m, 2H, 2H*; HC3', HaC5', HC2'*, HaC5'*), 3.57 – 3.50 (m, 1H, 1H*; HbC5', HbC5'*), 3.37 (s, 
3H; C2'OCH3), 3.33 (s, 3H*; C3'OCH3*), and 2.77 – 272 ppm (m, 1H, 1H*; N4CH3, 
N4CH3*); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 163.76 (C4*), 163.76 (C4), 155.30 (C2*), 
155.04 (C2), 139.87 (C6*), 139.72 (C6), 94.56 (C5*), 94.39 (C5), 89.35 (C1'*), 86.87(C1'), 
86.87 (C4'), 84.20 (C2'), 81.80(C4'*), 78.50(C3'*), 72.55 (C2'*), 68.13 (C3'), 60.55 (C5'*), 60.29 
(C5'), 57.54 (C2'OCH3), 57.39 (C2'OCH3*), 28.20 (N3CH3*), and 26.87 ppm (N3CH3); 
HR-MS (ESI+) for [C11H17N3O5Na]+: calc.: 294.1066, found: 294.1060; 
HPLC: gradient: 100 % HPLC buffer E, 0 % HPLC buffer F → 92 % HPLC buffer E, 8 % 
HPLC buffer F in 45 min; retention time = 23.1 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleosil 120-3-C18. 
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10.10.5 Synthesis of d3-Cm 
 
 
Scheme 46: Synthesis of d3-Cm. 
Reagents and conditions: NaH, d3-MeI, DMF, 0 °C to rt, 4.5 h, 19 %. 
 
10.10.5.1 4-Amino-1-(2'-O-trideuteromethyl-β-D-ribofuranosyl)-pyrimidin-2(1H)-
one (d3-Cm). 
 
 
 
Cytidine (4.58 g, 18.8 mmol, 1.00 eq) was suspended in dry DMF (77.0 mL) at 0 °C. NaH 
(60 % in mineral oil, 0.90 mg, 22.6 mmol, 1.20 eq,) was added carefully. The mixture was 
stirred at 0 °C for 1 h. d3-MeI (1.21 mL, 19.4 mmol, 1.03 eq) was added and the white 
suspension was stirred for 2.5 h at 0 °C. The suspension was allowed to warm to rt and stirred 
for an additional hour. The solution was filtered and the solvent was removed in vacuo. The 
resulting oil was dissolved in MeOH (20.0 mL). The solvent was removed in vacuo. The 
MeOH treatment was repeated twice. Silica and MeOH (20.0 mL) were added and the solvent 
removed in vacuo. The resulting solid was treated with MeOH (20.0 mL) twice. The dried 
mixture was applied to column chromatography (DCM/MeOH 20/1 to 10/1). The resulting 
solid was recrystallized from MeOH to yield d3-Cm (922 mg, 19 %) as white solid. 
 
Rf = 0.47 (DCM/MeOH 2/1); 
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M.p.: 251.8 – 253.7 °C; 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 7.90 (d, 3J(HC6,HC5)=7.5 Hz, 1H; HC6), 7.20 
(s, 2H; NH2), 5.84 (d, 3J(HC1',HC2')=4.0 Hz, 1H; HC1'), 5.71 (d, 3J(HC5,HC6)=7.5 Hz, 1H; 
HC5), 5.10 (t, 3J(C5'OH,H2C5')=5.2 Hz, 1H; C5'OH), 5.05 (d, 3J(C3'OH,HC3')=6.3 Hz, 1H; 
C3'OH), 4.05 (ddd, 3J(HC3',C3'OH)=6.3 Hz, 3J(HC3',HC4')=5.9 Hz, 3J(HC3',HC2')=5.1 Hz, 1H; 
HC3'), 3.81 (ddd, 3J(HC4',HC3')=5.9 Hz, 3J(HC4',HbC5')=3.1 Hz, 3J(HC4',HaC5')=2.9 Hz, 1H; 
HC4'), 3.70 – 3.62 (m, 2H; HC2' and HaC5'), and 3.55 ppm (ddd, 2J(HaC5',HbC5')=12.1 Hz, 
3J(HbC5',C5'OH)=5.2 Hz, 3J(HbC5',HC4')=3.1 Hz, 1H; HbC5'); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 165.62 (C4), 155.12 (C2), 141.14 (C6), 93.94 
(C5), 87.03 (C1'), 84.17 (C4'), 83.19 (C2'), 68.08 (C3'), 60.23 (C5'), and 57.67 ppm (sept, 
1J(CD3, CD3)=23 Hz; CD3); 
2D-NMR (46 MHz, D6-DMSO, 27 °C): δ = 3.33 (s; CD3); 
IR: 3326 bs (O-H valence), 3189 bm (N-H valence), 3063 w (C-H valence), 2904 w (C-H 
valence), 2063 w (C-D valence), 1643 s (C=O valence), 1611 s (C=O valence), 1496 s (N-H 
deform.), 1202 m (C-O-C valence), 1074 m (C-O-C valence), and 786 cm-1 w (C-H deform.); 
HR-MS (ESI-) for [C10H15N3O5]-: calc.: 259.1122, found: 259.1124. 
 
10.10.6 Synthesis of m3C 
 
 
Scheme 47: Synthesis of m3C. 
Reagents and conditions: Dimethylsulfate, DMF, 37 °C, 2 d, 7 %. 
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10.10.6.1 4-Imino-3-methyl-1-(β-D-ribofuranosyl)-3,4-dihydropyrimidin-2(1H)-one 
(m3C).[233] 
 
 
 
Cytidine (0.50 g, 2.06 mmol, 1.00 eq) was suspended in dry DMF (5.00 mL) at 0 °C. 
Dimethylsulfate (1.95 mL, 20.60 mmol, 10.0 eq) was added and the mixture was stirred at 
37 °C for 2 d. MeOH was added to a total volume of 20.0 mL. Ethyl acetate was added until a 
white precipitate appeared, which was collected by filtration. The resulting solid was 
recrystallized from MeOH and ethyl acetate twice to yield m3C (77 mg, 7 %) as white 
solid.[233] 
 
Rf = 0.47 (DCM/MeOH 3/1); 
1H NMR (400 MHz, CD3OD, 27 °C): δ = 8.48 (d, 3J(HC6,HC5)=7.9 Hz, 1H; HC6), 6.19 (d, 
3J(HC6,HC5)=7.9 Hz, 1H; HC5), 5.87 (d, 3J(HC1',HC2')=2.5 Hz, 1H; HC1'), 4.22 – 4.12 (m, 
2H; HC2',HC3'), 4.10 – 4.03 (m, 1H; HC4'), 3.93 (dd, 2J(HaC5',HbC5')=12.4 Hz, 
2J(HaC5',HC4')=2.2 Hz, 1H; HaC5'), 3.78 (dd, 2J(HaC5',HbC5')=12.4 Hz, 2J(HbC5',HC4')=2.4 Hz, 
1H; HbC5'), 3.51 ppm (s, 3H; CH3); 
13C NMR (101 MHz, CD3OD, 27 °C): δ = 161.26 (C4), 149.13 (C2), 143.51 (C6), 94.82 (C5), 
93.02 (C1'), 86.21(C4'), 76.25 (C2'), 70.11 (C3'), 61.19 (C5'), 30.95 ppm (CH3); 
HR-MS (ESI+) for [C10H16N3O5]+: calc.: 258.1090, found: 258.1084. 
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10.11 Synthesis of deazaguanosine nucleosides 
10.11.1 Studies towards the synthesis of queuosine 
 
 
Scheme 48: Studies towards the synthesis of queuosine. 
Reagents and conditions: a) Bromoacetaldehyde diethyl acetal, HCl, NaOAc, water, 90 °C and 80 °C, 
4 h, 74 %; b) POCl3, reflux, 2 h, 78 %; c) Pivaloyl chloride, pyridine, rt, 2 h, 64 %; d) NIS, THF, rt, 1 h, 
81 %; e) 1-acetyl-2,3,5-tribenzoyl-ribose, bistrimethylsilyl acetamide, trimethylsilyl triflate, MeCN, 
50 °C, 24 h, 59 %; f) DABCO, CsOAc, NaOAc, DMF, rt, 45 h, 57 %; g) Pd2(dba)3, triphenylphosphine, 
CO, tributyltin hydride, toluene, 50 °C, 2 h, 93 %. 
 
10.11.1.1 2-Amino-7H-pyrrolo[2,3-d]pyrimidin-4-one (29a).[257] 
 
 
 
Bromoacetaldehyde diethyl acetal (21.4 mL, 27.3 g, 138 mmol, 1.00 eq) were suspended in 
water (70.0 mL) and conc. hydrochloric acid (3.00 mL) was added. The mixture was stirred at 
90 °C until a clear solution was formed (approximately 30 min). The solution was cooled to rt 
and sodium acetate (13.6 g, 165 mmol, 1.20 eq) was added. This mixture was added to a 
suspension of 2,6-diamino-4-pyrimidinone 29 (20.0 g, 159 mmol, 1.15 eq) and sodium acetate 
(7.00 g, 85.4 mmol, 0.62 eq) in water (150 mL). The resulting mixture was stirred at 80 °C for 
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2 h. During this period the suspension first dissolved partially, before a white solid gradually 
precipitated. The obtained suspension was stirred at 0 °C for 90 min. The precipitate was 
collected and washed with little cold water and acetone. Drying in vacuo yielded 
nucleobase 29a (15.4 g, 74 %) as white solid.  
 
1H NMR (200 MHz, D6-DMSO, 27 °C): δ = 10.94 (s, 1H; HN), 10.35 (s, 1H; HN), 6.58 (d, 
3J(HC5,HC6)=3.2 Hz, 1H; HC5), 6.15 (d, 3J(HC6,HC5)=3.2 Hz, 1H; HC6), and 6.09 ppm (s, 
2H; NH2); 
HR-MS (EI+) for [C6H6N4O]+: calc.: 150.0542, found: 150.0544. 
 
10.11.1.2 2-Amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (30).[258] 
 
 
 
Nucleobase 29a (10.0 g, 67.0 mmol, 1.00 eq) was suspended in POCl3 (100 mL, 388 mmol, 
5.80 eq). The mixture was refluxed for 2 h. The solvent was removed carefully in vacuo. The 
resulting oil was carefully added to ice cold water (120 mL). The precipitate was removed by 
filtration and the filtrate was adjusted to pH = 2 with conc. ammonia. After standing for 1 h at 
0 °C the precipitate was collected by filtration and washed with little cold water and diethyl 
ether. Drying in vacuo yielded nucleobase 30 (8.70 g, 78 %) as yellow solid. Crude amine 30 
was introduced in the next reaction without further purification.  
 
10.11.1.3 4-Chloro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (30a).[216b] 
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Amine 30 (8.50 g, 50.4 mmol, 1.00 eq) was suspended in dry pyridine (120 mL) and pivaloyl 
chloride (21.3 g, 176 mmol, 3.50 eq) was added. The mixture was stirred at rt for 2 h. The 
solvent was removed in vacuo. The remaining mixture was dissolved in DCM and extracted 
with 0.1 M HCl twice. The organic phase was dried over MgSO4. Silica gel chromatography 
(DCM/MeOH 98/2) yielded amide 30a (8.15 g, 64 %) as white solid.  
Rf = 0.16 (DCM/MeOH 98/2); 
1H NMR (200 MHz, D6-DMSO, 27 °C): δ = 12.32 (s, 1H; NHCO), 10.02 (s, 1H; HN), 7.15 
(d, 3J(HC5,HC6)=3.6 Hz, 1H; HC5), 6.50 (d, 3J(HC6,HC5)=3.6 Hz, 1H; HC6), and 1.20 ppm 
(s, 9H; COC(CH3)3); 
HR-MS (EI+) for [C11H13ClN4O]+: calc.: 252.0778, found: 252.0782. 
 
10.11.1.4 4-Chloro-5-iodo-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (31).[216b] 
 
 
 
Nucleobase 30a (3.10 g, 12.3 mmol, 1.00 eq) were dissolved in dry THF (60.0 mL) and the 
flask was wrapped with aluminum foil to exclude light. N-Iodosuccinimide (3.04 g, 
13.51 mmol, 1.10 eq) was added. The mixture was stirred at rt for 1 h. The solvent was 
removed in vacuo. The remaining mixture was dissolved in DCM (500 mL) and extracted 
with water (200 mL). The organic phase was dried over MgSO4. Silica gel chromatography 
(DCM/MeOH 99/1) yielded nucleobase 31 (3.76 g, 81 %) as white solid. Alternatively, the 
crude product was recrystallized from little MeOH.  
Rf = 0.07 (DCM/MeOH 99/1); 
1H NMR (200 MHz, D6-DMSO, 27 °C): δ = 12.67 (s, 1H; NHCO), 10.09 (s, 1H; HN), 7.74 
(m, 1H; HC6), and 1.20 ppm (s, 9H; COC(CH3)3); 
HR-MS (EI+) for [C11H12ClIN4O]+: calc.: 377.9744, found: 377.9756. 
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10.11.1.5 4-Chloro-5-iodo-2-pivaloylamino-7-[(2',3',5'-tri-O-benzoyl)--D-
ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine (32).[216d] 
 
 
 
Nucleobase 31 (2.50 g, 6.60 mmol, 1.00 eq) was dissolved in dry MeCN (70.0 mL) and 
bistrimethylsilyl acetamide (2.00 mL, 1.66 g, 8.18 mmol, 1.24 eq) was added dropwise. The 
mixture was stirred at rt for 5 min. After addition of trimethylsilyl triflate (1.65 mL. 2.03 g, 
9.13 mmol, 1.40 eq) and 1-acetyl-2,3,5-tribenzoyl-ribose (2.22 g, 4.40 mmol, 0.67 eq) the 
mixture was stirred at 50 °C. 1-Acetyl-2,3,5-tribenzoyl-ribose (2.22 g, 4.40 mmol, 0.67 eq) 
was added after 6 h and 12 h. After stirring for 24 h DCM (200 mL) was added and the 
organic layer was extracted with sat. NaHCO3 solution (100 mL) and brine (100 mL) 
subsequently. The organic layer was dried over MgSO4. Purification by column 
chromatography (isohexane/ethyl acetate 8/1) yielded nucleoside 32 (4.43 g, 59 %) as yellow 
foam.  
As hardly separable side products open chained sugars (degraded starting material) were 
identified. 
 
Rf = 0.30 (isohexane/ethyl acetate 3/1); 
M.p.: 60.2 – 61.9 °C; 
1H NMR (400 MHz, CDCl3, 27 °C): δ = 8.24 (s, 1H; HN), 8.01 – 7.95 (m, 6H; HAr), 
7.59 - 7.52 (m, 3H; HAr), 7.44 – 7.32 (m, 7H; HAr and HC8), 6.47 (dd, 3J(HC3',HC4')=6.0 Hz, 
3J(HC3',HC2')=5.8 Hz, 1H; HC3'), 6.39 (d, 3J(HC1',HC2')=3.9 Hz, 1H; HC1'), 6.23 (dd, 
3J(HC2',HC3')=5.8 Hz, 3J(HC2',HC1')=3.9 Hz, 1H; HC2'), 4.86 (dd, 3J(HaC5',HbC5')=12.2 Hz, 
3J(HaC5',HC4')=3.4 Hz, 1H; HaC5'), 4.8 – 4.76 (m, 1H; HC4'), 4.67 (dd, 
3J(HbC5',HaC5')=12.2 Hz, 3J(HbC5',HC4')=4.4 Hz, 1H; HbC5'), and 1.29 ppm (s, 9H; C(CH3)3); 
13C NMR (101 MHz, CDCl3, 27 °C): δ = 175.35 (COC(CH3)3), 166.31 (ArCO), 165.62 
(ArCO), 165.45 (ArCO), 153.52 (C4), 151.77 (C7a), 151.68 (C2), 133.89 (Ar), 133.77 (Ar), 
133.58 (Ar), 130.12 (2C; Ar), 130.05 (2C; Ar), 129.74 (2C; Ar), 129.55 (Ar), 129.07 (Ar), 
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128.81 (Ar), 128.80 (2C; Ar), 128.69 (2C; Ar), 128.68 (2C; Ar), 114.29 (C6), 98.61 (C4a), 
88.50 (C1'), 80.28 (C4'), 74.75 (C2'), 71.58 (C3'), 63.64 (C5'), 53.74 (C5), 40.47 (COC(CH3)3), 
and 27.53 ppm (3C; COC(CH3)3); 
HR-MS (ESI+) for [C37H33ClIN4O8]+: calc.:823.1026, found: 823.1001. 
 
10.11.1.6 5-Iodo-4-oxo-2-pivaloylamino-7-[(2',3',5'-tri-O-benzoyl)--D-
ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine (33).[216d] 
 
 
 
Nucleoside 32 (1.01 g, 1.23 mmol, 1.00 eq), DABCO (137 mg, 1.23 mmol, 1.00 eq), and 
caesium acetate (705 mg, 3.67 mmol, 3.00 eq) in DMF (1.20 mL) were stirred at rt for 45 h. 
After addition of water (1.00 mL) the mixture was stirred for 30 min. Water (10.0 mL) was 
added and the mixture was extracted with ethyl acetate (10.0 mL) twice. The combined 
organic layers were washed with water (15.0 mL) and brine (15.0 mL) and dried over MgSO4. 
Purification via silica gel column chromatography (isohexane/ethyl acetate 2/1) yielded 
nucleoside 33 (0.56 g, 57 %) as white solid.  
 
Rf = 0.50 (isohexane/ethyl acetate 1/1); 
M.p.: 92.3 – 93.8 °C; 
1H NMR (300 MHz, CDCl3, 25 °C): δ = 11.53 (s, 1H; HNAr), 8.73 (s, 1H; NHPiv), 8.00 – 7.92 
(m, 2H; HAr), 7.92 – 7.84 (m, 2H; HAr), 7.78 – 7.69 (m, 2H; HAr), 7.61 – 7.27 (m, 9H; HAr), 
6.94 (s, 1H; HC6), 6.84 (dd, 3J(HC3',HC4')=8.5 Hz, 3J(HC3',HC2')=4.9 Hz, 1H; HC3'), 6.45 (dd, 
3J(HC2',HC3')=4.9 Hz, 3J(HC2',HC1')=1.7 Hz, 1H; HC2'), 5.99 (d, 3J(HC1',HC2')=1.7 Hz, 1H; 
HC1'), 4.80 – 4.54 (m, 3H, HC4', HaC5', and HbC5'), and 1.33 ppm (s, 9H; C(CH3)3); 
13C NMR (75 MHz, CDCl3, 27 °C): δ = 180.29 (COC(CH3)3), 166.26 (ArCO), 166.17 
(ArCO), 165.34 (ArCO), 156.85 (C4), 146.65 (C7a), 146.45 (C2), 133.97 (Ar), 133.94 (Ar), 
133.71 (Ar), 129.97 (2C; Ar), 129.92 (2C; Ar), 129.41 (2C; Ar), 129.15 (Ar), 128.94 (Ar), 
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128.86 (Ar), 128.78 (2C; Ar), 128.71 (2C; Ar), 128.65 (2C; Ar), 127.24 (C6), 106.73 (C4a), 
89.50 (C1'), 78.71 (C4'), 74.64 (C2'), 70.78 (C3'), 61.66 (C5'), 56.18 (C5), 40.41 (C(CH3)3), and 
27.04 ppm (3C; C(CH3)3); 
HR-MS (ESI-) for [C37H32IN4O9]-: calc.: 803.1219, found: 803.1210. 
 
10.11.1.7 5-Formyl-4-oxo-2-pivaloylamino-7-[(2',3',5'-tri-O-benzoyl)--D-
ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine (28). 
 
 
 
Under argon atmosphere nucleoside 33 (100 mg, 0.12 mmol, 1.00 eq), Pd2(dba)3 (11 mg, 
0.01 mmol, 0.01 eq), and triphenylphosphine (20 mg, 0.08 mmol, 0.60 eq) were dissolved in 
dry toluene (1.60 mL). The solution was cooled to -78 °C. High vacuum was applied for 2 sec 
and the flask was ventilated with argon. This approach was repeated three times. Then after 
application of high vacuum the flask was ventilated with CO. Again this procedure was 
repeated three times. CO atmosphere was sustained in the flask afterwards using a CO 
balloon. The solution was heated to 55 °C and stirred. Tributyltin hydride (40.0 μL, 
0.15 mmol, 1.20 eq) in dry toluene (0.95 mL) was added dropwise over a period of 2 h. 
Afterwards the reaction was allowed to cool to rt and the solvent was removed in vacuo. The 
resulting solid was purified via silica gel column chromatography (isohexane/ethyl acetate 
2/1) yielding nucleoside 28 (81 mg, 93 %) as white solid. 
 
Rf = 0.25 (isohexane/ethyl acetate 1/1); 
M.p.: 105.4 – 106.7 °C; 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 10.35 (s, 1H; HCO), 8.83 (s, 1H; NHPiv), 7.97 – 7.94 
(m, 2H; HAr), 7.92 – 7.87 (m, 2H; HAr), 7.77 – 7.72 (m, 2H; HAr), 7.62 – 7.50 (m, 3H; HAr), 
7.59 (s, 1H; HC6), 7.45 – 7.40 (m, 2H; HAr), 7.39 – 7.35 (m, 2H; HAr), 7.33 – 7.29 (m, 2H; 
HAr), 6.87 (dd, 3J(HC3',HC4')=8.4 Hz, 3J(HC3',HC2')=5.0 Hz, 1H; HC3'), 6.51 (dd, 
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3J(HC2',HC3')=5.0 Hz, 3J(HC2',HC1')=1.7 Hz, 1H; HC2'), 6.05 (d, 3J(HC1',HC2')=1.7 Hz, 1H; 
HC1'), 4.80 (ddd, 3J(HC4',HC3')=8.4 Hz, (HC4',HbC5')=3.4 Hz, 3J(HC4',HaC5')=3.2 Hz, 1H; 
HC4'), 4.74 (dd, 3J(HaC5',HbC5')=12.4 Hz, (HaC5',HC4')=3.2 Hz, 1H; HaC5'), 4.65 (dd, 
3J(HbC5',HaC5')=12.4 Hz, (HbC5',HC4')=3.4 Hz, 1H; HbC5'), and 1.36 ppm (s, 9H; C(CH3)3); 
13C NMR (151 MHz, CDCl3, 27 °C): δ = 186.29 (HCO), 180.53 (COC(CH3)3), 166.31 
(ArCO), 166.24 (ArCO), 165.37 (ArCO), 156.96 (C4), 147.56 (C7a), 147.41 (C2), 134.12 
(Ar), 134.06 (Ar), 133.83 (Ar), 130.04 (2C; Ar), 129.99 (2C; Ar), 129.46 (2C; Ar), 129.15 
(Ar), 128.87 (2C; Ar), 128.84 (Ar), 128.82 (Ar), 128.78 (2C; Ar), 128.65 (2C; Ar), 126.81 
(C6), 121.19 (C5), 104.89 (C4a), 90.68 (C1'), 79.03 (C4'), 74.59 (C2'), 70.81 (C3'), 61.61 (C5'), 
40.53 (COC(CH3)3), and 27.09 ppm (3C; COC(CH3)3); 
HR-MS (ESI-) for [C38H35IN4O10]+: calc.: 707.2348, found: 707.2348. 
 
Further reactions leading to queuosine were performed by E. M. Jahn, F. Klepper,[239c] and 
I. Thoma.[239a] Further reactions leading to isotopically labeled queuosine were performed by 
I. Thoma.[239a] 
 
10.11.2 Synthesis of PreQ0 via the queuosine route 
 
 
Scheme 49: Synthesis of PreQ0 via the queuosine route. 
Reagents and conditions: a) MeMgCl, iPrMgCl•LiCl, TosCN, toluene, -78 °C to rt, 18 h, 60 %; b) 28 % 
NH3 in H2O, 60 °C, 16 h, 78 %. 
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10.11.2.1 5-Cyano-4-oxo-2-pivaloylamino-7-[2',3',5'-O-tribenzoyl-β-D-
ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine (45). 
 
 
 
Nucleoside 33 (100 mg, 0.12 mmol, 1.00 eq) was dissolved in dry toluene (1.00 mL) and 
cooled to -65 °C. MeMgCl (2.56 M in THF, 0.09 mL, 0.23 mmol, 2.00 eq) was added 
dropwise and the resulting mixture was stirred for 1 h. Over a period of 1 h iPrMgCl•LiCl 
(1.06 M in THF, 0.30 mL, 0.31 mmol, 2.50 eq) in dry toluene (0.70 mL) was added with a 
syringe pump. The solution was stirred for 4 h at -65 °C. TosCN (135 mg, 0.74 mmol, 
6.00 eq) was added and the resulting mixture was allowed to warm to rt over a period of 16 h. 
Water (20.0 mL) and ethyl acetate (20.0 mL) were added to the solution. The organic layer 
was collected and the aqueous layer was extracted with ethyl acetate (3 × 20.0 mL). The 
combined organic layers were washed with brine (20.0 mL) and dried over MgSO4. 
Purification via column chromatography yielded nucleoside 45 (52 mg, 60 %) as white solid. 
 
Rf = 0.64 (isohexane/ethyl acetate 1/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.73 (s, 1H; NHCOC(CH3)3), 8.82 (s, 1H; HNAr), 
7.98 (m, 2H; Hortho), 7.91 (m, 2H; Hortho), 7.75 (m, 2H; Hortho), 7.59 (m, 3H; Hpara), 7.45 (m, 
2H; Hmeta), 7.39 (m, 2H; Hmeta), 7.38 (s, 1H; HC6), 7.35 (m, 2H; Hmeta), 6.85 (dd, 
3J(HC3',HC4')=8.4 Hz, 3J(HC3',HC2')=5.0 Hz, 1H; HC3'), 6.48 (dd, 3J(HC2',HC3')=5.0 Hz, 
3J(HC2',HC1')=1.6 Hz, 1H; HC2'), 6.02 (d, 3J(HC1',HC2')=1.6 Hz, 1H; HC1'), 4.81 (ddd, 
3J(HC4',HC3')=8.4 Hz, 3J(HC4',HbC5')=3.3 Hz, 3J(HC4',HaC5')=3.0 Hz, 1H; HC4'), 4.75 (dd, 
2J(HaC5',HbC5')=12.5 Hz, 3J(HaC5',HC4')=3.0 Hz, 1H; HaC5'), 4.68 (dd, 
2J(HbC5',HaC5')=12.5 Hz, 3J(HbC5',HC4')=3.3 Hz, 1H; HbC5'), and 1.37 ppm (s, 9H; 
COC(CH3)3); 
13C NMR (151 MHz, CDCl3, 25 °C): δ = 180.27 (COC(CH3)3), 166.03 (PhCO), 166.02 
(PhCO), 165.13 (PhCO), 155.32 (C4), 148.00 (C2), 146.41 (C7a), 133.94 (Ar), 133.88 (Ar), 
133.75 (Ar), 130.27 (C6), 129.80 (Ar), 129.75 (Ar), 129.13 (Ar), 128.82 (Ar), 128.66 (Ar), 
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128.58 (Ar), 128.55 (Ar), 128.51 (Ar), 128.47 (Ar), 105.35 and 113.36 (C4a and CN), 90.12 
and 90.14 (C5 and C1'), 78.99 (C4'), 74.26 (C2'), 70.52 (C3'), 61.18 (C5'), 40.32 (COC(CH3)3), 
and 26.83 ppm (3C; COC(CH3)3),  
IR: 3345 w (N-H valence), 3199 w (N-H valence), 2973 m (C-H valence), 2875 w (C-H 
valence), 2233 m (CN valence), 1724 s (C=O valence), 1673 s (C=C valence), and 
1262 cm-1 s (C-O-C valence); 
HR-MS (ESI–) for [C38H32N5O9]–: calc.: 702.2206, found: 702.2209. 
 
10.11.2.2 2-Amino-5-cyano-4-oxo-7-β-D-ribofuranosyl-7H-pyrrolo-[2,3-d]-
pyrimidine (PreQ0).[228-229] 
 
 
 
Nucleoside 45 (14.0 mg, 0.02 mmol) was dissolved in NH3 in H2O (28 %, 1.00 mL). The 
solution was stirred at 60 °C for 16 h. Subsequent removal of the solvent in vacuo resulted in 
a colorless oil, which was applied to column chromatography (ethyl acetate/MeOH 10/1). 
PreQ0 (4 mg, 78 %) was obtained as white solid.  
 
Rf = 0.30 (ethyl acetate/MeOH 5/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 10.86 (s, 1H; HNAr), 7.89 (s, 1H; HC6), 6.62 (s, 
2H; NH2), 6.05 (d, 3J(HC1',HC2')=5.9 Hz, 1H; HC1'), 4.28 (dd, 3J(HC2',HC1')=5.9 Hz, 
3J(HC2',HC3')=4.8 Hz, 1H; HC2'), 4.03 (dd, 3J(HC3',HC2')=4.8 Hz, 3J(HC3',HC4')=3.7 Hz, 1H; 
HC3'), 3.82 (ddd, 3J(HC4',HaC5')=4.1 Hz, 3J(HC4',HbC5')=4.0 Hz, 3J(HC4',HC3')=3.7 Hz, 1H; 
HC4'), 3.57 (dd, 2J(HaC5',HbC5')=11.9 Hz, 3J(HaC5',HC4')=4.1 Hz, 1H; HaC5'), and 3.50 ppm 
(dd, 2J(HbC5',HaC5')=11.9 Hz, 3J(HbC5',HC4')=4.0 Hz, 1H; HbC5'); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 157.21 (C4), 154.02 (C2), 151.38 (C7a), 127.48 
(C6), 115.32 (CN), 98.62 (C4a), 86.48 and 86.34 (C1' and C5), 85.09 (C4'), 74.07 (C2'), 70.23 
(C3'), and 61.23 ppm (C5'); 
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IR: 3305 s, 3219 s (N-H valence), 2935 m (C-H valence), 2229 m (CN valence), 1673 s, 
1591 m (N-H deform.), 1561 m (N-H deform.), 1426 w (C-H deform.), 1104 m (C-O-C 
valence), and 1047 cm-1 m (C-O-C valence); 
HR-MS (ESI–) for [C12H12N5O5]–: calc.: 306.0844, found: 306.0837. 
 
10.11.3 Synthesis of archaeosine via the queuosine route 
 
 
Scheme 50: Synthesis of archaeosine via the queuosine route. 
Reagents and conditions: HCl (g), MeOH, 7 M NH3 in MeOH, rt, 19 h, 40 %. 
 
10.11.3.1 2-Amino-5-amidinium-7-β-D-ribofuranosyl-7H-pyrrolo-[2,3-d]-
pyrimidine-4-one acetate (archaeosine).[218] 
 
 
 
Nucleoside 45 (30 mg, 0.04 mmol) was dissolved in MeOH (2.00 mL) under nitrogen and 
treated with gaseous HCl for 3 h. Subsequently, nitrogen was bubbled through the solution to 
remove the solvent. The resulting white solid was stirred in NH3 in MeOH (7 N, 2.00 mL) for 
16 h. Removal of the solvent in vacuo yielded a white solid, which was purified by 
HPL chromatography. The solvent was removed to give a 2 to 1 mixture of archaeosine and 
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triethylammonium acetate (8 mg, 40 %). Complete removal of the buffer lead to 
decomposition of the product yielding the corresponding nitrile compound.  
 
Rf = 0.57 (isopropanol/water/glacial acid 5/1/1); 
M.p.: decomposition > 215 °C; 
1H NMR (600 MHz, D2O, 27 °C): δ = 8.03 (s, 1H; HC6), 6.06 (d, 3J(HC1',HC2')=5.9 Hz, 1H; 
HC1'), 4.61 (dd, 3J(HC2',HC1')=5.9 Hz, 3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.38 (dd, 
3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=3.9 Hz, 1H; HC3'), 4.24 (ddd, 3J(HC4',HbC5')=4.2 Hz, 
3J(HC4',HC3')=3.9 Hz, 3J(HC4',HaC5')=3.1 Hz, 1H; HC4'), 3.90 (dd, 2J(HaC5',HbC5')=12.9 Hz, 
3J(HaC5',HC4')=3.1 Hz, 1H; HaC5'), 3.84 (dd, 2J(HbC5',HaC5')=12.9 Hz, 3J(HbC5',HC4')=4.2 Hz, 
1H; HbC5'), and 1.93 ppm (s, 3H; H3CCOO-); 
13C NMR (151 MHz, D2O, 27 °C): δ = 215.59 (H3CCOO-), 153.39, 154.75, 159.21, and 
162.19 (C7a, Camidine, C2, and C4), 125.32 (C6), 107.38 (C5), 98.16 (C4a), 87.94 (C1'), 85.27 
(C4'), 74.18 (C2'), 70.55 (C3'), 61.50 (C5'), and 23.43 ppm (CH3COO-); 
IR: 3368 s (N-H and O-H valence), 3176 s (N-H and O-H valence), 2931 s (N-H and O-H 
valence), 1660 s (C=N valence), 1560 m (N-H deform.), 1058 s (C-O valence), and 
1023 cm-1 s (C-O valence); 
HR-MS (ESI–) for [C12H15N6O5]–: calc.: 323.1109, found: 323.1116; 
HPLC: gradient: 100 % HPLC buffer E, 0 % HPLC buffer F → 80 % HPLC buffer E, 20 % 
HPLC buffer F in 45 min; retention time = 22.2 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleosil 120-3-C18. 
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10.11.4 Synthesis of PreQ0 
 
 
Scheme 51: Synthesis of PreQ0. 
Reagents and conditions: a) HCOOMe, NaOMe, THF, 0 °C to 10 °C, 4 h, b) NaOAc, 
2,6-diaminopyrimidine-4-one, water, THF, 50 °C to reflux, 3 h, 38 % (2 steps); c) pivaloyl chloride, 
pyridine, 85 °C, 2.0 h, 75 %; d) POCl3, TEBA, DMA, acetonitrile, 90 °C, 1 h, 75 %; e) acetone, conc. 
HCl, 0 °C, 2 h, 87 %; f) TBDMSCl, imidazole, DMF, rt, 16 h, 83 %; g) HMPA, tetrachloromethane, 
THF, -78 °C to rt, 4 h; h) NaH, acetonitrile, 0 °C to rt, 20 h, 20 %; j) Et3N, DABCO, NaOAc, DMF, rt, 
48 h, 81 %; k) trifluoroacetic acid, water, 0 °C, 4 h, 77 %; l) 28 % ammonia in water, 60 °C, 17 h, 99 %. 
 
10.11.4.1 2-Amino-5-cyano-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimindine-4-one 
(36).[222] 
 
 
 
Nucleobase 36 was synthesised according to literature.  
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1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 12.00 (s, 1H; HN3), 10.72 (s, 1H; HN7), 7.63 
(s, 1H; HC6), and 6.40 ppm (s, 2H; NH2); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 164.30 (C4), 158.24 (C2), 154.14 (C7a), 
128.22 (C6), 116.18 (CN), 99.48 (C4a), and 85.21 ppm (C5); 
IR: 3362 s (N-H valence), 3105 s (N-H valence), 2229 s (CN valence), 1627 vs (N-H2 
deform.), 1592 vs (aromatic vibration), and 1260 cm-1 s (C-N valence); 
HR-MS (ESI–) for [C7H4ON5]–: calc.: 174.0421, found: 174.0426. 
 
10.11.4.2 5-Cyano-3,4-dihydro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine-4-one 
(37). 
 
 
 
Nucleobase 36 (1.50 g, 8.60 mmol, 1.00 eq) was dissolved in pyridine (10.0 mL) and 
slowly treated with pivaloyl chloride (3.10 g, 26.0 mmol, 3.00 eq). The resulting 
suspension was stirred for 2 h at 85 °C. After cooling to rt a white solid precipitated, 
which was removed by filtration. The resulting solution was neutralised with NH3 in 
MeOH (7N) and left to stand at 4 °C for 16 h. The resulting precipitate was collected and 
washed with ethanol (20.0 mL) and diethyl ether (10.0 mL) to give the pivaloyl protected 
nucleobase 37 (1.70 g, 75 %) as brownish solid. 
 
Rf = 0.21 (DCM/MeOH 20/1); 
1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 12.65 (s, 1H; NHPiv), 12.11 (s, 1H; HN3) 
11.00 (s, 1H; HN7), 7.93 (s, 1H; HC6), and 1.25 ppm (s, 9H; CH3); 
13C NMR (150 MHz, D6-DMSO, 27 °C): δ = 181.73 (COC(CH3)3), 155.67 (C4), 148.38 
and 148.42 (C2 and C7a), 130.21 (C6), 115.17 (CN), 103.02 (C4a), 86.17 (C5), 39.96 
(C(CH3)3), and 26.27 ppm (3C; C(CH3)3); 
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IR: 3125 vs (N-H valence), 2228 s (CN valence), 1684 s (C=O valence), 1646 vs (C=C 
valence), 1608 vs (aromatic vibration), 1579 vs (N-H deform.), 1409 vs (C-H deform.), 
1239 s (C-N valence), 1176 s (C-N valence), and 782 cm-1 s (C-H deform.); 
HR-MS (ESI+) for [C12H13N5O2]+: calc.: 259.1069, found: 259.1088. 
 
10.11.4.3 4-Chloro-5-cyano-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (34). 
 
 
 
Nucleobase 37 (200 mg, 0.77 mmol, 1.00 eq) was suspended in acetonitrile (1.20 mL) and 
dimethylaniline (0.41 mL, 3.28 mmol, 4.30 eq), triethylbenzylammonium chloride (89 mg, 
0.39 mmol, 0.50 eq), and phosphorylchloride (0.72 mL, 7.70 mmol, 10.0 eq) were added. 
The suspension was heated to 90 °C for 1 h. The cooled down suspension was 
concentrated in vacuo and the resulting oil cautiously treated with ice. The acidic mixture 
was set to pH = 4 with conc. ammonia in methanol. The precipitate was collected by 
filtration and washed with water. Purification by column chromatography (isohexane/ethyl 
acetate 3/2) gave nucleobase 34 (160 mg, 75 %) as white solid. 
 
Rf = 0.65 (CHCl3/MeOH 9/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 13.35 (s, 1H; NHPiv), 10.27 (s, 1H; HN7), 
8.50 (s, 1H; HC6), and 1.22 ppm (s, 9H; C(CH3)3); 
13C NMR (150 MHz, D6-DMSO, 27 °C): δ = 175.83 (COC(CH3)3), 153.08 (C2), 152.79 
(C7a), 150.66 (C4), 137.51 (C6), 111.12 and 114.42 (C4a and CN), 83.37 (C5), 39.59 
(COC(CH3)3), and 26.72 (3C; COC(CH3)3); 
IR: 3448 w (N-H valence), 3160 vs (N-H valence), 2231 s (CN valence), 1708 s (C=O 
valence), 1563 vs (N-H deform.), 1521 s (N-H deform.), 1445 vs (C-H deform.), 1419 vs 
(C-H deform.), 1271 s (C-N valence), 1164 s (C-N valence), and 785 cm-1 s (C-H 
deform.); 
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HR-MS (ESI+) for [C12H13N5OCl]+: calc.: 278.0806, found: 278.0796. 
 
10.11.4.4 2',3'-O-Isopropylidene-α/β-D-ribofuranose (40).[224] 
 
 
 
D-Ribose 39 (25.0 g, 150 mmol) was suspended in acetone. Conc. HCl (25.0 L) was 
added at 0 °C and the mixture was stirred for 2 h. The resulting suspension was filtered 
through celite and activated charcoal. Concentration of the resulting solution gave the 
isopropylidene protected sugar 40 (33.0 g, 87 %) as white solid.  
 
Rf = 0.29 (DCM/MeOH 20/1); 
1H NMR (200 MHz, D6-DMSO, 27 °C): δ = 5.41 (s, 1H; HC1'), 4.83 (d, 
3J(HC2',HC3')=6.0 Hz, 1H; HC2'), 4.57 (d, 3J(HC3',HC2')=6.0 Hz, 1H; HC3'), 4.40 (m, 1H; 
HC4'), 3.72 (m, 2H; H2C5'), 1.47 (s, 3H; CH3), and 1.31 ppm (s, 3H; CH3); 
HR-MS (ESI+) for [C8H14O5]+: calc.: 190.0841, found: 190.0834. 
 
10.11.4.5 5'-(O-tbutyl-dimethylsilyl)-2',3'-(O-isopropylidene)-α/β-D-ribofuranose 
(41).[259] 
 
 
 
Sugar 40 (33.0 g, 174 mmol, 1.00 eq) and imidazole (29.0 g, 422 mmol, 2.42 eq) were 
dissolved in DMF (60.0 mL). TBDMSCl (27.4 g, 182 mmol, 1.05 eq) was added and the 
solution was stirred at rt for 16 h. The reaction mixture was treated with water (100 mL) 
and extracted with ethyl acetate (3 × 250 mL). The combined organic phases were 
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extracted with water (120 mL) twice and dried over MgSO4. Removal of the solvent in 
vacuo yielded the protected sugar 41 (44.0 g, 83 %) as a white solid, which was used 
without purification in the next step. An analytically pure sample was obtained by column 
chromatography (isohexane/ethyl acetate 7/1). 
 
Rf = 0.60 (CHCl3/MeOH 10/1); 
1H NMR (600 MHz, D6-DMSO, 27 °C): δ = 6.43 (d, 3J(C1'OH,HC1')=4.5 Hz, 1H; C1'OH), 
5.19 (d, 3J(HC1',C1'OH)=4.5 Hz, 1H; HC1'), 4.63 (d, 3J(HC3',HC2')=6.0 Hz, 1H; HC3'), 
4.46 (d, 3J(HC2',HC3')=6.0 Hz, 1H; HC2'), 3.95 (t, 3J(HC4',HC5')=6.4 Hz, 1H; HC4'), 3.59 
(d, 3J(HC3',HC2')=6.4 Hz, 2H; H2C5'), 1.37 (s, 3H; CH3), 1.25 (s, 3H; CH3), 0.88 (s, 9H; 
Si(CH3)2C(CH3)3), and 0.06 ppm (s, 6H; Si(CH3)2C(CH3)3); 
13C NMR (600 MHz, D6-DMSO, 27 °C): δ = 111.17 (C(CH3)2), 101.82 (C1'), 85.91 (C4'), 
85.56 (C2'), 81.81 (C3'), 64.29 (C5'), 26.36 (C(CH3)2), 25.75 (3C; Si(CH3)2C(CH3)3), 24.74 
(C(CH3)2), 17.95 (Si(CH3)2C(CH3)3), -5.34 and -5.44 ppm (2C; Si(CH3)2C(CH3)3); 
IR: 3345 s (O-H valence), 2939 s (C-H valence), 2861 s (C-H valence), 1382 w (C-H 
deform.), 1258 s (C-O-C valence), 1084 vs (C-O-C valence), and 1062 cm-1 vs (C-O-C 
valence); 
HR-MS (ESI–) for [C14H27O5Si]–: calc.: 303.1633, found: 303.1626. 
 
10.11.4.6 1'-Chloro-5'-(O-tbutyl-dimethylsilyl)-2',3'-O-isopropylidene-α/β-D-
ribofuranose (38).[259] 
 
 
 
Sugar 41 (1.12 g, 3.70 mmol, 1.00 eq) and CCl4 (0.50 mL, 5.92 mmol, 1.60 eq) were 
dissolved in dry THF (10.0 mL). HMPA (0.80 mL, 4.44 mmol, 1.20 eq) was added 
dropwise at -78 °C over a period of 5 min. After stirring at -78 °C for 2 h the mixture was 
allowed to warm to rt upon which a white solid precipitated. The obtained suspension 
containing chloro sugar 38 was used in the subsequent reaction in situ. 
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10.11.4.7 4-Chloro-5-cyano-7-[2',3'-(O-isopropylidene)-5'-(O-tbutyl-dimethylsilyl)-β-
D-ribofuranosyl]-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (42). 
 
 
 
Acetonitrile (100 mL) was dried over 4 Å mole sieves for 1 h before addition of 
nucleobase 34 (1.10 g, 3.97 mmol, 1.00 eq) and NaH (95 %, 220 mg, 5.56 mmol, 1.40 eq). 
The solution was stirred at rt for 1 h. The suspension containing sugar 38 (1.80 g, 
5.56 mmol, 1.40 eq) was added dropwise over a period of 20 min at 0 °C. The resulting 
solution was stirred at rt for 16 h. After removal of the solvent in vacuo the product was 
treated with water (50.0 mL) and ethyl acetate (50.0 mL). The layers were separated and 
the water layer extracted with ethyl acetate (100 mL) twice. The combined organic layers 
were washed with brine (200 mL) and dried over MgSO4. The crude mixture was purified 
by column chromatography (isohexane/ethyl acetate 7/1) to yield nucleoside 42 (441 mg, 
20 %) as white solid. An analytically pure sample was obtained via HPL chromatography. 
 
Rf = 0.85 (isohexane/ethyl acetate 1/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 10.51 (s, 1H; NHPiv), 8.64 (s, 1H; HC6), 
6.25 (d, 3J(HC1',HC2')=1.3 Hz, 1H; HC1'), 5.45 (dd, 3J(HC2',HC3')=6.3 Hz, 
3J(HC2',HC1')=1.3 Hz, 1H; HC2'), 5.21 (dd, 3J(HC3',HC2')=6.3 Hz, 3J(HC3',HC4')=3.7 Hz, 
1H; HC3'), 4.12 (ddd, 3J(HC4',HaC5')=6.0 Hz, 3J(HC4',HbC5')=5.2 Hz, 
3J(HC4',HC3')=3.7 Hz, 1H; HC4'), 3.67 (dd, 3J(HaC5',HbC5')=11.3 Hz, 
3J(HaC5',HC4')=6.0 Hz, 1H; HaC5'), 3.64 (dd, 3J(HbC5',HaC5')=11.3 Hz, 
3J(HbC5',HC4')=5.2 Hz, 1H; HbC5'), 1.51 (s, 3H; endo-C(CH3)2), 1.32 (s, 3H; 
exo-C(CH3)2), 1.22 (s, 9H; COC(CH3)3), 0.73 (s, 9H; Si(CH3)2C(CH3)3), -0.13 (s, 3H; 
Si(CH3)2C(CH3)3), and -0.16 ppm (s, 3H; Si(CH3)2C(CH3)3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 175.87 (COC(CH3)3), 151.20 and 153.11 (C2 
and C4), 150.94 (C7a), 138.22 (C6), 112.89 and 113.59 (C4a and CN), 112.89 (C(CH3)2), 
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90.59 (C1'), 87.95 (C4'), 84.19(C5), 83.68 (C2'), 80.59 (C3'), 63.36 (C5'), 39.84 
(COC(CH3)3), 26.86 (endo-C(CH3)2), 26.62 (3C; COC(CH3)3), 25.65 (3C; 
Si(CH3)2C(CH3)3), 25.16 (exo-C(CH3)2), 17.95 (Si(CH3)2C(CH3)3), -5.59 
(Si(CH3)2C(CH3)3), and -5.66 ppm (Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C26H39ClN5O5Si]+: calc.: 564.2404, found: 564.2368; 
HPLC: gradient: 100 % hexane, 0 % ethyl acetate → 30 % isohexane, 70 % ethyl acetate in 
45 min; retention time = 24.9 min; flow: 0.5 mL/min; column: CC 250/4 Nucleodur 100-5. 
 
10.11.4.8 5-Cyano-3,4-dihydro-2-pivaloylamino-7-[2',3'-(O-isopropylidene)-5'-(O-
tbutyl-dimethylsilyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine-4-one 
(43). 
 
 
 
Nucleoside 42 (74 mg, 0.13 mmol, 1.00 eq) was dissolved in DMF (2.00 mL). Et3N 
(39 mg, 0.05 mL, 0.39 mmol, 3.00 eq), NaOAc (32 mg, 0.39 mmol, 3.00 eq) und DABCO 
(15 mg, 0.13 mmol, 1.00 eq) were added. The mixture was stirrred at rt for 48 h. 
Afterwards water (1.00 mL) was added and the solution was stirred for 1 h. The mixture 
was extracted with ethyl acetate (10.0 mL) three times. The combined organic phases 
were washed with brine (20.0 mL) and dried over MgSO4. Purification via column 
chromatography (isohexane/ethyl acetate 3/1) gave nucleoside 43 (58 mg, 81 %) as white 
foam. 
 
Rf = 0.56 (isohexane/ethyl acetate 1/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 12.24 (s, 1H, NHCO), 11.03 (s, 1H; HNAr), 8.14 
(s, 1H; HC6), 6.25 (d, 3J(HC1',HC2')=2.2 Hz, 1H; HC1'), 5.13 (dd, 3J(HC2',HC3')=6.3 Hz, 
3J(HC2',HC1')=2.2 Hz, 1H; HC2'), 4.96 (dd, 3J(HC3',HC2')=6.3 Hz, 3J(HC3',HC4')=3.8 Hz, 1H; 
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HC3'), 4.14 (ddd, 3J(HC4',HbC5')=4.9 Hz, 3J(HC4',HaC5')=4.3 Hz, 3J(HC4',HC3')=3.8 Hz, 1H; 
HC4'), 3.73 (dd, 3J(HaC5',HbC5')=11.4 Hz, 3J(HaC5',HC4')=4.3 Hz, 1H; HaC5'), 3.69 (dd, 
2J(HbC5',HaC5')=11.4 Hz, 3J(HbC5',HC4')=4.9 Hz, 1H; HbC5'), 1.51 (s, 3H; endo-C(CH3)2), 1.32 
(s, 3H; exo-C(CH3)2), 1.25 (s, 9H; COC(CH3)3), 0.85 (s, 9H; Si(CH3)2C(CH3)3), and 0.02 ppm 
(s, 6H; Si(CH3)2C(CH3)3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 181.14 (COC(CH3)3), 155.35 (C4), 149.00 
(C7a), 147.90 (C2), 129.73 (C6), 114.28 (C(CH3)2), 113.39 (CN), 103.10 (C4a), 88.29 (C1'), 
87.30 (C5), 86.42 (C4'), 82.93 (C2'), 80.44 (C3'), 63.04 (C5'), 40.05 (COC(CH3)3), 26.94 
(endo-C(CH3)2), 26.25 (3C; COC(CH3)3), 25.75 (3C; Si(CH3)2C(CH3)3), 25.23 
(exo-C(CH3)2), 18.03 (Si(CH3)2C(CH3)3), -5.51 (Si(CH3)2C(CH3)3), and -5.54 ppm 
(Si(CH3)2C(CH3)3); 
IR: 3163 bm (N-H valence), 2933 s (C-H valence), 2232 s (CN valence), 1671 s (C=C 
valence), 1606 s (aromatic vibration), 1542 m (N-H deform.), 1250 m (C-O-C valence), 
1077 s (C-O-C valence), 833 s (C-H deform.), and 780 cm-1 s (C-H deform.); 
HR-MS (ESI+) for [C26H39O6N5NaSi]+: calc.: 568.2562, found: 568.2572. 
 
10.11.4.9 5-Cyano-3,4-dihydro-2-pivaloylamino-7-β-D-ribofuranosyl-7H-
pyrrolo[2,3-d]pyrimidine-4-one (44). 
 
 
 
Nucleoside 43 (18 mg, 0.03 mmol, 1.00 eq) was dissolved in water (0.15 mL) and 
trifluoroacetic acid (0.35 mL, 4.57 mmol, 152 eq) was added at 0 °C. The mixture was 
stirred at 0 °C for 4 h before removing the solvent in vacuo at 0 °C. The resulting solid 
was dissolved in water (2 mL) and stirred at rt over a period of 10 min. Concentration 
yielded a colorless oil, which was purified via column chromatography (DCM/MeOH 
10/1). Nucleoside 44 (10 mg, 77 %) was obtained as a white solid. 
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Rf = 0.38 (DCM/MeOH 10/1); 
M.p.: > 210 °C (decomposition); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 12.21 (s, 1H; NHCO), 11.17 (s, 1H; HNAr), 8.25 
(s, 1H; HC6), 6.08 (d, 3J(HC1',HC2')=6.3 Hz, 1H; HC1'), 4.32 (dd, 3J(HC2',HC1')=6.3 Hz, 
3J(HC2',HC3')=4.5 Hz, 1H; HC2'), 4.09 (dd, 3J(HC3',HC2')=4.5 Hz, 3J(HC3',HC4')=2.9 Hz, 1H; 
HC3'), 3.89 (ddd, 3J(HC4',HbC5')=4.4 Hz, 3J(HC4',HaC5')=4.3 Hz, 3J(HC4',HC3')=2.9 Hz, 1H; 
HC4'), 3.61 (dd, 2J(HaC5',HbC5')=12.0 Hz, 3J(HaC5',HC4')=4.3 Hz, 1H; HaC5'), 3.54 (dd, 
2J(HbC5',HaC5')=12.0 Hz, 3J(HbC5',HC4')= 4.4Hz, 1H; HbC5'), and 1.25 ppm (s, 9H; 
COC(CH3)3); 
13C NMR (101 MHz, D6-DMSO, 27 °C): δ = 181.30 (COC(CH3)3), 155.38 (C4), 148.96 (C2), 
148.61 (C7a), 129.62 (C6), 114.63 (CN), 102.92 (C4a), 87.05 (C5), 86.33 (C1'), 85.43 (C4'), 
74.23 (C2'), 70.35 (C3'), 61.21 (C5'), 40.04 (COC(CH3)3), and 26.23 (3C; COC(CH3)3); 
IR: 3482 bm (O-H valence), 3417 s (O-H valence), 3152 bm (N-H valence), 2966 m (C-H 
valence), 2884 m (C-H valence), 2233 m (CN valence), 1693 s (C=C valence), 1659 s (C=C 
valence), 1598 m (N-H deform.), 1557 m (N-H deform.), 1538 m (N-H deform.), 1411 m 
(C-H deform.), 1091 m (C-O-C valence), and 775 cm-1 m (C-H deform.); 
HR-MS (ESI+) for [C17H21N5O6Na]+: calc.: 414.1384, found: 414.1363. 
 
10.11.4.10 2-Amino-5-cyano-4-oxo-7-β-D-ribofuranosyl-7H-pyrrolo-[2,3-d]-
pyrimidine (PreQ0).[228-229] 
 
 
 
Nucleoside 44 (18 mg, 0.05 mmol) was dissolved in NH3 in H2O (28 %, 4 mL). The solution 
was stirred at 60 °C for 17 h. Subsequent removal of the solvent in vacuo resulted in a 
colorless oil, which was purified via column chromatography (ethyl acetate/MeOH 7/1) 
yielding PreQ0 (14 mg, 99 %) as white solid.  
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Rf = 0.30 (ethyl acetate/MeOH 5/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 10.86 (s, 1H; HNAr), 7.89 (s, 1H; HC6), 6.62 (s, 
2H; NH2), 6.05 (d, 3J(HC1',HC2')=5.9 Hz, 1H; HC1'), 4.28 (dd, 3J(HC2',HC1')=5.9 Hz, 
3J(HC2',HC3')=4.8 Hz, 1H; HC2'), 4.03 (dd, 3J(HC3',HC2')=4.8 Hz, 3J(HC3',HC4')=3.7 Hz, 1H; 
HC3'), 3.82 (ddd, 3J(HC4',HaC5')=4.1 Hz, 3J(HC4',HbC5')=4.0 Hz, 3J(HC4',HC3')=3.7 Hz, 1H; 
HC4'), 3.57 (dd, 2J(HaC5',HbC5')=11.9 Hz, 3J(HaC5',HC4')=4.1 Hz, 1H; HaC5'), and 3.50 ppm 
(dd, 2J(HbC5',HaC5')=11.9 Hz, 3J(HbC5',HC4')=4.0 Hz, 1H; HbC5'); 
13C NMR (151 MHz, D6-DMSO, 27 °C): δ = 157.21 (C4), 154.02 (C2), 151.38 (C7a), 127.48 
(C6), 115.32 (CN), 98.62 (C4a), 86.48 and 86.34 (C1' and C5), 85.09 (C4'), 74.07 (C2'), 70.23 
(C3'), and 61.23 ppm (C5'); 
IR: 3305 s (N-H valence), 3219 s (N-H valence), 2935 m (C-H valence), 2229 m (CN 
valence), 1673 s (C=O valence), 1633 s (N-H deform.), 1591 m (N-H deform.), 1561 m (N-H 
deform.), 1426 w (C-H deform.), 1104 m (C-O-C valence), and 1047 cm-1 m (C-O-C valence); 
HR-MS (ESI–) for [C12H12N5O5]–: calc.: 306.0844, found: 306.0837. 
 
10.11.5 Synthesis of archaeosine 
 
 
Scheme 52: Synthesis of archaeosine. 
Reagents and conditions: HCl (g), MeOH, 7 M NH3 in MeOH, rt, 19 h, 30 %. 
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10.11.5.1 2-Amino-5-amidinium-7-β-D-ribofuranosyl-7H-pyrrolo-[2,3-d]-
pyrimidine-4-one acetate.[218] 
 
 
 
PreQ0 (10.0 mg, 0.03 mmol) was dissolved in MeOH (2.00 mL) and treated with gaseous HCl 
for 3 h. Subsequently, nitrogen was bubbled through the solution to remove the solvent. The 
resulting white solid was stirred in NH3 in MeOH (7 N, 2.00 mL) for 16 h. Removal of the 
solvent in vacuo yielded a white solid, which was purified by HPL chromatography. The 
solvent was removed to give a 2 to 1 mixture of the desired product and triethylammonium 
acetate (4 mg, 30 %). Complete removal of the buffer lead to decomposition of the product 
yielding the corresponding nitrile compound.  
 
Rf = 0.57 (isopropanol/water/glacial acid 5/1/1); 
M.p.: decomposition > 215 °C; 
1H NMR (600 MHz, D2O, 27 °C): δ = 8.03 (s, 1H; HC6), 6.06 (d, 3J(HC1',HC2')=5.9 Hz, 1H; 
HC1'), 4.61 (dd, 3J(HC2',HC1')=5.9 Hz, 3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.38 (dd, 
3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=3.9 Hz, 1H; HC3'), 4.24 (ddd, 3J(HC4',HbC5')=4.2 Hz, 
3J(HC4',HC3')=3.9 Hz, 3J(HC4',HaC5')=3.1 Hz, 1H; HC4'), 3.90 (dd, 2J(HaC5',HbC5')=12.9 Hz, 
3J(HaC5',HC4')=3.1 Hz, 1H; HaC5'), 3.84 (dd, 2J(HbC5',HaC5')=12.9 Hz, 3J(HbC5',HC4')=4.2 Hz, 
1H; HbC5'), and 1.93 ppm (s, 3H; H3CCOO-); 
13C NMR (151 MHz, D2O, 27 °C): δ = 215.59 (H3CCOO-), 153.39, 154.75, 159.21, and 
162.19 (C7a, Camidine, C2, and C4), 125.32 (C6), 107.38 (C5), 98.16 (C4a), 87.94 (C1'), 85.27 
(C4'), 74.18 (C2'), 70.55 (C3'), 61.50 (C5'), and 23.43 ppm (CH3COO-); 
IR: 3368 s (N-H and O-H valence), 3176 s (N-H and O-H valence), 2931 s (N-H and O-H 
valence), 1660 s (C=N valence), 1560 m (N-H deform.), 1058 s (C-O valence), and 
1023 cm-1 s (C-O valence); 
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HR-MS (ESI–) for [C12H15N6O5]–: calc.: 323.1109, found: 323.1116; 
HPLC: gradient: 100 % HPLC buffer E, 0 % HPLC buffer F → 80 % HPLC buffer E, 20 % 
HPLC buffer F in 45 min; retention time = 22.2 min; flow: 0.5 mL/min; column: CC 250/4 
Nucleosil 120-3-C18. 
 
10.12 Synthesis of DMT-TBDMS-protected RNA nucleosides 
10.12.1 Synthesis of DMT-TBDMS-protected ms2i6A 
 
 
Scheme 53: Synthesis of nucleoside 46. 
Reagents and conditions: a) tBu2Si(OTf)2, imidazole, TBDMSCl, DMF, 0 °C to 60 °C, 3 h; 
b) HF-pyridine, pyridine, DCM, MeOTMS, 0 °C, 2 h; c) DMTCl, pyridine, MeOH, 0 °C, 16 h, 52 % 
(3 steps). 
 
10.12.1.1 6-(3-Methyl-2-butenyl-1-amino)-2-methylthio-9-[2'-(O-tbutyl-
dimethylsilyl)-3',5'-(O-di-tbutylsilandiyl)--D-ribofuranosyl]-9H-purine (47). 
 
 
 
Nucleoside ms2i6A (326 mg, 0.86 mmol, 1.00 eq) was dissolved in dry DMF (1.70 ml) and 
cooled to 0 °C. Di-tbutyl-silyl-ditriflate (306 l, 0.95 mmol, 1.10 eq) was added dropwise. 
After stirring for 30 min at 0 °C imidazole (291 mg, 4.28 mmol, 5.00 eq) was added and the 
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reaction mixture was allowed to warm to rt. The mixture was stirred for 30 min and 
TBDMSCl (158 mg, 1.03 mmol, 1.20 eq) was added. The solution was heated to 60 °C for 
2 h. The reaction was stopped by addition of H2O (10.0 mL). The aq. layer was extracted 
three times with DCM (10.0 mL). The combined organic phases were extracted with brine 
(10 ml) and dried over MgSO4. Removal of the solvent gave a white foam, which was applied 
in the next reaction without further purification. An analytical sample of nucleoside 47 was 
obtained via column chromatography (DCM/MeOH 100/1). 
 
Rf = 0.64 (DCM/MeOH 40/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 7.50 (s, 1H; HC8), 5.75 (s, 1H; HC1'), 5.53 (s, 1H; 
HN), 5.26 – 5.22 (m, 1H; CH2CHC(CH3)2), 4.59 (d, 3J(HC2',HC3')=4.9 Hz, 1H; HC2'), 4.37 
(dd, 2J(HaC5',HbC5')=9.2 Hz, 3J(HaC5',HC4')=5.1 Hz, 1H; HaC5'), 4.32 (dd, 
3J(HC3',HC4')=9.5 Hz, 3J(HC3',HC2')=4.9 Hz, 1H; HC3'), 4.11 – 4.05 (m, 3H; HC4' and 
CH2CHC(CH3)2), 3.92 (dd, 3J(HC4',HbC5')=10.3 Hz, 2J(HbC5',HaC5')=9.3 Hz, 1H; HbC5'), 2.47 
(s, 3H; SCH3), 1.67 (s, 3H; CH2CHC(CH3)2), 1.65 (s, 3H; CH2CHC(CH3)2), 1.00 (s, 9H; 
O2Si(C(CH3)3)2), 0.97 (s, 9H; O2Si(C(CH3)3)2), 0.84 (s, 9H; Si(CH3)2C(CH3)3), 0.07 (s, 3H; 
Si(CH3)2C(CH3)3), and 0.06 ppm (s, 3H; Si(CH3)2C(CH3)3); 
13C NMR (150 MHz, CDCl3, 27 °C): δ = 166.47 (C2), 154.05 (C4), 149.23 (C6), 137.24 (C8), 
136.94 (CH2CHC(CH3)2), 120.44 (CH2CHC(CH3)2), 118.08 (C5), 92.52 (C1'), 76.33 (C3'), 
75.33 (C2'), 74.65 (C4'), 68.00 (C5'), 38.61 (CH2CHC(CH3)2), 27.76 (3C; O2Si(C(CH3)3)2), 
27.27 (3C; O2Si(C(CH3)3)2), 26.12 (3C; Si(CH3)2(C(CH3)3), 25.90 (CH2CHC(CH3)2), 22.92 
(O2Si(C(CH3)3)2), 20.60 (O2Si(C(CH3)3)2), 18.57 (Si(CH3)2(C(CH3)3), 18.22 
(CH2CHC(CH3)2), 14.78 (SCH3), -4.08 (Si(CH3)2C(CH3)3), and -4.74 ppm 
(Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C30H54N5O4SSi2]+: calc.: 636.3429, found: 636.3430. 
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10.12.1.2 6-(3-Methyl-2-butenyl-1-amino)-2-methylthio-9-(2'-(O-tbutyl-
dimethylsilyl)--D-ribofuranosyl)-9H-purine (47a). 
 
 
 
The equivalents given in this protocol refer to the amount of ms2i6A employed in this three 
step reaction sequence. HF-pyridine (86.0 L, 0.85 mmol, 1.00 eq) was diluted in dry 
pyridine (534 mL, 6.62 mmol, 8.00 eq) at 0 °C. The total crude product of the preceding 
reaction was dissolved in dry DCM (4.30 mL) and cooled to 0 °C. The HF-pyridine solution 
was added dropwise to the nucleoside solution. The resulting mixture was stirred at 0 °C for 
2 h. MeOTMS (594 L, 4.34 mmol, 5.00 eq) was added and the reaction was allowed to 
warm to rt and stirred for 30 min. The solvent was removed in vacuo and the resulting oil was 
treated with H2O (10.0 mL) and DCM (10.0 mL). The aq. layer was extracted with DCM 
(10.0 mL) three times. The combined organic phases were extracted with brine (10.0 mL) and 
dried over MgSO4. Removal of the solvent gave a white foam, which was applied in the next 
reaction without further purification. An analytical sample of nucleoside 47a was obtained via 
column chromatography (DCM/MeOH 50/1). 
 
Rf = 0.34 (DCM/MeOH 40/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 7.56 (s, 1H; HC8), 5.72 (s, 1H; HN), 5.64 (d, 
3J(HC1',HC2')=7.3 Hz, 1H; HC1'), 5.34 (m, 1H; CH2CHC(CH3)2), 5.16 (dd, 
3J(C2'H,C1'H)=7.2 Hz, 3J(HC2',HC3')=4.9 Hz, 1H; HC2'), 4.32 (d, 3J(HC3',HC2')=4.9 Hz, 1H; 
HC3'), 4.30 (m, 1H; HC4'), 4.20 (m, 2H; CH2CHC(CH3)2), 3.94 (m, 1H; HaC5'), 3.72 (m, 1H; 
HbC5'), 2.57 (s, 3H; SCH3), 1.74 (s, 3H; CH2CHC(CH3)2), 1.60 (s, 3H; CH2CHC(CH3)2), 0.79 
(s, 9H; Si(CH3)2C(CH3)3), -0.15 (s, 3H; Si(CH3)2C(CH3)3), and -0.36 ppm (s, 3H; 
Si(CH3)2C(CH3)3); 
13C NMR (151 MHz, CDCl3, 27 °C): δ = 166.50 (C2), 154.09 (C4), 148.90 (C6), 139.25 (C8), 
137.20 (CH2CHC(CH3)2), 120.16 (CH2CHC(CH3)2), 119.15 (C5), 91.19 (C1'), 87.60 (C4'), 
74.06 (C2'), 73.07 (C3'), 63.69 (C5'), 38.63 (CH2CHC(CH3)2), 25.91 (CH2CHC(CH3)2), 25.77 
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(Si(CH3)2(C(CH3)3), 18.23 (3C; CH2CHC(CH3)2), 18.05 (Si(CH3)2(C(CH3)3), 14.80 (SCH3), 
-5.06 (Si(CH3)2C(CH3)3), and -5.16 ppm (Si(CH3)2C(CH3)3). 
 
10.12.1.3 6-(3-methyl-2-butenyl-1-amino)-2-methylthio-9-(5'-O-dimethoxytrityl-2'-
(O-tbutyl-dimethylsilanyl)-β-D-ribofuranosyl)-9H-purine (46). 
 
N
N
N
NH
SN
O
OTBDMSOH
O
O
O
 
 
The equivalents given in this protocol refer to the amount of ms2i6A employed in this three 
step reaction sequence. The total crude product of the preceding reaction was dissolved in dry 
pyridine (1.70 mL) and cooled to 0 °C. Dimethoxytrityl chloride (320 mg, 0.95 mmol, 
1.10 eq) was added the resulting mixture was stirred at 0 °C for 16 h. Methanol (38.0 µL) was 
added and the solution was stirred for 30 min at rt. DCM (15.0 mL) and water (10.0 mL) were 
added and the layers were separated. The DCM layer was extracted with sat. NaHCO3 
solution (10.0 mL) three times. The combined organic layers were dried over MgSO4. The 
solvent was removed and the oil was applied to column chromatography (isohexane/ethyl 
acetate 10/1 to 2/1, 0.5 vol% Et3N). Nucleoside 46 (352 mg, 52 %, 3 steps) was obtained as 
white foam. 
 
Rf = 0.10 (DCM/MeOH 40/1); 
1H NMR (600 MHz, CDCl3, 27 °C) δ = 7.80 (s, 1H; HC8), 7.37 (d, 
3J(HorthoPh,HmetaPh)=7.5 Hz, 2H; HorthoPh), 7.27 – 7.23 (m, 4H; HorthoPhOMe), 7.19 (dd, 
3J(HmetaPh,HorthoPh)=7.5 Hz, 3J(HmetaPh,HparaPh)=7.3 Hz, 2H; HmetaPh), 7.18 (t, 
3J(HparaPh,HmetaPh)=7.3 Hz, 1H; HparaPh), 6.78 – 6.72 (m, 4H; HmetaPhOMe), 5.91 (d, 
3J(HC1',HC2')=4.3 Hz, 1H; HC1'), 5.72 (s, 1H; HN), 5.36 – 5.30 (m, 1H; CH2CHC(CH3)2), 
4.66 (dd, 3J(HC2',HC3')=4.5 Hz, 3J(HC2',HC1')=4.3 Hz, 1H; HC2'), 4.62 (dd, 
3J(HC3',HC4')=4.9 Hz, 3J(HC3',HC2')=4.5 Hz, 1H; HC3'), 4.22 – 4.13 (m, 2H; 
CH2CHC(CH3)2), 4.13 – 4.10 (m, 1H; HC4'), 3.75 (s, 6H; PhOCH3), 3.40 (dd, 
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2J(HaC5',HbC5')=10.5 Hz, 3J(HaC5',HC4')=3.5 Hz, 1H; HaC5'), 3.26 (dd, 
2J(HbC5',HaC5')=10.6 Hz, 3J(HbC5',HC4')=4.5 Hz, 1H; HbC5'), 2.48 (s, 3H; SCH3), 1.73 (s, 3H; 
CH2CHC(CH3)2), 1.71 (s, 3H; CH2CHC(CH3)2), 0.85 (s, 9H; Si(CH3)2C(CH3)3), 0.10 (s, 3H; 
Si(CH3)2C(CH3)3), and 0.01 ppm (s, 3H; Si(CH3)2C(CH3)3); 
13C NMR (151 MHz, CDCl3, 27 °C) δ = 166.08 (C2), 158.71 (C4), 158.69 (2C; CparaPhOMe), 
154.02 (C6), 144.65 (CipsoPh), 137.91 (C8), 136.78 (CH2CHC(CH3)2), 135.94 (2C; 
CipsoPhOMe), 130.24 (4C; CorthoPhOMe), 128.36 (2C; CorthoPh), 128.02 (2C; CmetaPh), 127.04 
(2C; CparaPh), 120.54 (CH2CHC(CH3)2), 118.02 (C5), 113.34 (4C; CmetaPhOMe), 89.56 (C1'), 
86.66 (CPh(PhOMe)2), 84.37 (C4'), 74.61 (C2'), 72.41 (C3'), 63.33 (C5'), 55.40 (2C; OCH3), 
41.13 (CH2CHC(CH3)2), 25.94 (3C; Si(CH3)2(C(CH3)3), 25.89 (CH2CHC(CH3)2), 18.25 
(Si(CH3)2(C(CH3)3), 18.21 (CH2CHC(CH3)2), 14.77 (SCH3), and -4.52 ppm (2C; 
Si(CH3)2(C(CH3)3); 
HR-MS (ESI+) for [C43H56N5O6SSi]+: calc.: 798.3714, found: 798.3745. 
 
10.12.2 Synthesis of DMT-TBDMS-protected m2A 
 
 
Scheme 54: Synthesis of nucleoside 51. 
Reagents and conditions: a) tBu2Si(OTf)2, TBDMSCl, DMF, -5 °C to rt, 21 h; b) Isobutyryl chloride, 
pyridine, DMF, 0 °C, 25 min; c) HF-pyridine, pyridine, DCM, MeOTMS, -13 °C to rt, 2 h; d) DMTCl, 
pyridine, MeOH, rt, 3.5 h, 37 % (4 steps). 
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10.12.2.1 6-Amino-2-methyl-9-(2'-(O-tbutyl-dimethylsilyl)-3',5'-(O-di-
tbutylsilandiyl)--D-ribofuranosyl)-9H-purine (48). 
 
 
 
Nucleoside m2A (700 mg, 2.50 mmol, 1.00 eq) was dissolved in dry DMF (5.00 mL) and 
cooled to -5 °C. Di-tbutyl-silyl-ditriflate (1.62 ml, 5.00 mmol, 2.00 eq) was added dropwise. 
After stirring for 5 h at -5 °C TBDMSCl (755 mg, 5.00 mmol, 2.00 eq) was added. The 
cooling bath was removed and the reaction was stirred for 16 h at rt. The reaction was stopped 
by addition of water (20.0 mL). The aq. layer was extracted three times with DCM (20.0 mL). 
The combined organic phases were extracted with brine (20.0 mL) and dried over MgSO4. 
Removal of the solvent gave a white foam, which was applied in the next reaction without 
further purification. An analytical sample of nucleoside 48 was obtained via column 
chromatography (DCM/MeOH 100/1). 
 
Rf = 0.50 (DCM/MeOH 8/1);  
1H NMR (600 MHz, CDCl3, 27 °C): δ = 7.72 (s, 1H; HC8), 5.84 (s, 1H; HC1'), 4.56 (d, 
3J(HC2',HC3')=4.7 Hz, 1H; HC2'), 4.52 (dd, 3J(HC3',HC4')=9.5 Hz, 3J(HC3',HC2')=4.7 Hz, 1H; 
HC3'), 4.47 (dd, 2J(HaC5',HbC5')=9.3 Hz, 3J(HaC5',HC4')=5.1 Hz, 1H; HaC5'), 4.20 (ddd, 
3J(HC4',HbC5')=10.3 Hz, 3J(HC4',HC3')=9.5 Hz, 3J(HC4',HaC5')=5.1 Hz, 1H; HC4'), 4.02 (dd, 
3J(HbC5',HC4')=10.3 Hz, 2J(HbC5',HaC5')=9.3 Hz, 1H; HbC5'), 2.52 (s, 3H; CH3), 1.03 (s, 18H; 
O2Si(C(CH3)3)2), 0.92 (s, 9H; Si(CH3)2C(CH3)3), 0.16 (s, 3H; Si(CH3)2C(CH3)3), and 
0.13 ppm (s, 2H; Si(CH3)2C(CH3)3); 
13C NMR (150 MHz, CDCl3, 27 °C): δ = 162.81 (C2), 155.18 (C4), 149.92 (C6), 138.30 (C8), 
118.26 (C5), 92.84 (C1'), 75.91 (C3'), 75.75 (C2'), 74.95 (C4'), 68.07 (C5'), 27.50 (3C; 
O2Si(C(CH3)3)2), 27.50 (3C; O2Si(C(CH3)3)2), 26.14 (3C; Si(CH3)2C(CH3)3), 25.69 (CH3), 
22.97 (O2Si(C(CH3)3)2), 20.57 (O2Si(C(CH3)3)2), 18.56 (Si(CH3)2C(CH3)3), -4.07 
(Si(CH3)2C(CH3)3), and -4.76 ppm (Si(CH3)2C(CH3)3); 
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HR-MS (ESI+) for [C25H46N5O4Si2]+: calc.: 536.3083, found: 536.3086. 
 
10.12.2.2 6-Isobutyrylamido-2-methyl-9-(2'-(O-tbutyl-dimethylsilyl)-3',5'-(O-di-
tbutylsilandiyl)--D-ribofuranosyl)-9H-purine (50). 
 
 
 
The equivalents given in this protocol refer to the amount of m2A employed in this four step 
reaction sequence. The total crude product of the preceding reaction was dissolved in dry 
DMF (0.50 mL) and dry pyridine (0.16 mL) and cooled to 0 °C. Isobutyryl chloride (522 l, 
5.00 mmol, 2.00 eq) was added. After stirring for 25 min at 0 °C DCM (10.0 mL) and water 
(10.0 mL) were added. The layers were separated and the aq. layer was extracted with DCM 
(10.0 mL) three times. The combined organic phases were extracted with brine (20.0 mL) and 
dried over MgSO4. Removal of the solvent gave a white foam, which was applied in the next 
reaction without further purification. An analytical sample of nucleoside 50 was obtained via 
column chromatography (DCM/MeOH 200/1). 
 
Rf = 0.83 (DCM/MeOH 8/1);  
1H NMR (600 MHz, CDCl3, 27 °C): δ = 7.94 (s, 1H; HC8), 5.91 (s, 1H; HC1'), 4.54 (d, 
3J(HC2',HC3')=4.9 Hz, 1H; HC2'), 4.48 (dd, 3J(HC3',HC4')=9.2 Hz, 3J(HC3',HC2')=4.9 Hz, 1H; 
HC3'), 4.44 (dd, 2J(HaC5',HbC5')=9.5 Hz, 3J(HaC5',HC4')=4.9 Hz, 1H; HaC5'), 4.22 (ddd, 
3J(HC4',HbC5')=10.4 Hz, 3J(HC4',HC3')=9.2 Hz, 3J(HC4',HaC5')=4.9 Hz, 1H; HC4'), 4.01 (dd, 
3J(HbC5',HC4')=10.4 Hz, 2J(HbC5',HaC5')=9.5 Hz, 1H; HbC5'), 3.19 – 3.08 (m, 1H; 
COCH(CH3)2), 2.66 (s, 3H; CH3), 1.27 (d, 3J(COCH(CH3)2,COCH(CH3)2)=3.6 Hz, 3H; 
COCH(CH3)2), 1.26 (d, 3J(COCH(CH3)2,COCH(CH3)2)=3.6 Hz, 3H; COCH(CH3)2), 1.05 (s, 
9H; O2Si(C(CH3)3)2), 1.02 (s, 9H; O2Si(C(CH3)3)2), 0.92 (s, 9H; Si(CH3)2C(CH3)3), 0.16 (s, 
3H; Si(CH3)2C(CH3)3), and 0.14 ppm (s, 3H; Si(CH3)2C(CH3)3); 
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13C NMR (150 MHz, CDCl3, 27 °C): δ = 181.91 (COCH(CH3)2), 162.67 (C2), 151.72 (C6), 
149.36 (C4), 140.49 (C8), 121.27 (C5), 92.72 (C1'), 76.00 (C3'), 75.79 (C2'), 74.96 (C4'), 68.03 
(C5'), 36.10 (COCH(CH3)2). 27.70 (3C; O2Si(C(CH3)3)2), 27.21 (3C; O2Si(C(CH3)3)2), 26.12 
(3C; Si(CH3)2C(CH3)3), 25.79 (CH3) 22.96 (O2Si(C(CH3)3)2), 20.55 (O2Si(C(CH3)3)2), 19.42 
(COCH(CH3)2), 19.39 (COCH(CH3)2), 18.55 (Si(CH3)2C(CH3)3), -4.06 (Si(CH3)2C(CH3)3), 
and -4.78 ppm (Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C29H52N5O5Si2]+: calc.: 606.3502, found: 606.3512. 
 
10.12.2.3 6-Isobutyrylamido-2-methyl-9-(2'-(O-tbutyl-dimethylsilyl)--D-
ribofuranosyl)-9H-purine (50a). 
 
 
 
The equivalents given in this protocol refer to the amount of m2A employed in this four step 
reaction sequence. The total crude product of the preceding reaction was dissolved in dry 
DCM (12.0 mL) and the solution cooled to -13 °C. HF-pyridine (250 L, 2.50 mmol, 1.00 eq) 
was diluted in dry pyridine (1.50 mL). The HF-pyridine solution was added dropwise to the 
nucleoside solution at -13 °C. The resulting mixture was stirred at -13 °C for 2 h. MeOTMS 
(1.40 mL, 10.0 mmol, 4.00 eq) was added and the reaction was allowed to warm to rt and 
stirred for 30 min. Water (10.0 mL), DCM (10.0 mL), and sat. NaHCO3 (10.0 mL) were 
added. The layers were separated and the aq. layer was extracted three times with DCM 
(10.0 mL). The combined organic phases were extracted with brine (30.0 mL) and dried over 
MgSO4. Removal of the solvent gave a white foam, which was applied in the next reaction 
without further purification. An analytical sample of nucleoside 50a was obtained via column 
chromatography (DCM/MeOH 100/1). 
 
Rf = 0.81 (DCM/MeOH 8/1);  
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1H NMR (600 MHz, CDCl3, 27 °C): δ = 7.87 (s, 1H; HC8), 5.75 (d, 3J(HC1',HC2')=7.4 Hz, 
1H; HC1'), 5.10 (dd, 3J(HC2',HC1')=7.4, 3J(HC2',HC3')=4.8 Hz, 1H; HC2'), 4.38 – 4.35 (m, 1H; 
HC4'), 4.34 (d, 3J(HC3',HC2')=4.8 Hz, 1H; HC3'), 3.98 – 3.93 (m, 1H; HaC5'), 3.78 – 3.71 (m, 
1H; HbC5'), 3.31 – 3.22 (m, 1H; COCH(CH3)2), 2.72 (s, 3H; CH3), 1.30 (d, 
3J(COCH(CH3)2,COCH(CH3)2)=4.1 Hz, 3H; COCH(CH3)2), 1.29 (d, 
3J(COCH(CH3)2,COCH(CH3)2)=4.1 Hz, 3H; COCH(CH3)2), 0.78 (s, 9H; Si(CH3)2C(CH3)3), 
-0.19 (s, 3H; Si(CH3)2C(CH3)3), and -0.41 ppm (s, 3H; Si(CH3)2C(CH3)3); 
13C NMR (150 MHz, CDCl3, 27 °C): δ = 176.39 (COCH(CH3)2), 162.78 (C2), 150.91 (C4), 
149.89 (C6), 142.43 (C8), 121.79 (C5), 91.52 (C1'), 87.88 (C4'), 74.46 (C2'), 73.09 (C3'), 63.61 
(C5'), 36.31 (COCH(CH3)2), 25.81 (CH3), 25.72 (Si(CH3)2(C(CH3)3), 19.36 (COCH(CH3)2), 
19.30 (3C; COCH(CH3)2), 18.04 (Si(CH3)2(C(CH3)3), -5.06 (Si(CH3)2C(CH3)3), and 
-5.21 ppm (Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C21H36N5O5Si]+: calc.: 466.2480, found: 466.2485. 
 
10.12.2.4 6-Isobutyrylamido-2-methyl-9-(5'-O-dimethoxytrityl-2'-(O-tbutyl-
dimethylsilanyl)-β-D-ribofuranosyl)-9H-purine (51). 
 
 
 
The equivalents given in this protocol refer to the amount of m2A employed in this four step 
reaction sequence. The total crude product of the preceding reaction was dissolved in dry 
pyridine (1.60 mL). Dimethoxytrityl chloride (72 mg, 0.21 mmol, 1.20 eq) was added and the 
resulting mixture was stirred at rt for 3 h. Water (1.00 mL) was added and the solution was 
stirred for additional 30 min at rt. DCM (10.0 mL) and water (10.0 mL) were added and the 
layers were separated. The aq. layer was extracted three times with DCM (10.0 mL). The 
combined organic layers were extracted with brine (20.0 mL) and dried over MgSO4. The 
solvent was removed and the oil was purified via column chromatography (isohexane/ethyl 
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acetate 10/1 to 2/1, 1.0 vol% Et3N). Nucleoside 51 (50 mg, 37 %, 4 steps) was obtained as 
white foam. 
 
Rf = 0.90 (DCM/MeOH 18/1);  
1H NMR (600 MHz, CDCl3, 27 °C) δ = 8.08 (s, 1H; HC8), 7.42 – 7.37 (m, 2H; HorthoPh), 
7.31 – 7.26 (m, 4H; HorthoPhOMe), 7.23 – 7.19 (m, 2H; HmetaPh), 7.17 – 7.14 (m, 1H; 
HparaPh), 6.78 – 6.73 (m, 4H; HmetaPhOMe), 6.02 (d, 3J(HC1',HC2')=4.8 Hz, 1H; HC1'), 4.88 
(dd, 3J(HC2',HC3')=4.9 Hz, 3J(HC2',HC1')=4.8 Hz, 1H; HC2'), 4.32 (dd, 3J(HC3',HC2')=4.9 Hz, 
3J(HC3',HC4')=4.2 Hz, 1H; HC3'), 4.22 (ddd, 3J(HC4',HC3')=4.2 Hz, 3J(HC4',HbC5')=4.1 Hz, 
3J(HC4',HaC5')=3.2 Hz, 1H; HC4'), 3.72 (s, 3H; PhOCH3), 3.72 (s, 3H; PhOCH3), 3.49 (dd, 
2J(HaC5',HbC5')=10.6 Hz, 3J(HaC5',HC4')=3.2 Hz, 1H; HaC5'), 3.36 (dd, 
2J(HbC5',HaC5')=10.6 Hz, 3J(HbC5',HC4')=4.1 Hz, 1H; HbC5'), 3.21 – 3.14 (m, 1H; 
COCH(CH3)2), 2.55 (s, 3H; CH3), 1.26 (d, 3J(COCHC(CH3)2,COCHC(CH3)2)=0.6 Hz, 3H; 
COCHC(CH3)2), 1.24 (d, 3J(COCHC(CH3)2,COCHC(CH3)2)=0.6 Hz, 3H; COCHC(CH3)2), 
0.81 (s, 9H; Si(CH3)2C(CH3)3), -0.03 (s, 3H; Si(CH3)2C(CH3)3) and -0.13 ppm (s, 3H; 
Si(CH3)2C(CH3)3); 
13C NMR (151 MHz, CDCl3, 27 °C) δ = 176.36 (COCH(CH3)2), 162.66 (C2), 158.69 (2C; 
CparaPhOMe), 152.11 (C6), 149.02 (C4), 144.66 (CipsoPh), 140.87 (C8), 135.74 (CipsoPhOMe), 
135.69 (CipsoPhOMe), 130.20 (2C; CorthoPhOMe), 130.19 (2C; CorthoPhOMe), 128.24 (2C; 
CorthoPh), 128.01 (2C; CmetaPh), 127.07 (CparaPh), 120.74 (C5), 113.32 (2C; CmetaPhOMe), 
113.32 (2C; CmetaPhOMe), 88.58 (C1'), 86.72 (CPh(PhOMe)2), 84.15 (C4'), 75.87 (C2'), 71.42 
(C3'), 63.47 (C5'), 55.31 (2C; OCH3), 36.10 (COCH(CH3)2), 26.02 (CH3), 25.71 (3C; 
Si(CH3)2(C(CH3)3), 19.32 (COCH(CH3)2), 19.31 (COCH(CH3)2), 18.06 (Si(CH3)2(C(CH3)3), 
-4.81 (Si(CH3)2(C(CH3)3), and -4.52 ppm (Si(CH3)2(C(CH3)3); 
HR-MS (ESI+) for [C42H54N5O7Si]+: calc.: 768.3787, found: 768.3797. 
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10.12.3 Synthesis of DMT-TBDMS-protected formyl-deazaguanosine 
 
 
Scheme 55: Synthesis of nucleoside 52. 
Reagents and conditions: a) 2 M NaOH, dioxane, rt, 50 min, 60 %; b) tBu2Si(OTf)2, imidazole, 
TBDMSCl, DMF, 0 °C to rt, 22 h; c) HF-pyridine, pyridine, DCM, MeOTMS, -5 °C to rt, 3 h; d) DMTCl, 
pyridine, MeOH, rt, 16 h, 69 % (3 steps); e) Pd2(dba)3, PPh3, CO, toluene, 55 °C, 1 h, 81 %. 
 
10.12.3.1 3,4-Dihydro-5-iodo-2-pivaloylamino-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-
d]pyrimidine-4-one (53). 
 
 
 
Nucleoside 33 (1.00 g, 2.03 mmol, 1.00 eq) was dissolved in dioxane (10.0 mL) and 
aq. NaOH (2 M, 5.00 mL) was added dropwise. The resulting suspension was stirred for 
50 min at rt. The solution was neutralized with HCl (2 M). The solvent was removed in vacuo 
and the resulting oil was dissolved in water (10.0 mL). The pH of the mixture was adjusted to 
3.0 with HCl (2 M). The suspension was extracted with diethyl ether (10.0 mL) twice. The 
combined organic layers were extracted with water (10.0 mL). The combined aqueous layers 
were neutralized with NaOH (2 M) and the solvent was removed in vacuo. Nucleoside 53 
(0.37 g, 60 %) was obtained after column chromatography (DCM/MeOH 20/1) as almost 
colorless oil. 
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Rf = 0.52 (DCM/MeOH 8/1); 
1H NMR (400 MHz, D6-DMSO, 27 °C): δ = 7.43 (s, 1H; HC6), 6.13 (d, 
3J(HC1',HC2')=5.5 Hz, 1H; HC1'), 4.34 (dd, 3J(HC2',HC1')=5.5 Hz, 3J(HC2',HC3')=5.4 Hz, 1H; 
HC2'), 4.24 (dd, 3J(HC3',HC2')=5.4 Hz, 3J(HC3',HC4')=3.7 Hz, 1H; HC3'), 4.02 (ddd, 
3J(HC4',HC3')=3.7 Hz, 3J(HC4',HbC5')=3.6 Hz, 3J(HC4',HaC5')=3.2 Hz, 1H; HC4'), 3.81 (dd, 
3J(HaC5',HbC5')=12.2 Hz, 3J(HaC5',HC4')=3.2 Hz, 1H; HaC5'), 3.49 (dd, 
3J(HbC5',HaC5')=12.2 Hz, 3J(HbC5',HC4')=3.6 Hz, 1H; HbC5'), and 1.31 ppm (COC(CH3)3); 
13C NMR: δ = 180.1, 156.5, 146.0, 127.2, 106.3, 91.3, 86.2, 73.8, 72.2, 63.3, 54.0, 40.3, and 
27.1 ppm; E. M. Jahn, personal communication; 
IR: 3319 m (O-H valence), 1668 s (C=O valence), 1605 s (aromatic vibration), 1539 m (N-H 
deform.), 1420 m (C-H deform.), 1050 m (C-O valence), 777 cm-1 w (C-Hal valence); E. M. 
Jahn, personal communication; 
HR-MS (ESI+) for [C16H21IN4O6]+: calc.: 493.0579, found: 493.0574; E. M. Jahn, personal 
communication. 
 
10.12.3.2 3,4-Dihydro-5-iodo-2-pivaloylamino-7-[(2'-(O-tbutyl-dimethylsilyl)-3',5'-
(O-di-tbutylsilandiyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine-4-one 
(54). 
 
 
 
Nucleoside 53 (367 mg, 0.75 mmol, 1.00 eq) was dissolved in dry DMF (5.00 mL) and cooled 
to 0 °C. Di-tbutyl-silyl-ditriflate (0.49 mL, 662 mg, 1.50 mmol, 2.00 eq) was added dropwise. 
After stirring for 15 min at -5 °C imidazole (254 mg, 3.73 mmol, 5.00 eq) was added and the 
solution was stirred at rt for 6 h. TBDMSCl (227 mg, 1.50 mmol, 2.00 eq) was added and the 
mixture was stirred at rt for 16 h. The aq. layer was extracted with DCM (20.0 mL) three 
times. The combined organic phases were extracted with brine (20.0 mL) and dried over 
MgSO4. Removal of the solvent gave a white foam, which was used in the next reaction 
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without further purification. An analytical sample of nucleoside 54 was obtained via column 
chromatography (DCM/MeOH 200/1). 
 
Rf = 0.24 (DCM/MeOH 50/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.65 (s, 1H; NHCO), 7.82 (s, 1H; HNAr), 6.79 (s, 
1H; HC6), 5.92 (s, 1H; HC1'), 4.46 (dd, 3J(HaC5',HbC5')=9.3 Hz, 3J(HaC5',HC4')=5.1 Hz, 1H; 
HaC5'), 4.25 (d, 3J(HC2',HC3')=4.8 Hz, 1H; HC2'), 4.12 (ddd, 3J(HC4',HC5')=10.2 Hz, 
3J(HC4',HC3')=10.1 Hz, 3J(HC4',HaC5')=5.1 Hz, 1H; HC4'), 4.01 (dd, 3J(HC3',HC2')=4.8 Hz, 
3J(HC3',HC4')=10.1 Hz, 1H; HC3'), 3.99 (dd, 3J(HbC5',HC4')=10.2 Hz, 3J(HaC5', HbC5')=9.3 Hz, 
1H; HbC5') 1.30 (s, 9H; COC(CH3)3), 1.05 (s, 9H; O2Si(C(CH3)3)2), 1.01 (s, 9H; 
O2Si(C(CH3)3)2), 0.91 (s, 9H; Si(CH3)2C(CH3)3), 0.12 (s, 3H; Si(CH3)2C(CH3)3), and 
0.11 ppm (s, 3H, Si(CH3)2C(CH3)3); 
13C NMR (150 MHz, CDCl3, 27 °C): δ = 179.55 (COC(CH3)3), 156.88 (C4), 146.65 (C7a), 
146.51 (C2), 123.80 (C6), 106.26 (C4a), 91.97 (C1'), 76.73 (C3'), 76.38 (C2'), 74.44 (C4'), 
68.06 (C5'), 56.09 (C5), 40.38 (COC(CH3)3), 27.71 (3C; O2Si(C(CH3)3)2), 27.26 (3C; 
COC(CH3)3), 27.23 (3C; O2Si(C(CH3)3)2), 26.14 (3C; Si(CH3)2(C(CH3)3), 23.00 
(O2Si(C(CH3)3)2), 20.58 (O2Si(C(CH3)3)2), 18.68 (Si(CH3)2(C(CH3)3), -3.96 
(Si(CH3)2C(CH3)3), and -4.76 ppm (Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C30H52IN4O6Si2]+: calc.: 747.2465, found: 747.2477. 
 
10.12.3.3 3,4-Dihydro-5-iodo-2-pivaloylamino-7-[(2'-O-tert-butyl-dimethylsilyl)-β-D-
ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine-4-one (54a). 
 
 
 
The equivalents given in this protocol refer to the amount of nucleoside 54 employed in this 
three step reaction sequence. The total crude product of the preceding reaction was dissolved 
in dry DCM (3.75 mL) and cooled to -5 °C. HF-pyridine (0.08 mL, 2.77 mmol, 2.00 eq) in 
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dry pyridine (0.47 mL) was added dropwise. After stirring for 3 h at -5 °C excess MeOTMS 
(0.43 mL, 3.12 mmol, 4.16 eq) was added and the solution was stirred at rt for 30 min. 
Sat. NaHCO3 (5.00 mL) and DCM (5.00 mL) were added. The layers were separated and the 
organic layer was extracted with DCM (20.0 mL) twice. The combined organic phases were 
extracted with brine (20.0 mL) and dried over MgSO4. Removal of the solvent gave a white 
foam, which was used in the next reaction without further purification. An analytical sample 
of nucleoside 54a was obtained via column chromatography (DCM/MeOH 100/1). 
 
Rf = 0.61 (DCM/MeOH 8/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.68 (s, 1H; NHCO), 8.07 (s, 1H; HNAr), 6.86 (s, 
1H; HC6), 5.52 (d, 3J(HC1',HC2')=7.1 Hz, 1H; HC1'), 4.72 (dd, 3J(HC2',HC1')=7.1 Hz, 
3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.28 (m, 1H; HC4'), 4.23 (d, 3J(HC3',HC2')=5.2 Hz, 1H; 
HC3'), 3.92 (dd, 3J(HaC5',HbC5')=12.3 Hz, 3J(HaC5'H,C4')=2.0 Hz, 1H; HaC5'), 3.74 (m, 1H; 
HbC5'), 1.31 (s, 9H; COC(CH3)3), 0.82 (s, 9H; Si(CH3)2C(CH3)3), -0.13 (s, 3H; 
Si(CH3)2C(CH3)3), and -0.28 ppm (s, 3H; Si(CH3)2C(CH3)3); 
13C NMR (150 MHz, CDCl3, 27 °C): δ = 179.93 (COC(CH3)3), 156.53 (C4), 146.62 (C7a), 
145.42 (C2), 127.98 (C6), 107.82 (C4a), 92.99 (C1'), 86.86 (C4'), 75.02 (C2'), 72.61 (C3'), 
63.63 (C5'), 54.57 (C5), 40.50 (COC(CH3)3), 27.17 (3C; COC(CH3)3), 25.74 (3C; 
Si(CH3)2(C(CH3)3), 18.12 (Si(CH3)2(C(CH3)3), -5.08 (Si(CH3)2C(CH3)3), and -5.13 ppm 
(Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C22H36IN4O6Si]+: calc.: 607.1443, found: 607.1454. 
 
10.12.3.4 3,4-Dihydro-5-iodo-2-pivaloylamino-7-[(2'-O-tbutyl-dimethylsilyl)-(5'-O-
dimethoxytrityl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine-4-one (55). 
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The equivalents given in this protocol refer to the amount of nucleoside 54 employed in this 
three step reaction sequence. The total crude product of the preceding reaction was dissolved 
in dry pyridine (4.00 mL) and DMTCl (304 mg, 0.90 mmol, 1.20 eq) was added. After stirring 
for 16 h at rt MeOH (4.00 mL) was added and the solution was concentrated to about 4 mL in 
vacuo. DCM (20.0 mL), water (10.0 mL), and sat. NaHCO3 solution (10.0 mL) were added. 
The layers were separated and the aqueous layer was extracted with DCM (20.0 mL). The 
combined organic phases were extracted with brine (20.0 mL) and dried over MgSO4. 
Nucleoside 55 (473 mg, 69 %, 3 steps) was obtained via column chromatography 
(isohexane/ethyl acetate 10/1 to 2/1) as yellow foam. 
 
Rf = 0.32 (DCM/MeOH 50/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.84 (s, 1H; NHCO), 8.47 (s, 1H; HNAr), 
7.53 - 7.49 (m, 2H; HorthoPh), 7.43 – 7.39 (m, 4H; HorthoPhOMe), 7.38 – 7.34 (m, 2H; 
HmetaPh), 7.35 (s, 1H; HC6), 7.31 – 7.27 (m, 1H; HparaPh), 6.93 – 6.88 (m, 4H; HmetaPhOMe), 
6.02 (d, 3J(HC1',HC2')=6.3 Hz, 1H; HC1'), 4.66 (dd, 3J(HC2',HC1')=6.3 Hz, 
3J(HC2',HC3')=5.2 Hz, 1H; HC2'), 4.31 (dd, 3J(HC3',HC2')=5.2 Hz, 3J(HC3',HC4')=2.4 Hz, 1H; 
HC3'), 4.27 (ddd, 3J(HC4',HbC5')=3.2 Hz, 3J(HC4',HaC5')=2.4 Hz, 3J(HC4',HC3')=2.4 Hz, 1H; 
HC4'), 3.86 – 3.83 (m, 6H; PhOCH3), 3.50 (dd, 2J(HaC5',HbC5')=10.7 Hz, 
3J(HaC5',HC4')=2.4 Hz, 1H; HaC5'), 3.41 (dd, 2J(HbC5',HaC5')=10.7 Hz, 3J(HbC5',HC4')=3.2 Hz, 
1H; HbC5'), 1.32 (s, 9H; COC(CH3)3), 0.89 (s, 9H; Si(CH3)2C(CH3)3), 0.06 (s, 3H; 
Si(CH3)2C(CH3)3), and -0.12 ppm (s, 3H; Si(CH3)2C(CH3)3); 
13C NMR (151 MHz, CDCl3, 27 °C): δ = 179.95 (COC(CH3)3), 158.77 (CparaPhOMe), 158.76 
(CparaPhOMe),  157.01 (C4), 147.89 (C7a), 146.64 (C2), 144.63 (CipsoPh), 135.70 
(CipsoPhOMe), 135.58 (CipsoPhOMe), 130.26 (2C; CorthoPhOMe), 130.16 (2C; CorthoPhOMe), 
128.22 (2C; CorthoPh), 128.16 (2C; CmetaPh), 127.17 (CparaPh), 124.64 (C6), 113.45 (4C; 
CmetaPhOMe), 105.90 (C4a), 87.17 (C1'), 86.94 (CPh(PhOMe)2), 84.05 (C4'), 76.75 (C2'), 
72.01 (C3'), 63.90 (C5'), 55.86 (C5), 55.38 (OCH3), 55.37 (OCH3), 40.28 (COC(CH3)3), 27.00 
(3C; COC(CH3)3), 25.63 (3C; Si(CH3)2(C(CH3)3), 18.04 (Si(CH3)2(C(CH3)3), -5.06 
(Si(CH3)2C(CH3)3), and -5.09 ppm (Si(CH3)2C(CH3)3); 
HR-MS (ESI+) for [C43H54IN4O8Si]+: calc.: 909.2750, found: 909.2779. 
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10.12.3.5 3,4-Dihydro-5-formyl-2-pivaloylamino-7-[(2'-O-tert-butyl-dimethylsilyl)-
(5'-O-dimethoxytrityl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine-4-one 
(52). 
 
 
 
Under argon atmosphere nucleoside 55 (473 mg, 0.52 mmol, 1.00 eq), Pd2(dba)3 (54 mg, 
0.05 mmol, 0.10 eq), PPh3 (81 mg, 0.31 mmol, 0.60 eq) was dissolved in dry toluene 
(6.40 mL). The solution was cooled to -78 °C. High vacuum was applied for 2 sec and the 
flask was ventilated with argon. This approach was repeated three times. After application of 
high vacuum the flask was ventilated with CO. Again this procedure was repeated three times. 
CO atmosphere was sustained in the flask afterwards using a CO balloon. The solution was 
heated to 55 °C and stirred. Tributyltin hydride (0.21 mL, 0.62 mmol, 1.20 eq) in toluene 
(3.00 mL) was added dropwise over a period of 1 h. Afterwards the reaction was stirred at 
55 °C for 20 min and allowed to cool to rt. The solvent was removed in vacuo. The resulting 
solid was purified via column chromatography (isohexane/ethyl acetate 5/1 to 2/1) yielding 
nucleoside 52 (341 mg, 81 %) as white solid. 
 
Rf = 0.14 (DCM/MeOH 50/1); 
M.p.: 56.8 – 57.3 °C; 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.99 (s, 1H; NHCO), 10.15 (s, 1H; HCO) 8.58 (s, 
1H; HNAr), 7.71 (s, 1H; HC6), 7.66 – 7.58 (m, 2H; HAr), 7.51 – 7.46 (m, 4H; HAr), 
7.44 - 7.36 (m, 2H; HAr), 7.33 – 7.29 (m, 1H; HAr), 6.80 – 6.75 (m, 4H; HmetaPhOMe), 5.93 
(d, 3J(HC1',HC2')=6.0 Hz, 1H; HC1'), 4.52 (dd, 3J(HC2',HC1')=6.0 Hz, 3J(HC2',HC3')=4.7 Hz, 
1H; HC2'), 4.20 – 4.16 (m, 2H; HC3' and HC4'), 3.74 – 3.71 (m, 6H; PhOCH3), 3.41 – 3.35 (m, 
1H; HaC5'), 3.34 – 3.29 (m, 1H; HbC5'), 1.19 (s, 9H; COC(CH3)3), 0.78 (s, 9H; 
Si(CH3)2C(CH3)3), -0.07 (s, 3H; Si(CH3)2C(CH3)3), and -0.25 ppm (s, 3H; Si(CH3)2C(CH3)3); 
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13C NMR (151 MHz, CDCl3, 27 °C): δ = 185.61 (HCO), 180.24 (COC(CH3)3), 158.79 (2C; 
CparaPhOMe), 156.97 (C4), 147.48 and 147.51 (C7a and C2), 144.73 (CipsoPh), 132.99 
(CipsoPhOMe), 132.30 (CipsoPhOMe), 130.20 (4C; CorthoPhOMe), 128.13 (2C; CorthoPh), 
127.17 (CparaPh), 124.68 (C6), 113.43 (4C; CmetaPhOMe), 103.87 (C4a), 87.68 (C1'), 86.87 
(CPh(PhOMe)2), 84.28 (C4'), 76.90 (C2'), 71.77 (C3'), 63.73 (C5'), 55.36 (3C; C5 and OCH3), 
40.33 (COC(CH3)3), 26.94 (3C; COC(CH3)3), 25.63 (3C; Si(CH3)2(C(CH3)3), 17.69 
(Si(CH3)2(C(CH3)3), -5.01 (Si(CH3)2C(CH3)3), and -5.07 ppm (Si(CH3)2C(CH3)3); 
IR: 3199 bw (O-H valence, N-H valence), 2956 m (-CH3 and C-H valence), 2930 m (C-H 
valence), 2856 w (CH3 valence), 1662 s (C=O valence), 1604 s (C=O valence), 1508 s (N-H 
deform.), 1248 s (C-N valence), and 1175 cm-1 s (C-O valence); 
HR-MS (ESI-) for [C44H53N4O9Si]-: calc.: 809.3587, found: 809.3579. 
 
10.13 Syntheses of further nucleosides 
10.13.1 2,4-Dimethyl-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 
(45a). 
 
 
 
ZnCl2 (1.0 M in diethyl ether, 0.28 mL, 0.28 mmol, 1.50 eq) was cooled to 0 °C and slowly 
treated with MeMgCl (2.56 M in THF, 0.22 mL, 0.56 mmol, 3.00 eq). The suspension was 
stirred for 2 h. Nucleoside 33 (100 mg, 0.19 mmol, 1.00 eq) and Pd(PPh3)4 (22 mg, 
0.02 mmol, 0.10 eq) were dissolved in dry THF (1.00 mL) and cooled to 0 °C. The suspension 
was added to the nucleoside solution. The resulting mixture was stirred at rt for 18 h. Sat. 
NaH2PO4 solution (10.0 mL) was added to the reaction mixture. The aqueous phase was 
extracted with DCM (15.0 mL) three times. The combined organic phases were washed with 
brine (30.0 mL) and dried over MgSO4. Purification via column chromatography yielded 4-
chloro-2-methyl-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 45 (32 mg, 40 %) and 
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2,4-dimethyl-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 45a (33 mg, 43%) as white 
foams. 
 
Nucleoside 45: see chapter 10.8.1.2 
Nucleoside 45a: 
Rf = 0.32 (DCM/MeOH 18/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 8.07 (s, 1H; HC6), 6.17 (d, 3J(HC1',HC2')=5.0 Hz, 
1H; HC1'), 5.98 (dd, 3J(HC2',HC1')=5.0 Hz, 3J(HC2',HC3')=5.0 Hz, 1H; HC2'), 5.77 (dd, 
3J(HC3',HC2')=5.0 Hz, 1H; HC3'), 4.45 (m, 2H; HaC5' and HC4'), 4.37 (m, 1H; HbC5'), 2.81 (s, 
3H; H3C), 2.78 (s, 3H; H3C), 2.15 (s, 3H; H3CCO), 2.09 (s, 3H; H3CCO), and 2.08 ppm (s, 
3H; H3CCO); 
13C NMR (150 MHz, CDCl3, 27 °C): δ = 170.28 (CH3CO), 169.52 (CH3CO), 169.34 
(CH3CO), 162.43 (C6), 159.42 (C2), 150.61 (C4), 141.47 (C8), 131.45 (C5), 86.39 (C1'), 
80.16 (C4'), 73.02 (C2'), 70.59 (C3'), 63.09 (C5'), 25.96 (CH3), 20.69 (CH3CO), 20.53 
(CH3CO), 20.39 (CH3CO), and 19.46 ppm (CH3); 
HR-MS (ESI+) for [C18H23N4O7]+: calc.: 407.1561, found: 407.1548. 
 
10.13.2 3,4-Dihydro-7-[2',3',5'-O-tribenzoyl-β-D-ribofuranosyl]-2-
pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine-4-one. 
 
 
 
Side product during Grignard reaction of the 7-iodo-deazaG (Chapter 10.11.2.1). 
 
Rf = 0.24 (isohexane/ethyl acetate 1/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.62 (s, 1H; NHCO), 8.75 (s, 1H; HNAr), 8.00 (m, 
2H; HBzortho), 7.91 (m, 2H; HBzortho), 7.76 (m, 2H; HBzortho), 7.57 (m, 3H; HBzpara), 7.44 (m, 
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2H; HBzmeta), 7.38 (m, 2H; HBzmeta), 7.32 (m, 2H; HBzmeta), 6.94 (dd, 3J(HC3',HC4')=8.3 Hz, 
3J(HC3',HC2')=5.0 Hz, 1H; HC3'), 6.87 (d, 3J(HC5/6,HC5/6)=3.5 Hz, 1H; HC5/6), 6.68 (d, 
3J(HC5/6,HC5/6)=3.5 Hz, 1H; HC5/6), 6.52 (dd, 3J(HC2',HC3')=5.0 Hz, 
3J(HC2',HC1')=1.6 Hz, 1H; HC2'), 6.08 (d, 3J(HC1',HC2')=1.6 Hz, 1H; HC1'), 4.78 (ddd, 
3J(HC4',HC3')=8.3 Hz, 3J(HC4',HbC5')=3.2 Hz, 3J(HC4',HaC5')=3.0 Hz, 1H; HC4'), 4.72 (dd, 
2J(HaC5',HbC5')=12.5 Hz, 3J(HaC5',HC4')=3.0 Hz, 1H; HaC5'), 4.65 (dd, 
2J(HbC5',HaC5')=12.5 Hz, 3J(HbC5',HC4')=3.2 Hz, 1H; HbC5'), and 1.36 (s, 9H; COC(CH3)3); 
13C NMR (125 MHz, CDCl3, 25 C): δ = 179.91 (COC(CH3)3), 166.11 (PhCO), 165.95 
(PhCO), 165.17 (PhCO), 157.52 (C4), 146.13 and 146.33 (C7a and C2), 133.72 (Bzpara), 
133.68 (Bzpara), 133.46 (Bzpara), 129.80 (2C; Bzortho), 129.75 (2C; Bzortho), 129.26 (2C; Bzortho), 
129.06 (Bzipso), 128.89 (Bzipso), 128.79(Bzipso), 128.58 (2C; Bzmeta), 128.49 (2C; Bzmeta), 
128.36 (2C; Bzmeta), 104.39, 106.52, and 122.47 (C4a, C5, and C6), 89.56 (C1'), 78.31 (C4'), 
74.63 (C2'), 70.70 (C3'), 61.62 (C5'), 40.18 (3C; COC(CH3)3), and 26.92 ppm (COC(CH3)3); 
HR-MS (ESI-) for [C37H33N4O9]-: calc.: 677.2253, found: 677.2256. 
 
10.13.3 5-(N,N-Diallylamino)methyl-3,4-dihydro-7-(2',3',5'-O-tribenzoyl-β-
D-ribofuranosyl)-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine-4-one 
(60). 
 
 
 
Nucleoside 33 (50 mg, 0.06 mmol, 1.00 eq) was dissolved in dry toluene (0.50 mL) and 
cooled to -65 °C. MeMgCl (2.56 M in THF, 0.05 mL, 0.12 mmol, 2.00 eq) was added 
dropwise and the resulting mixture was stirred for 1 h. Over a period of 1 h iPrMgCl•LiCl 
(1.06 M in THF, 0.15 mL, 0.13 mmol, 2.5 eq) was added with a syringe pump. The solution 
was stirred for 4 h at -65 °C. A solution of N,N,N',N'-tetraallylmethanediamine (134 mg, 
0.62 mmol, 10.0 eq) in dry DCM was cooled to 0 °C and trifluoroacetic acid anhydride 
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(0.09 mL, 0.62 mmol, 10.0 eq) was added dropwise. The resulting solution was stirred for 2 h 
at rt and then cooled to -20 °C. The Grignard solution prepared beforehand was added to the 
solution of the electrophile. The resulting mixture was left to warm to rt over 16 h. Water 
(20.0 mL) and ethyl acetate (20.0 mL) were added to the solution. The aq. layer was extracted 
with ethyl acetate (20.0 mL) three times. The combined organic layers were washed with 
brine (20.0 mL) and dried over MgSO4. Purification via column chromatography yielded 
nucleoside 60 (25 mg, 51 %) as white solid. 
 
Rf = 0.45 (isohexane/ethyl acetate 1/1); 
1H NMR (600 MHz, CDCl3, 27 °C): δ = 11.61 (s, 1H; NHCO), 8.89 (s, 1H; HNAr), 8.00 (m, 
2H; HBzortho), 7.89 (m, 2H; HBzortho), 7.70 (m, 2H; HBzortho), 7.61 (m, 1H; HBzpara), 7.55 (m, 
1H; HBzpara), 7.51 (m, 1H; HBzpara), 7.46 (m, 2H; HBzmeta), 7.36 (m, 2H; HBzmeta), 7.28 (m, 
2H; HBzmeta), 7.13 (dd, 3J(HC3',HC4')=9.0 Hz, 3J(HC3',HC2')=5.0 Hz, 1H; HC3'), 6.78 (d, 
3J(HC1',HC2')=0.8 Hz, 1H; HC1'), 6.62 (dd, 3J(HC2',HC3')=5.0 Hz, 3J(HC2',HC1')=0.8 Hz, 1H; 
HC2'), 6.52 (s, 1H; HC6), 5.77 (dddd, 3J(C10H,C11HtransHcis)2)=17.1 Hz, 
3J(C10H,C11HtransHcis)2)=10.2 Hz, 3J(C10H,C9HaHb)=6.7 Hz, 3J(C10H,C9HaHb)=6.3 Hz, 2H; 
C10H), 5.14 (dd, 3J(C11HtransHcis,C10H)=17.1 Hz, 2J(C11HtransHcis,C11HtransHcis)2)=1.4 Hz, 
2H; C11HtransHcis), 5.07 (dd, 3J(C11HtransHcis,C10H)=10.2 Hz, 
2J(C11HtransHcis,C11HtransHcis)=1.4 Hz, 2H; C11HtransHcis), 4.74 (ddd, 3J(HC4',HC3')=9.0 Hz, 
3J(HC4',HbC5')=3.1 Hz, 3J(HC4',HaC5')=3.0 Hz, 1H; HC4'), 4.72 (dd, 2J(HaC5',HbC5')=11.9 Hz, 
3J(HaC5',HC4')=3.0 Hz, 1H; HaC5'), 4.62 (dd, 2J(HbC5',HaC5')=11.9 Hz, 3J(HbC5',HC4')=3.1 Hz, 
1H; HbC5'), 3.87 (d, 2J(C8HaHb,C8HaHb)=13.9 Hz, 1H; C8HaHb), 3.51 (d, 
2J(C8HaHb,C8HaHb)=13.9 Hz, 1H; C8HaHb), 3.16 (dd, 2J(C9aHb,C9HaHb)=14.0 Hz, 
3J(C9aHb,C10H)=6.3 Hz, 2H; C9aHb), 2.97 (dd, 2J(C9HaHb,C9HaHb)=14.0 Hz, 
3J(C9aHb,C10H)=6.7 Hz, 2H; C9aHb), and 1.35 ppm (s, 9H; COC(CH3)3); 
13C NMR (125 MHz, CDCl3, 25 C): δ = 180.00 (COC(CH3)3), 166.17 (PhCO), 166.13 
(PhCO), 165.18 (PhCO), 157.31 (C4), 147.56 (C7a), 145.84 (C2), 134.80 (2C; C10), 133.58 
(Cpara), 133.55 (Cpara), 133.37 (Cpara), 131.97 (C5), 129.73 (2C; CBzortho), 129.69 (2C; 
CBzortho), 129.26 (CBzipso), 129.21 (2C; CBzortho), 129.14 (CBzipso), 128.93 (CBzipso), 128.55 
(2C; CBzmeta), 128.44 (2C; CBzmeta), 128.27 (2C; CBzmeta), 117.99 (2C; C11), 105.25 (C4a), 
105.11 (C6), 87.30 (C1'), 77.43 (C4'), 74.95 (C2'), 70.74 (C3'), 61.43 (C5'), 55.86 (2C; C9), 
49.93 (C8), 40.16 (COC(CH3)3), and 26.87 ppm (3C; COC(CH3)3); 
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IR: 3349 w (N-H valence), 3216 w (N-H valence), 2958 m (C-H valence), 2924 m (C-H 
valence), 1722 s (C=O valence), 1669 s (C=O valence), 1603 s (C=O valence), and 
1262 cm-1 s (C-O-C valence); 
HR-MS (ESI+) for [C44H46N5O9]+: calc.: 788.3290, found: 788.3282. 
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11 Appendix 
11.1 Abbreviations 
 
A Adenosine 
aa-tRNA Aminoacyl-tRNA 
ADA-SCID Adenosine deaminase-severe combined immunodeficiency disease 
AIDS Acquired immune deficiency syndrome  
ALL Acute lymphoblastic leukemia 
AML Acute myeloid leukemia  
ATT 6-Aza-2-thiothymine  
C Cytidine 
conc. Concentrated 
dA Deoxyadenosine 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
dba Dibenzylideneacetone 
dC Deoxycytidine 
DCM Dichloromethane 
dG Deoxyguanosine 
DMA N,N-Dimethylaniline  
DMEM Dulbecco's Modified Eagle's Medium 
DMF Dimethylformamide 
DMT Dimethoxytrityl 
DNA  Deoxyribonucleic acid 
dT Deoxythymidine 
E. coli Escherichia coli 
EDTA Ethylendiamine tetraacetate 
EI Electron ionization 
ESI Elektrospray ionisation 
EtBr Ethidium bromide 
G Guanosine 
HIV-1 Human immunodeficiency virus type 1 
HMPA Hexamethylphosphoramide 
HPLC High performance liquid chromatography, 
HR-MS  High resolution mass spectrometry 
IR Infra red 
kb Kilobase 
KPhth Potassium phthalimide 
LB Lysogeny broth 
LC Liquid chromatography 
M.p. Melting point 
MELAS Mitochondrial encephalomyopathies, encephalopathy, lactic acidosis, and stroke-like 
episodes 
MeOTMS Methoxytrimethylsilane 
MERRF Myoclonus epilepsy associated with ragged-red fibers 
MLASA Mitochondrial myopathy and sideroblastic anemia 
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mRNA Messanger ribonucleic acid 
MS Mass spectrometry 
mt  Mitochondrial 
n Amount of substance 
NIS N-Iodosuccinimide  
NMR Nuclear magnetic resonance 
OD Optical density 
Pa Pascal 
PBS Primer binding site 
pH Pondus hydrogenii 
Ph.D. Doctor of philosophy in arts and sciences 
ppm Parts per million 
Rf Rate of flow 
RNA Ribonucleic acid 
rpm Rotation per minute 
rt Room temperature 
SAM S-Adenosyl-L-methionin  
sat. Saturated 
SCID Severe combined immunodeficiency 
SILAC Stable isotope labeling with amino acids in cell culture 
ss Single stranded 
TBDMS tert-Butyldimethylsilyl 
TEBA Triethylbenzylammonium chloride  
TGT tRNA-guanine transglycosylase 
THF Tetrahydrofurane 
TMS Trimethylsilyl 
TosCN Tosylcyanide 
tRNA Transfer ribonucleic acid 
U Uridine 
UV Ultraviolet 
vol. Volume 
w/v Weight per volume 
YPD Yeast extract peptone dextrose 
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11.2 Detailed quantification data of the screening of modification levels in mammalian tissues 
Tissues  Am t6A i6A ms2i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Heart Mean value 45.9 175.4 29.0 18.4 372.9 673.1 29.6 12.0 638.2 11.0 810.9 
 Standard deviation 3.3 8.2 2.7 7.0 22.7 61.3 0.0 0.0 3.0 0.4 19.1 
 Standard deviation in % 7.2 4.7 9.4 38.0 6.1 9.1 0.0 0.3 0.5 3.5 2.4 
             
Liver Mean value 20.5 214.6 39.6 4.7 562.7 1,176.5 55.2 33.6 1,059.6 21.9 941.6 
 Standard deviation 4.8 6.4 2.7 0.8 26.1 54.7 4.6 2.9 43.6 1.8 23.6 
 Standard deviation in % 23.2 3.0 6.8 17.9 4.6 4.7 8.4 8.7 4.1 8.0 2.5 
             
Kidney Mean value 68.4 177.8 30.7 8.4 451.5 896.0 32.3 21.1 816.3 15.8 871.6 
 Standard deviation 19.1 7.7 0.5 0.3 25.4 55.0 13.8 4.7 40.3 1.5 35.5 
 Standard deviation in % 28.0 4.3 1.8 3.7 5.6 6.1 42.8 22.3 4.9 9.5 4.1 
             
Tongue Mean value 45.4 170.6 25.7 12.7 395.9 794.0 21.9 15.2 698.7 11.3 846.5 
 Standard deviation 10.5 4.9 2.9 4.7 0.6 7.5 0.1 1.3 5.8 0.3 6.6 
 Standard deviation in % 23.1 2.9 11.4 36.7 0.2 0.9 0.7 8.5 0.8 2.3 0.8 
             
Lung Mean value 58.5 184.1 33.6 4.3 427.2 879.3 33.9 21.7 793.6 13.9 876.3 
 Standard deviation 16.3 8.5 2.9 0.5 27.0 45.4 11.3 1.5 28.2 1.1 16.1 
 Standard deviation in % 27.8 4.6 8.5 12.2 6.3 5.2 33.3 7.0 3.6 7.9 1.8 
             
Spine marrow Mean value 61.8 198.6 36.0 4.2 457.0 970.7 50.8 26.0 799.5 11.8 911.0 
 Standard deviation 1.7 2.7 0.1 0.4 2.8 13.1 0.3 0.1 1.5 0.1 11.4 
 Standard deviation in % 2.7 1.4 0.3 9.9 0.6 1.3 0.6 0.3 0.2 1.0 1.2 
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Tissues  Am t6A i6A ms2i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Cerebellum Mean value 67.8 237.3 41.7 15.1 566.8 1,036.4 83.5 29.0 829.4 17.5 1,102.8 
 Standard deviation 6.1 0.6 0.3 0.1 1.2 1.2 4.8 1.9 13.8 0.0 6.7 
 Standard deviation in % 9.0 0.2 0.6 0.4 0.2 0.1 5.7 6.5 1.7 0.2 0.6 
             
Cerebrum Mean value 139.9 165.8 26.1 10.3 406.2 682.2 57.2 20.3 586.8 10.5 732.6 
 Standard deviation 15.9 2.8 1.5 0.1 7.3 34.6 3.8 1.2 0.1 0.6 26.3 
 Standard deviation in % 11.3 1.7 5.9 0.5 1.8 5.1 6.6 5.7 0.0 5.9 3.6 
             
Spleen Mean value 80.4 182.1 30.7 2.8 464.3 793.6 42.7 26.1 690.5 13.9 833.6 
 Standard deviation 12.6 8.9 1.0 0.0 19.6 29.5 5.9 2.2 13.4 0.4 45.2 
 Standard deviation in % 15.6 4.9 3.2 1.5 4.2 3.7 13.8 8.4 1.9 2.9 5.4 
             
Thyroid gland Mean value 199.9 43.0 8.6 - 122.6 203.8 - 8.8 240.4 4.7 271.9 
 Standard deviation 6.9 4.6 0.6 - 11.5 12.6 - 1.0 19.0 0.2 2.8 
 Standard deviation in % 3.5 10.8 7.1 - 9.4 6.2 - 11.0 7.9 4.7 1.0 
Table 18: Modification numbers per 1000 tRNAs in different pork tissues. 
The table lists the average values calculated from the modification content of two different animals. From each animal at least two independent samples were 
investigated. For each sample at least three independent digests and measurements were performed. 5.9 % mean standard deviation was obtained for all 
nucleosides excluding Am. 14.7 % mean standard deviation was obtained for Am. 
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Tissues  Am t6A i6A ms2i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Heart 1 Mean value 48.2 169.6 30.9 13.4 356.8 629.8 29.6 12.0 636.0 11.2 797.4 
 Standard deviation 9.7 6.1 1.1 4.2 4.0 18.3 1.1 0.5 34.6 0.5 10.4 
 Standard deviation in % 20.1 3.6 3.7 31.1 1.1 2.9 3.9 3.8 5.4 4.2 1.3 
             
Heart 2 Mean value 43.5 181.3 27.1 23.3 389.0 716.5 29.6 12.1 640.3 10.7 824.5 
 Standard deviation 12.1 7.1 3.0 3.4 40.7 85.2 0.9 1.1 38.8 1.1 28.5 
 Standard deviation in % 27.8 3.9 11.0 14.4 10.5 11.9 3.1 9.0 6.1 10.5 3.5 
             
Liver 1 Mean value 23.8 210.1 37.7 4.1 544.2 1,137.8 58.5 35.7 1,028.7 20.6 958.3 
 Standard deviation 2.2 2.2 0.4 0.4 18.1 0.8 4.6 1.6 7.7 0.8 39.4 
 Standard deviation in % 9.4 1.0 1.1 9.0 3.3 0.1 7.9 4.6 0.8 3.7 4.1 
             
Liver 2 Mean value 17.1 219.1 41.5 5.3 581.1 1,215.2 51.9 31.5 1,090.4 23.1 925.0 
 Standard deviation 1.2 12.1 1.9 0.0 39.5 86.9 1.9 3.4 39.5 0.9 30.0 
 Standard deviation in % 6.8 5.5 4.6 0.7 6.8 7.2 3.7 10.9 3.6 3.9 3.2 
             
Kidney 1 Mean value 81.9 172.4 30.3 8.6 433.5 857.1 22.5 17.8 787.9 14.8 846.5 
 Standard deviation 23.7 19.1 2.8 1.7 30.1 89.1 2.1 2.1 43.0 2.0 25.5 
 Standard deviation in % 28.9 11.1 9.4 19.7 6.9 10.4 9.4 11.6 5.5 13.3 3.0 
             
Kidney 2 Mean value 54.8 183.3 31.1 8.2 469.5 934.9 42.1 24.5 844.8 16.9 896.7 
 Standard deviation 15.8 2.9 2.9 4.0 3.7 10.7 0.1 3.8 3.8 0.4 40.4 
 Standard deviation in % 28.8 1.6 9.2 48.3 0.8 1.1 0.2 15.4 0.4 2.5 4.5 
             
Tongue 1 Mean value 52.8 167.2 23.6 9.4 395.5 799.4 22.0 14.3 694.6 11.1 841.8 
 Standard deviation 8.2 12.4 1.9 3.6 18.8 66.5 1.6 1.7 23.0 1.1 37.2 
 Standard deviation in % 15.6 7.4 8.2 38.2 4.8 8.3 7.2 12.2 3.3 9.8 4.4 
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Tissues  Am t6A i6A ms2i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Tongue 2 Mean value 37.9 174.0 27.7 16.0 396.4 788.7 21.8 16.1 702.8 11.5 851.1 
 Standard deviation 1.4 0.6 2.8 1.0 0.4 3.1 1.2 0.3 13.7 0.6 16.3 
 Standard deviation in % 3.6 0.3 10.2 6.4 0.1 0.4 5.4 2.1 2.0 5.6 1.9 
             
Lung 1 Mean value 47.0 178.1 31.6 3.9 408.0 847.2 25.9 20.7 773.7 13.2 864.9 
 Standard deviation 1.2 4.3 0.1 0.2 5.3 3.2 4.6 0.7 0.1 1.2 3.7 
 Standard deviation in % 2.5 2.4 0.3 5.2 1.3 0.4 17.6 3.5 0.0 8.8 0.4 
             
Lung 2 Mean value 70.0 190.1 35.7 4.6 446.3 911.3 41.9 22.8 813.6 14.7 887.7 
 Standard deviation 5.0 5.0 2.2 1.6 19.5 32.7 0.5 0.6 24.6 0.2 25.3 
 Standard deviation in % 7.2 2.6 6.3 34.8 4.4 3.6 1.3 2.5 3.0 1.3 2.8 
             
Spine marrow 1 Mean value 63.0 200.5 36.1 4.5 459.0 961.4 51.0 26.1 798.5 11.9 919.1 
 Standard deviation 7.6 4.3 1.3 0.4 8.3 28.4 3.1 1.1 17.2 0.8 56.6 
 Standard deviation in % 12.1 2.1 3.5 8.5 1.8 3.0 6.1 4.2 2.2 7.1 6.2 
             
Spine marrow 2 Mean value 60.7 196.7 35.9 3.9 454.9 979.9 50.6 26.0 800.6 11.7 903.0 
 Standard deviation 17.5 2.8 1.4 0.8 14.3 20.1 2.2 2.0 2.8 0.6 25.5 
 Standard deviation in % 28.9 1.4 3.8 20.6 3.2 2.1 4.3 7.6 0.3 5.4 2.8 
             
Cerebellum 1 Mean value 72.1 237.7 41.9 15.2 567.6 1,035.6 86.8 30.3 839.1 17.6 1,098.1 
             
Cerebellum 2 Mean value 63.5 236.9 41.5 15.1 566.0 1,037.2 80.1 27.6 819.6 17.5 1,107.5 
             
Cerebrum 1 Mean value 151.1 163.8 25.0 10.3 401.0 657.7 59.9 21.2 586.9 10.1 714.1 
 Standard deviation 27.9 10.8 1.7 1.1 30.5 44.2 5.1 1.0 22.3 0.8 61.6 
 Standard deviation in % 18.5 6.6 6.7 11.1 7.6 6.7 8.6 4.7 3.8 8.2 8.6 
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Tissues  Am t6A i6A ms2i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Cerebrum 2 Mean value 128.7 167.8 27.2 10.3 411.3 706.7 54.6 19.5 586.7 11.0 751.2 
 Standard deviation 0.1 7.8 0.7 1.0 6.1 19.0 1.5 0.7 18.7 0.4 38.1 
 Standard deviation in % 0.1 4.6 2.5 9.3 1.5 2.7 2.8 3.8 3.2 3.8 5.1 
             
Spleen 1 Mean value 89.3 175.8 30.0 2.7 450.4 772.8 38.6 24.5 681.0 13.6 801.7 
 Standard deviation 6.7 2.6 0.0 0.9 14.4 16.6 0.7 2.2 1.6 0.4 6.6 
 Standard deviation in % 7.5 1.5 0.1 31.1 3.2 2.1 1.7 9.1 0.2 3.0 0.8 
             
Spleen 2 Mean value 71.5 188.4 31.4 2.8 478.2 814.5 46.9 27.6 699.9 14.2 865.5 
 Standard deviation 11.2 9.7 1.9 1.0 30.7 76.0 0.7 0.3 87.3 1.5 102.8 
 Standard deviation in % 15.6 5.1 5.9 35.3 6.4 9.3 1.5 1.0 12.5 10.5 11.9 
             
Thyroid gland 1 Mean value 195.0 46.3 9.1 - 130.7 212.7 - 9.5 253.9 4.8 273.9 
 Standard deviation 32.6 5.6 1.6 - 28.7 52.0 - 1.2 28.2 1.4 26.7 
 Standard deviation in % 16.7 12.1 17.3 - 22.0 24.4 - 12.5 11.1 28.4 9.7 
             
Thyroid gland 2 Mean value 204.8 39.7 8.2 - 114.4 194.9 - 8.2 227.0 4.5 269.9 
 Standard deviation 63.5 4.5 0.5 - 8.6 11.6 - 1.6 5.9 0.4 23.3 
 Standard deviation in % 31.0 11.4 6.3 - 7.5 6.0 - 20.2 2.6 8.6 8.6 
Table 19: Modification numbers per 1000 tRNAs in different pork tissues. 
The table lists the average values calculated from the modification content of at least two independent samples from one animal. For each sample at least three 
independent digests and measurements were performed. 6.7 % mean standard deviation was obtained for all nucleosides excluding Am. 17.0 % mean standard 
deviation was obtained for Am. 
 
Detailed data on the modification levels of the cell lines presented in chapter 5.3.6 have been provided by M. Wagner (personal communication) and 
will be available from his upcoming thesis. 
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11.2.1 Stress response of tRNA modification levels in E. coli 
 
External stimulation m2A / pmol m6A / pmol 
Aerob (full medium) Mean value 121.4 29.3 
Standard deviation 3.4 0.5 
Standard deviation in % 2.8 1.6 
Anaerob (full medium) Mean value 112.6 28.4 
Standard deviation 16.9 0.3 
Standard deviation in % 15.0 1.2 
Aerob (minimal medium) Mean value 125.0 29.4 
Standard deviation 7.2 0.1 
Standard deviation in % 5.8 0.3 
Anaerob (minimal medium) Mean value 125.0 30.6 
Standard deviation 5.4 1.9 
Standard deviation in % 4.3 6.2 
pH = 5.5; OD = 0.5 Mean value 125.1 30.1 
Standard deviation 4.5 0.4 
Standard deviation in % 3.6 1.2 
pH = 5.5; OD = 2.0 Mean value 120.5 30.6 
Standard deviation 13.2 1.5 
Standard deviation in % 10.9 4.8 
Desferal Mean value 109.7 31.2 
Standard deviation 5.4 0.5 
Standard deviation in % 4.9 1.5 
2-Fluor-adenosine Mean value 105.7 29.8 
Standard deviation 4.1 1.3 
Standard deviation in % 3.9 4.4 
50 °C Mean value 98.3 29.9 
Standard deviation 6.8 1.4 
Standard deviation in % 6.9 4.5 
H2O2 Mean value 105.8 26.9 
Standard deviation 8.2 1.9 
Standard deviation in % 7.8 6.9 
NaCl Mean value 124.1 28.2 
Standard deviation 7.3 1.2 
Standard deviation in % 5.9 4.1 
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External stimulation m2A m6A 
pH = 4.6 Mean value 78.7 21.5 
Standard deviation 3.1 0.3 
Standard deviation in % 4.0 1.3 
pH = 5.5 Mean value 98.8 28.1 
Standard deviation 10.2 1.7 
Standard deviation in % 10.3 6.1 
pH = 7.5 Mean value 91.3 26.9 
Standard deviation 9.8 3.1 
Standard deviation in % 10.7 11.6 
pH = 8.6 Mean value 110.8 30.3 
Standard deviation 1.4 0.8 
Standard deviation in % 1.3 2.8 
pH = 9.5 Mean value 28.0 19.9 
Standard deviation 0.9 1.8 
Standard deviation in % 3.0 9.1 
Chloramphenicol Mean value 110.6 31.0 
Standard deviation 12.0 0.0 
Standard deviation in % 10.9 0.0 
Gentamycin Mean value 107.0 29.1 
Standard deviation 3.9 1.7 
Standard deviation in % 3.6 5.9 
Streptomycin Mean value 91.7 27.4 
Standard deviation 2.9 1.0 
Standard deviation in % 3.1 3.6 
Spectinomycin Mean value 110.2 32.8 
Standard deviation 4.0 0.3 
Standard deviation in % 3.6 0.9 
Table 20: Modification content in E. coli grown under different external stimulations. 
The table lists the average values calculated from the modification content of at least two independent 
experiments. For each experiment at least three independent digests and measurements were 
performed. 
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11.2.2 Isotope based quantification of the new sixth DNA-nucleoside 
hydroxymethyl-dC in brain 
 
Brain section  Mouse 1 Mouse 2 Mouse 3 Mouse 4 Average 
mouse 1-4 
Cerebral Cortex  4.45 4.68 4.72 4.15 4.50 
 SD 0.45 0.46 0.11 0.12 0.23 
 RSD / % 10.02 9.78 2.30 3.00 5.03 
Brainstem  4.68 4.36 4.44 4.51 4.50 
 SD 0.40 0.22 0.23 0.01 0.12 
 RSD / % 8.47 4.98 5.25 0.19 2.59 
Olfactory Bulb  4.37 4.42 4.66 4.68 4.54 
 SD 0.05 0.49 0.12 0.19 0.13 
 RSD / % 1.19 11.13 2.57 3.98 2.87 
Cerebellum  4.29 4.57 4.41 4.28 4.39 
 SD 0.26 0.25 0.10 0.33 0.12 
 RSD / % 5.97 5.54 2.25 7.65 2.68 
Retina  4.67 4.39 4.58 4.27 4.48 
 SD 0.15 0.16 0.32 0.16 0.15 
 RSD / % 3.25 3.76 7.05 3.74 3.43 
Hippocampus  3.81 4.30 4.68 4.64 4.31 
 SD - - 0.67 0.24 0.31 
 RSD / % - - 14.31 5.07 7.27 
Hypothalamus  3.73 2.93 3.33 
 SD - - 0.40 
 RSD / % - - 12.02 
Hippocampus  3.44 3.53 - - 3.48 
(1 day old) SD - - - - 0.04 
Table 21: Nucleoside percentages of 5-MedC to dG in different brain sections. 
Each mouse brain section is listed with the determined values, the standard deviation (SD) and the 
relative standard deviation (RSD). The average mouse values are listed in the last column. For 
hypothalamus, the DNA of mouse 1 + 2 and 3+4 were mixed, respectively. 
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Brain section  Mouse 1 Mouse 2 Mouse 3 Mouse 4 Average mouse 1-4 
Cerebral Cortex  0.67 0.69 0.59 0.65 0.65 
 SD 0.03 0.02 0.01 0.04 0.04 
 RSD / % 3.73 2.19 1.23 5.91 5.82 
Brainstem  0.52 0.51 0.56 0.62 0.55 
 SD 0.02 0.05 0.03 0.02 0.04 
 RSD / % 3.68 9.32 5.72 2.91 7.95 
Olfactory Bulb  0.54 0.53 0.55 0.51 0.53 
 SD 0.06 0.01 0.01 0.00 0.02 
 RSD / % 10.24 1.16 1.29 0.87 3.05 
Cerebellum  0.33 0.33 0.33 0.33 0.33 
 SD 0.01 0.01 0.00 0.05 0.00 
 RSD / % 4.09 4.09 0.70 13.75 0.49 
Retina  0.32 0.31 0.31 0.29 0.31 
 SD 0.01 0.02 0.00 0.02 0.01 
 RSD / % 4.46 5.66 0.22 8.01 4.03 
Hippocampus  0.63 0.60 0.52 0.58 0.59 
 SD - - 0.00 0.04 0.04 
 RSD / % - - 0.40 6.74 7.28 
Hypothalamus  0.72 0.65 0.69 
 SD - 
- 
- 
- 
0.03 
 RSD / % 5.08 
Hippocampus  0.31 0.36 - - 0.34 
(1 day old) SD - - - - 0.02 
 RSD / % - - - - 7.38 
Table 22: Nucleoside percentages of 5-OHMedC to dG in different brain sections.  
Each mouse brain section is listed with the determined values, the standard deviation (SD) and the 
relative standard deviation (RSD). The average mouse values are listed in the last column. For 
hypothalamus, the DNA of mouse 1 + 2 and 3+4 were mixed, respectively. 
 
11.3 Crystallographic data 
11.3.1 Crystallographic data for nucleoside 11 
Crystal parameter and data collection details for nucleoside 11 
Chemical formula C16H18N5O10 
Molecular weight 475.80 
Space group C 1 2 1 (5) - monoclinic 
a, b, c (Å) 21.5839(5), 7.7028(2), 13.3544(3) 
α, β, γ (°) 90, 121.339 (2), 90 
V (Å3) 1896.33 (8) 
Z 4 
Dber. (g/cm3) 1.667 
μMoKα (mm) 0.273 
F(000) 984 
Temperature (K) 373 (2) 
Radiation λ (Å) MoKα, 0,71073 
θmin, θmax (°) 3.67, 30.09 
h -30 → 30 
k -10 → 10 
l -18 → 18 
Chapter 11 Appendix 
208 
Measured reflexes 12985 
Independent reflexes 5534 
Rint 0.0561 
observed reflexes [I > 2σ(I)] 4145 
NReflexes, NParameter 5534, 334 
R, ωR2, S 0.0309, 0.0554, 0.916 
Ω = 1/[σ2(F02) + (0.247 • P)2 + 0.0 • P] P = (F02 + 2 Fc2)/3 
Table 23: Crystal parameter and data collection details 
 
Atom X Y Z Ueq 
Cl1 0.10032(2) 0.86710(5) 0.43356(3) 0.02061(9) 
O4 -0.36051(5) 1.23461(14) 0.20767(9) 0.0200(2) 
O2 -0.22669(5) 1.20821(13) 0.40406(9) 0.0168(2) 
O3 -0.18007(6) 1.47486(14) 0.46785(10) 0.0228(3) 
N4 -0.07752(7) 1.26446(16) 0.32463(11) 0.0163(3) 
N3 0.04795(7) 1.18098(17) 0.40295(11) 0.0162(3) 
O1 -0.25304(6) 1.14057(13) 0.11886(9) 0.0188(2) 
C1 0.03043(8) 1.0161(2) 0.39084(13) 0.0163(3) 
C2 -0.04037(8) 0.96032(19) 0.34663(14) 0.0152(3) 
N1 -0.15572(6) 1.01020(17) 0.28151(11) 0.0162(3) 
C5 -0.00707(8) 1.29969(19) 0.36921(14) 0.0162(3) 
C10 -0.19871(8) 1.3367(2) 0.48594(14) 0.0186(3) 
C3 -0.09061(8) 1.0941(2) 0.31725(14) 0.0148(3) 
C9 -0.23111(8) 1.2480(2) 0.29616(13) 0.0157(3) 
C6 -0.22693(8) 1.0840(2) 0.23608(14) 0.0155(3) 
N2 -0.07307(7) 0.79737(16) 0.32812(12) 0.0193(3) 
C4 -0.14048(9) 0.83446(19) 0.29052(14) 0.0186(3) 
N5 0.01336(8) 1.46668(19) 0.38138(14) 0.0224(3) 
C8 -0.30344(8) 1.3241(2) 0.20240(14) 0.0171(3) 
C11 -0.19528(10) 1.2839(2) 0.59630(16) 0.0240(4) 
C12 -0.42343(9) 1.3252(2) 0.16660(15) 0.0255(4) 
C7 -0.30684(8) 1.2739(2) 0.08889(14) 0.0184(3) 
O6 -0.35443(6) 1.52727(15) -0.03271(10) 0.0239(3) 
O7 -0.30339(6) 1.72270(16) 0.11389(11) 0.0329(3) 
O5 -0.42895(7) 1.47475(18) 0.13916(14) 0.0446(4) 
C14 -0.29062(9) 1.4170(2) 0.02828(16) 0.0217(4) 
C15 -0.35422(9) 1.6756(2) 0.02026(15) 0.0238(4) 
C16 -0.42370(11) 1.7737(3) -0.05037(19) 0.0313(4) 
C13 -0.48181(10) 1.2122(3) 0.15852(17) 0.0314(4) 
Table 24: Atom coordinates and equivalent anisotropic temperature factors for non-hydrogen atoms 
(Å2). 
 
Atom X Y Z Uiso 
H141  ‐0.2484(8)  1.4787(18)  0.0841(12)  0.000(3) 
H61  ‐0.2558(7)  0.999(2)  0.2365(12)  0.004(3) 
H91  ‐0.1926(8)  1.327(2)  0.3122(13)  0.015(4) 
H81  ‐0.3075(8)  1.448(2)  0.2078(12)  0.009(4) 
H142  ‐0.2825(7)  1.367(2)  ‐0.0324(13)  0.013(4) 
H4  ‐0.1783(8)  0.751(2)  0.2713(12)  0.005(4) 
H162  ‐0.4252(9)  1.855(3)  0.0044(17)  0.041(5) 
H71  ‐0.3551(9)  1.224(2)  0.0323(14)  0.016(4) 
H163  ‐0.4184(9)  1.832(2)  ‐0.1074(16)  0.030(5) 
H131  ‐0.4641(12)  1.127(3)  0.224(2)  0.057(7) 
H132  ‐0.5196(12)  1.279(3)  0.1586(18)  0.051(6) 
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H113  ‐0.1610(12)  1.200(3)  0.6352(18)  0.051(6) 
H51  ‐0.0154(12)  1.546(3)  0.3696(19)  0.046(7) 
H112  ‐0.2411(12)  1.244(3)  0.5786(17)  0.046(6) 
H52  0.0575(11)  1.482(3)  0.4187(18)  0.037(6) 
H161  ‐0.4636(13)  1.704(3)  ‐0.078(2)  0.061(7) 
H111  ‐0.1806(11)  1.382(3)  0.6497(18)  0.056(6) 
H133  ‐0.4992(12)  1.147(3)  0.093(2)  0.056(7) 
Table 25: Atom coordinates and equivalent isotropic temperature factors for hydrogen atoms (Å2). 
 
Atom U11 U22 U33 U23 U13 U12 
Cl1 0.01430(17) 0.01689(18) 0.0261(2) -0.00054(17) 0.00730(15) 0.00375(16) 
O4 0.0130(5) 0.0225(6) 0.0273(6) 0.0028(5) 0.0123(5) 0.0017(4) 
O2 0.0189(6) 0.0146(6) 0.0174(5) -0.0021(4) 0.0097(5) -0.0029(4) 
O3 0.0211(6) 0.0151(6) 0.0296(7) -0.0041(5) 0.0114(5) -0.0018(4) 
N4 0.0161(7) 0.0116(7) 0.0214(7) 0.0020(5) 0.0099(6) 0.0010(5) 
N3 0.0138(7) 0.0139(7) 0.0207(7) 0.0020(5) 0.0088(6) 0.0022(5) 
O1 0.0184(6) 0.0193(6) 0.0180(6) 0.0027(5) 0.0089(5) 0.0061(4) 
C1 0.0149(7) 0.0180(8) 0.0144(8) 0.0000(6) 0.0066(6) 0.0033(6) 
C2 0.0159(8) 0.0135(8) 0.0160(8) -0.0018(6) 0.0081(7) 0.0003(6) 
N1 0.0137(6) 0.0130(7) 0.0211(7) 0.0009(5) 0.0084(6) 0.0014(5) 
C5 0.0175(8) 0.0149(8) 0.0174(8) 0.0008(6) 0.0098(7) 0.0018(6) 
C10 0.0112(7) 0.0217(9) 0.0211(8) -0.0048(6) 0.0071(6) 0.0022(6) 
C3 0.0135(8) 0.0166(8) 0.0132(8) 0.0010(6) 0.0062(6) 0.0015(6) 
C9 0.0138(8) 0.0142(8) 0.0190(8) -0.0008(6) 0.0086(7) -0.0001(6) 
C6 0.0126(8) 0.0153(8) 0.0176(8) -0.0007(6) 0.0072(7) -0.0012(6) 
N2 0.0175(7) 0.0165(7) 0.0229(8) -0.0017(5) 0.0097(6) 0.0005(5) 
C4 0.0183(8) 0.0130(9) 0.0221(8) -0.0019(6) 0.0089(7) -0.0003(6) 
N5 0.0135(8) 0.0128(8) 0.0376(9) 0.0009(6) 0.0111(7) 0.0014(6) 
C8 0.0142(8) 0.0135(8) 0.0248(9) 0.0024(6) 0.0109(7) 0.0012(6) 
C11 0.0201(10) 0.0289(10) 0.0236(10) -0.0056(8) 0.0118(8) -0.0018(8) 
C12 0.0156(8) 0.0403(12) 0.0203(9) 0.0028(8) 0.0092(7) 0.0052(7) 
C7 0.0138(8) 0.0182(8) 0.0215(8) 0.0028(6) 0.0081(7) 0.0041(6) 
O6 0.0235(6) 0.0228(6) 0.0238(6) 0.0050(5) 0.0112(5) 0.0047(5) 
O7 0.0264(7) 0.0233(7) 0.0370(7) -0.0035(6) 0.0081(6) -0.0053(5) 
O5 0.0280(7) 0.0414(9) 0.0668(10) 0.0248(7) 0.0264(7) 0.0183(6) 
C14 0.0209(9) 0.0211(9) 0.0254(9) 0.0051(7) 0.0137(8) 0.0045(7) 
C15 0.0257(9) 0.0162(8) 0.0311(10) 0.0040(7) 0.0160(8) -0.0020(7) 
C16 0.0297(11) 0.0249(11) 0.0345(12) 0.0058(9) 0.0132(9) 0.0092(8) 
C13 0.0192(9) 0.0515(14) 0.0234(11) -0.0007(10) 0.0108(8) -0.0053(9) 
Table 26: Anisotropic temperature factors for non-hydrogen atoms (Å2). 
 
Atom 1 Atom 2 Distance Atom 1 Atom 2 Distance 
Cl1 C1 1.7387(15) C4 H4 0.962(15) 
O4 C12 1.3631(19) N5 H51 0.82(2) 
O4 C8 1.4449(18) N5 H52 0.82(2) 
O2 C10 1.3614(18) C8 C7 1.529(2) 
O2 C9 1.4269(18) C8 H81 0.966(15) 
O3 C10 1.2056(19) C11 H113 0.92(2) 
N4 C3 1.3353(19) C11 H112 0.94(2) 
N4 C5 1.3412(19) C11 H111 0.97(2) 
N3 C1 1.311(2) C12 O5 1.195(2) 
N3 C5 1.3758(19) C12 C13 1.489(3) 
O1 C6 1.4282(19) C7 C14 1.513(2) 
O1 C7 1.4421(18) C7 H71 0.994(16) 
C1 C2 1.389(2) O6 C15 1.342(2) 
C2 C3 1.396(2) O6 C14 1.4543(19) 
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C2 N2 1.3976(19) O7 C15 1.213(2) 
N1 C4 1.383(2) C14 H141 0.952(14) 
N1 C3 1.386(2) C14 H142 0.993(15) 
N1 C6 1.4436(19) C15 C16 1.496(2) 
C5 N5 1.342(2) C16 H162 0.98(2) 
C10 C11 1.493(2) C16 H163 0.940(19) 
C9 C8 1.522(2) C16 H161 0.92(2) 
C9 C6 1.524(2) C13 H131 1.00(2) 
C9 H91 0.960(16) C13 H132 0.96(2) 
C6 H61 0.909(15) C13 H133 0.90(2) 
N2 C4 1.3003(19)    
Table 27: Bond length (Å). 
 
Atom 1 Atom 2 Atom 3 Angle Atom 1 Atom 2 Atom 3 Angle 
C12 O4 C8 115.60(12) O4 C8 C7 108.96(12) 
C10 O2 C9 115.06(12) C9 C8 C7 102.59(12) 
C3 N4 C5 112.28(13) O4 C8 H81 110.9(9) 
C1 N3 C5 117.32(13) C9 C8 H81 114.4(9) 
C6 O1 C7 108.86(11) C7 C8 H81 111.4(9) 
N3 C1 C2 122.35(14) C10 C11 H113 111.3(13) 
N3 C1 Cl1 116.98(11) C10 C11 H112 109.6(12) 
C2 C1 Cl1 120.67(12) H113 C11 H112 110.3(19) 
C1 C2 C3 114.41(14) C10 C11 H111 110.0(13) 
C1 C2 N2 134.08(14) H113 C11 H111 106.0(17) 
C3 C2 N2 111.47(13) H112 C11 H111 109.6(17) 
C4 N1 C3 105.87(12) O5 C12 O4 122.43(16) 
C4 N1 C6 125.10(13) O5 C12 C13 126.55(17) 
C3 N1 C6 128.90(13) O4 C12 C13 111.00(16) 
N4 C5 N5 118.22(13) O1 C7 C14 106.89(12) 
N4 C5 N3 126.67(14) O1 C7 C8 106.77(12) 
N5 C5 N3 115.10(14) C14 C7 C8 116.17(13) 
O3 C10 O2 122.39(15) O1 C7 H71 108.0(9) 
O3 C10 C11 126.01(15) C14 C7 H71 108.6(9) 
O2 C10 C11 111.60(14) C8 C7 H71 110.1(9) 
N4 C3 N1 128.39(14) C15 O6 C14 117.34(13) 
N4 C3 C2 126.94(14) O6 C14 C7 108.05(12) 
N1 C3 C2 104.66(13) O6 C14 H141 112.9(8) 
O2 C9 C8 114.51(12) C7 C14 H141 109.8(8) 
O2 C9 C6 111.25(13) O6 C14 H142 106.8(8) 
C8 C9 C6 101.69(12) C7 C14 H142 109.9(9) 
O2 C9 H91 108.4(9) H141 C14 H142 109.4(11) 
C8 C9 H91 109.7(9) O7 C15 O6 123.44(15) 
C6 C9 H91 111.2(9) O7 C15 C16 124.83(17) 
O1 C6 N1 107.93(12) O6 C15 C16 111.72(15) 
O1 C6 C9 103.11(12) C15 C16 H162 105.4(11) 
N1 C6 C9 116.55(13) C15 C16 H163 104.4(11) 
O1 C6 H61 110.3(9) H162 C16 H163 111.4(17) 
N1 C6 H61 107.2(9) C15 C16 H161 112.3(15) 
C9 C6 H61 111.6(10) H162 C16 H161 106.6(17) 
C4 N2 C2 103.40(12) H163 C16 H161 116.4(17) 
N2 C4 N1 114.60(14) C12 C13 H131 113.4(13) 
N2 C4 H4 125.5(9) C12 C13 H132 111.9(12) 
N1 C4 H4 119.8(9) H131 C13 H132 106.8(17) 
C5 N5 H51 121.1(15) C12 C13 H133 107.7(15) 
C5 N5 H52 114.5(14) H131 C13 H133 105.0(19) 
H51 N5 H52 122(2) H132 C13 H133 111.8(18) 
O4 C8 C9 108.16(12)     
Table 28: Bond angle (°). 
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Torsion atoms Torsion angle Torsion atoms Torsion angle 
1 2 3 4  1 2 3 4  
C5 N3 C1 C2 -0.4(2) C3 N1 C6 C9 -41.5(2) 
C5 N3 C1 Cl1 179.93(11) O2 C9 C6 O1 163.65(11) 
N3 C1 C2 C3 -0.4(2) C8 C9 C6 O1 41.31(14) 
Cl1 C1 C2 C3 179.28(12) O2 C9 C6 N1 -78.34(16) 
N3 C1 C2 N2 -177.76(17) C8 C9 C6 N1 159.32(13) 
Cl1 C1 C2 N2 1.9(2) C1 C2 N2 C4 176.56(17) 
C3 N4 C5 N5 -179.93(16) C3 C2 N2 C4 -0.87(18) 
C3 N4 C5 N3 1.3(2) C2 N2 C4 N1 0.45(18) 
C1 N3 C5 N4 -0.1(2) C3 N1 C4 N2 0.12(19) 
C1 N3 C5 N5 -178.89(14) C6 N1 C4 N2 176.44(14) 
C9 O2 C10 O3 1.1(2) C12 O4 C8 C9 154.73(13) 
C9 O2 C10 C11 -179.40(12) C12 O4 C8 C7 -94.46(15) 
C5 N4 C3 N1 176.39(15) O2 C9 C8 O4 -39.20(17) 
C5 N4 C3 C2 -2.2(2) C6 C9 C8 O4 80.87(14) 
C4 N1 C3 N4 -179.50(16) O2 C9 C8 C7 -154.26(12) 
C6 N1 C3 N4 4.4(3) C6 C9 C8 C7 -34.19(14) 
C4 N1 C3 C2 -0.64(17) C8 O4 C12 O5 -7.4(2) 
C6 N1 C3 C2 -176.77(14) C8 O4 C12 C13 171.04(14) 
C1 C2 C3 N4 1.9(2) C6 O1 C7 C14 135.47(13) 
N2 C2 C3 N4 179.83(15) C6 O1 C7 C8 10.52(15) 
C1 C2 C3 N1 -177.02(13) O4 C8 C7 O1 -98.67(13) 
N2 C2 C3 N1 0.95(18) C9 C8 C7 O1 15.81(15) 
C10 O2 C9 C8 -92.90(15) O4 C8 C7 C14 142.24(13) 
C10 O2 C9 C6 152.51(12) C9 C8 C7 C14 -103.27(15) 
C7 O1 C6 N1 -156.44(11) C15 O6 C14 C7 99.14(16) 
C7 O1 C6 C9 -32.55(15) O1 C7 C14 O6 163.58(12) 
C4 N1 C6 O1 -101.64(16) C8 C7 C14 O6 -77.40(17) 
C3 N1 C6 O1 73.81(18) C14 O6 C15 O7 1.7(2) 
C4 N1 C6 C9 143.02(15) C14 O6 C15 C16 -178.48(15) 
Table 29: Torsion angle (°). 
 
11.3.2 Crystallographic data for ms2i6A 
Crystal parameter and data collection details for ms2i6A 
Chemical formula C16H23N5O4S 
Molecular weight 381.45 
Space group P 21 21 21 (19) - orthorhombic 
a, b, c (Å) 5.0993(2), 11.3043(4), 30.6517(11) 
α, β, γ (°) 90, 90, 90 
V (Å3) 1766.89(11) 
Z 4 
Dber. (g/cm3) 1.434 
μMoKα (mm) 0.217 
F(000) 808 
Temperature (K) 773 (2) 
Radiation λ (Å) MoKα, 0.71073 
θmin, θmax (°) 3.78, 30.10 
h -7 → 7 
k -15 → 15 
l -43 → 43 
Measured reflexes 24115 
Independent reflexes 5187 
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Rint 0,0775 
observed reflexes [I > 2σ(I)] 2412 
NReflexes, NParameter 5187, 2412 
R, ωR2, S 0.0351, 0.0495, 0.790 
Ω = 1/[σ2(F02) + (0.204 • P)2 + 0.0 • P] P = (F02 + 2 Fc2)/3 
Table 30: Crystal parameter and data collection details 
 
Atom X Y Z Ueq 
C1 0.8801(4) 0.16780(19) 0.92806(6) 0.0320(5) 
C10 1.1534(4) 0.3191(2) 0.76126(7) 0.0324(5) 
C11 0.0991(5) 0.5036(2) 0.97416(7) 0.0355(6) 
C12 0.2137(4) 0.59759(19) 1.00337(6) 0.0349(5) 
C13 0.1371(4) 0.62608(17) 1.04296(7) 0.0334(5) 
C14 0.2674(6) 0.7224(2) 1.06882(9) 0.0501(7) 
C15 -0.0814(4) 0.5670(2) 1.06697(7) 0.0514(7) 
C16 0.2569(6) 0.6706(2) 0.84019(9) 0.0445(6) 
C2 0.7622(4) 0.31309(16) 0.88521(6) 0.0239(4) 
C3 0.6274(4) 0.31543(16) 0.92424(6) 0.0246(5) 
C4 0.5568(4) 0.47494(16) 0.86218(6) 0.0265(5) 
C5 0.4405(4) 0.40510(17) 0.92979(5) 0.0252(4) 
C6 1.0785(4) 0.15882(17) 0.85408(6) 0.0261(5) 
C7 0.9163(4) 0.10274(17) 0.81813(6) 0.0245(4) 
C8 1.2565(4) 0.21522(17) 0.78699(6) 0.0269(5) 
C9 1.1173(4) 0.09758(17) 0.78157(6) 0.0256(5) 
N1 0.9272(3) 0.21630(13) 0.88792(5) 0.0272(4) 
N2 0.7052(3) 0.22310(14) 0.95139(5) 0.0318(4) 
N3 0.7349(3) 0.39202(13) 0.85218(4) 0.0256(4) 
N4 0.4134(3) 0.48715(13) 0.89830(4) 0.0260(4) 
N5 0.2853(3) 0.41034(16) 0.96500(5) 0.0322(5) 
O2 1.2434(2) 0.24194(10) 0.83336(4) 0.0294(3) 
O3 0.8045(3) -0.00475(12) 0.83141(5) 0.0354(4) 
O4 1.2999(3) 0.00436(13) 0.78949(4) 0.0321(4) 
O5 0.8784(3) 0.33809(12) 0.76666(5) 0.0304(3) 
S1 0.51997(11) 0.58146(4) 0.820730(16) 0.03771(15)
Table 31: Atom coordinates and equivalent anisotropic temperature factors for non-hydrogen atoms 
(Å2). 
 
Atom X Y Z Uiso 
H1 0.974(3) 0.0989(15) 0.9367(5) 0.023(5) 
H101 1.168(3) 0.3021(14) 0.7304(6) 0.023(5) 
H102 1.262(4) 0.3869(18) 0.7684(6) 0.042(6) 
H111 0.050(3) 0.5405(15) 0.9466(6) 0.026(5) 
H112 -0.059(4) 0.4714(17) 0.9874(6) 0.048(7) 
H12 0.368(4) 0.6396(15) 0.9907(5) 0.032(5) 
H141 0.414(5) 0.760(2) 1.0530(7) 0.068(8) 
H142 0.145(4) 0.7897(18) 1.0735(6) 0.043(6) 
H143 0.324(4) 0.6932(18) 1.0983(7) 0.056(7) 
H15A -0.1160 0.4912 1.0541 0.062 
H15B -0.2361 0.6151 1.0653 0.062 
H15C -0.0325 0.5565 1.0970 0.062 
H161 0.232(4) 0.7321(19) 0.8198(7) 0.056(7) 
H162 0.305(4) 0.7094(19) 0.8675(8) 0.064(8) 
H163 0.109(6) 0.632(2) 0.8446(8) 0.100(12) 
H3 0.661(5) -0.010(2) 0.8204(7) 0.063(9) 
H4 1.260(4) -0.0524(18) 0.7740(6) 0.045(7) 
H5 0.297(4) 0.3613(16) 0.9827(5) 0.024(6) 
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H50 0.834(5) 0.361(2) 0.7932(8) 0.094(11) 
H6 1.190(3) 0.1005(14) 0.8687(5) 0.018(4) 
H7 0.791(3) 0.1569(15) 0.8101(5) 0.020(5) 
H8 1.444(3) 0.2062(13) 0.7790(5) 0.017(4) 
H9 1.044(3) 0.0885(13) 0.7527(5) 0.014(4) 
Table 32: Atom coordinates and equivalent isotropic temperature factors for hydrogen atoms (Å2). 
 
Atom U11 U22 U33 U23 U13 U12 
S1 0.0472(4) 0.0331(3) 0.0328(3) 0.0090(2) 0.0052(3) 0.0071(3) 
O2 0.0307(8) 0.0301(8) 0.0272(8) -0.0001(6) -0.0031(6) -0.0037(7) 
O3 0.0354(10) 0.0303(9) 0.0404(9) 0.0043(7) -0.0018(8) -0.0062(7) 
O4 0.0328(9) 0.0279(9) 0.0355(9) -0.0082(7) -0.0069(7) 0.0068(8) 
O5 0.0322(9) 0.0323(9) 0.0268(8) 0.0053(7) -0.0012(7) 0.0045(7) 
N1 0.0345(11) 0.0262(9) 0.0208(9) 0.0008(7) -0.0025(8) 0.0020(8) 
N2 0.0455(12) 0.0276(10) 0.0223(9) 0.0029(7) -0.0009(9) 0.0094(9) 
N3 0.0290(9) 0.0242(9) 0.0235(9) 0.0028(7) -0.0020(7) 0.0011(8) 
N4 0.0326(10) 0.0242(9) 0.0213(9) -0.0015(7) 0.0022(7) 0.0012(8) 
N5 0.0449(12) 0.0301(11) 0.0215(10) 0.0050(9) 0.0067(9) 0.0090(10) 
C1 0.0422(14) 0.0297(12) 0.0240(11) 0.0045(10) -0.0041(10) 0.0059(12) 
C2 0.0275(12) 0.0198(11) 0.0243(11) -0.0022(8) -0.0054(9) -0.0003(10) 
C3 0.0316(12) 0.0212(11) 0.0210(11) -0.0008(8) -0.0015(9) -0.0030(10) 
C4 0.0302(12) 0.0259(11) 0.0235(10) 0.0015(8) -0.0040(9) -0.0037(10) 
C5 0.0357(12) 0.0219(10) 0.0180(10) -0.0017(8) -0.0011(9) -0.0028(11) 
C6 0.0270(12) 0.0264(11) 0.0251(11) 0.0021(9) -0.0037(10) 0.0056(10) 
C7 0.0226(11) 0.0222(12) 0.0288(11) 0.0039(9) -0.0031(10) 0.0034(10) 
C8 0.0217(12) 0.0353(13) 0.0236(11) -0.0008(9) 0.0015(10) -0.0004(11) 
C9 0.0271(11) 0.0298(12) 0.0199(11) -0.0002(9) -0.0062(9) 0.0045(11) 
C10 0.0335(15) 0.0337(14) 0.0299(14) 0.0020(11) -0.0022(10) -0.0034(11) 
C11 0.0405(15) 0.0354(14) 0.0305(13) 0.0028(11) 0.0038(11) 0.0060(13) 
C12 0.0390(14) 0.0269(13) 0.0388(13) 0.0013(10) 0.0122(11) 0.0000(12) 
C13 0.0337(13) 0.0320(13) 0.0344(12) -0.0004(9) 0.0004(10) 0.0047(10) 
C14 0.0551(19) 0.0396(16) 0.0556(19) -0.0126(13) 0.0040(17) 0.0001(16) 
C15 0.0465(16) 0.0630(17) 0.0448(14) -0.0127(12) 0.0133(12) -0.0089(14) 
C16 0.0521(19) 0.0400(16) 0.0415(16) 0.0060(13) -0.0040(14) 0.0128(15) 
Table 33: Anisotropic temperature factors for non-hydrogen atoms (Å2). 
 
Atom 1 Atom 2 Distance Atom 1 Atom 2 Distance 
S1 C4 1.7605(17) C6 H6 0.979(15) 
S1 C16 1.781(3) C7 C9 1.520(2) 
O2 C6 1.412(2) C7 H7 0.917(17) 
O2 C8 1.455(2) C8 C10 1.509(3) 
O3 C7 1.403(2) C8 C9 1.517(3) 
O3 H3 0.81(2) C8 H8 0.991(17) 
O4 C9 1.427(2) C9 H9 0.965(14) 
O4 H4 0.82(2) C10 H101 0.968(16) 
O5 C10 1.428(2) C10 H102 0.97(2) 
O5 H50 0.88(3) C11 C12 1.507(3) 
N1 C1 1.368(2) C11 H111 0.976(17) 
N1 C2 1.383(2) C11 H112 0.97(2) 
N1 C6 1.447(2) C12 C13 1.315(2) 
N2 C1 1.303(2) C12 H12 0.997(18) 
N2 C3 1.393(2) C13 C15 1.493(3) 
N3 C4 1.341(2) C13 C14 1.502(3) 
N3 C2 1.357(2) C14 H141 0.99(2) 
N4 C4 1.334(2) C14 H142 0.99(2) 
N4 C5 1.346(2) C14 H143 1.00(2) 
N5 C5 1.340(2) C15 H15A 0.9600 
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N5 C11 1.446(3) C15 H15B 0.9600 
N5 H5 0.778(17) C15 H15C 0.9600 
C1 H1 0.952(17) C16 H161 0.94(2) 
C2 C3 1.380(2) C16 H162 0.98(2) 
C3 C5 1.402(3) C16 H163 0.89(3) 
C6 C7 1.517(2)    
Table 34: Bond length (Å). 
 
Atom 1 Atom 2 Atom 3 Angle Atom 1 Atom 2 Atom 3 Angle 
C4 S1 C16 103.05(11) C10 C8 H8 106.7(9) 
C6 O2 C8 109.20(14) C9 C8 H8 109.5(9) 
C7 O3 H3 108.4(17) O4 C9 C8 108.87(15) 
C9 O4 H4 108.3(15) O4 C9 C7 110.05(15) 
C10 O5 H50 113.6(18) C8 C9 C7 101.62(15) 
C1 N1 C2 105.33(16) O4 C9 H9 109.2(9) 
C1 N1 C6 123.93(16) C8 C9 H9 112.0(9) 
C2 N1 C6 129.56(15) C7 C9 H9 114.8(9) 
C1 N2 C3 103.09(17) O5 C10 C8 113.48(18) 
C4 N3 C2 111.03(15) O5 C10 H101 102.6(10) 
C4 N4 C5 117.87(15) C8 C10 H101 109.2(10) 
C5 N5 C11 125.20(18) O5 C10 H102 114.5(12) 
C5 N5 H5 119.1(14) C8 C10 H102 107.4(11) 
C11 N5 H5 115.7(14) H101 C10 H102 109.5(14) 
N2 C1 N1 114.93(19) N5 C11 C12 112.01(18) 
N2 C1 H1 125.8(9) N5 C11 H111 108.2(10) 
N1 C1 H1 119.3(9) C12 C11 H111 108.3(10) 
N3 C2 C3 125.67(17) N5 C11 H112 110.5(12) 
N3 C2 N1 128.89(16) C12 C11 H112 109.7(11) 
C3 C2 N1 105.43(15) H111 C11 H112 108.0(15) 
C2 C3 N2 111.22(17) C13 C12 C11 127.3(2) 
C2 C3 C5 117.24(17) C13 C12 H12 118.6(10) 
N2 C3 C5 131.54(17) C11 C12 H12 114.1(10) 
N4 C4 N3 129.31(16) C12 C13 C15 124.5(2) 
N4 C4 S1 118.01(14) C12 C13 C14 122.2(2) 
N3 C4 S1 112.68(13) C15 C13 C14 113.25(19) 
N5 C5 N4 119.12(18) C13 C14 H141 112.8(13) 
N5 C5 C3 122.11(17) C13 C14 H142 110.8(12) 
N4 C5 C3 118.77(16) H141 C14 H142 102.5(17) 
O2 C6 N1 109.95(15) C13 C14 H143 111.3(12) 
O2 C6 C7 106.04(14) H141 C14 H143 111(2) 
N1 C6 C7 114.68(16) H142 C14 H143 107.5(16) 
O2 C6 H6 108.0(9) C13 C15 H15A 109.5 
N1 C6 H6 106.5(9) C13 C15 H15B 109.5 
C7 C6 H6 111.6(9) H15A C15 H15B 109.5 
O3 C7 C6 111.90(16) C13 C15 H15C 109.5 
O3 C7 C9 117.06(16) H15A C15 H15C 109.5 
C6 C7 C9 100.58(15) H15B C15 H15C 109.5 
O3 C7 H7 112.0(11) S1 C16 H161 107.2(13) 
C6 C7 H7 107.1(10) S1 C16 H162 110.6(13) 
C9 C7 H7 107.2(10) H161 C16 H162 105.6(18) 
O2 C8 C10 109.44(17) S1 C16 H163 114.3(18) 
O2 C8 C9 105.51(15) H161 C16 H163 111(2) 
C10 C8 C9 117.52(17) H162 C16 H163 108(2) 
O2 C8 H8 107.8(9)     
Table 35: Bond angle (°). 
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Torsion atoms Torsion angle Torsion atoms Torsion angle 
1 2 3 4  1 2 3 4  
C3 N2 C1 N1 0.7(2) N2 C3 C5 N4 177.18(18) 
C2 N1 C1 N2 -0.5(2) C8 O2 C6 N1 -142.70(15) 
C6 N1 C1 N2 -169.06(18) C8 O2 C6 C7 -18.19(19) 
C4 N3 C2 C3 0.1(3) C1 N1 C6 O2 -138.63(17) 
C4 N3 C2 N1 -178.98(17) C2 N1 C6 O2 55.7(2) 
C1 N1 C2 N3 179.19(18) C1 N1 C6 C7 102.0(2) 
C6 N1 C2 N3 -13.1(3) C2 N1 C6 C7 -63.7(3) 
C1 N1 C2 C3 0.00(19) O2 C6 C7 O3 161.62(14) 
C6 N1 C2 C3 167.72(17) N1 C6 C7 O3 -76.9(2) 
N3 C2 C3 N2 -178.81(18) O2 C6 C7 C9 36.59(18) 
N1 C2 C3 N2 0.4(2) N1 C6 C7 C9 158.11(16) 
N3 C2 C3 C5 2.0(3) C6 O2 C8 C10 119.31(17) 
N1 C2 C3 C5 -178.81(16) C6 O2 C8 C9 -8.02(19) 
C1 N2 C3 C2 -0.7(2) O2 C8 C9 O4 -85.63(18) 
C1 N2 C3 C5 178.4(2) C10 C8 C9 O4 152.09(18) 
C5 N4 C4 N3 -1.6(3) O2 C8 C9 C7 30.49(18) 
C5 N4 C4 S1 179.50(13) C10 C8 C9 C7 -91.8(2) 
C2 N3 C4 N4 -0.3(3) O3 C7 C9 O4 -46.1(2) 
C2 N3 C4 S1 178.65(12) C6 C7 C9 O4 75.33(18) 
C16 S1 C4 N4 -5.85(18) O3 C7 C9 C8 -161.36(16) 
C16 S1 C4 N3 175.07(16) C6 C7 C9 C8 -39.93(17) 
C11 N5 C5 N4 -5.0(3) O2 C8 C10 O5 -68.1(2) 
C11 N5 C5 C3 176.24(19) C9 C8 C10 O5 52.1(3) 
C4 N4 C5 N5 -175.19(16) C5 N5 C11 C12 -94.9(2) 
C4 N4 C5 C3 3.6(2) N5 C11 C12 C13 -116.2(2) 
C2 C3 C5 N5 174.97(17) C11 C12 C13 C15 1.1(3) 
N2 C3 C5 N5 -4.1(3) C11 C12 C13 C14 -179.7(2) 
C2 C3 C5 N4 -3.8(3)      
Table 36: Torsion angle (°). 
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Establishment of actinometry as basis for etch rate prediction.  
01/2004 – 04/2004 Research Internship 
Osram Opto Semiconductors, Research and Development, Regensburg 
Investigation of actinometry in process development. 
07/2003 – 12/2003 Research Internship 
University of Oxford, Hodgson Group, Oxford 
Investigation of catalytic enantioselective intermolecular 2,3-carbonyl-
ylide-cycloaddition and its application in natural product synthesis of 
nemorensic acids. 
04/2003 – 07/2003 Organic Chemistry Tutor, Ludwig-Maximilians-University, Munich 
04/2001 – 10/2001 Research Assistant, GPC Biotech AG, Munich  
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EDUCATION 
 
10/2000 – 07/2006 Chemistry Diploma 
Ludwig-Maximilians-University, Munich, grade: 1.5 
08/1999 – 07/2000 Civil Service 
Hospital Nuremberg, Microbiological Laboratory, Nuremberg 
07/1990 – 07/1999 High School 
Willibald-Gluck-Gymnasium, Neumarkt, grade: 2.2 
Award for environmental science, “Jugend forscht”, 1999. 
 
FURTHER TRAININGS 
 
12/2008 LTQ Orbitrap Biotech Operations Training Course 
ThermoFisher Scientific Training Institute, Munich 
10/2008 Crash Course “Project Management” 
Ludwig-Maximilians-University, Munich 
06/2008 Crash Course “Führung und Motivation sowie Förderung der 
Kommunikation, Zusammenarbeit und Leistung im Team” 
LMU Center for Leadership and People Management, Munich 
06/2007 Nucleic Acid Chemical Biology (NACB) Ph.D. Summer School 
 University of Southern Denmark, Odense 
 
PERSONAL SKILLS AND ACTIVITIES 
 
Languages German native speaker 
English fluent 
French  basic 
Computer Skills Microsoft: Word, Excel, Powerpoint 
Adobe: Photoshop, Illustrator 
PyMOL 
Activities Member of the GDCh and the JCF (Jungchemikerforum) Munich 
 Member of the organizing team for the JCF Alpenforum 2008-2010 
 Cooking, Reading, Rock Climbing, Snowboarding, Sailing 
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PUBLICATIONS 
 
6. M. Münzel, D. Globisch, T. Brückl, M. Wagner, V. Welzmiller, S. Michalakis, M. Müller, 
M. Biel, and T. Carell, Quantification of the Sixth DNA-Base Hydroxymethyl-dC in the 
Brain, Angew. Chem. 2010, accepted (hot paper). 
 
5. T. Brückl, D. Globisch, M. Wagner, M. Müller, and T. Carell, Parallel isotope-based 
quantification of modified tRNA nucleosides, Angew. Chem. Int. Ed. 2009, 48, 7932–7934 
(hot paper). 
 
4. T. Brückl, F. Klepper, K. Gutsmiedl & T. Carell, A short and efficient synthesis of the 
tRNA nucleosides PreQ0 and archaeosine, Org. Biomol. Chem. 2007, 5, 3821–3825. 
 
3. T. Brückl & H. Zull, Actinometry of inductively coupled Cl2/N2 plasmas for dry etching of 
GaAs, J. Appl. Phys. 2005, 98, 023307. 
 
2. D. M. Hodgson, F. Le Strat, T. D. Avery, A. C. Donohue & T. Brückl, Stereocontrolled 
synthesis of the nemorensic acids using 6-diazoheptane-2,5-dione in carbonyl ylide 
cycloadditions, J. Org. Chem. 2004, 69, 8796–8803. 
 
1. D. M. Hodgson, T. Brückl, R. Glen, A. H. Labande, D. A. Selden, A. G. Dossetter & A. J. 
Redgrave, Catalytic enantioselective intermolecular cycloadditions of 2-diazo-3,6-
diketoester-derived carbonyl ylides with alkene dipolarophiles, Proc. Natl. Acad. Sci. USA 
2004, 101, 5450–5454, Asymmetric Catalysis Special Feature. 
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CONFERENCE PRESENTATIONS 
 
7. Poster Presentation: 42nd IUPAC Congress, Chemistry Solutions, Quantitative analysis of 
modified tRNA nucleosides, Glasgow, United Kingdom, 2nd to 7th 
August 2009. 
 
6. Poster Presentation: Bayer Ph.D. Student Course 2009, Quantitation of modified tRNA 
nucleosides from E. coli, pork, HeLa, and HCT, Cologne, Germany, 
5th to 9th July 2009. 
 
5. Poster Presentation: Synthesefest 2009 – A Celebration of Organic Chemistry in Munich, 
Synthesis of the modified tRNA nucleosides queuosine,  archaeosine, 
ms2io6A, and m2A, Munich, Germany, 17th and 18th March 2009. 
 
4. Oral Presentation: 11th JCF-Frühjahrssymposium, 2-methylthio-N-6-hydroxyisopen-
tenyl-adenosine (ms2io6A), 2-Methyladenosine (m2A), queuosine (Q), 
and archaeosine (G*) – Total syntheses of modified 
tRNA nucleosides, Essen, Germany, 11th to 14th March 2009. 
 
3. Poster Presentation: ORCHEM 2008, Making modifications – Total synthesis of modified 
tRNA nucleosides, Weimar, Germany, 1st to 3rd September 2008. 
 
2. Oral Presentation: 3rd Nucleic Acid Chemical Biology Ph.D. Summer School, Total 
synthesis of queuosine (Q) and archaeosine (G*), Odense, Denmark, 
24th to 28th June 2007. 
 
1. Invited Speaker: Plasma Processing Technologies for Compound Semiconductors 
Workshop, Actinometry of Cl2/N2 plasmas and its extension to the 
first ever straightforward etch rate prediction, Regensburg, 
Germany, 22nd and 23rd May 2006. 
